Unnamed: 0 stringlengths 3 8 | Date stringlengths 23 23 | Article_title stringlengths 1 250 | Stock_symbol stringlengths 1 5 | Url stringlengths 44 135 | Publisher stringclasses 1 value | Author stringclasses 1 value | Article stringlengths 1 343k | Lsa_summary stringlengths 3 53.9k | Luhn_summary stringlengths 1 53.9k | Textrank_summary stringlengths 1 53.9k | Lexrank_summary stringlengths 1 53.9k |
|---|---|---|---|---|---|---|---|---|---|---|---|
34600.0 | 2022-10-14 00:00:00 UTC | Notable Friday Option Activity: NTNX, MHO, ABUS | ABUS | https://www.nasdaq.com/articles/notable-friday-option-activity%3A-ntnx-mho-abus | nan | nan | Among the underlying components of the Russell 3000 index, we saw noteworthy options trading volume today in Nutanix Inc (Symbol: NTNX), where a total of 17,202 contracts have traded so far, representing approximately 1.7 million underlying shares. That amounts to about 81.6% of NTNX's average daily trading volume over the past month of 2.1 million shares. Especially high volume was seen for the $25 strike put option expiring November 18, 2022, with 1,551 contracts trading so far today, representing approximately 155,100 underlying shares of NTNX. Below is a chart showing NTNX's trailing twelve month trading history, with the $25 strike highlighted in orange:
M/I Homes Inc (Symbol: MHO) options are showing a volume of 2,040 contracts thus far today. That number of contracts represents approximately 204,000 underlying shares, working out to a sizeable 77.4% of MHO's average daily trading volume over the past month, of 263,540 shares. Particularly high volume was seen for the $50 strike call option expiring January 20, 2023, with 1,000 contracts trading so far today, representing approximately 100,000 underlying shares of MHO. Below is a chart showing MHO's trailing twelve month trading history, with the $50 strike highlighted in orange:
And Arbutus Biopharma Corp (Symbol: ABUS) options are showing a volume of 5,153 contracts thus far today. That number of contracts represents approximately 515,300 underlying shares, working out to a sizeable 70.8% of ABUS's average daily trading volume over the past month, of 727,565 shares. Especially high volume was seen for the $2.50 strike put option expiring March 17, 2023, with 2,250 contracts trading so far today, representing approximately 225,000 underlying shares of ABUS. Below is a chart showing ABUS's trailing twelve month trading history, with the $2.50 strike highlighted in orange:
For the various different available expirations for NTNX options, MHO options, or ABUS options, visit StockOptionsChannel.com.
Today's Most Active Call & Put Options of the S&P 500 »
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Especially high volume was seen for the $2.50 strike put option expiring March 17, 2023, with 2,250 contracts trading so far today, representing approximately 225,000 underlying shares of ABUS. Below is a chart showing MHO's trailing twelve month trading history, with the $50 strike highlighted in orange: And Arbutus Biopharma Corp (Symbol: ABUS) options are showing a volume of 5,153 contracts thus far today. That number of contracts represents approximately 515,300 underlying shares, working out to a sizeable 70.8% of ABUS's average daily trading volume over the past month, of 727,565 shares. | That number of contracts represents approximately 515,300 underlying shares, working out to a sizeable 70.8% of ABUS's average daily trading volume over the past month, of 727,565 shares. Below is a chart showing MHO's trailing twelve month trading history, with the $50 strike highlighted in orange: And Arbutus Biopharma Corp (Symbol: ABUS) options are showing a volume of 5,153 contracts thus far today. Especially high volume was seen for the $2.50 strike put option expiring March 17, 2023, with 2,250 contracts trading so far today, representing approximately 225,000 underlying shares of ABUS. | Below is a chart showing ABUS's trailing twelve month trading history, with the $2.50 strike highlighted in orange: For the various different available expirations for NTNX options, MHO options, or ABUS options, visit StockOptionsChannel.com. Below is a chart showing MHO's trailing twelve month trading history, with the $50 strike highlighted in orange: And Arbutus Biopharma Corp (Symbol: ABUS) options are showing a volume of 5,153 contracts thus far today. That number of contracts represents approximately 515,300 underlying shares, working out to a sizeable 70.8% of ABUS's average daily trading volume over the past month, of 727,565 shares. | Below is a chart showing ABUS's trailing twelve month trading history, with the $2.50 strike highlighted in orange: For the various different available expirations for NTNX options, MHO options, or ABUS options, visit StockOptionsChannel.com. Below is a chart showing MHO's trailing twelve month trading history, with the $50 strike highlighted in orange: And Arbutus Biopharma Corp (Symbol: ABUS) options are showing a volume of 5,153 contracts thus far today. That number of contracts represents approximately 515,300 underlying shares, working out to a sizeable 70.8% of ABUS's average daily trading volume over the past month, of 727,565 shares. |
34601.0 | 2022-10-05 00:00:00 UTC | We Think Arbutus Biopharma (NASDAQ:ABUS) Can Afford To Drive Business Growth | ABUS | https://www.nasdaq.com/articles/we-think-arbutus-biopharma-nasdaq%3Aabus-can-afford-to-drive-business-growth | nan | nan | We can readily understand why investors are attracted to unprofitable companies. For example, biotech and mining exploration companies often lose money for years before finding success with a new treatment or mineral discovery. But while history lauds those rare successes, those that fail are often forgotten; who remembers Pets.com?
So should Arbutus Biopharma (NASDAQ:ABUS) shareholders be worried about its cash burn? For the purposes of this article, cash burn is the annual rate at which an unprofitable company spends cash to fund its growth; its negative free cash flow. Let's start with an examination of the business' cash, relative to its cash burn.
How Long Is Arbutus Biopharma's Cash Runway?
A company's cash runway is calculated by dividing its cash hoard by its cash burn. In June 2022, Arbutus Biopharma had US$150m in cash, and was debt-free. Importantly, its cash burn was US$36m over the trailing twelve months. That means it had a cash runway | So should Arbutus Biopharma (NASDAQ:ABUS) shareholders be worried about its cash burn? For example, biotech and mining exploration companies often lose money for years before finding success with a new treatment or mineral discovery. But while history lauds those rare successes, those that fail are often forgotten; who remembers Pets.com? | So should Arbutus Biopharma (NASDAQ:ABUS) shareholders be worried about its cash burn? For the purposes of this article, cash burn is the annual rate at which an unprofitable company spends cash to fund its growth; its negative free cash flow. How Long Is Arbutus Biopharma's Cash Runway? | So should Arbutus Biopharma (NASDAQ:ABUS) shareholders be worried about its cash burn? For the purposes of this article, cash burn is the annual rate at which an unprofitable company spends cash to fund its growth; its negative free cash flow. Let's start with an examination of the business' cash, relative to its cash burn. | So should Arbutus Biopharma (NASDAQ:ABUS) shareholders be worried about its cash burn? We can readily understand why investors are attracted to unprofitable companies. For example, biotech and mining exploration companies often lose money for years before finding success with a new treatment or mineral discovery. |
34602.0 | 2022-08-23 00:00:00 UTC | We Did The Math VTWV Can Go To $165 | ABUS | https://www.nasdaq.com/articles/we-did-the-math-vtwv-can-go-to-%24165 | nan | nan | Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and computed the weighted average implied analyst target price for the ETF itself. For the Vanguard Russell 2000 Value ETF (Symbol: VTWV), we found that the implied analyst target price for the ETF based upon its underlying holdings is $165.29 per unit.
With VTWV trading at a recent price near $132.10 per unit, that means that analysts see 25.13% upside for this ETF looking through to the average analyst targets of the underlying holdings. Three of VTWV's underlying holdings with notable upside to their analyst target prices are MacroGenics, Inc (Symbol: MGNX), Arbutus Biopharma Corp (Symbol: ABUS), and Innovid Corp (Symbol: CTV). Although MGNX has traded at a recent price of $3.80/share, the average analyst target is 423.68% higher at $19.90/share. Similarly, ABUS has 200.22% upside from the recent share price of $2.29 if the average analyst target price of $6.88/share is reached, and analysts on average are expecting CTV to reach a target price of $9.75/share, which is 192.79% above the recent price of $3.33. Below is a twelve month price history chart comparing the stock performance of MGNX, ABUS, and CTV:
Below is a summary table of the current analyst target prices discussed above:
NAME SYMBOL RECENT PRICE AVG. ANALYST 12-MO. TARGET % UPSIDE TO TARGET
Vanguard Russell 2000 Value ETF VTWV $132.10 $165.29 25.13%
MacroGenics, Inc MGNX $3.80 $19.90 423.68%
Arbutus Biopharma Corp ABUS $2.29 $6.88 200.22%
Innovid Corp CTV $3.33 $9.75 192.79%
Are analysts justified in these targets, or overly optimistic about where these stocks will be trading 12 months from now? Do the analysts have a valid justification for their targets, or are they behind the curve on recent company and industry developments? A high price target relative to a stock's trading price can reflect optimism about the future, but can also be a precursor to target price downgrades if the targets were a relic of the past. These are questions that require further investor research.
10 ETFs With Most Upside To Analyst Targets »
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Vanguard Russell 2000 Value ETF VTWV $132.10 $165.29 25.13% MacroGenics, Inc MGNX $3.80 $19.90 423.68% Arbutus Biopharma Corp ABUS $2.29 $6.88 200.22% Innovid Corp CTV $3.33 $9.75 192.79% Are analysts justified in these targets, or overly optimistic about where these stocks will be trading 12 months from now? Three of VTWV's underlying holdings with notable upside to their analyst target prices are MacroGenics, Inc (Symbol: MGNX), Arbutus Biopharma Corp (Symbol: ABUS), and Innovid Corp (Symbol: CTV). Similarly, ABUS has 200.22% upside from the recent share price of $2.29 if the average analyst target price of $6.88/share is reached, and analysts on average are expecting CTV to reach a target price of $9.75/share, which is 192.79% above the recent price of $3.33. | Three of VTWV's underlying holdings with notable upside to their analyst target prices are MacroGenics, Inc (Symbol: MGNX), Arbutus Biopharma Corp (Symbol: ABUS), and Innovid Corp (Symbol: CTV). Similarly, ABUS has 200.22% upside from the recent share price of $2.29 if the average analyst target price of $6.88/share is reached, and analysts on average are expecting CTV to reach a target price of $9.75/share, which is 192.79% above the recent price of $3.33. Vanguard Russell 2000 Value ETF VTWV $132.10 $165.29 25.13% MacroGenics, Inc MGNX $3.80 $19.90 423.68% Arbutus Biopharma Corp ABUS $2.29 $6.88 200.22% Innovid Corp CTV $3.33 $9.75 192.79% Are analysts justified in these targets, or overly optimistic about where these stocks will be trading 12 months from now? | Similarly, ABUS has 200.22% upside from the recent share price of $2.29 if the average analyst target price of $6.88/share is reached, and analysts on average are expecting CTV to reach a target price of $9.75/share, which is 192.79% above the recent price of $3.33. Three of VTWV's underlying holdings with notable upside to their analyst target prices are MacroGenics, Inc (Symbol: MGNX), Arbutus Biopharma Corp (Symbol: ABUS), and Innovid Corp (Symbol: CTV). Below is a twelve month price history chart comparing the stock performance of MGNX, ABUS, and CTV: Below is a summary table of the current analyst target prices discussed above: | Vanguard Russell 2000 Value ETF VTWV $132.10 $165.29 25.13% MacroGenics, Inc MGNX $3.80 $19.90 423.68% Arbutus Biopharma Corp ABUS $2.29 $6.88 200.22% Innovid Corp CTV $3.33 $9.75 192.79% Are analysts justified in these targets, or overly optimistic about where these stocks will be trading 12 months from now? Three of VTWV's underlying holdings with notable upside to their analyst target prices are MacroGenics, Inc (Symbol: MGNX), Arbutus Biopharma Corp (Symbol: ABUS), and Innovid Corp (Symbol: CTV). Similarly, ABUS has 200.22% upside from the recent share price of $2.29 if the average analyst target price of $6.88/share is reached, and analysts on average are expecting CTV to reach a target price of $9.75/share, which is 192.79% above the recent price of $3.33. |
34603.0 | 2022-08-06 00:00:00 UTC | Bullish: Analysts Just Made A Noticeable Upgrade To Their Arbutus Biopharma Corporation (NASDAQ:ABUS) Forecasts | ABUS | https://www.nasdaq.com/articles/bullish%3A-analysts-just-made-a-noticeable-upgrade-to-their-arbutus-biopharma-corporation | nan | nan | Arbutus Biopharma Corporation (NASDAQ:ABUS) shareholders will have a reason to smile today, with the analysts making substantial upgrades to this year's statutory forecasts. The consensus statutory numbers for both revenue and earnings per share (EPS) increased, with their view clearly much more bullish on the company's business prospects. Investor sentiment seems to be improving too, with the share price up 9.5% to US$2.53 over the past 7 days. Whether the upgrade is enough to drive the stock price higher is yet to be seen, however.
Following the upgrade, the current consensus from Arbutus Biopharma's five analysts is for revenues of US$38m in 2022 which - if met - would reflect a solid 15% increase on its sales over the past 12 months. The loss per share is expected to ameliorate slightly, reducing to US$0.47. However, before this estimates update, the consensus had been expecting revenues of US$32m and US$0.52 per share in losses. We can see there's definitely been a change in sentiment in this update, with the analysts administering a sizeable upgrade to this year's revenue estimates, while at the same time reducing their loss estimates.
NasdaqGS:ABUS Earnings and Revenue Growth August 6th 2022
There was no major change to the consensus price target of CA$8.08, perhaps suggesting that the analysts remain concerned about ongoing losses despite the improved earnings and revenue outlook. There's another way to think about price targets though, and that's to look at the range of price targets put forward by analysts, because a wide range of estimates could suggest a diverse view on possible outcomes for the business. There are some variant perceptions on Arbutus Biopharma, with the most bullish analyst valuing it at CA$9.00 and the most bearish at CA$4.00 per share. Note the wide gap in analyst price targets? This implies to us that there is a fairly broad range of possible scenarios for the underlying business.
Of course, another way to look at these forecasts is to place them into context against the industry itself. It's clear from the latest estimates that Arbutus Biopharma's rate of growth is expected to accelerate meaningfully, with the forecast 33% annualised revenue growth to the end of 2022 noticeably faster than its historical growth of 23% p.a. over the past five years. By contrast, our data suggests that other companies (with analyst coverage) in a similar industry are forecast to grow their revenue at 14% per year. It seems obvious that, while the growth outlook is brighter than the recent past, the analysts also expect Arbutus Biopharma to grow faster than the wider industry.
The Bottom Line
The most important thing here is that analysts reduced their loss per share estimates for this year, reflecting increased optimism around Arbutus Biopharma's prospects. They also upgraded their revenue estimates for this year, and sales are expected to grow faster than the wider market. Some investors might be disappointed to see that the price target is unchanged, but we feel that improving fundamentals are usually a positive - assuming these forecasts are met! So Arbutus Biopharma could be a good candidate for more research.
Still, the long-term prospects of the business are much more relevant than next year's earnings. At Simply Wall St, we have a full range of analyst estimates for Arbutus Biopharma going out to 2024, and you can see them free on our platform here..
Of course, seeing company management invest large sums of money in a stock can be just as useful as knowing whether analysts are upgrading their estimates. So you may also wish to search this free list of stocks that insiders are buying.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Arbutus Biopharma Corporation (NASDAQ:ABUS) shareholders will have a reason to smile today, with the analysts making substantial upgrades to this year's statutory forecasts. NasdaqGS:ABUS Earnings and Revenue Growth August 6th 2022 There was no major change to the consensus price target of CA$8.08, perhaps suggesting that the analysts remain concerned about ongoing losses despite the improved earnings and revenue outlook. Following the upgrade, the current consensus from Arbutus Biopharma's five analysts is for revenues of US$38m in 2022 which - if met - would reflect a solid 15% increase on its sales over the past 12 months. | NasdaqGS:ABUS Earnings and Revenue Growth August 6th 2022 There was no major change to the consensus price target of CA$8.08, perhaps suggesting that the analysts remain concerned about ongoing losses despite the improved earnings and revenue outlook. Arbutus Biopharma Corporation (NASDAQ:ABUS) shareholders will have a reason to smile today, with the analysts making substantial upgrades to this year's statutory forecasts. It seems obvious that, while the growth outlook is brighter than the recent past, the analysts also expect Arbutus Biopharma to grow faster than the wider industry. | NasdaqGS:ABUS Earnings and Revenue Growth August 6th 2022 There was no major change to the consensus price target of CA$8.08, perhaps suggesting that the analysts remain concerned about ongoing losses despite the improved earnings and revenue outlook. Arbutus Biopharma Corporation (NASDAQ:ABUS) shareholders will have a reason to smile today, with the analysts making substantial upgrades to this year's statutory forecasts. There's another way to think about price targets though, and that's to look at the range of price targets put forward by analysts, because a wide range of estimates could suggest a diverse view on possible outcomes for the business. | NasdaqGS:ABUS Earnings and Revenue Growth August 6th 2022 There was no major change to the consensus price target of CA$8.08, perhaps suggesting that the analysts remain concerned about ongoing losses despite the improved earnings and revenue outlook. Arbutus Biopharma Corporation (NASDAQ:ABUS) shareholders will have a reason to smile today, with the analysts making substantial upgrades to this year's statutory forecasts. There's another way to think about price targets though, and that's to look at the range of price targets put forward by analysts, because a wide range of estimates could suggest a diverse view on possible outcomes for the business. |
34604.0 | 2022-08-04 00:00:00 UTC | Arbutus Biopharma (ABUS) Reports Q2 Loss, Tops Revenue Estimates | ABUS | https://www.nasdaq.com/articles/arbutus-biopharma-abus-reports-q2-loss-tops-revenue-estimates | nan | nan | Arbutus Biopharma (ABUS) came out with a quarterly loss of $0.10 per share versus the Zacks Consensus Estimate of a loss of $0.13. This compares to loss of $0.23 per share a year ago. These figures are adjusted for non-recurring items.
This quarterly report represents an earnings surprise of 23.08%. A quarter ago, it was expected that this biopharmaceutical company would post a loss of $0.13 per share when it actually produced a loss of $0.11, delivering a surprise of 15.38%.
Over the last four quarters, the company has surpassed consensus EPS estimates three times.
Arbutus, which belongs to the Zacks Medical - Biomedical and Genetics industry, posted revenues of $14.24 million for the quarter ended June 2022, surpassing the Zacks Consensus Estimate by 165.39%. This compares to year-ago revenues of $2.33 million. The company has topped consensus revenue estimates three times over the last four quarters.
The sustainability of the stock's immediate price movement based on the recently-released numbers and future earnings expectations will mostly depend on management's commentary on the earnings call.
Arbutus shares have lost about 36.8% since the beginning of the year versus the S&P 500's decline of -12.8%.
What's Next for Arbutus?
While Arbutus has underperformed the market so far this year, the question that comes to investors' minds is: what's next for the stock?
There are no easy answers to this key question, but one reliable measure that can help investors address this is the company's earnings outlook. Not only does this include current consensus earnings expectations for the coming quarter(s), but also how these expectations have changed lately.
Empirical research shows a strong correlation between near-term stock movements and trends in earnings estimate revisions. Investors can track such revisions by themselves or rely on a tried-and-tested rating tool like the Zacks Rank, which has an impressive track record of harnessing the power of earnings estimate revisions.
Ahead of this earnings release, the estimate revisions trend for Arbutus: mixed. While the magnitude and direction of estimate revisions could change following the company's just-released earnings report, the current status translates into a Zacks Rank #3 (Hold) for the stock. So, the shares are expected to perform in line with the market in the near future. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here.
It will be interesting to see how estimates for the coming quarters and current fiscal year change in the days ahead. The current consensus EPS estimate is -$0.13 on $5.45 million in revenues for the coming quarter and -$0.51 on $33.06 million in revenues for the current fiscal year.
Investors should be mindful of the fact that the outlook for the industry can have a material impact on the performance of the stock as well. In terms of the Zacks Industry Rank, Medical - Biomedical and Genetics is currently in the top 33% of the 250 plus Zacks industries. Our research shows that the top 50% of the Zacks-ranked industries outperform the bottom 50% by a factor of more than 2 to 1.
One other stock from the same industry, Intra-Cellular Therapies (ITCI), is yet to report results for the quarter ended June 2022. The results are expected to be released on August 9.
This biopharmaceutical company is expected to post quarterly loss of $0.79 per share in its upcoming report, which represents a year-over-year change of +7.1%. The consensus EPS estimate for the quarter has been revised 2.7% lower over the last 30 days to the current level.
Intra-Cellular Therapies' revenues are expected to be $49.22 million, up 145.5% from the year-ago quarter.
5 Stocks Set to Double
Each was handpicked by a Zacks expert as the #1 favorite stock to gain +100% or more in 2021. Previous recommendations have soared +143.0%, +175.9%, +498.3% and +673.0%.
Most of the stocks in this report are flying under Wall Street radar, which provides a great opportunity to get in on the ground floor.
Today, See These 5 Potential Home Runs >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Arbutus Biopharma Corporation (ABUS): Free Stock Analysis Report
IntraCellular Therapies Inc. (ITCI): Free Stock Analysis Report
To read this article on Zacks.com click here.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Arbutus Biopharma (ABUS) came out with a quarterly loss of $0.10 per share versus the Zacks Consensus Estimate of a loss of $0.13. Arbutus Biopharma Corporation (ABUS): Free Stock Analysis Report Empirical research shows a strong correlation between near-term stock movements and trends in earnings estimate revisions. | Arbutus Biopharma Corporation (ABUS): Free Stock Analysis Report Arbutus Biopharma (ABUS) came out with a quarterly loss of $0.10 per share versus the Zacks Consensus Estimate of a loss of $0.13. Arbutus, which belongs to the Zacks Medical - Biomedical and Genetics industry, posted revenues of $14.24 million for the quarter ended June 2022, surpassing the Zacks Consensus Estimate by 165.39%. | Arbutus Biopharma (ABUS) came out with a quarterly loss of $0.10 per share versus the Zacks Consensus Estimate of a loss of $0.13. Arbutus Biopharma Corporation (ABUS): Free Stock Analysis Report Arbutus, which belongs to the Zacks Medical - Biomedical and Genetics industry, posted revenues of $14.24 million for the quarter ended June 2022, surpassing the Zacks Consensus Estimate by 165.39%. | Arbutus Biopharma (ABUS) came out with a quarterly loss of $0.10 per share versus the Zacks Consensus Estimate of a loss of $0.13. Arbutus Biopharma Corporation (ABUS): Free Stock Analysis Report The company has topped consensus revenue estimates three times over the last four quarters. |
34605.0 | 2022-07-27 00:00:00 UTC | Bristol Myers Squibb (BMY) Q2 Earnings and Revenues Surpass Estimates | ABUS | https://www.nasdaq.com/articles/bristol-myers-squibb-bmy-q2-earnings-and-revenues-surpass-estimates | nan | nan | Bristol Myers Squibb (BMY) came out with quarterly earnings of $1.93 per share, beating the Zacks Consensus Estimate of $1.79 per share. This compares to earnings of $1.93 per share a year ago. These figures are adjusted for non-recurring items.
This quarterly report represents an earnings surprise of 7.82%. A quarter ago, it was expected that this biopharmaceutical company would post earnings of $1.92 per share when it actually produced earnings of $1.96, delivering a surprise of 2.08%.
Over the last four quarters, the company has surpassed consensus EPS estimates three times.
Bristol Myers, which belongs to the Zacks Medical - Biomedical and Genetics industry, posted revenues of $11.89 billion for the quarter ended June 2022, surpassing the Zacks Consensus Estimate by 3.72%. This compares to year-ago revenues of $11.7 billion. The company has topped consensus revenue estimates four times over the last four quarters.
The sustainability of the stock's immediate price movement based on the recently-released numbers and future earnings expectations will mostly depend on management's commentary on the earnings call.
Bristol Myers shares have added about 18.1% since the beginning of the year versus the S&P 500's decline of -17.7%.
What's Next for Bristol Myers?
While Bristol Myers has outperformed the market so far this year, the question that comes to investors' minds is: what's next for the stock?
There are no easy answers to this key question, but one reliable measure that can help investors address this is the company's earnings outlook. Not only does this include current consensus earnings expectations for the coming quarter(s), but also how these expectations have changed lately.
Empirical research shows a strong correlation between near-term stock movements and trends in earnings estimate revisions. Investors can track such revisions by themselves or rely on a tried-and-tested rating tool like the Zacks Rank, which has an impressive track record of harnessing the power of earnings estimate revisions.
Ahead of this earnings release, the estimate revisions trend for Bristol Myers: mixed. While the magnitude and direction of estimate revisions could change following the company's just-released earnings report, the current status translates into a Zacks Rank #3 (Hold) for the stock. So, the shares are expected to perform in line with the market in the near future. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here.
It will be interesting to see how estimates for the coming quarters and current fiscal year change in the days ahead. The current consensus EPS estimate is $1.95 on $11.42 billion in revenues for the coming quarter and $7.46 on $46.3 billion in revenues for the current fiscal year.
Investors should be mindful of the fact that the outlook for the industry can have a material impact on the performance of the stock as well. In terms of the Zacks Industry Rank, Medical - Biomedical and Genetics is currently in the top 29% of the 250 plus Zacks industries. Our research shows that the top 50% of the Zacks-ranked industries outperform the bottom 50% by a factor of more than 2 to 1.
Another stock from the same industry, Arbutus Biopharma (ABUS), has yet to report results for the quarter ended June 2022. The results are expected to be released on August 4.
This biopharmaceutical company is expected to post quarterly loss of $0.13 per share in its upcoming report, which represents a year-over-year change of +43.5%. The consensus EPS estimate for the quarter has remained unchanged over the last 30 days.
Arbutus Biopharma's revenues are expected to be $5.37 million, up 130.3% from the year-ago quarter.
Just Released: Zacks Top 10 Stocks for 2022
In addition to the investment ideas discussed above, would you like to know about our 10 top picks for the entirety of 2022?
From inception in 2012 through 2021, the Zacks Top 10 Stocks portfolios gained an impressive +1,001.2% versus the S&P 500’s +348.7%. Now our Director of Research has combed through 4,000 companies covered by the Zacks Rank and has handpicked the best 10 tickers to buy and hold. Don’t miss your chance to get in…because the sooner you do, the more upside you stand to grab.
See Stocks Now >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Bristol Myers Squibb Company (BMY): Free Stock Analysis Report
Arbutus Biopharma Corporation (ABUS): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Another stock from the same industry, Arbutus Biopharma (ABUS), has yet to report results for the quarter ended June 2022. Arbutus Biopharma Corporation (ABUS): Free Stock Analysis Report Empirical research shows a strong correlation between near-term stock movements and trends in earnings estimate revisions. | Another stock from the same industry, Arbutus Biopharma (ABUS), has yet to report results for the quarter ended June 2022. Arbutus Biopharma Corporation (ABUS): Free Stock Analysis Report Bristol Myers, which belongs to the Zacks Medical - Biomedical and Genetics industry, posted revenues of $11.89 billion for the quarter ended June 2022, surpassing the Zacks Consensus Estimate by 3.72%. | Another stock from the same industry, Arbutus Biopharma (ABUS), has yet to report results for the quarter ended June 2022. Arbutus Biopharma Corporation (ABUS): Free Stock Analysis Report Bristol Myers Squibb (BMY) came out with quarterly earnings of $1.93 per share, beating the Zacks Consensus Estimate of $1.79 per share. | Another stock from the same industry, Arbutus Biopharma (ABUS), has yet to report results for the quarter ended June 2022. Arbutus Biopharma Corporation (ABUS): Free Stock Analysis Report Not only does this include current consensus earnings expectations for the coming quarter(s), but also how these expectations have changed lately. |
34606.0 | 2022-07-06 00:00:00 UTC | All You Need to Know About Arbutus (ABUS) Rating Upgrade to Buy | ABUS | https://www.nasdaq.com/articles/all-you-need-to-know-about-arbutus-abus-rating-upgrade-to-buy | nan | nan | Arbutus Biopharma (ABUS) could be a solid addition to your portfolio given its recent upgrade to a Zacks Rank #2 (Buy). This rating change essentially reflects an upward trend in earnings estimates -- one of the most powerful forces impacting stock prices.
The Zacks rating relies solely on a company's changing earnings picture. It tracks EPS estimates for the current and following years from the sell-side analysts covering the stock through a consensus measure -- the Zacks Consensus Estimate.
The power of a changing earnings picture in determining near-term stock price movements makes the Zacks rating system highly useful for individual investors, since it can be difficult to make decisions based on rating upgrades by Wall Street analysts. These are mostly driven by subjective factors that are hard to see and measure in real time.
As such, the Zacks rating upgrade for Arbutus is essentially a positive comment on its earnings outlook that could have a favorable impact on its stock price.
Most Powerful Force Impacting Stock Prices
The change in a company's future earnings potential, as reflected in earnings estimate revisions, has proven to be strongly correlated with the near-term price movement of its stock. The influence of institutional investors has a partial contribution to this relationship, as these big professionals use earnings and earnings estimates to calculate the fair value of a company's shares. An increase or decrease in earnings estimates in their valuation models simply results in higher or lower fair value for a stock, and institutional investors typically buy or sell it. Their transaction of large amounts of shares then leads to price movement for the stock.
For Arbutus, rising earnings estimates and the consequent rating upgrade fundamentally mean an improvement in the company's underlying business. And investors' appreciation of this improving business trend should push the stock higher.
Harnessing the Power of Earnings Estimate Revisions
Empirical research shows a strong correlation between trends in earnings estimate revisions and near-term stock movements, so it could be truly rewarding if such revisions are tracked for making an investment decision. Here is where the tried-and-tested Zacks Rank stock-rating system plays an important role, as it effectively harnesses the power of earnings estimate revisions.
The Zacks Rank stock-rating system, which uses four factors related to earnings estimates to classify stocks into five groups, ranging from Zacks Rank #1 (Strong Buy) to Zacks Rank #5 (Strong Sell), has an impressive externally-audited track record, with Zacks Rank #1 stocks generating an average annual return of +25% since 1988. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here >>>>.
Earnings Estimate Revisions for Arbutus
For the fiscal year ending December 2022, this biopharmaceutical company is expected to earn -$0.51 per share, which is a change of 38.6% from the year-ago reported number.
Analysts have been steadily raising their estimates for Arbutus. Over the past three months, the Zacks Consensus Estimate for the company has increased 10.1%.
Bottom Line
Unlike the overly optimistic Wall Street analysts whose rating systems tend to be weighted toward favorable recommendations, the Zacks rating system maintains an equal proportion of 'buy' and 'sell' ratings for its entire universe of more than 4000 stocks at any point in time. Irrespective of market conditions, only the top 5% of the Zacks-covered stocks get a 'Strong Buy' rating and the next 15% get a 'Buy' rating. So, the placement of a stock in the top 20% of the Zacks-covered stocks indicates its superior earnings estimate revision feature, making it a solid candidate for producing market-beating returns in the near term.
You can learn more about the Zacks Rank here >>>
The upgrade of Arbutus to a Zacks Rank #2 positions it in the top 20% of the Zacks-covered stocks in terms of estimate revisions, implying that the stock might move higher in the near term.
Zacks Names "Single Best Pick to Double"
From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all.
It’s a little-known chemical company that’s up 65% over last year, yet still dirt cheap. With unrelenting demand, soaring 2022 earnings estimates, and $1.5 billion for repurchasing shares, retail investors could jump in at any time.
This company could rival or surpass other recent Zacks’ Stocks Set to Double like Boston Beer Company which shot up +143.0% in little more than 9 months and NVIDIA which boomed +175.9% in one year.
Free: See Our Top Stock and 4 Runners Up >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Arbutus Biopharma Corporation (ABUS): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Arbutus Biopharma (ABUS) could be a solid addition to your portfolio given its recent upgrade to a Zacks Rank #2 (Buy). Arbutus Biopharma Corporation (ABUS): Free Stock Analysis Report As such, the Zacks rating upgrade for Arbutus is essentially a positive comment on its earnings outlook that could have a favorable impact on its stock price. | Arbutus Biopharma (ABUS) could be a solid addition to your portfolio given its recent upgrade to a Zacks Rank #2 (Buy). Arbutus Biopharma Corporation (ABUS): Free Stock Analysis Report The power of a changing earnings picture in determining near-term stock price movements makes the Zacks rating system highly useful for individual investors, since it can be difficult to make decisions based on rating upgrades by Wall Street analysts. | Arbutus Biopharma (ABUS) could be a solid addition to your portfolio given its recent upgrade to a Zacks Rank #2 (Buy). Arbutus Biopharma Corporation (ABUS): Free Stock Analysis Report Most Powerful Force Impacting Stock Prices The change in a company's future earnings potential, as reflected in earnings estimate revisions, has proven to be strongly correlated with the near-term price movement of its stock. | Arbutus Biopharma (ABUS) could be a solid addition to your portfolio given its recent upgrade to a Zacks Rank #2 (Buy). Arbutus Biopharma Corporation (ABUS): Free Stock Analysis Report Most Powerful Force Impacting Stock Prices The change in a company's future earnings potential, as reflected in earnings estimate revisions, has proven to be strongly correlated with the near-term price movement of its stock. |
34607.0 | 2022-06-09 00:00:00 UTC | Pre-market Movers: SYM, FNCH, SGLY, SCKT, FRGE… | ABUS | https://www.nasdaq.com/articles/pre-market-movers%3A-sym-fnch-sgly-sckt-frge... | nan | nan | (RTTNews) - The following are some of the stocks making big moves in Thursday's pre-market trading (as of 07.25 A.M. ET).
In the Green
Singularity Future Technology Ltd. (SGLY) is up over 14% at $4.35 Quantum Computing, Inc. (QUBT) is up over 12% at $3.87 Arbutus Biopharma Corporation (ABUS) is up over 11% at $2.99 Cognex Corporation (CGNX) is up over 10% at $52.86 Hemisphere Media Group, Inc. (HMTV) is up over 9% at $7.69 Celanese Corporation (CE) is up over 6% at $168.11 TG Therapeutics, Inc. (TGTX) is up over 5% at $5.31
In the Red
Symbotic Inc. (SYM) is down over 18% at $16.40 Finch Therapeutics Group, Inc. (FNCH) is down over 16% at $2.21 Socket Mobile, Inc. (SCKT) is down over 14% at $2.99 Forge Global Holdings, Inc. (FRGE) is down over 13% at $12.47 Bilibili Inc. (BILI) is down over 9% at $26.81 PDS Biotechnology Corporation (PDSB) is down over 9% at $3.63 Uranium Royalty Corp. (UROY) is down over 8% at $3.01 VivoPower International PLC (VVPR) is down over 8% at $2.06 Five Below, Inc. (FIVE) is down over 7% at $124.65
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | In the Green Singularity Future Technology Ltd. (SGLY) is up over 14% at $4.35 Quantum Computing, Inc. (QUBT) is up over 12% at $3.87 Arbutus Biopharma Corporation (ABUS) is up over 11% at $2.99 Cognex Corporation (CGNX) is up over 10% at $52.86 Hemisphere Media Group, Inc. (HMTV) is up over 9% at $7.69 Celanese Corporation (CE) is up over 6% at $168.11 TG Therapeutics, Inc. (TGTX) is up over 5% at $5.31 In the Red Symbotic Inc. (SYM) is down over 18% at $16.40 Finch Therapeutics Group, Inc. (FNCH) is down over 16% at $2.21 Socket Mobile, Inc. (SCKT) is down over 14% at $2.99 Forge Global Holdings, Inc. (FRGE) is down over 13% at $12.47 Bilibili Inc. (BILI) is down over 9% at $26.81 PDS Biotechnology Corporation (PDSB) is down over 9% at $3.63 Uranium Royalty Corp. (UROY) is down over 8% at $3.01 VivoPower International PLC (VVPR) is down over 8% at $2.06 Five Below, Inc. (FIVE) is down over 7% at $124.65 The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. (RTTNews) - The following are some of the stocks making big moves in Thursday's pre-market trading (as of 07.25 A.M. ET). | In the Green Singularity Future Technology Ltd. (SGLY) is up over 14% at $4.35 Quantum Computing, Inc. (QUBT) is up over 12% at $3.87 Arbutus Biopharma Corporation (ABUS) is up over 11% at $2.99 Cognex Corporation (CGNX) is up over 10% at $52.86 Hemisphere Media Group, Inc. (HMTV) is up over 9% at $7.69 Celanese Corporation (CE) is up over 6% at $168.11 TG Therapeutics, Inc. (TGTX) is up over 5% at $5.31 In the Red Symbotic Inc. (SYM) is down over 18% at $16.40 Finch Therapeutics Group, Inc. (FNCH) is down over 16% at $2.21 Socket Mobile, Inc. (SCKT) is down over 14% at $2.99 Forge Global Holdings, Inc. (FRGE) is down over 13% at $12.47 Bilibili Inc. (BILI) is down over 9% at $26.81 PDS Biotechnology Corporation (PDSB) is down over 9% at $3.63 Uranium Royalty Corp. (UROY) is down over 8% at $3.01 VivoPower International PLC (VVPR) is down over 8% at $2.06 Five Below, Inc. (FIVE) is down over 7% at $124.65 The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. (RTTNews) - The following are some of the stocks making big moves in Thursday's pre-market trading (as of 07.25 A.M. ET). | In the Green Singularity Future Technology Ltd. (SGLY) is up over 14% at $4.35 Quantum Computing, Inc. (QUBT) is up over 12% at $3.87 Arbutus Biopharma Corporation (ABUS) is up over 11% at $2.99 Cognex Corporation (CGNX) is up over 10% at $52.86 Hemisphere Media Group, Inc. (HMTV) is up over 9% at $7.69 Celanese Corporation (CE) is up over 6% at $168.11 TG Therapeutics, Inc. (TGTX) is up over 5% at $5.31 In the Red Symbotic Inc. (SYM) is down over 18% at $16.40 Finch Therapeutics Group, Inc. (FNCH) is down over 16% at $2.21 Socket Mobile, Inc. (SCKT) is down over 14% at $2.99 Forge Global Holdings, Inc. (FRGE) is down over 13% at $12.47 Bilibili Inc. (BILI) is down over 9% at $26.81 PDS Biotechnology Corporation (PDSB) is down over 9% at $3.63 Uranium Royalty Corp. (UROY) is down over 8% at $3.01 VivoPower International PLC (VVPR) is down over 8% at $2.06 Five Below, Inc. (FIVE) is down over 7% at $124.65 The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. (RTTNews) - The following are some of the stocks making big moves in Thursday's pre-market trading (as of 07.25 A.M. ET). | In the Green Singularity Future Technology Ltd. (SGLY) is up over 14% at $4.35 Quantum Computing, Inc. (QUBT) is up over 12% at $3.87 Arbutus Biopharma Corporation (ABUS) is up over 11% at $2.99 Cognex Corporation (CGNX) is up over 10% at $52.86 Hemisphere Media Group, Inc. (HMTV) is up over 9% at $7.69 Celanese Corporation (CE) is up over 6% at $168.11 TG Therapeutics, Inc. (TGTX) is up over 5% at $5.31 In the Red Symbotic Inc. (SYM) is down over 18% at $16.40 Finch Therapeutics Group, Inc. (FNCH) is down over 16% at $2.21 Socket Mobile, Inc. (SCKT) is down over 14% at $2.99 Forge Global Holdings, Inc. (FRGE) is down over 13% at $12.47 Bilibili Inc. (BILI) is down over 9% at $26.81 PDS Biotechnology Corporation (PDSB) is down over 9% at $3.63 Uranium Royalty Corp. (UROY) is down over 8% at $3.01 VivoPower International PLC (VVPR) is down over 8% at $2.06 Five Below, Inc. (FIVE) is down over 7% at $124.65 The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. (RTTNews) - The following are some of the stocks making big moves in Thursday's pre-market trading (as of 07.25 A.M. ET). |
34608.0 | 2022-05-05 00:00:00 UTC | Arbutus Biopharma (ABUS) Q1 2022 Earnings Call Transcript | ABUS | https://www.nasdaq.com/articles/arbutus-biopharma-abus-q1-2022-earnings-call-transcript | nan | nan | Image source: The Motley Fool.
Arbutus Biopharma (NASDAQ: ABUS)
Q1 2022 Earnings Call
May 05, 2022, 8:45 a.m. ET
Contents:
Prepared Remarks
Questions and Answers
Call Participants
Prepared Remarks:
Operator
Good day, and thank you for standing by. Welcome to the Arbutus Biopharma 2022 first quarter financial results and corporate update conference call. [Operator instructions] Please be advised that today's conference is being recorded. [Operator instructions] I would now like to hand the conference over to your first speaker today, Lisa Caperelli, vice president of investor relations.
Thank you. And please go ahead.
Lisa Caperelli -- Vice President, Investor Relations
Thank you, operator. Good morning, everyone, and thank you for joining Arbutus' first quarter 2022 financial results and corporate update call. Joining me today from the Arbutus executive team are Bill Collier, president and chief executive officer; David Hastings, chief financial officer; Dr. Gaston Picchio, chief development officer; and Dr.
Mike Sofia, chief scientific officer. Bill will begin with a corporate update, followed by Dr. Sofia, who will provide an update on our preclinical programs. Dave Hastings will then provide a review of the company's first quarter 2022 financial results.
10 stocks we like better than Arbutus Biopharma
When our award-winning analyst team has a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor, has tripled the market.*
They just revealed what they believe are the ten best stocks for investors to buy right now... and Arbutus Biopharma wasn't one of them! That's right -- they think these 10 stocks are even better buys.
See the 10 stocks
*Stock Advisor returns as of April 7, 2022
After opening remarks, we will open the call up for Q&A. Gaston Picchio will be available to address clinical-related questions. Before we begin, we'd like to remind you that some of the statements made during the call today are forward-looking statements, which are subject to a number of risks and uncertainties that may cause our actual results to differ materially, including those described in our most recent annual report on 10-K, quarterly report on Form 10-Q to be filed later today and from time to time in other documents filed with the SEC. I will now turn the call over to Bill.
Bill?
Bill Collier -- President and Chief Executive Officer
Thank you, Lisa, and good morning, everybody. Thank you for joining us. We appreciate your continued interest and support in Arbutus Biopharma. As you saw in this morning's press release with our first quarter 2022 financial and corporate update, we are on track to deliver on multiple key milestones across our chronic hepatitis B and coronavirus programs.
In fact, we anticipate reporting data from four clinical trials that are evaluating either 729 or 836 during this year. And importantly, as Dave will discuss later in this call, we are well positioned financially with a projected cash runway into the second quarter of 2024. Now before I turn the call over to Mike Sofia to run through the progress the team has made in advancing our proprietary early research compounds, I'd like to highlight some of the progress we've achieved toward our three-pronged HBV strategy to provide a functional cure for chronic HBV infection. As you know, that three-pronged approach consists of suppressing S-antigen, reducing HBV DNA and boosting the immune system.
Starting with our lead HBV compound 729, our proprietary RNAi therapeutic. In clinical trials to date, 729 has shown a sustained reduction in S-antigen and in some patients, an increased HBV-specific immune response. To further assess this activity, 729, together with standard of care, nucleoside analog is currently being evaluated in combination with other approved or investigational compounds in two Phase IIa clinical trials with a third trial expected to begin enrollment shortly. The first trial, AB-729-201 is assessing the safety and tolerability of 729 plus interferon in patients with NUC-suppressed chronic HBV.
This trial initiated last year is continuing to enroll patients and is on track to report initial data in the second half of 2022. The second trial is being conducted by Assembly Bio and is evaluating 729 with Assembly's core inhibitor, vebicorvir. Late in the first quarter, Assembly reported that this trial was fully enrolled with data expected in the second half of 2022. The third trial, AB-729-202 will evaluate the safety, antiviral activity and immunogenicity of Vaccitech's therapeutic vaccine or placebo after administration of 729, again in NUC-suppressed chronic HBV patients.
Sites are being activated for this trial with plans to dose patients in the first half of 2022. As we explore 729 in these Phase IIa clinical trials, the goal is to utilize these learnings to identify the best combination of compounds that we can then explore in Phase IIb as we focus on developing a functional cure for HBV. One last point I'd like to make about 729. We anticipate reporting additional key data from the Phase Ia/Ib clinical trial, AB-729-001 at a medical conference this year.
That data will include new on-treatment data for patients enrolled in cohort K, which are HBV DNA negative and e-antigen positive patients that received 90 milligrams of 729 every eight weeks. It will also include additional data for patients in cohorts E, F, G, I, and J. These cohorts assessed 60 milligram or 90 milligram every four, eight or 12 weeks as well as long-term follow-up data for patients who completed treatment and have discontinued 729 and discontinued new therapy. We're looking forward to seeing the treatment discontinuation data as this will be our first glimpse into potential functional cure data, albeit with a small subset of patients.
Now in addition, our next-generation oral capsid inhibitor, AB-836, in combination with NUC therapy is designed to eliminate viral replication and reduce HBV DNA. Preliminary data that we reported last year from our clinical trial AB-836-001 has shown that 836 is generally safe and well tolerated and provides robust antiviral activity. We're on track to report data from this trial in the first half of 2022. Now moving on to our coronavirus efforts.
We're focusing on identifying and developing new antiviral small molecules to treat COVID-19 and future coronavirus outbreaks. Our research efforts are focused on two essential targets critical for replication across all coronaviruses. nsp5 protease and nsp12 polymerase. We're continuing to advance our efforts to nominate an nsp5 protease or Mpro clinical candidate that we can move into IND-enabling studies this year.
We're also continuing the lead optimization activities for an nsp12 viral polymerase candidate. Finally, we continue to assess the potential opportunity in oncology with our oral PD-L1 program. I'm really proud of the progress that the Arbutus team continues to make in advancing these compounds and look forward to sharing data throughout the year. I'll now turn the call over to Dr.
Mike Sofia for an update on our HBV preclinical assets. Over to you, Mike.
Mike Sofia -- Chief Scientific Officer
Thanks, Bill. In the HCV space, we have two important preclinical assets, AB-161 and AB-101, both of which are currently undergoing IND-enabling studies with the goal of completing those studies in the second half of this year. Starting with our oral RNA destabilizer, AB-161, I'd like to walk you through our RNA destabilizer history and how we selected AB-161 as our next-generation compound. So in our quest to develop acute functional cure for chronic hepatitis B, we always believe that a small molecule RNA destabilizer could provide a key piece necessary for providing a proprietary oral treatment regimen.
Mechanistically, RNA destabilizers target the host proteins, PAPD5 and 7, which are involved in regulating the stability of HBV RNA transcripts. In doing so, RNA destabilizers lead to the degradation of HBV RNAs and, thus, reduce S-antigen levels and inhibit viral replication. This activity of RNA destabilizers is supported by several preclinical proof-of-concept studies in multiple animal models. Our first-generation RNA destabilizer, AB-452, inhibited [Inaudible] production in vitro and in vivo using an AAV-HBV mouse model.
We discontinued development of this compound based on peripheral neuropathy findings observed in a 90-day preclinical safety study conducted in two species. Despite this setback, we still believe that the HBV RNA destabilizer mechanism of action is compelling and has the potential to lead to an all oral therapy for patients with hepatitis B. Our vigorous research efforts led us to the development of our next-generation oral RNA destabilizer or AB-161. The strategy for this compound was to focus on a liver-centric chemotype to reduce systemic exposure of free compound and mitigate the peripheral neuropathy seen with the earlier compound AB-452.
This was important that this new compound had differentiated chemistry compared to not only AB-452, but also any competitor RNA destabilizer. In addition, we wanted to maintain the robust antiviral potency seen with the first-generation destabilizers. AB-161 was selected as the compound to advance based on antiviral activity seen in vitro. Specifically, AB-161 showed potent antiviral activity in multiple HBV cell models.
It was active across all HBV genotypes, maintain activity against NUC-resistant variants. It was selective against HBV versus many other viruses that inhibit the production of multiple viral protein products and more specifically, reduced serum S-antigen in AAV-HBV mouse models. To examine whether this liver-centric approach could avoid the peripheral neuropathy issues observed in our earlier compound AB-452, multiple ADME, toxicology and PK studies were conducted. These show that AB-161 achieved a high liver to plasma ratio when administered orally in three species.
Our studies concluded that AB-161 achieved a desirable ADME and PK profile. In in vivo non-GLP safety studies, we undertook an extensive assessment of several development compounds with particular focus on agents that demonstrated the cleanest profile as it related to the proper neuropathy concerns. To that end, we believe that AB-161 meets the high bar we set and showed an improved safety profile compared to AB-452. We are continuing to conduct IND-enabling studies with AB-161, including 90-day GLP studies in two species to further confirm our belief in our strategy to address the safety issues seen with AB-452.
All of these studies are intended to give us confidence that we have a safe compound to move into clinical trials. Now moving on to AB-101, our PD-L1 oral small molecule inhibitor. It has been our long-standing strategy to combine agents that reduce the HBV-specific immune tolerizing agent S-antigen with agents that can further reawaken the immune system. We believe we can do this with AB-101.
The immune system of HBV [Inaudible] infected patients is tolerized to recognize the virus or infected cells. To achieve a functional cure and long-term HBV viral control, we believe that highly functional HBV-specific T cells are required. However, HPV-specific T cells become functionally defective and greatly reduced in number during chronic HBV infection. Immune checkpoints such as PD-1, PD-L1, play an important role in the induction and maintenance of immune tolerance and in T cell activation.
Therefore, we hypothesize that one approach to reawaken HBV-specific T cells is to block the PD-1, PD-L1 protein interaction and hopefully break HBV-specific immune tolerance. Support for this approach was observed in preclinical animal model studies where checkpoint blockade in combination with other direct antivirals had both DNA clearance with sustained viral suppression. Through our research efforts and preclinical work, we selected AB-101 as a lead candidate based on in vitro potency, immune restoration, in vivo efficacy, selectivity and safety. IND-enabling studies are currently underway.
We look forward to sharing more data on both of these compounds as it becomes available throughout the year. I will now turn the call over to Dave Hastings for a brief financial update. Dave?
Dave Hastings -- Chief Financial Officer
Thanks, Mike, and good morning, everybody. As I've mentioned in the past, our key financial metric is cash and financial runway. Our cash, cash equivalents, and investments was approximately $221.8 million as of March 31, 2022 as compared to approximately $191 million as of December 31, 2021. Now during the three months ended March 31, 2022, we received a $40 million upfront payment from Qilu Pharmaceutical for the exclusive commercialization license agreement for AB-729 in Greater China, $15 million of gross proceeds from Qilu's equity investment and approximately $300,000 of proceeds from our ATM.
These cash inflows were partially offset by $23.4 million of cash used in operations. We expect a net cash burn between $90 million to $95 million in 2022, not including the $55 million of proceeds received from Qilu and believe our cash runway will be sufficient to fund operations into the second quarter of 2024. Now in terms of our Qilu transaction, we are accounting for the upfront and premium on the equity investment as deferred license revenue that will be recognized over time, currently estimated at two years, based on labor hours expended by our employees to perform our manufacturing obligations under the technology transfer and license agreement, including tech transfer assistance and clinical drug supply. So based on hours incurred, we recorded $9.6 million of revenue in the first quarter of 2022.
In closing, we are well positioned financially to advance our mission to develop a functional cure for HBV and a treatment for COVID-19 and potential future coronavirus outbreaks. And with that, I will turn the call back to Bill. Bill?
Bill Collier -- President and Chief Executive Officer
Thank you very much, Dave, and thanks to Mike Sofia as well. Operator, I think we can now open up the lines for a question-and-answer session.
Questions & Answers:
Operator
[Operator instructions] Our first question comes from the line of Roy Buchanan of JMP Securities. Your line is now open.
Roy Buchanan -- JMP Securities -- Analyst
Great. Thanks for taking the questions. I guess I'm going to start on the coronavirus program. You guys are targeting a pan-coronavirus approach for both the protease and polymerase, I believe.
Can you just tell me if the polymerase shows the same level of conservation across the coronaviruses as the protease? And then maybe just looking forward too far a bit, but you kind of view the larger opportunity as something more broad possibly used in primary care, possibly against the common cold coronaviruses? Or do you think the larger opportunities potentially hospital use government stocking?
Bill Collier -- President and Chief Executive Officer
Mike, would you like to take the first one?
Mike Sofia -- Chief Scientific Officer
Yes. Right. I'll answer the first part. So yes, when we chose these two targets, we chose them because both are highly conserved across all known coronaviruses.
So the idea of both a pan-coronavirus nsp5 main protease and one paying coronavirus for nsp12 viral polymerase are all still in play for us. So yes, we are looking at a general pan-coronavirus strategy.
Gaston Picchio -- Chief Development Officer
And the approach would be to look at treatment first, but it wouldn't be impossible to think about prophylaxis prevention strategies of coronavirus as well.
Mike Sofia -- Chief Scientific Officer
I think just to add to question on that. I mean if you look at Paxlovid, certainly, the Pfizer compound did reduce hospitalizations, but has now been shown not to have any effect on pre-exposure prophylaxis, which is an area that we would like to enter into.
Roy Buchanan -- JMP Securities -- Analyst
Yes. I'm assuming you're not going to need ritonavir and maybe you'll have better lung accessibility, etc. So -- looking forward to the next generation of compounds. The question on 161, I guess it sounds like -- I'm not sure if you guys have discussed this previously, but it sounds like the conclusion is that the neuropathy is an on-target effect.
Is that correct?
Mike Sofia -- Chief Scientific Officer
Well, I mean, we haven't definitively proven that. But certainly, the data that we have accumulated today seems to point to that. And that's why our strategy was developed as we described it. If we can get a liver-centric agent that minimizes peripheral exposure, we believe we can overcome the peripheral neuropathy concerns.
Roy Buchanan -- JMP Securities -- Analyst
OK. Great. And have you guys disclosed the amount for the ratio of the liver levels to the serum?
Mike Sofia -- Chief Scientific Officer
No. We have not yet disclosed that.
Roy Buchanan -- JMP Securities -- Analyst
OK. Great. I'll hop back in queue. Thanks.
Operator
Our second question comes from the line of Dennis Ding of Jefferies. Your line is now open.
Dennis Ding -- Jefferies -- Analyst
Hi. Good morning. Thanks for taking the question. Two questions for me, one on hep B.
Can you just please comment on the two Phase II triple combo data that's coming at the end of the year in terms of number of patients and duration of treatment? And what are the next steps you need to take to get the functional cure data? I guess, specifically, have you guys decided when will patients be taken off the drug? And then my second question is around the protease inhibitor. Can you talk about the preclinical work you guys have done so far? Have you run biochemical assays yet to measure potency? And how confident are you in the potency profile of this drug versus Paxlovid?
Bill Collier -- President and Chief Executive Officer
OK. Thanks for your questions, Dennis. Gaston, do you want to take the first, and then we'll have Mike Sofia follow up on the protease.
Gaston Picchio -- Chief Development Officer
Sure. Thank you. Good morning. So in terms of the two Phase IIa studies, one the triple ones, one is in collaboration with Assembly.
That study now is fully enrolled. It has 60 patients. And by the end of the year, we presumably will have on treatment data. We will not have the data at the end of therapy.
That's going to take a bit longer, but we will have -- but we believe it's meaningful data on treatment. In terms of what we expect, I mean, it's a little bit premature to say, but we obviously hope that the addition of the -- or the combination of the three directs will result in deeper and hopefully, on treatment loss of S-antigen. And obviously, we will see whether that happens or not. In terms of the triple with interferon, that's a relatively smaller study.
That study is enrolling, and we hope to have some preliminary on-treatment data as well by the end of the year. And I think in response to your question about, I mean, when we will stop patients, both studies call for stopping patients, but more importantly, our Phase Ia/Ib study, it's already stopping patients based on the criteria that we defined. As I mentioned before, the criteria is multifactorial, but one of the important elements is the threshold of S-antigen, and we're using less than 100 to decide the patient is ready to stop NUC therapy. And obviously, we're following those patients after NUC therapy -- after stopping NUC therapy and trying to assess functional cure.
Now one thing I want to point out that what we're doing in the Phase I study is not happening uniformly across all patients. The study was amended to offer the opportunity for patients and investigators to decide whether they want to stop NUC therapy. And obviously, not everyone is opting to stop NUC therapy, although they may meet the criteria. So I cannot define exactly how many patients we will be presenting in the future.
Bill Collier -- President and Chief Executive Officer
All right. And then, Mike, on the protease?
Mike Sofia -- Chief Scientific Officer
Yes. So to answer your question about the protease, so we have a whole battery of studies that we do. So we do do biochemical intrinsic activity studies against SARS-CoV-2, but also protein Mpro, but also the Mpros from the other or, let's say, a representative set of other coronaviruses that we do. So we get this sort of sense of pan-coronavirus activity.
Then we have sort of in vitro whole cell infectivity assays that we study the compounds again. Again, it's not only SARS-CoV-2, but against other coronaviruses. We do a lot of, let's say, biophysical studies to ensure that we understand how these molecules are binding. We have done co-crystal X-ray structures.
So we know where they bind and it helps guide us doing some of the sort of lead optimization work that we continue to do with the compound. And as far as other coronaviruses are concerned, were our targets, so certainly, our main target is SARS-CoV-2 with the pan-coronavirus, but obviously, looking into the future, how one could potentially apply these agents to other coronavirus infections that are not SARS-CoV-2 sort of certainly a possibility, but we're focused on SARS-CoV-2 at this current time.
Operator
Our next question comes from the line of Ed Arce of H.C. Wainwright. Your line is now open.
Thomas Yip -- H.C. Wainwright and Company -- Analyst
Hi. Good morning, everyone. This is Thomas Yip asking a couple of questions for Ed. So first question regarding the 729-202 combination study with VTP-300 that was discussed earlier.
Can you go over some more details of the study? How many patients should we expect to be in the study? And also any specific geographical focus there?
Bill Collier -- President and Chief Executive Officer
Yes. Gaston?
Gaston Picchio -- Chief Development Officer
Sure. So that's a Phase IIa study where we start dosing with AB-729 and then patients get randomized into receiving VTP-300 or placebo. The VTP-300 is just a combination of two different vectors. One is [Inaudible] causing HBV sequences and then MVA causing also HBV sequences.
So the study is being done in collaboration with Vaccitech. The study has already achieved some regulatory approvals in the different countries. But unfortunately, one of the countries that we selected to start the study was the Ukraine. And as everyone knows, obviously, given the war, we will not be able to initiate screening and randomization in that country.
So we are now shifting our focus into other jurisdictions. We have other countries that were already planned that are going to be screening and randomizing patients very soon. But given the loss and the uncertainty with Ukraine, we are also trying to identify other countries where we can move in as fast as possible.
Thomas Yip -- H.C. Wainwright and Company -- Analyst
Got it. Understood. Thank you for the details of the study. And then I believe there was one of the questions earlier regarding the two combination studies with 729 that we expect initial data in second half.
At which point we begin to expect a decision regarding which combination is more superior over than the others, and therefore, would be the one to move ahead in future clinical studies?
Bill Collier -- President and Chief Executive Officer
Yes. That's the intent. So I don't know if, Gaston, you want to add any additional color. I think you can tell that we're working hard to try and assess the role that 729 can play in a variety of different combinations.
So once the data comes through, we'll be in a much better position to decide the go-forward combo. Gaston?
Gaston Picchio -- Chief Development Officer
Yes. I think it's a little bit of a challenging question. It depends on the data, really. I mean the data, the interim data, for example, would be spectacular, then one could eventually make a decision at risk.
If one the size of the data is not clear cut, then you have to wait longer to decide whether it's worth pursuing one path or the other. So really, it is a very difficult question to answer at this point. And it's -- I mean, the only thing I can say is going to be data driven.
Thomas Yip -- H.C. Wainwright and Company -- Analyst
We certainly look forward to the data in the second half of this year.
Understood. Thank you for taking our questions. We look forward to the data in the second half this year. Thank you.
Operator
Our next question comes from the line of Brian Skorney of Baird. Your line is now open.
Luke Herrmann -- Robert W. Baird and Company -- Analyst
Hey. This is Luke Herrmann on for Brian. Thanks for taking our questions. For the on-treatment data in the combos here, are there any other data points beyond us that you think might be indicative of a durable off-treatment effect? Or is that really going to be the most informative data point for future plans? And then on 161, is there a chance we could see any of the existing preclinical data prior to the result of the IND-enabling studies? Or will that be reassessed once the IND-enabling studies are done? Thanks.
Bill Collier -- President and Chief Executive Officer
OK. So Gaston for the first one, then Mike.
Gaston Picchio -- Chief Development Officer
Yes. Great question. I mean it's very interesting the question because I think if you look at the recent final guidance on HBV drug development issued by the FDA on April 6, S-antigen continues to be the main endpoint. So S will certainly play a very important role -- central role in making decisions.
Having said that, as everyone knows, everyone is interested in other markers. And we are running those markers such as, but not limited to, HBV RNA and core-related antigen. However, I mean, if you read some of the recent publications, there is a little bit of a mix. There are a little bit of a mixed bag regarding the value that these markers on treatment may provide in terms of predicting durable S-antigen loss response or functional cure, if you wish.
So we are trying to include as many as possible, whether their value is going to be proven. I can't really tell it at this point in time. But certainly, we're including things, biomarkers beyond S-antigen.
Mike Sofia -- Chief Scientific Officer
Yes. And on the 161 question. Yes, it is possible that we would present at a scientific meeting in the not-too-distant future, some of the preclinical data on 161 to demonstrate superiority to 452. So that is a possibility.
There are a couple of opportunities clearly later this year that could provide that disclosure.
Luke Herrmann -- Robert W. Baird and Company -- Analyst
That's it. Thanks. All right. Thank you.
Operator
And next, we have Roy Buchanan of JMP Securities. Your line is now open.
Roy Buchanan -- JMP Securities -- Analyst
I just wonder if you could give us any color on the potential -- on the presentation at EASL, I think you said seven abstracts quite a bit. I assume there's going to be 729 data there. Is it possible to see the cohort K data there? Anything for 161? Thanks.
Bill Collier -- President and Chief Executive Officer
Yes. Good question. I'm going to throw that one to Gaston. I think what we said in the press release is that we've had seven submissions approved for presentation.
But I think Gaston, you can get some additional color based on what EASL have produced.
Gaston Picchio -- Chief Development Officer
Yes. Sure. So Roy, I mean, if you go to -- obviously, we need to be very careful about we don't reach the embargo on disclosing what is it that we're going to be presenting, etc., etc. So I'm sure you appreciate that from our end.
So -- but if you or anyone goes to the EASL website today, you can see that there is an orange link and it will list all of the abstracts that were approved in the first round of acceptances that EASL did back in December. So -- and there, you will see that out of the seven that we announced, five are included in that list. And those range from an abstract on our PD-L1 checkpoint inhibitor. And there are some -- there's one on AB-836, our capsid inhibitor.
And then there's three on aspects of 729, immunology of 729 and cytokines, etc. And there is one on preclinical activity or durability of response of siRNAs. So you can read the titles and if anyone can read the titles and see what the titles are all about. So that's how much I can say.
I cannot really say what we're going to be disclosing or including in the recently accepted two other presentations, which actually deal with 729.
Roy Buchanan -- JMP Securities -- Analyst
OK. Very good. That's helpful. Thank you.
Operator
Our next question comes from the line of Keay Nakae of Chardan. Your line is now open.
Keay Nakae -- Chardan Capital Markets -- Analyst
Yes. Gaston, can you update us on the status of enrollment Part 3 for 836?
Gaston Picchio -- Chief Development Officer
We haven't disclosed the status of enrollment of our Part 3 studies. But I mean, as you will see, we are looking forward to presenting 836 data and as we indicated, including at least three cohorts.
Keay Nakae -- Chardan Capital Markets -- Analyst
OK. So the next data presentation for 836, it will be for three different patient cohorts in Part 3?
Gaston Picchio -- Chief Development Officer
Part 3, yes. Thanks. I mean -- sorry, Part 3, it will include everything because we made a disclosure back in December on Parts 1 and 2, but everything will be included.
Keay Nakae -- Chardan Capital Markets -- Analyst
Right. Three different dose levels from Part 3 in the next data release?
Gaston Picchio -- Chief Development Officer
Yes. This is what was included in the -- basically, this is what was included in the design that we presented back in December. So Part 1, Part 2, and Part 3 will be included in the presentation.
Operator
There are no further questions coming in at this time. I'm now turning the call back to Bill Collier, CEO of Arbutus. Thank you.
Bill Collier -- President and Chief Executive Officer
Thank you. And thank you for your questions, everybody. Thanks for joining us this morning. We obviously appreciate your continued interest, and we especially look forward to providing further updates as we advance our clinical and preclinical programs and report additional data from our 729 and 836 clinical trials at upcoming medical conferences.
And with that said, thank you very much. And operator, thank you for your assistance. That concludes our call.
Operator
[Operator signoff]
Duration: 40 minutes
Call participants:
Lisa Caperelli -- Vice President, Investor Relations
Bill Collier -- President and Chief Executive Officer
Mike Sofia -- Chief Scientific Officer
Dave Hastings -- Chief Financial Officer
Roy Buchanan -- JMP Securities -- Analyst
Gaston Picchio -- Chief Development Officer
Dennis Ding -- Jefferies -- Analyst
Thomas Yip -- H.C. Wainwright and Company -- Analyst
Luke Herrmann -- Robert W. Baird and Company -- Analyst
Keay Nakae -- Chardan Capital Markets -- Analyst
More ABUS analysis
All earnings call transcripts
This article is a transcript of this conference call produced for The Motley Fool. While we strive for our Foolish Best, there may be errors, omissions, or inaccuracies in this transcript. As with all our articles, The Motley Fool does not assume any responsibility for your use of this content, and we strongly encourage you to do your own research, including listening to the call yourself and reading the company's SEC filings. Please see our Terms and Conditions for additional details, including our Obligatory Capitalized Disclaimers of Liability.
The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Arbutus Biopharma (NASDAQ: ABUS) Q1 2022 Earnings Call May 05, 2022, 8:45 a.m. Operator [Operator signoff] Duration: 40 minutes Call participants: Lisa Caperelli -- Vice President, Investor Relations Bill Collier -- President and Chief Executive Officer Mike Sofia -- Chief Scientific Officer Dave Hastings -- Chief Financial Officer Roy Buchanan -- JMP Securities -- Analyst Gaston Picchio -- Chief Development Officer Dennis Ding -- Jefferies -- Analyst Thomas Yip -- H.C. Wainwright and Company -- Analyst Luke Herrmann -- Robert W. Baird and Company -- Analyst Keay Nakae -- Chardan Capital Markets -- Analyst More ABUS analysis All earnings call transcripts This article is a transcript of this conference call produced for The Motley Fool. To examine whether this liver-centric approach could avoid the peripheral neuropathy issues observed in our earlier compound AB-452, multiple ADME, toxicology and PK studies were conducted. | Operator [Operator signoff] Duration: 40 minutes Call participants: Lisa Caperelli -- Vice President, Investor Relations Bill Collier -- President and Chief Executive Officer Mike Sofia -- Chief Scientific Officer Dave Hastings -- Chief Financial Officer Roy Buchanan -- JMP Securities -- Analyst Gaston Picchio -- Chief Development Officer Dennis Ding -- Jefferies -- Analyst Thomas Yip -- H.C. Wainwright and Company -- Analyst Luke Herrmann -- Robert W. Baird and Company -- Analyst Keay Nakae -- Chardan Capital Markets -- Analyst More ABUS analysis All earnings call transcripts This article is a transcript of this conference call produced for The Motley Fool. Arbutus Biopharma (NASDAQ: ABUS) Q1 2022 Earnings Call May 05, 2022, 8:45 a.m. Joining me today from the Arbutus executive team are Bill Collier, president and chief executive officer; David Hastings, chief financial officer; Dr. Gaston Picchio, chief development officer; and Dr. Mike Sofia, chief scientific officer. | Operator [Operator signoff] Duration: 40 minutes Call participants: Lisa Caperelli -- Vice President, Investor Relations Bill Collier -- President and Chief Executive Officer Mike Sofia -- Chief Scientific Officer Dave Hastings -- Chief Financial Officer Roy Buchanan -- JMP Securities -- Analyst Gaston Picchio -- Chief Development Officer Dennis Ding -- Jefferies -- Analyst Thomas Yip -- H.C. Wainwright and Company -- Analyst Luke Herrmann -- Robert W. Baird and Company -- Analyst Keay Nakae -- Chardan Capital Markets -- Analyst More ABUS analysis All earnings call transcripts This article is a transcript of this conference call produced for The Motley Fool. Arbutus Biopharma (NASDAQ: ABUS) Q1 2022 Earnings Call May 05, 2022, 8:45 a.m. Joining me today from the Arbutus executive team are Bill Collier, president and chief executive officer; David Hastings, chief financial officer; Dr. Gaston Picchio, chief development officer; and Dr. Mike Sofia, chief scientific officer. | Operator [Operator signoff] Duration: 40 minutes Call participants: Lisa Caperelli -- Vice President, Investor Relations Bill Collier -- President and Chief Executive Officer Mike Sofia -- Chief Scientific Officer Dave Hastings -- Chief Financial Officer Roy Buchanan -- JMP Securities -- Analyst Gaston Picchio -- Chief Development Officer Dennis Ding -- Jefferies -- Analyst Thomas Yip -- H.C. Wainwright and Company -- Analyst Luke Herrmann -- Robert W. Baird and Company -- Analyst Keay Nakae -- Chardan Capital Markets -- Analyst More ABUS analysis All earnings call transcripts This article is a transcript of this conference call produced for The Motley Fool. Arbutus Biopharma (NASDAQ: ABUS) Q1 2022 Earnings Call May 05, 2022, 8:45 a.m. And as far as other coronaviruses are concerned, were our targets, so certainly, our main target is SARS-CoV-2 with the pan-coronavirus, but obviously, looking into the future, how one could potentially apply these agents to other coronavirus infections that are not SARS-CoV-2 sort of certainly a possibility, but we're focused on SARS-CoV-2 at this current time. |
34609.0 | 2022-05-05 00:00:00 UTC | Arbutus Biopharma (ABUS) Reports Q1 Loss, Tops Revenue Estimates | ABUS | https://www.nasdaq.com/articles/arbutus-biopharma-abus-reports-q1-loss-tops-revenue-estimates | nan | nan | Arbutus Biopharma (ABUS) came out with a quarterly loss of $0.11 per share versus the Zacks Consensus Estimate of a loss of $0.13. This compares to loss of $0.21 per share a year ago. These figures are adjusted for non-recurring items.
This quarterly report represents an earnings surprise of 15.38%. A quarter ago, it was expected that this biopharmaceutical company would post a loss of $0.16 per share when it actually produced a loss of $0.15, delivering a surprise of 6.25%.
Over the last four quarters, the company has surpassed consensus EPS estimates two times.
Arbutus, which belongs to the Zacks Medical - Biomedical and Genetics industry, posted revenues of $12.58 million for the quarter ended March 2022, surpassing the Zacks Consensus Estimate by 118.16%. This compares to year-ago revenues of $2.11 million. The company has topped consensus revenue estimates three times over the last four quarters.
The sustainability of the stock's immediate price movement based on the recently-released numbers and future earnings expectations will mostly depend on management's commentary on the earnings call.
Arbutus shares have lost about 36% since the beginning of the year versus the S&P 500's decline of -9.8%.
What's Next for Arbutus?
While Arbutus has underperformed the market so far this year, the question that comes to investors' minds is: what's next for the stock?
There are no easy answers to this key question, but one reliable measure that can help investors address this is the company's earnings outlook. Not only does this include current consensus earnings expectations for the coming quarter(s), but also how these expectations have changed lately.
Empirical research shows a strong correlation between near-term stock movements and trends in earnings estimate revisions. Investors can track such revisions by themselves or rely on a tried-and-tested rating tool like the Zacks Rank, which has an impressive track record of harnessing the power of earnings estimate revisions.
Ahead of this earnings release, the estimate revisions trend for Arbutus: favorable. While the magnitude and direction of estimate revisions could change following the company's just-released earnings report, the current status translates into a Zacks Rank #2 (Buy) for the stock. So, the shares are expected to outperform the market in the near future. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here.
It will be interesting to see how estimates for the coming quarters and current fiscal year change in the days ahead. The current consensus EPS estimate is -$0.14 on $5.84 million in revenues for the coming quarter and -$0.56 on $25.55 million in revenues for the current fiscal year.
Investors should be mindful of the fact that the outlook for the industry can have a material impact on the performance of the stock as well. In terms of the Zacks Industry Rank, Medical - Biomedical and Genetics is currently in the bottom 41% of the 250 plus Zacks industries. Our research shows that the top 50% of the Zacks-ranked industries outperform the bottom 50% by a factor of more than 2 to 1.
Another stock from the same industry, Pulmatrix, Inc. (PULM), has yet to report results for the quarter ended March 2022.
This company is expected to post quarterly loss of $1.41 per share in its upcoming report, which represents a year-over-year change of +21.7%. The consensus EPS estimate for the quarter has remained unchanged over the last 30 days.
Pulmatrix, Inc.'s revenues are expected to be $1.07 million, down 23% from the year-ago quarter.
Zacks Names "Single Best Pick to Double"
From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all.
It’s a little-known chemical company that’s up 65% over last year, yet still dirt cheap. With unrelenting demand, soaring 2022 earnings estimates, and $1.5 billion for repurchasing shares, retail investors could jump in at any time.
This company could rival or surpass other recent Zacks’ Stocks Set to Double like Boston Beer Company which shot up +143.0% in little more than 9 months and NVIDIA which boomed +175.9% in one year.
Free: See Our Top Stock and 4 Runners Up >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Arbutus Biopharma Corporation (ABUS): Free Stock Analysis Report
Pulmatrix, Inc. (PULM): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Arbutus Biopharma (ABUS) came out with a quarterly loss of $0.11 per share versus the Zacks Consensus Estimate of a loss of $0.13. Arbutus Biopharma Corporation (ABUS): Free Stock Analysis Report Empirical research shows a strong correlation between near-term stock movements and trends in earnings estimate revisions. | Arbutus Biopharma Corporation (ABUS): Free Stock Analysis Report Arbutus Biopharma (ABUS) came out with a quarterly loss of $0.11 per share versus the Zacks Consensus Estimate of a loss of $0.13. Arbutus, which belongs to the Zacks Medical - Biomedical and Genetics industry, posted revenues of $12.58 million for the quarter ended March 2022, surpassing the Zacks Consensus Estimate by 118.16%. | Arbutus Biopharma (ABUS) came out with a quarterly loss of $0.11 per share versus the Zacks Consensus Estimate of a loss of $0.13. Arbutus Biopharma Corporation (ABUS): Free Stock Analysis Report Arbutus, which belongs to the Zacks Medical - Biomedical and Genetics industry, posted revenues of $12.58 million for the quarter ended March 2022, surpassing the Zacks Consensus Estimate by 118.16%. | Arbutus Biopharma (ABUS) came out with a quarterly loss of $0.11 per share versus the Zacks Consensus Estimate of a loss of $0.13. Arbutus Biopharma Corporation (ABUS): Free Stock Analysis Report The company has topped consensus revenue estimates three times over the last four quarters. |
34610.0 | 2022-05-04 00:00:00 UTC | AnaptysBio, Inc. (ANAB) Reports Q1 Loss, Lags Revenue Estimates | ABUS | https://www.nasdaq.com/articles/anaptysbio-inc.-anab-reports-q1-loss-lags-revenue-estimates | nan | nan | AnaptysBio, Inc. (ANAB) came out with a quarterly loss of $1.31 per share versus the Zacks Consensus Estimate of a loss of $0.87. This compares to loss of $0.66 per share a year ago. These figures are adjusted for non-recurring items.
This quarterly report represents an earnings surprise of -50.57%. A quarter ago, it was expected that this company would post earnings of $2.28 per share when it actually produced a loss of $1.13, delivering a surprise of -149.56%.
Over the last four quarters, the company has surpassed consensus EPS estimates two times.
AnaptysBio, Inc., which belongs to the Zacks Medical - Biomedical and Genetics industry, posted revenues of $0.97 million for the quarter ended March 2022, missing the Zacks Consensus Estimate by 87.99%. This compares to year-ago revenues of $11.25 million. The company has topped consensus revenue estimates two times over the last four quarters.
The sustainability of the stock's immediate price movement based on the recently-released numbers and future earnings expectations will mostly depend on management's commentary on the earnings call.
AnaptysBio, Inc. Shares have lost about 29.6% since the beginning of the year versus the S&P 500's decline of -12.4%.
What's Next for AnaptysBio, Inc.
While AnaptysBio, Inc. Has underperformed the market so far this year, the question that comes to investors' minds is: what's next for the stock?
There are no easy answers to this key question, but one reliable measure that can help investors address this is the company's earnings outlook. Not only does this include current consensus earnings expectations for the coming quarter(s), but also how these expectations have changed lately.
Empirical research shows a strong correlation between near-term stock movements and trends in earnings estimate revisions. Investors can track such revisions by themselves or rely on a tried-and-tested rating tool like the Zacks Rank, which has an impressive track record of harnessing the power of earnings estimate revisions.
Ahead of this earnings release, the estimate revisions trend for AnaptysBio, Inc. Mixed. While the magnitude and direction of estimate revisions could change following the company's just-released earnings report, the current status translates into a Zacks Rank #3 (Hold) for the stock. So, the shares are expected to perform in line with the market in the near future. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here.
It will be interesting to see how estimates for the coming quarters and current fiscal year change in the days ahead. The current consensus EPS estimate is -$0.70 on $13.28 million in revenues for the coming quarter and -$3.26 on $34.62 million in revenues for the current fiscal year.
Investors should be mindful of the fact that the outlook for the industry can have a material impact on the performance of the stock as well. In terms of the Zacks Industry Rank, Medical - Biomedical and Genetics is currently in the bottom 40% of the 250 plus Zacks industries. Our research shows that the top 50% of the Zacks-ranked industries outperform the bottom 50% by a factor of more than 2 to 1.
Another stock from the same industry, Arbutus Biopharma (ABUS), has yet to report results for the quarter ended March 2022. The results are expected to be released on May 5.
This biopharmaceutical company is expected to post quarterly loss of $0.13 per share in its upcoming report, which represents a year-over-year change of +38.1%. The consensus EPS estimate for the quarter has remained unchanged over the last 30 days.
Arbutus Biopharma's revenues are expected to be $5.77 million, up 173.3% from the year-ago quarter.
5 Stocks Set to Double
Each was handpicked by a Zacks expert as the #1 favorite stock to gain +100% or more in 2021. Previous recommendations have soared +143.0%, +175.9%, +498.3% and +673.0%.
Most of the stocks in this report are flying under Wall Street radar, which provides a great opportunity to get in on the ground floor.
Today, See These 5 Potential Home Runs >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
AnaptysBio, Inc. (ANAB): Free Stock Analysis Report
Arbutus Biopharma Corporation (ABUS): Free Stock Analysis Report
To read this article on Zacks.com click here.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Another stock from the same industry, Arbutus Biopharma (ABUS), has yet to report results for the quarter ended March 2022. Arbutus Biopharma Corporation (ABUS): Free Stock Analysis Report Empirical research shows a strong correlation between near-term stock movements and trends in earnings estimate revisions. | Arbutus Biopharma Corporation (ABUS): Free Stock Analysis Report Another stock from the same industry, Arbutus Biopharma (ABUS), has yet to report results for the quarter ended March 2022. AnaptysBio, Inc., which belongs to the Zacks Medical - Biomedical and Genetics industry, posted revenues of $0.97 million for the quarter ended March 2022, missing the Zacks Consensus Estimate by 87.99%. | Another stock from the same industry, Arbutus Biopharma (ABUS), has yet to report results for the quarter ended March 2022. Arbutus Biopharma Corporation (ABUS): Free Stock Analysis Report AnaptysBio, Inc. (ANAB) came out with a quarterly loss of $1.31 per share versus the Zacks Consensus Estimate of a loss of $0.87. | Another stock from the same industry, Arbutus Biopharma (ABUS), has yet to report results for the quarter ended March 2022. Arbutus Biopharma Corporation (ABUS): Free Stock Analysis Report Not only does this include current consensus earnings expectations for the coming quarter(s), but also how these expectations have changed lately. |
34611.0 | 2022-03-18 00:00:00 UTC | Canadian Pfizer partner sues to head off patent lawsuit over COVID-19 vaccine | ABUS | https://www.nasdaq.com/articles/canadian-pfizer-partner-sues-to-head-off-patent-lawsuit-over-covid-19-vaccine | nan | nan | By Blake Brittain
March 18 (Reuters) - The biotech company that makes mRNA-delivery technology for Pfizer's PFE.N COVID-19 vaccine sued Arbutus Biopharma Corp ABUS.O in Manhattan federal court on Friday, seeking to head off claims that the vaccine infringes Arbutus' patents.
Canada-based Acuitas Therapeutics Inc said Arbutus and partner Genevant Sciences have threatened to sue for potentially billions of dollars in "unjustified royalties" over the vaccine Pfizer developed with Germany's BioNTech SE BNTX.O.
Acuitas asked the court to find that the Pfizer/BioNTech vaccine does not infringe Arbutus patents and that several Arbutus patents are invalid.
A representative for Arbutus did not immediately respond to a request for comment on Acuitas' claims.
The lawsuit is part of a growing web of patent disputes over COVID-19 vaccine technology. Arbutus sued Moderna MRNA.O over its mRNA technology last month, but has not yet sued Pfizer or Acuitas.
Pfizer and Moderna were hit with patent lawsuits on Thursday by Alnylam Pharmaceuticals Inc ALNY.O, which argued its own lipid nanoparticle mRNA-delivery technology was "essential" to both of the widely used COVID-19 vaccines.
Pfizer said last month that it expected $32 billion in revenue from its vaccine this year. Moderna has said its vaccine earned the company $17.7 billion in revenue in 2021.
(Reporting by Blake Brittain in Washington, D.C.; Editing by David Bario and Bill Berkrot)
((blake.brittain@thomsonreuters.com))
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | By Blake Brittain March 18 (Reuters) - The biotech company that makes mRNA-delivery technology for Pfizer's PFE.N COVID-19 vaccine sued Arbutus Biopharma Corp ABUS.O in Manhattan federal court on Friday, seeking to head off claims that the vaccine infringes Arbutus' patents. Canada-based Acuitas Therapeutics Inc said Arbutus and partner Genevant Sciences have threatened to sue for potentially billions of dollars in "unjustified royalties" over the vaccine Pfizer developed with Germany's BioNTech SE BNTX.O. Pfizer and Moderna were hit with patent lawsuits on Thursday by Alnylam Pharmaceuticals Inc ALNY.O, which argued its own lipid nanoparticle mRNA-delivery technology was "essential" to both of the widely used COVID-19 vaccines. | By Blake Brittain March 18 (Reuters) - The biotech company that makes mRNA-delivery technology for Pfizer's PFE.N COVID-19 vaccine sued Arbutus Biopharma Corp ABUS.O in Manhattan federal court on Friday, seeking to head off claims that the vaccine infringes Arbutus' patents. Acuitas asked the court to find that the Pfizer/BioNTech vaccine does not infringe Arbutus patents and that several Arbutus patents are invalid. Arbutus sued Moderna MRNA.O over its mRNA technology last month, but has not yet sued Pfizer or Acuitas. | By Blake Brittain March 18 (Reuters) - The biotech company that makes mRNA-delivery technology for Pfizer's PFE.N COVID-19 vaccine sued Arbutus Biopharma Corp ABUS.O in Manhattan federal court on Friday, seeking to head off claims that the vaccine infringes Arbutus' patents. Canada-based Acuitas Therapeutics Inc said Arbutus and partner Genevant Sciences have threatened to sue for potentially billions of dollars in "unjustified royalties" over the vaccine Pfizer developed with Germany's BioNTech SE BNTX.O. Acuitas asked the court to find that the Pfizer/BioNTech vaccine does not infringe Arbutus patents and that several Arbutus patents are invalid. | By Blake Brittain March 18 (Reuters) - The biotech company that makes mRNA-delivery technology for Pfizer's PFE.N COVID-19 vaccine sued Arbutus Biopharma Corp ABUS.O in Manhattan federal court on Friday, seeking to head off claims that the vaccine infringes Arbutus' patents. Canada-based Acuitas Therapeutics Inc said Arbutus and partner Genevant Sciences have threatened to sue for potentially billions of dollars in "unjustified royalties" over the vaccine Pfizer developed with Germany's BioNTech SE BNTX.O. Pfizer said last month that it expected $32 billion in revenue from its vaccine this year. |
34612.0 | 2022-03-17 00:00:00 UTC | Alnylam files patent infringement lawsuits against Pfizer, Moderna | ABUS | https://www.nasdaq.com/articles/alnylam-files-patent-infringement-lawsuits-against-pfizer-moderna-0 | nan | nan | Adds details from Alnylam statement, background
March 17 (Reuters) - Alnylam Pharmaceuticals Inc ALNY.O said on Thursday it has filed separate lawsuits in the Delaware federal court against Pfizer Inc PFE.N and Moderna Inc MRNA.O, seeking damages for infringement of a patent in the manufacture and sale of their mRNA COVID-19 vaccines.
Alnylam said it was seeking compensation for use of its lipid nanoparticles (LNP) technology that carries and delivers RNA-based therapeutics or vaccines in the body.
Pfizer and Moderna's vaccines infringe Alnylam's patent through the use of a lipid formulated into LNPs that protect and deliver the vaccines' mRNA, the pharmaceutical firm said.
Arbutus Biopharma Corp ABUS.O sued Moderna in the Delaware federal court last month, claiming Moderna's COVID-19 vaccine infringes its patents.
Alnylam said it does not intend to take action that impedes the production, sale or distribution of the vaccines.
(Reporting by Manojna Maddipatla in Bengaluru; Editing by Krishna Chandra Eluri)
((manojna.kalyani@thomsonreuters.com; +91 8061822700;))
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Arbutus Biopharma Corp ABUS.O sued Moderna in the Delaware federal court last month, claiming Moderna's COVID-19 vaccine infringes its patents. Adds details from Alnylam statement, background March 17 (Reuters) - Alnylam Pharmaceuticals Inc ALNY.O said on Thursday it has filed separate lawsuits in the Delaware federal court against Pfizer Inc PFE.N and Moderna Inc MRNA.O, seeking damages for infringement of a patent in the manufacture and sale of their mRNA COVID-19 vaccines. Alnylam said it was seeking compensation for use of its lipid nanoparticles (LNP) technology that carries and delivers RNA-based therapeutics or vaccines in the body. | Arbutus Biopharma Corp ABUS.O sued Moderna in the Delaware federal court last month, claiming Moderna's COVID-19 vaccine infringes its patents. Adds details from Alnylam statement, background March 17 (Reuters) - Alnylam Pharmaceuticals Inc ALNY.O said on Thursday it has filed separate lawsuits in the Delaware federal court against Pfizer Inc PFE.N and Moderna Inc MRNA.O, seeking damages for infringement of a patent in the manufacture and sale of their mRNA COVID-19 vaccines. Pfizer and Moderna's vaccines infringe Alnylam's patent through the use of a lipid formulated into LNPs that protect and deliver the vaccines' mRNA, the pharmaceutical firm said. | Arbutus Biopharma Corp ABUS.O sued Moderna in the Delaware federal court last month, claiming Moderna's COVID-19 vaccine infringes its patents. Adds details from Alnylam statement, background March 17 (Reuters) - Alnylam Pharmaceuticals Inc ALNY.O said on Thursday it has filed separate lawsuits in the Delaware federal court against Pfizer Inc PFE.N and Moderna Inc MRNA.O, seeking damages for infringement of a patent in the manufacture and sale of their mRNA COVID-19 vaccines. Pfizer and Moderna's vaccines infringe Alnylam's patent through the use of a lipid formulated into LNPs that protect and deliver the vaccines' mRNA, the pharmaceutical firm said. | Arbutus Biopharma Corp ABUS.O sued Moderna in the Delaware federal court last month, claiming Moderna's COVID-19 vaccine infringes its patents. Adds details from Alnylam statement, background March 17 (Reuters) - Alnylam Pharmaceuticals Inc ALNY.O said on Thursday it has filed separate lawsuits in the Delaware federal court against Pfizer Inc PFE.N and Moderna Inc MRNA.O, seeking damages for infringement of a patent in the manufacture and sale of their mRNA COVID-19 vaccines. Pfizer and Moderna's vaccines infringe Alnylam's patent through the use of a lipid formulated into LNPs that protect and deliver the vaccines' mRNA, the pharmaceutical firm said. |
34613.0 | 2022-03-09 00:00:00 UTC | This 1 New Threat Could Punish Moderna Stock | ABUS | https://www.nasdaq.com/articles/this-1-new-threat-could-punish-moderna-stock | nan | nan | Despite being hot off $18.5 billion in revenue from sales of its coronavirus vaccine last year, Moderna (NASDAQ: MRNA) might just have trouble brewing. On Feb. 28, Arbutus Biopharma (NASDAQ: ABUS) initiated a lawsuit against Moderna, claiming that the company had infringed on several patents with its Spikevax vaccine. In particular, Arbutus took issue with the lipid nanoparticle (LNP) technology used as a drug delivery system for Moderna's jabs.
Though it's unclear exactly what terms or how much money Arbutus is looking for with the lawsuit, investors can assume that the threat to Moderna is real. And if the company is forced to settle, it could potentially be for quite a mighty sum -- here's why.
Image source: Getty Images.
It's all about the nanoparticles
Lipid nanoparticles are critical for Moderna, and its vaccine likely couldn't work the same way without them. Thus, the company has spent a lot of time fiddling with its lipid nanoparticle technology to optimize its efficiency. The situation is doubtlessly the same for Arbutus, even if its intended purposes for the technology may be different.
And therein lies the problem for Moderna. In 2019, it challenged one of Arbutus's patents for LNPs, but the challenge was rejected as the patent was found to be valid, and the rejection was upheld in an appeals court in mid-2020. Now, the fight has come home.
Let's crunch a few numbers to get a rough estimate for how much losing the lawsuit might impact Moderna's stock.
In prior situations where Arbutus has licensed its LNP technology to its collaborators, it has sought royalties in the low-single-digit range as a percentage of sales. Taking Moderna's Q4 revenue of $7.2 billion as an example, if we assume Arbutus would want 2%, it'd work out to be $144 million. It's true that 2% isn't much, but it's also unlikely that Arbutus would be satisfied with getting the licensing fees from only one quarter's worth of sales of Spikevax.
Since 2020, Moderna has made around $19.3 billion, with another $19 billion expected to be on the way this year. So, 2% of that works out to be more than $386 million, which wouldn't be a problem to pay off, given the company's $10.7 billion in cash.
And while investors probably wouldn't be thrilled about missing out on 2% of future revenue, it probably wouldn't harm the stock much.
The impact could be much higher
There's just one (giant) complication standing in the way of this lawsuit being a negligible issue for shareholders.
While Arbutus's royalties might be small for other biotechs that license its technology directly, in the past, it commanded rates as high as 20% for sublicensors like Genevant, a private biotech that it owns 40% of the equity in. And there's one very inconvenient factor that might mean that it'll attempt to get Moderna to pay that higher rate.
In 2017, Moderna was sublicensing Arbutus's LNP technology via a private company called Acuitas. But Arbutus successfully claimed in a legal fight against Acuitas that the company hadn't been granted permission to sublicense anything for the purpose of vaccine development.
Therefore, it's remotely possible that Moderna will be on the hook for 20% of its vaccine revenues rather than 2%. If it ends up losing the lawsuit and paying the higher rate, it could be liable for upwards of $3.8 billion, based on its cumulative jab sales.
That'd hardly sink Moderna, but it'd definitely leave a dent in its stock price. Furthermore, it'd call a lot of the biotech's successes into question. Investors should be wary of the potentially significant psychological impact of the company losing a case about something that's so foundational to its business.
But don't go selling your shares just yet. Lawsuits can take many years to conclude, and at the moment, there's no way to know which way the case will break. Even if Moderna loses the lawsuit, the company will be able to survive, as it has more than $10.7 billion in cash at the ready.
10 stocks we like better than Moderna Inc.
When our award-winning analyst team has a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor, has tripled the market.*
They just revealed what they believe are the ten best stocks for investors to buy right now... and Moderna Inc. wasn't one of them! That's right -- they think these 10 stocks are even better buys.
See the 10 stocks
*Stock Advisor returns as of January 20, 2022
Alex Carchidi has no position in any of the stocks mentioned. The Motley Fool recommends Moderna Inc. The Motley Fool has a disclosure policy.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | On Feb. 28, Arbutus Biopharma (NASDAQ: ABUS) initiated a lawsuit against Moderna, claiming that the company had infringed on several patents with its Spikevax vaccine. But Arbutus successfully claimed in a legal fight against Acuitas that the company hadn't been granted permission to sublicense anything for the purpose of vaccine development. If it ends up losing the lawsuit and paying the higher rate, it could be liable for upwards of $3.8 billion, based on its cumulative jab sales. | On Feb. 28, Arbutus Biopharma (NASDAQ: ABUS) initiated a lawsuit against Moderna, claiming that the company had infringed on several patents with its Spikevax vaccine. In particular, Arbutus took issue with the lipid nanoparticle (LNP) technology used as a drug delivery system for Moderna's jabs. In 2017, Moderna was sublicensing Arbutus's LNP technology via a private company called Acuitas. | On Feb. 28, Arbutus Biopharma (NASDAQ: ABUS) initiated a lawsuit against Moderna, claiming that the company had infringed on several patents with its Spikevax vaccine. In 2017, Moderna was sublicensing Arbutus's LNP technology via a private company called Acuitas. * They just revealed what they believe are the ten best stocks for investors to buy right now... and Moderna Inc. wasn't one of them! | On Feb. 28, Arbutus Biopharma (NASDAQ: ABUS) initiated a lawsuit against Moderna, claiming that the company had infringed on several patents with its Spikevax vaccine. So, 2% of that works out to be more than $386 million, which wouldn't be a problem to pay off, given the company's $10.7 billion in cash. In 2017, Moderna was sublicensing Arbutus's LNP technology via a private company called Acuitas. |
34614.0 | 2022-03-03 00:00:00 UTC | Arbutus Biopharma (ABUS) Q4 2021 Earnings Call Transcript | ABUS | https://www.nasdaq.com/articles/arbutus-biopharma-abus-q4-2021-earnings-call-transcript | nan | nan | Image source: The Motley Fool.
Arbutus Biopharma (NASDAQ: ABUS)
Q4 2021 Earnings Call
Mar 03, 2022, 8:45 a.m. ET
Contents:
Prepared Remarks
Questions and Answers
Call Participants
Prepared Remarks:
Operator
Good day, and thank you for standing by. Welcome to the Arbutus Biopharma Corporation fourth quarter and year-end 2021 financial results and corporate update conference call. [Operator instructions] I would now like to hand the conference to your speaker today, Lisa Caperelli, vice president of investor relations. Please go ahead.
Lisa Caperelli -- Vice President, Investor Relations
Thank you, Katherine. Good morning, everyone, and thank you for joining Arbutus' fourth quarter and year-end financial and business update call. Joining me today from the Arbutus executive team are Bill Collier, president and chief executive officer; David Hastings, chief financial officer; Dr. Gaston Picchio, chief development officer; and Dr.
Mike Sofia, chief scientific officer. Bill will begin with a review of recent accomplishments and clinical developments, followed by Dave Hastings who will provide a review of the company's fourth quarter and year-end financial results. After opening remarks, we will open the call up for Q&A. Gaston Picchio and Mike Sofia will be available to address clinical and scientific-related questions.
10 stocks we like better than Arbutus Biopharma
When our award-winning analyst team has a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor, has tripled the market.*
They just revealed what they believe are the ten best stocks for investors to buy right now... and Arbutus Biopharma wasn't one of them! That's right -- they think these 10 stocks are even better buys.
See the 10 stocks
*Stock Advisor returns as of January 20, 2022
Before we begin, we'd like to remind you that some of the statements made during the call today are forward-looking statements, which are subject to a number of risks and uncertainties that may cause our actual results to differ materially, including those described in our annual report on 10-K being filed later today. With that, I'll turn the call over to Bill. Bill?
Bill Collier -- President and Chief Executive Officer
Thank you, Lisa. Good morning, everyone. Thank you for joining us. We appreciate your interest and your support of Arbutus Biopharma.
This morning, we issued our fourth quarter and year-end financial and business update press release, which provides updates on our clinical and preclinical programs directed at finding a functional cure for patients with hepatitis B and the treatment for coronavirus infections, including SARS-CoV-2. If I had to sum up the past year in one word, it would be transformative, and I'll explain why. In 2021, the Arbutus team did a fantastic job of advancing our proprietary early research compounds into IND-enabling studies. Specifically, our oral RNA destabilizer that we now refer to as AB-161 and also our oral PD-L1 inhibitor, which we're calling AB-101.
The potential addition of the PD-L1 inhibitor, AB-101 in a proprietary combination with our RNAi therapeutics 729 and our capsid inhibitor 836, would allow us to explore our three-pronged strategy to provide a functional cure for chronic HBV infection. As you know, this three-pronged approach consists of suppressing surface antigen, reducing HBV DNA and boosting the immune system. Now the potential role for the RNA destabilizer 161 in our approach is the opportunity to provide a proprietary oral treatment regimen for HBV. We're excited about this progress and look forward to completing the IND-enabling studies for both of these compounds in the second half of this year.
Now, in addition, we secured both strategic and clinical partnerships that in line with our strategic initiatives, allowed us, first of all, to initiate multiple combination clinical trials to evaluate 729 as a cornerstone therapy with other compounds in patients with HBV. Secondly, we expanded the geographic reach of 729 to China to address the largest HBV patient population. And thirdly, we've been able to broaden our pipeline to include development programs against coronavirus infections. And I'd like to elaborate on the strategic accomplishments, starting with our combination trials with our lead HBV compound 729.
With the compelling safety and efficacy data from our Phase 1a/1b clinical trial, in 2021, we moved 729 into three Phase 2a clinical trials to evaluate 729 as a cornerstone therapy in combination with one or more approved investigational compounds. As enrollment continues or is near completion in these trials, data is expected in the second half of this year from our clinical trial evaluating 729, a nucleotide analog and interferon as well as data from our partnered trial evaluating 729 with Assembly's core inhibitor. Now with respect to our partnered program with Antios' liver-targeted NUC, as we mentioned in our press release today, enrollment is complete in this cohort. However, the majority of patients were enrolled in Ukraine, which obviously is currently in a state of war and these patients may be lost a follow-up before completing the study.
Therefore, Arbutus and Antios may report limited data on a reduced number of patients from this clinical trial. Also, as a reminder, we do have a fourth Phase 2a combination trial that we expect to initiate in the first half of this year to evaluate 729 combined with VTP-300, that's the Vaccitech therapeutic vaccine and a NUC. Our goal is to utilize the learnings from all of these trials to provide insights with the potential to de-risk the use of our proprietary compounds in combination with 729 to develop a functional cure for HBV as well as to support our go-forward clinical and regulatory strategy for Phase 2b development. Now let's move on to expanding the geographic reach of AB-729.
At the end of last year, we executed an important strategic partnership with Qilu Pharmaceutical, one of the leading pharmaceutical companies in China. For us to reach the largest HBV patient population in need of a functional cure for chronic HBV infection, it was essential to find a strategic partner with significant experience in developing, manufacturing, and commercializing products in Mainland China, Hong Kong, Macau, and Taiwan. As part of our discussions, Qilu conducted extensive diligence before completion of the agreement. Based on their belief and the potential of 729 to be a safe and effective treatment option for HBV, Qilu paid us $40 million upfront and made a $15 million equity investment in Arbutus along with potential additional payments of up to $245 million, consisting of certain development, regulatory and sales milestones.
Finally, as part of this transaction, we're also entitled to receive double-digit tiered royalties up to the low 20s percent on annual net sales of 729 in their territories. This is one of the largest early clinical deals conducted with a Chinese company. As important, this partnership also allows us and Qilu to maximize the potential clinical value that 729 can bring to the millions of underserved patients in China. As we collaborate with Qilu on a clinical development strategy for 729 in China, we plan to provide updates on our progress.
Now finding a functional cure for patients with HBV remains a key initiative for Arbutus but we also recognize the urgent need to identify new antiviral small molecules to treat COVID-19 and future coronavirus outbreaks. We've expanded our pipeline to include preclinical programs targeting coronaviruses. We're focusing our research efforts on two essential targets critical for replication across all coronaviruses, those being the nsp5 protease and the nsp12 polymerase. In December, through our partnership with X-Chem and Proteros biostructures, we identified unique and differentiated pan-coronavirus assets that inhibit the SARS CoV-2 nsp5 main protease or Mpro, which is a validated target for the treatment of COVID-19 and potential future coronavirus outbreaks.
We recognize the importance of rapidly developing oral small molecules in addition to vaccines to address this pandemic as it transitions to an endemic phase. To that end, we intend to advance an Mpro clinical candidate into IND-enabling studies this year. We are also continuing to lead optimization activities for an nsp12 viral pylorimrase candidate. Now aside from our progress in our research efforts and partnerships to achieve our strategic initiatives.
In 2021, we continued to build convincing safety and efficacy data with AB-729 and AB-836. Both of these compounds are undergoing rigorous evaluation at various dose levels and dosing intervals in cohorts of patients with various baseline characteristics. This comprehensive body of evidence that we're building gives us the confidence that the dose and dosing interval we intend to advance into later-stage clinical trials will be best suited to be safe and effective. This year, we anticipate reporting key data for AB-729 that will include new on-treatment data on multiple cohorts of patients included in the Phase 1a/1b clinical trial as well as long-term follow-up data for patients who completed treatment and have discontinued AB-729 and NUC therapy.
We also expect to report additional AB-836 data from Part 3 of the Phase 1a/1b clinical trial that will inform potential future clinical trial development. I'm proud of the enormous progress the Arbutus team has made this last year to position the company for multiple key clinical milestones and significant growth in 2022. And I look forward to keeping all of our shareholders informed of our progress and planned continued success. Now lastly, as you saw in our press release on Monday, along with Genevant Sciences, we filed a lawsuit in the United States District Court for the District of Delaware against Moderna and an affiliate of Moderna, seeking damages for infringement of certain US patents in the manufacture and sale of mRNA-1273, that's Moderna's vaccine for COVID-19.
The patents relate to nucleic acid lipid particles and lipid verticals as well as compositions and methods for their use. As you may recall, in December 2021, the United States Court of Appeals for the Federal Circuit rejected Moderna's appeal of a prior decision of the US Patent Trial and Appeals Board holding all claims of the asserted 069 patent to be patentable and dismissed Moderna's appeal challenging a similar finding of patentability with respect to certain claims of the asserted 435 pattern. Moderna had initiated interparties review IPR challenges against these patents in 2018 and 2019. Now Arbutus and our licensee Genevant do not seek an injunction or otherwise seek to impede the sale, manufacture, or distribution of mRNA-1273.
However, we do see fair compensation for Moderna's use of our patented technology that was developed with great effort and a great expense, without which Moderna's COVID-19 vaccine would not have been successful. Now I do recognize that this litigation is a great interest to our shareholders and that many of you will have questions. We believe that the lawsuit we have filed is the appropriate way to resolve our claims. I ask that you'd be patient with us as we will not be able to provide any additional commentary on our allegations or our litigation strategy aside from what is in the publicly filed complaint other than to say we intend to pursue all appropriate avenues to defend our intellectual property rights.
With that, I'll now turn the call over to Dave Hastings for a brief financial update.
Dave Hastings -- Chief Financial Officer
Thanks, Bill, and good morning, everybody. As I've mentioned in the past, our key financial metric is cash and financial runway. Our cash, cash equivalents, and investments was approximately $191 million as of December 31st, 2021, as compared to approximately $123 million as of December 31st, 2020. The ending cash, cash equivalents, and investments balance as of December 31st, 2021, does not include the $40 million upfront payment and a $15 million equity investment received in January 2022 from Qilu Pharmaceutical as part of the exclusive licensing agreement and strategic partnership to develop and commercialize AB-729 in China.
Our cash used from operations for the year ended December 31st, 2021, was $67.5 million, which was offset by approximately $135 million and of net proceeds from the issuance of common shares under Arbutus's ATM program. For 2022, we expect our aggregate cash use to range from $90 million to $95 million, and therefore, we expect our current cash runway to be sufficient to fund operations into the second quarter of 2024. I would like to now discuss the relationship with Genevant, especially as it relates to the Moderna patent infringement lawsuit that was filed on Monday. Now back in 2018, along with Roivant Sciences, we launched Genevant as a company that focus on RNA-based therapeutics.
We licensed Genevant rights to our LNP technology for RNA-based applications outside of HBV, and we currently have a 16% equity interest in Genevant. Now under this licensing agreement, if Genevant receives proceeds from an action for infringement by any third parties of our Arbutus' intellectual property license of Genevant. We would be entitled to receive after deduction of litigation costs, either 20% of the proceeds received by Genevant or if less tiered low single-digit royalties on net sales of the infringing product, inclusive of the proceeds from litigation or settlement, which, in that case, would be treated as net sales. So with that, and in closing, we have established a strong financial foundation to advance the company's mission to develop a functional cure for HBV and a treatment for COVID-19 and potential future coronavirus outbreaks.
Bill?
Bill Collier -- President and Chief Executive Officer
Thanks very much, Dave. And operator, why don't we open up the lines now for Q&A.
Questions & Answers:
Operator
Thank you [Operator instructions] Our first question comes from Roy Buchanan with JMP Securities. Your line is open.
Roy Buchanan -- JMP Securities -- Analyst
Hey. Great. Thanks for taking the questions. Appreciate the details on the litigation stuff.
First question on 836. Anything you can say about what to expect from the data later this half. You've shown good reductions in viral DNA at 100 milligrams already. Any early thoughts about how the program might take shape in the second half? And then looking at the slide, just to verify cohorts, I&J have not started, correct?
Bill Collier -- President and Chief Executive Officer
Gaston is on the call this morning. Gaston, do you want to take that question?
Gaston Picchio -- Chief Development Officer
Sure. Hi, Roy. So let me start with the last part of your question. I&J have not started yet.
Right now, we have -- we're conducting the three first cohorts, the 50, the 100, and the 200-milligram cohorts and the data will be reported in the first half of this year. Once we have the data, I think we'll decide on the next steps. We have already some plans in mind, but we need to see the final data before making those final.
Roy Buchanan -- JMP Securities -- Analyst
OK. Great. And then you guys had a case of rash and an ALT elevation earlier. I'm not sure if you can say, but any additional observations of either of those events?
Gaston Picchio -- Chief Development Officer
We cannot comment on that. I think the data will be reported at the time when it's reported in the first half of the year.
Roy Buchanan -- JMP Securities -- Analyst
OK. Great. Just thought I'd try. And then what's gating for starting the Phase 2a with VTP-300? And then you mentioned in the slides starting a Phase 2b, assuming positive results.
Do you think that would be a larger triple combo trial? Or do you think you might be able to work in an additional core inhibitor or some other agent have a quadruple combination?
Bill Collier -- President and Chief Executive Officer
So the VTP-300, it's already approved in some of the countries where we are going to be executing the study. So it's just a question of activation of clinical sites and so forth. So it will -- hopefully, we'll be starting very soon. I think we indicated in the first half, but already has been filed in a number of countries, and we just got some approvals.
Secondly, in terms of the Phase 2b study, yes. So we obviously, from 836 to make those final decisions as to whether 836 will be part of the mix for a larger Phase 2b study. We also want to see some of our preliminary data in combination with interferon as well. And also, we want to see other data that's emerging in the field, for example, checkpoint inhibition.
So there's a number of pieces of data that we are looking forward to see in the course of this year that will help us shape our final Phase 2b strategy. We cannot really define what that will be at this point in time.
Roy Buchanan -- JMP Securities -- Analyst
OK. Great. And one, just check the box for Dave, and then I'll jump back into the queue. The net cash burn, $90 million to $95 million this year.
I just want to double-check. Does that include both components of the Qilu payments in January? Thanks.
Dave Hastings -- Chief Financial Officer
Well, yes. No. So the cash burn is a net cash burn. The only thing that really reduces that is the Onpattro [Inaudible] royalties, Roy.
And in terms of revenue recognition for the Qilu agreement, that $40 million was received in January. So the accounting really starts in Q1. We would expect to defer that revenue recognition over a period of time as we transfer the technology to manufacture AB-729 to Qilu? And that might take a couple of years.
Roy Buchanan -- JMP Securities -- Analyst
OK. Thank you.
Operator
Thank you. Our next question comes from Dennis Ding with Jefferies. Your line is open.
Dennis Ding -- Jefferies -- Analyst
Hi. Good morning and thanks for taking the question. Two for me, if I may. First question is on our hepatitis B.
Can you just talk about what you'd like to see from the various triple combo studies reading out in the second half? And what do you want to see to give you confidence that there will be a higher probability of success for functional care, which I would think is coming 2023, 2024? And then my second question is around your protease inhibitor. I don't really think people are really appreciating that you guys have this asset. So can you just comment on when that will go into the clinic? And can you just talk about your ideal drug profile there? Specifically, how has preclinical studies panned out in terms of potency and your projected human PK? Thank you very much.
Bill Collier -- President and Chief Executive Officer
Gaston, do you want to take the first one, and then we'll have Mike Sofia talk about the protease.
Gaston Picchio -- Chief Development Officer
Yes. Sure. Can you repeat because you're breaking up a little bit when you were asking the HBV part of the question, please repeat the question?
Dennis Ding -- Jefferies -- Analyst
Yeah. Yeah. Sure. Can you just talk about the data that's coming in the second half for your triple combo studies? And what you'd like to see to give you more confidence that there will be a higher probability of success for functional cure?
Gaston Picchio -- Chief Development Officer
Sure. So when it comes to the -- specifically when it comes to, for example, the interferon study, what we would like to see, hopefully, is a deeper S-antigen decline and hopefully some of the participants in the study getting to undetectable levels on treatment. Something that, as we've reported, we have not seen with 729 and NUC pretty much nobody has been with an siRNA and NUC. So the addition of interferon, we believe it's going to contribute to a deeper, maybe faster S-antigen suppression.
Obviously, then that's when it comes to that particular study with additional interferon then. We have another interesting piece of data that's coming out, which is what happens after stopping NUC therapy in patients who have been on 729 plus NUC for 48 weeks, then they stop 729 for an additional 6 months, and now they are eventually stopping the NUC. There, I think we would like to see two things. One is whether the S-antigen either is sustainable, reduced at the lower levels that we are requiring to be able to stop the NUC, which is below 100 IU per ml.
And secondly, we would like to see what happens to HBV DNA, whether HBV DNA comes back, or we see a relapse like pretty much everyone sees after something NUC or is HBV-DNA hold back as a result of the additional maybe 729, which also could lead to a different concept, not necessarily functional cure, which is completely of S-antigen but could lead to a sustained biological response, which is HBV does not come back after stopping all therapies, which potentially could be beneficial for the patients as well.
Mike Sofia -- Chief Scientific Officer
Yep. Hi, Dennis. This is Mike Sofia. So the answer to couple of your comments.
Look, as far as a profile for the molecule, we are certainly clearly aware of the developments in the field. And so our molecule, we're definitely trying to target to have a profile that differentiates it from what else is out there. For example, I could say that we want a molecule that we don't need [Inaudible] boosting like [Inaudible] requires. We believe that's a disadvantage for general patient population.
We clearly want an oral once-a-day dosing regimen to be competitive in the space. And clearly, a molecule with very competitive, if not exceptional potency overall. So I think those are the general characteristics that we're looking for. Now as far as where we are, we have -- we're in sort of lead-optimization here.
We expect -- fully expect to nominate the compound in the second quarter of this year, sort of the latter part of the second quarter of this year, and then obviously rapidly move into IND-enabling studies and move as quickly as possible to get that molecule into the clinic. So that's sort of the general overall profile and plan that we have, realizing that there is a sense of urgency for us and our program, but also for patients and trying to identify ways to accelerate the IND-enabling study aspects of this program.
Dennis Ding -- Jefferies -- Analyst
Thank you. That's helpful.
Operator
Thank you. Our next question comes from Ed Arce with H.C. Wainwright. Your line is open.
Ed Arce -- H.C. Wainwright and Company -- Analyst
Hi, everyone. Thanks for taking my questions. Congrats on a very productive year. First question is on AB-836.
As I'm looking across the many data readouts that you plan to have this coming -- or this year, it would appear this is the only one in the first half. Part 3, I think you mentioned earlier cohorts I&J have not started yet. So just wondering the additional data, could you give us a little more detail on what you expect any more either additional data from previously enrolled cohorts or the initial take from cohorts I&J.
Gaston Picchio -- Chief Development Officer
So I mean, as we said, I mean, the data will be reported in the first half. So really, I can't comment on any additional results from those that we reported back in December of 2021 on the 100-milligram -- on the 100-milligram cohort, which looks very promising, the 3.1 log drop in HBV DNA. I think places 836 as among the most competitive of inhibitors with a point with a very good safety profile. So I think we have to wait until we report the totality of the data for the 50, 100, and 200.
If -- as I mentioned, we have started I&J, but if we have any preliminary data on I&J by the time we are ready to report, we will report that as well. But that depends on recruitment speed. I think given what we've seen so far with [Technical difficulty] I think it's fair to say that we are very confident that 836 is going to emerge as a very strong capsid inhibitor. And again, I mean, just to reiterate what I said before.
We need to see that data and analyze it critically to decide whether 836 should move forward in combination with 729 and other agents. Given what we've seen so far, I think I would lean to say yes. But I think we have to see the totality of the data for making the final decision. But given what we've seen so far, based on the 3.1 log decay in HBV DNA, it looks like a very strong contender and that can contribute significantly to a combination of regimen.
Ed Arce -- H.C. Wainwright and Company -- Analyst
Right. Great. OK. And then turning to 729.
As you mentioned, three readouts. It looks like all in the second half with peginterferon, vebicorvir, and the ASPIN compound all combination trials. Maybe you could give us a little more clarity on sort of the order of these, if it's possible, perhaps which at first, it would appear, perhaps that ASPIN, the ASPIN trial, combo that's completed perhaps that one is first? And then I have a follow-up.
Bill Collier -- President and Chief Executive Officer
Yes. So let me just comment on that, and then I'll hand over to Gaston as well. So as we mentioned this morning, the study with Antios, that's the one study in our lineup where the majority of the patients were recruited in Ukraine. And although that was a study that I think was close to completion, we're just really not sure right now how we can follow up those patients in an efficient or typical manner.
So that's why we have tweaked our guidance today and just indicated that for that study, we may be able to report some limited data on a fewer number of patients. But that's one study where clearly, the Ukraine situation has had an impact. Now our other studies, I should point out, we've got a fairly well-distributed set of sites in different countries and that's why we're maintaining our guidance on the interferon study and the Assembly applicable study. I just wanted to kind of cover that off and then hand over to Gaston.
Gaston Picchio -- Chief Development Officer
So I think as we indicated, the three studies in collaboration, I think will be reported in the second half. When it comes to the 729 data [Technical difficulty] the first half or the second half as everyone knows, I mean, obviously, there is an important lever meeting that has been shifted, but still is within the first half. So that's always a good opportunity to present our data in a scientific forum. And then in the second half, obviously, there is meeting where the data could be presented.
We prefer to share the data with the scientific community to get it scrutinized in a more scientific way. So those are the two options that we have. The 729 data is going to be more distributed along the year than the second.
Ed Arce -- H.C. Wainwright and Company -- Analyst
OK. That's helpful. It was -- your audio was cutting in and out a little bit, but I think I got the gist of what you were saying. A couple more quick follow-ups, if I may.
Just on the data readouts. I wanted to get your take, if possible, and this is either for Michael or Gaston. On the efficacy readouts from these combo trials, obviously, looking at HP S-antigen declines. And looking at certain things like the proportion that is below lower limit of quantification or the HBV DNA or RNA that is not detectable.
Just wondering, as you collect that data and analyze it from these trials later this year, are there, in your mind, any sort of minimum proportion of patients or any sort of specific thresholds that you're looking for, just to be helpful.
Gaston Picchio -- Chief Development Officer
No. No. I'll start. And we don't have a predefined prescale or portion of patients that need a certain-criteria like at least, just say this as an example, because 50% of the patients have undetectable HBV R.
So we will just look at the data in [Technical difficulty] we'll determine what those proposals are, but we don't have any predefine. When it comes to S-antigen, obviously, aspirationally, we will have to see as many patients as possible, losing S-antigen either [Technical difficulty] or after treatment is continued. But we don't have [Technical difficulty] proportion of patients.
Ed Arce -- H.C. Wainwright and Company -- Analyst
OK. Fair enough. And one, just one quick last question. Around the use of the ATM, is this something that the company intends to continue as it did pretty extensively last year?
Bill Collier -- President and Chief Executive Officer
Yeah. I mean, I think we obviously the life science company and have to use all the tools in the toolbox to ensure that the companies appropriately capitalized. And while we don't pay out specific plans, that's certainly one element of our ability to fund the company. So I'll just leave it at that.
Ed Arce -- H.C. Wainwright and Company -- Analyst
Great. Thanks so much for answering my questions.
Gaston Picchio -- Chief Development Officer
Thanks Ed.
Bill Collier -- President and Chief Executive Officer
Thank you, Ed.
Operator
Thank you. Our next question comes from Brian Skorney with Baird. Your line is open.
Brian Skorney -- Robert W. Baird and Company -- Analyst
Hey. Good morning, everyone. Thanks for taking my question. Mike, I was hoping you could give us a little bit of a background on the discovery process of AB-101.
I know developing small molecules to disrupt protein-protein interactions has been tough, but when successful, it's been pretty successful. So can you kind of walk us through how 101 interacts with PD-L1? Is it a PD-1 non-medic? And maybe you could give us details on what the molecular weight is? And have you shown any data on oral bioavailability from the preclinical work so far? Thanks.
Mike Sofia -- Chief Scientific Officer
Yes. Sure. Sure. We did present a little bit of data at HepDART 2021.
So look, the molecules are in the slightly larger molecular weight range, OK? I would say, around 700 or so. However, we had good oral bioavailability for these agents. Now the process that we have gone through, there have been some historical data published on some small molecules that bind to PD-L1 that we sort of jumped off on and sort of introduced some very novel aspects to it ourselves and then began to investigate how these molecules work. And the way these molecules work is not like a typical antibody, which basically binds and blocks.
What they do, is they bind to a specific site on PD-L1. They cause dimerization of PD-L1 is on the surface of the cell. This results in an internalization of the protein and ultimate degradation of that protein. So this happens actually really quite quickly.
And so you then sort of have the significant depletion of PD-L1 on the cell surface. This then translates clearly into a very similar phenotype that you would see in an antibody. In fact, we showed that these PD-L1 small molecules do result in immune reactivation in HBV-specific T cells by looking at interferon -- interferon increases. We see, in fact, an in vivo animal model given an oral once-a-day dose of this agent and this is in an MC38 tumor model that we see reductions in tumor size that are comparable to the use of antibodies.
So that will be using atezolizumab as the comparator. So these molecules do work by different mechanism, but ultimately provide the same biological outcome that one sees we're using in antibody. So the process that we've gone through is clearly to identify molecules that bind to the receptor that have this functional effect of internalization and then obviously doing typical PK assessments to optimize the PK profile that we're interested in and then evaluate from an in vivo model to see if that translates to in vivo efficacy and obviously move forward from there. So I hope that answers your question.
Brian Skorney -- Robert W. Baird and Company -- Analyst
Yes. It did. Thank you very much, Mike.
Operator
Thank you. And we have a follow-up from Roy Buchanan with JMP Securities.
Roy Buchanan -- JMP Securities -- Analyst
Hey. Thanks for taking the follow-up. Just really quick on the 729 Phase 1. You mentioned that patients coming off of 729 and the NUC.
Just wondering if you could give us a sense of the data that we'll see how long they'll be off the NUC maybe. Thanks.
Bill Collier -- President and Chief Executive Officer
Gaston?
Gaston Picchio -- Chief Development Officer
Yeah. It's difficult to say. Let me just point out the following. In that study that we've amended to give that option to investigator and participants.
They obviously stopped 729, and they're being off 729 for six months. And after that point, after being off 729, they have the option to discontinue the NUC. And again, this is not, let's say, mandated by the protocol. It was an option that investigators and the patients have based on certain criteria that we have not disclosed.
The moment that they choose to do that, they're being follow-up, obviously, very carefully to -- for safety reasons and also to monitor whether S-antigen continues and so the client goes back up or HBV-DNA and other biomarkers as HBV RNA and so forth. The duration after that follow-up is going to be very variable because some patients have chosen to stop a while ago, others are doing that as we speak. So it's going to be a wide range of follow-ups. I cannot really pinpoint what the exact follow-up time will be by the time we do the data cut to present that data.
Roy Buchanan -- JMP Securities -- Analyst
OK. Thank you.
Operator
Thank you. And I'm showing no further questions in the queue. I'd like to turn the call back to management for any closing remarks.
Bill Collier -- President and Chief Executive Officer
Thank you very much indeed. And thanks, everyone, for joining us this morning and for your questions. We look forward to keeping you updated as we move forward with many of the clinical milestones we've mentioned today, including the announcement of additional data from our combination trials evaluating 729 as a cornerstone therapy and also our Phase 1a/1b clinical trials with 729 and 836. So with that, thank you all again.
And operator, that concludes our call.
Operator
[Operator signoff]
Duration: 43 minutes
Call participants:
Lisa Caperelli -- Vice President, Investor Relations
Bill Collier -- President and Chief Executive Officer
Dave Hastings -- Chief Financial Officer
Roy Buchanan -- JMP Securities -- Analyst
Gaston Picchio -- Chief Development Officer
Dennis Ding -- Jefferies -- Analyst
Mike Sofia -- Chief Scientific Officer
Ed Arce -- H.C. Wainwright and Company -- Analyst
Brian Skorney -- Robert W. Baird and Company -- Analyst
More ABUS analysis
All earnings call transcripts
This article is a transcript of this conference call produced for The Motley Fool. While we strive for our Foolish Best, there may be errors, omissions, or inaccuracies in this transcript. As with all our articles, The Motley Fool does not assume any responsibility for your use of this content, and we strongly encourage you to do your own research, including listening to the call yourself and reading the company's SEC filings. Please see our Terms and Conditions for additional details, including our Obligatory Capitalized Disclaimers of Liability.
The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Arbutus Biopharma (NASDAQ: ABUS) Q4 2021 Earnings Call Mar 03, 2022, 8:45 a.m. Operator [Operator signoff] Duration: 43 minutes Call participants: Lisa Caperelli -- Vice President, Investor Relations Bill Collier -- President and Chief Executive Officer Dave Hastings -- Chief Financial Officer Roy Buchanan -- JMP Securities -- Analyst Gaston Picchio -- Chief Development Officer Dennis Ding -- Jefferies -- Analyst Mike Sofia -- Chief Scientific Officer Ed Arce -- H.C. Wainwright and Company -- Analyst Brian Skorney -- Robert W. Baird and Company -- Analyst More ABUS analysis All earnings call transcripts This article is a transcript of this conference call produced for The Motley Fool. Now finding a functional cure for patients with HBV remains a key initiative for Arbutus but we also recognize the urgent need to identify new antiviral small molecules to treat COVID-19 and future coronavirus outbreaks. | Operator [Operator signoff] Duration: 43 minutes Call participants: Lisa Caperelli -- Vice President, Investor Relations Bill Collier -- President and Chief Executive Officer Dave Hastings -- Chief Financial Officer Roy Buchanan -- JMP Securities -- Analyst Gaston Picchio -- Chief Development Officer Dennis Ding -- Jefferies -- Analyst Mike Sofia -- Chief Scientific Officer Ed Arce -- H.C. Wainwright and Company -- Analyst Brian Skorney -- Robert W. Baird and Company -- Analyst More ABUS analysis All earnings call transcripts This article is a transcript of this conference call produced for The Motley Fool. Arbutus Biopharma (NASDAQ: ABUS) Q4 2021 Earnings Call Mar 03, 2022, 8:45 a.m. Joining me today from the Arbutus executive team are Bill Collier, president and chief executive officer; David Hastings, chief financial officer; Dr. Gaston Picchio, chief development officer; and Dr. Mike Sofia, chief scientific officer. | Operator [Operator signoff] Duration: 43 minutes Call participants: Lisa Caperelli -- Vice President, Investor Relations Bill Collier -- President and Chief Executive Officer Dave Hastings -- Chief Financial Officer Roy Buchanan -- JMP Securities -- Analyst Gaston Picchio -- Chief Development Officer Dennis Ding -- Jefferies -- Analyst Mike Sofia -- Chief Scientific Officer Ed Arce -- H.C. Wainwright and Company -- Analyst Brian Skorney -- Robert W. Baird and Company -- Analyst More ABUS analysis All earnings call transcripts This article is a transcript of this conference call produced for The Motley Fool. Arbutus Biopharma (NASDAQ: ABUS) Q4 2021 Earnings Call Mar 03, 2022, 8:45 a.m. Joining me today from the Arbutus executive team are Bill Collier, president and chief executive officer; David Hastings, chief financial officer; Dr. Gaston Picchio, chief development officer; and Dr. Mike Sofia, chief scientific officer. | Operator [Operator signoff] Duration: 43 minutes Call participants: Lisa Caperelli -- Vice President, Investor Relations Bill Collier -- President and Chief Executive Officer Dave Hastings -- Chief Financial Officer Roy Buchanan -- JMP Securities -- Analyst Gaston Picchio -- Chief Development Officer Dennis Ding -- Jefferies -- Analyst Mike Sofia -- Chief Scientific Officer Ed Arce -- H.C. Wainwright and Company -- Analyst Brian Skorney -- Robert W. Baird and Company -- Analyst More ABUS analysis All earnings call transcripts This article is a transcript of this conference call produced for The Motley Fool. Arbutus Biopharma (NASDAQ: ABUS) Q4 2021 Earnings Call Mar 03, 2022, 8:45 a.m. This year, we anticipate reporting key data for AB-729 that will include new on-treatment data on multiple cohorts of patients included in the Phase 1a/1b clinical trial as well as long-term follow-up data for patients who completed treatment and have discontinued AB-729 and NUC therapy. |
34615.0 | 2022-03-03 00:00:00 UTC | Arbutus Biopharma (ABUS) Reports Q4 Loss, Misses Revenue Estimates | ABUS | https://www.nasdaq.com/articles/arbutus-biopharma-abus-reports-q4-loss-misses-revenue-estimates | nan | nan | Arbutus Biopharma (ABUS) came out with a quarterly loss of $0.15 per share versus the Zacks Consensus Estimate of a loss of $0.16. This compares to loss of $0.23 per share a year ago. These figures are adjusted for non-recurring items.
This quarterly report represents an earnings surprise of 6.25%. A quarter ago, it was expected that this biopharmaceutical company would post a loss of $0.24 per share when it actually produced a loss of $0.24, delivering no surprise.
Over the last four quarters, the company has surpassed consensus EPS estimates two times.
Arbutus, which belongs to the Zacks Medical - Biomedical and Genetics industry, posted revenues of $3.21 million for the quarter ended December 2021, missing the Zacks Consensus Estimate by 5.29%. This compares to year-ago revenues of $2.39 million. The company has topped consensus revenue estimates two times over the last four quarters.
The sustainability of the stock's immediate price movement based on the recently-released numbers and future earnings expectations will mostly depend on management's commentary on the earnings call.
Arbutus shares have lost about 20.6% since the beginning of the year versus the S&P 500's decline of -8%.
What's Next for Arbutus?
While Arbutus has underperformed the market so far this year, the question that comes to investors' minds is: what's next for the stock?
There are no easy answers to this key question, but one reliable measure that can help investors address this is the company's earnings outlook. Not only does this include current consensus earnings expectations for the coming quarter(s), but also how these expectations have changed lately.
Empirical research shows a strong correlation between near-term stock movements and trends in earnings estimate revisions. Investors can track such revisions by themselves or rely on a tried-and-tested rating tool like the Zacks Rank, which has an impressive track record of harnessing the power of earnings estimate revisions.
Ahead of this earnings release, the estimate revisions trend for Arbutus: favorable. While the magnitude and direction of estimate revisions could change following the company's just-released earnings report, the current status translates into a Zacks Rank #2 (Buy) for the stock. So, the shares are expected to outperform the market in the near future. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here.
It will be interesting to see how estimates for the coming quarters and current fiscal year change in the days ahead. The current consensus EPS estimate is -$0.15 on $3.46 million in revenues for the coming quarter and -$0.61 on $14.08 million in revenues for the current fiscal year.
Investors should be mindful of the fact that the outlook for the industry can have a material impact on the performance of the stock as well. In terms of the Zacks Industry Rank, Medical - Biomedical and Genetics is currently in the bottom 40% of the 250 plus Zacks industries. Our research shows that the top 50% of the Zacks-ranked industries outperform the bottom 50% by a factor of more than 2 to 1.
Another stock from the same industry, HOOKIPA Pharma Inc. (HOOK), has yet to report results for the quarter ended December 2021.
This company is expected to post quarterly loss of $0.54 per share in its upcoming report, which represents a year-over-year change of -17.4%. The consensus EPS estimate for the quarter has been revised 62.9% higher over the last 30 days to the current level.
HOOKIPA Pharma Inc.'s revenues are expected to be $4.31 million, down 16.5% from the year-ago quarter.
7 Best Stocks for the Next 30 Days
Just released: Experts distill 7 elite stocks from the current list of 220 Zacks Rank #1 Strong Buys. They deem these tickers "Most Likely for Early Price Pops."
Since 1988, the full list has beaten the market more than 2X over with an average gain of +25.4% per year. So be sure to give these hand-picked 7 your immediate attention.
See them now >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Arbutus Biopharma Corporation (ABUS): Free Stock Analysis Report
HOOKIPA Pharma Inc. (HOOK): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Arbutus Biopharma (ABUS) came out with a quarterly loss of $0.15 per share versus the Zacks Consensus Estimate of a loss of $0.16. Arbutus Biopharma Corporation (ABUS): Free Stock Analysis Report Empirical research shows a strong correlation between near-term stock movements and trends in earnings estimate revisions. | Arbutus Biopharma (ABUS) came out with a quarterly loss of $0.15 per share versus the Zacks Consensus Estimate of a loss of $0.16. Arbutus Biopharma Corporation (ABUS): Free Stock Analysis Report Arbutus, which belongs to the Zacks Medical - Biomedical and Genetics industry, posted revenues of $3.21 million for the quarter ended December 2021, missing the Zacks Consensus Estimate by 5.29%. | Arbutus Biopharma (ABUS) came out with a quarterly loss of $0.15 per share versus the Zacks Consensus Estimate of a loss of $0.16. Arbutus Biopharma Corporation (ABUS): Free Stock Analysis Report Arbutus, which belongs to the Zacks Medical - Biomedical and Genetics industry, posted revenues of $3.21 million for the quarter ended December 2021, missing the Zacks Consensus Estimate by 5.29%. | Arbutus Biopharma (ABUS) came out with a quarterly loss of $0.15 per share versus the Zacks Consensus Estimate of a loss of $0.16. Arbutus Biopharma Corporation (ABUS): Free Stock Analysis Report While Arbutus has underperformed the market so far this year, the question that comes to investors' minds is: what's next for the stock? |
34616.0 | 2022-03-02 00:00:00 UTC | Axsome (AXSM) Posts Narrower-Than-Expected Q4 Loss | ABUS | https://www.nasdaq.com/articles/axsome-axsm-posts-narrower-than-expected-q4-loss | nan | nan | Axsome Therapeutics, Inc. AXSM incurred a loss of 90 cents per share for fourth-quarter 2021, narrower than the Zacks Consensus Estimate of a loss of 99 cents but wider than the year-ago loss of 78 cents.
Axsome does not have any approved product in its portfolio currently. As a result, the company is yet to generate revenues from the same.
Quarter in Detail
Research and development expenses were $13.8 million for the quarter, down 20.7% from the year-ago period owing to the completion of a few clinical studies.
General and administrative expenses were $18.8 million, up 81.7% year over year. The significant increase was due to higher pre-commercialization activities related to the potential launch of AXS-05 and AXS-07.
As of Dec 31, 2021, Axsome had cash worth $86.5 million compared with $114.6 million on Sep 30, 2021.
Full-Year Results
For 2021, Axsome incurred a loss of $3.47 per share compared with the year-ago loss of $2.77.
2022 Guidance
Management believes that its cash balance as of December-end and term-loan facility will be enough to fund operations into 2024.
Axsome expects an increase in operating expenses on account of pipeline development and commercialization activities.
Pipeline Update
Axsome’s key pipeline candidates including AXS-05, AXS-07, AXS-12 and AXS-14 are currently being developed for multiple central nervous system indications.
AXS-05
AXS-05, one of Axsome’s lead candidates, is being developed for treating major depressive disorder (“MDD”), treatment-resistant depression (“TRD”), smoking cessation and agitation associated with Alzheimer's disease (“AD”).
The company’s new drug application (“NDA”) seeking approval for AXS-05 for MDD is under priority review with the FDA. Last year, the FDA identified deficiencies related to analytical methods in the chemistry, manufacturing, and controls section of the NDA for AXS-05. AXSM has already submitted a response to these deficiencies, which have been duly received by the FDA. Although the FDA has not identified any other inconsistencies in the NDA, it is yet to provide a timeline regarding the decision date on the NDA for AXS-05.
On itsearnings call AXSM said that since the responses filed by it are not major amendments to the NDA, it expects to receive a decision in the near future. In the meantime, Axsome has already completed creating the drug's marketing materials and the tactical planning for its potential launch.
Shares of Axsome gained 10.2% on Mar 1, as investors anticipate the FDA approval of AXS-05 following the company’s advance preparations for the candidate’s commercial launch. Yet, Axsome’s stock has declined 18% so far this year compared with the industry’s 16.2% fall.
Image Source: Zacks Investment Research
The company is currently enrolling patients in the phase III ACCORD study evaluating the safety and efficacy of AXS-05 for treating agitation associated with AD. In the course of the study, AXSM observed lower blinded relapse events than expected. While the company expects that this observation is based on the drug’s greater-than-anticipated overall durability of effect, it would also have implications on the study’s duration. Based on these implications, AXSM plans to consult with the FDA regarding the study’s design and later on provide an update on the same.
Axsome plans to start a pivotal phase II/III study for AXS-05 as a potential treatment for smoking cessation. The timing of the initiation will be informed later this year.
Others
Another lead candidate, AXS-07, has been developed for the acute treatment of migraine. The NDA for the candidate has already been filed and is currently under review. The FDA remains on track to provide a decision on the NDA by Apr 30, 2022, including completion of the inspection of a contract manufacturing facility within the decision date. The FDA previously notified the company that it would not be able to complete the inspection before the decision date.
Axsome’s AXS-12 is being developed to treat narcolepsy, a sleep disorder characterized by excessive sleepiness. The candidate is currently enrolling patients in the phase III SYMPHONY study for the given indication. Top-line data from this study is expected in first-half 2023.
AXS-14 is the company’s candidate for the treatment of fibromyalgia. The treatment has already achieved primary endpoints in phase II and phase III studies for the management of fibromyalgia. An NDA is expected to be filed in 2023, following successful completion of manufacturing and other activities related to the candidate.
Axsome Therapeutics, Inc. Price
Axsome Therapeutics, Inc. price | Axsome Therapeutics, Inc. Quote
Zacks Rank & Other Stocks to Consider
Axsome currently has a Zacks Rank #2 (Buy). Other top-ranked stocks in the overall healthcare sector include Adaptimmune Therapeutics ADAP, Arbutus Biopharma ABUS and Arvinas ARVN, each carrying a Zacks Rank #2 at present. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Adaptimmune Therapeutics’ loss per share estimates for 2022 have narrowed from 99 cents to 91 cents in the past 30 days. Earnings of Adaptimmune Therapeutics beat estimates in three of the last four quarters and missed the mark on a single occasion, with the average surprise being 0.9%.
Arbutus Biopharma’s loss per share estimates for 2022 have narrowed from 63 cents to 61 cents in the past 30 days. In the trailing four quarters, earnings of Arbutus Biopharma beat estimates once, missed the same twice and met the mark on another occasion, delivering an average negative surprise of 3.6%.
Arvinas’ loss per share estimates for 2022 have narrowed from $3.23 to $3.19 in the past 30 days. The same for 2023 has narrowed from $3.89 to $3.82 in the past 30 days. Earnings of Arvinas missed estimates in each of the last four quarters, with the average negative surprise being 47.9%.
Bitcoin, Like the Internet Itself, Could Change Everything
Blockchain and cryptocurrency has sparked one of the most exciting discussion topics of a generation. Some call it the “Internet of Money” and predict it could change the way money works forever. If true, it could do to banks what Netflix did to Blockbuster and Amazon did to Sears. Experts agree we’re still in the early stages of this technology, and as it grows, it will create several investing opportunities.
Zacks’ has just revealed 3 companies that can help investors capitalize on the explosive profit potential of Bitcoin and the other cryptocurrencies with significantly less volatility than buying them directly.
See 3 crypto-related stocks now >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Adaptimmune Therapeutics PLC (ADAP): Free Stock Analysis Report
Arbutus Biopharma Corporation (ABUS): Free Stock Analysis Report
Axsome Therapeutics, Inc. (AXSM): Free Stock Analysis Report
Arvinas, Inc. (ARVN): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Other top-ranked stocks in the overall healthcare sector include Adaptimmune Therapeutics ADAP, Arbutus Biopharma ABUS and Arvinas ARVN, each carrying a Zacks Rank #2 at present. Arbutus Biopharma Corporation (ABUS): Free Stock Analysis Report Image Source: Zacks Investment Research The company is currently enrolling patients in the phase III ACCORD study evaluating the safety and efficacy of AXS-05 for treating agitation associated with AD. | Other top-ranked stocks in the overall healthcare sector include Adaptimmune Therapeutics ADAP, Arbutus Biopharma ABUS and Arvinas ARVN, each carrying a Zacks Rank #2 at present. Arbutus Biopharma Corporation (ABUS): Free Stock Analysis Report AXS-05, one of Axsome’s lead candidates, is being developed for treating major depressive disorder (“MDD”), treatment-resistant depression (“TRD”), smoking cessation and agitation associated with Alzheimer's disease (“AD”). | Other top-ranked stocks in the overall healthcare sector include Adaptimmune Therapeutics ADAP, Arbutus Biopharma ABUS and Arvinas ARVN, each carrying a Zacks Rank #2 at present. Arbutus Biopharma Corporation (ABUS): Free Stock Analysis Report Axsome Therapeutics, Inc. AXSM incurred a loss of 90 cents per share for fourth-quarter 2021, narrower than the Zacks Consensus Estimate of a loss of 99 cents but wider than the year-ago loss of 78 cents. | Other top-ranked stocks in the overall healthcare sector include Adaptimmune Therapeutics ADAP, Arbutus Biopharma ABUS and Arvinas ARVN, each carrying a Zacks Rank #2 at present. Arbutus Biopharma Corporation (ABUS): Free Stock Analysis Report Axsome expects an increase in operating expenses on account of pipeline development and commercialization activities. |
34617.0 | 2022-02-28 00:00:00 UTC | Arbutus files patent infringement lawsuit against Moderna | ABUS | https://www.nasdaq.com/articles/arbutus-files-patent-infringement-lawsuit-against-moderna | nan | nan | Adds Arbutus executive comment, background
Feb 28 (Reuters) - Arbutus Biopharma Corp ABUS.O said on Monday it had filed a lawsuit against Moderna Inc MRNA.O seeking damages for infringement of patents related to its COVID-19 vaccine.
The lawsuit comes after a federal appeals court in December rejected Moderna's challenge to patents belonging to Arbutus Biopharma that were licensed to Genevant Sciences Inc.
The court let stand an administrative panel's findings that Arbutus' patents - which may cover technology used in the vaccines - were valid, as the science involved was not previously known.
Moderna did not immediately respond to a Reuters request for comment.
Arbutus and Genevant do not seek to interfere with the sale, manufacturing or distribution of Moderna's COVID-19 vaccine, said Arbutus Chief Executive Officer William Collier in a statement.
"However, we seek fair compensation for Moderna's use of our patented technology that was developed with great effort and at great expense, without which Moderna's COVID-19 vaccine would not have been successful."
Genevant Sciences was launched in 2018 by Arbutus and Roivant Sciences Ltd ROIV.O. Roivant owns about 80% of Genevant and Arbutus holds the remainder stake.
(Reporting by Amruta Khandekar; Editing by Shinjini Ganguli)
((Amruta.Khandekar@thomsonreuters.com;))
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Adds Arbutus executive comment, background Feb 28 (Reuters) - Arbutus Biopharma Corp ABUS.O said on Monday it had filed a lawsuit against Moderna Inc MRNA.O seeking damages for infringement of patents related to its COVID-19 vaccine. The lawsuit comes after a federal appeals court in December rejected Moderna's challenge to patents belonging to Arbutus Biopharma that were licensed to Genevant Sciences Inc. The court let stand an administrative panel's findings that Arbutus' patents - which may cover technology used in the vaccines - were valid, as the science involved was not previously known. | Adds Arbutus executive comment, background Feb 28 (Reuters) - Arbutus Biopharma Corp ABUS.O said on Monday it had filed a lawsuit against Moderna Inc MRNA.O seeking damages for infringement of patents related to its COVID-19 vaccine. Arbutus and Genevant do not seek to interfere with the sale, manufacturing or distribution of Moderna's COVID-19 vaccine, said Arbutus Chief Executive Officer William Collier in a statement. Genevant Sciences was launched in 2018 by Arbutus and Roivant Sciences Ltd ROIV.O. | Adds Arbutus executive comment, background Feb 28 (Reuters) - Arbutus Biopharma Corp ABUS.O said on Monday it had filed a lawsuit against Moderna Inc MRNA.O seeking damages for infringement of patents related to its COVID-19 vaccine. The lawsuit comes after a federal appeals court in December rejected Moderna's challenge to patents belonging to Arbutus Biopharma that were licensed to Genevant Sciences Inc. Arbutus and Genevant do not seek to interfere with the sale, manufacturing or distribution of Moderna's COVID-19 vaccine, said Arbutus Chief Executive Officer William Collier in a statement. | Adds Arbutus executive comment, background Feb 28 (Reuters) - Arbutus Biopharma Corp ABUS.O said on Monday it had filed a lawsuit against Moderna Inc MRNA.O seeking damages for infringement of patents related to its COVID-19 vaccine. The lawsuit comes after a federal appeals court in December rejected Moderna's challenge to patents belonging to Arbutus Biopharma that were licensed to Genevant Sciences Inc. Genevant Sciences was launched in 2018 by Arbutus and Roivant Sciences Ltd ROIV.O. |
34618.0 | 2022-02-25 00:00:00 UTC | Intellia (NTLA) Q4 Loss Wider Than Expected, Revenues Up Y/Y | ABUS | https://www.nasdaq.com/articles/intellia-ntla-q4-loss-wider-than-expected-revenues-up-y-y | nan | nan | Intellia Therapeutics NTLA incurred a loss of $1.09 per share for fourth-quarter 2021, wider than the year-ago loss of 69 cents and the Zacks Consensus Estimate of a loss of 91 cents.
Intellia’s total revenues, which comprise collaboration revenues, came in at $12.9 million for the fourth quarter compared with $6.6 million reported in the year-ago period. The top line also beat the Zacks Consensus Estimate of $9.6 million.
The significant year-over-year increase in revenues was on account of revenues of $5.8 million recorded by the company from its joint venture with AvenCell.
Quarter in Detail
For the reported quarter, research and development expenses were $71.2 million, up 86.1% from the year-ago figure due to increased costs for developing the company’s lead programs.
General and administrative expenses also surged 105.4% year over year to $22.1 million due to higher employee-related costs.
As of Dec 31, 2021, NTLA had cash, cash equivalents and marketable securities of $1,086 million compared with $1,148.7 million on Sep 30, 2021.
Full-Year Results
For 2021, Intellia generated revenues of $33.1 million, reflecting a significant year-over-year decline from the year-ago figure of $58 million.
For the same period, the company reported earnings of $3.78 per share versus the year-ago loss of $2.40.
Pipeline Updates
Intellia remains focused on developing curative therapeutics using the CRISPR/Cas9 technology. The company is evaluating its lead in-vivo genome-editing candidate, NTLA-2001, in a two-part phase I study for treating transthyretin amyloidosis with polyneuropathy. The company plans to present interim data from part 1 of the study on Feb 28 and start part 2 in first-quarter 2022.
Shares of Intellia were up 9.3% on Thursday, probably as investors expect positive updates from this study.
NTLA has risen 52.2% in the past year against the industry’s 39.2% decline.
Image Source: Zacks Investment Research
Please note that NTLA-2001 is part of Intellia’s co-development and co-promotion agreement with Regeneron Pharmaceuticals REGN. While NTLA is the lead party for NTLA-2001, Regeneron shares 25% of the development costs and commercial profits. Both Intellia and Regeneron are also developing therapies for hemophilia A and B.
Intellia initiated a phase I/II study evaluating another pipeline candidate NTLA-2002 for the treatment of hereditary angioedema (“HAE”) in December 2021. NTLA-2002 aims to prevent HAE attacks by suppressing plasma kallikrein activity. Interim data from the study is expected in second-half 2022.
NTLA-5001 is the company’s first wholly-owned ex-vivo genome editing candidate for the treatment of cancer. In fourth-quarter 2021, Intellia started patient screening in a phase I/IIa study evaluating NTLA-5001 in adults with persistent or recurrent AML who have previously received first-line therapy.
Alongside its Q4 earnings release, Intellia announced that it nominated two new CRISPR-based development candidates to enter clinical studies. NTLA nominated NTLA-2003, an in-vivo candidate, for the treatment of alpha-1 antitrypsin deficiency (AATD)-associated liver disease. Intellia also nominated its first ex-vivo allogenic CAR-T therapy NTLA-6001 for the treatment of CD30-expressing hematologic cancers. NTLA is advancing both the candidates toward an IND filing so as to initiate clinical studies.
The company is also expanding its pipeline with acquisitions and collaborations. Earlier this month, NTLA acquired a closely-held Rewrite Therapeutics to expand its gene-editing technology platforms and partnered with ONK Therapeutics to develop new therapies for cancer. Last month, NTLA announced a partnership with Kyverna Therapeutics to develop an allogeneic CD19 CAR T-cell therapy to treat a variety of B-cell-mediated auto-immune diseases.
Intellia Therapeutics, Inc. Price
Intellia Therapeutics, Inc. price | Intellia Therapeutics, Inc. Quote
Zacks Rank & Stocks to Consider
Intellia currently carries a Zacks Rank #3 (Hold). Some better-ranked stocks in the overall healthcare sector include Arbutus Biopharma ABUS and Vertex Pharmaceuticals VRTX, each carrying a Zacks Rank #2 (Buy) at present. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Arbutus Biopharma’s loss per share estimates for 2022 have narrowed from 63 cents to 61 cents in the past 30 days. Earnings of ABUS beat estimates in one of the last four quarters, met the mark once and missed the same on the other two occasions, delivering a negative surprise of 3.6%, on average.
Vertex Pharmaceuticals’ earnings per share estimates for 2022 have increased from $13.35 to $14.33 in the past 30 days. The same for 2023 has risen from $14.12 to $15.31 in the past 30 days. Shares of VRTX have risen 8.1% in the past year.
Earnings of Vertex Pharmaceuticals beat estimates in each of the last four quarters, with the average being 10%.
Infrastructure Stock Boom to Sweep America
A massive push to rebuild the crumbling U.S. infrastructure will soon be underway. It’s bipartisan, urgent, and inevitable. Trillions will be spent. Fortunes will be made.
The only question is “Will you get into the right stocks early when their growth potential is greatest?”
Zacks has released a Special Report to help you do just that, and today it’s free. Discover 5 special companies that look to gain the most from construction and repair to roads, bridges, and buildings, plus cargo hauling and energy transformation on an almost unimaginable scale.
Download FREE: How to Profit from Trillions on Spending for Infrastructure >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Regeneron Pharmaceuticals, Inc. (REGN): Free Stock Analysis Report
Vertex Pharmaceuticals Incorporated (VRTX): Free Stock Analysis Report
Arbutus Biopharma Corporation (ABUS): Free Stock Analysis Report
Intellia Therapeutics, Inc. (NTLA): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Some better-ranked stocks in the overall healthcare sector include Arbutus Biopharma ABUS and Vertex Pharmaceuticals VRTX, each carrying a Zacks Rank #2 (Buy) at present. Earnings of ABUS beat estimates in one of the last four quarters, met the mark once and missed the same on the other two occasions, delivering a negative surprise of 3.6%, on average. Arbutus Biopharma Corporation (ABUS): Free Stock Analysis Report | Some better-ranked stocks in the overall healthcare sector include Arbutus Biopharma ABUS and Vertex Pharmaceuticals VRTX, each carrying a Zacks Rank #2 (Buy) at present. Earnings of ABUS beat estimates in one of the last four quarters, met the mark once and missed the same on the other two occasions, delivering a negative surprise of 3.6%, on average. Arbutus Biopharma Corporation (ABUS): Free Stock Analysis Report | Some better-ranked stocks in the overall healthcare sector include Arbutus Biopharma ABUS and Vertex Pharmaceuticals VRTX, each carrying a Zacks Rank #2 (Buy) at present. Earnings of ABUS beat estimates in one of the last four quarters, met the mark once and missed the same on the other two occasions, delivering a negative surprise of 3.6%, on average. Arbutus Biopharma Corporation (ABUS): Free Stock Analysis Report | Some better-ranked stocks in the overall healthcare sector include Arbutus Biopharma ABUS and Vertex Pharmaceuticals VRTX, each carrying a Zacks Rank #2 (Buy) at present. Earnings of ABUS beat estimates in one of the last four quarters, met the mark once and missed the same on the other two occasions, delivering a negative surprise of 3.6%, on average. Arbutus Biopharma Corporation (ABUS): Free Stock Analysis Report |
34619.0 | 2022-02-24 00:00:00 UTC | Agios (AGIO) Loss Wider Than Expected in Q4, Revenues Nil | ABUS | https://www.nasdaq.com/articles/agios-agio-loss-wider-than-expected-in-q4-revenues-nil | nan | nan | Agios Pharmaceuticals, Inc. AGIO reported a loss of $1.81 per share from continued operations for the fourth quarter of 2021, wider than the Zacks Consensus Estimate of a loss of $1.71 as well as the year-ago quarter’s loss of $1.22.
Following the sale of its oncology portfolio to France-based pharmaceutical company Servier, AGIO recorded zero revenues for the fourth quarter. The Zacks Consensus Estimate for the metric was $2.1 million. In the year-ago quarter, Agios recorded $44 million of total revenues.
Last week, the FDA approved its lead pipeline candidate mitapivat for hemolytic anemia in adults with pyruvate kinase (PK) deficiency. The drug to be marketed by the trade name of Pyrukynd is the first disease-modifying therapy approved to treat this rare and debilitating blood disorder. A regulatory application for the drug for a similar indication is pending in the European Union and a decision is expected by this year-end.
Shares of Agios were down 2.5% in pre-market trading on Feb 24 following the above announcement. In fact, the stock has declined 47.9% in the trailing 12 months compared with the industry’s 19.2% decrease.
Image Source: Zacks Investment Research
Quarter in Detail
Research & development expenses increased 23.4% year over year to $73.3 million due to a rise in cost related to the planned initiation of late-stage studies of Pyrukynd for thalassemia and sickle cell disease (SCD), a blood disorder.
Selling, general and administrative expenses were up 21.7% year over year to $31.5 million, primarily due to launch preparations for Pyrukynd as well as expenses incurred to educate consumers about the PK deficiency disease
At the end of December 2021, cash, cash equivalents and marketable securities were $1.3 billion compared with $1.4 billion at the end of September 2021.
Pipeline Updates
Apart from PK deficiency, Agios is evaluating Pyrukynd for SCD and thalassemia indications.
AGIO initiated two phase III studies, namely ENERGIZE and ENERGIZE-T, to evaluate Pyrukynd for thalassemia in adults, with one segment being not regularly transfused while the other being regularly transfused. Agios plans to complete enrolment in both studies by 2022-end. Agios also plans to initiate two phase III studies that evaluate Pyrukynd in pediatric patients who are not regularly transfused and are regularly transfused, respectively, by mid-2022.
AGIO also initiated the phase II/III RISE UP study evaluating Pyrukynd for SCD. It plans to complete enrolling patients in the study by 2022-end.
Apart from Pyrukynd, Agios is evaluating AG-946, its next-generation pyruvate kinase-R activator. AGIO is currently evaluating the candidate in a phase I study for the treatment of hemolytic anemia.
Agios also intends to evaluate AG-946 for other indications. While a phase I study to evaluate the candidate for SCD is expected to begin in first-half 2022, a phase IIa study on the candidate for low- to intermediate-risk myelodysplastic syndrome (MDS) is planned to start by 2022-end.
Agios Pharmaceuticals, Inc. Price
Agios Pharmaceuticals, Inc. price | Agios Pharmaceuticals, Inc. Quote
Zacks Rank & Stocks to Consider
Currently, Agios has a Zacks Rank #3 (Hold). Better-ranked stocks in the overall healthcare sector include Adaptimmune Therapeutics ADAP, Arbutus Biopharma ABUS and Vertex Pharmaceuticals VRTX, each carrying a Zacks Rank #2 (Buy) at present. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Adaptimmune Therapeutics’ loss per share estimates for 2022 have narrowed from 99 cents to 91 cents in the past 30 days. Earnings of ADAP beat estimates in three of the last four quarters and missed the mark on a single occasion, the average surprise being 0.9%.
Arbutus Biopharma’s loss per share estimates for 2022 have narrowed from 63 cents to 61 cents in the past 30 days. Earnings of ABUS beat estimates in one of the last four quarters, met the mark once and missed the same on the other two occasions. ABUS delivered a negative surprise of 3.6%, on average.
Vertex Pharmaceuticals’ earnings per share estimates for 2022 have increased from $13.35 to $14.33 in the past 30 days. The same for 2023 has risen from $14.12 to $15.31 in the past 30 days. Shares of VRTX have risen 6.3% in the past year.
Earnings of Vertex Pharmaceuticals beat estimates in each of the last four quarters, the average being 10%.
Zacks Names "Single Best Pick to Double"
From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all.
It’s a little-known chemical company that’s up 65% over last year, yet still dirt cheap. With unrelenting demand, soaring 2022 earnings estimates, and $1.5 billion for repurchasing shares, retail investors could jump in at any time.
This company could rival or surpass other recent Zacks’ Stocks Set to Double like Boston Beer Company which shot up +143.0% in little more than 9 months and NVIDIA which boomed +175.9% in one year.
Free: See Our Top Stock and 4 Runners Up >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Vertex Pharmaceuticals Incorporated (VRTX): Free Stock Analysis Report
Agios Pharmaceuticals, Inc. (AGIO): Free Stock Analysis Report
Adaptimmune Therapeutics PLC (ADAP): Free Stock Analysis Report
Arbutus Biopharma Corporation (ABUS): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Better-ranked stocks in the overall healthcare sector include Adaptimmune Therapeutics ADAP, Arbutus Biopharma ABUS and Vertex Pharmaceuticals VRTX, each carrying a Zacks Rank #2 (Buy) at present. Earnings of ABUS beat estimates in one of the last four quarters, met the mark once and missed the same on the other two occasions. ABUS delivered a negative surprise of 3.6%, on average. | Better-ranked stocks in the overall healthcare sector include Adaptimmune Therapeutics ADAP, Arbutus Biopharma ABUS and Vertex Pharmaceuticals VRTX, each carrying a Zacks Rank #2 (Buy) at present. Earnings of ABUS beat estimates in one of the last four quarters, met the mark once and missed the same on the other two occasions. ABUS delivered a negative surprise of 3.6%, on average. | Better-ranked stocks in the overall healthcare sector include Adaptimmune Therapeutics ADAP, Arbutus Biopharma ABUS and Vertex Pharmaceuticals VRTX, each carrying a Zacks Rank #2 (Buy) at present. Earnings of ABUS beat estimates in one of the last four quarters, met the mark once and missed the same on the other two occasions. ABUS delivered a negative surprise of 3.6%, on average. | Better-ranked stocks in the overall healthcare sector include Adaptimmune Therapeutics ADAP, Arbutus Biopharma ABUS and Vertex Pharmaceuticals VRTX, each carrying a Zacks Rank #2 (Buy) at present. Earnings of ABUS beat estimates in one of the last four quarters, met the mark once and missed the same on the other two occasions. ABUS delivered a negative surprise of 3.6%, on average. |
34620.0 | 2022-02-22 00:00:00 UTC | Halozyme Therapeutics (HALO) Q4 Earnings and Revenues Surpass Estimates | ABUS | https://www.nasdaq.com/articles/halozyme-therapeutics-halo-q4-earnings-and-revenues-surpass-estimates | nan | nan | Halozyme Therapeutics (HALO) came out with quarterly earnings of $0.42 per share, beating the Zacks Consensus Estimate of $0.40 per share. This compares to earnings of $0.50 per share a year ago. These figures are adjusted for non-recurring items.
This quarterly report represents an earnings surprise of 5%. A quarter ago, it was expected that this biopharmaceutical company would post earnings of $0.42 per share when it actually produced earnings of $0.55, delivering a surprise of 30.95%.
Over the last four quarters, the company has surpassed consensus EPS estimates four times.
Halozyme Therapeutics, which belongs to the Zacks Medical - Biomedical and Genetics industry, posted revenues of $102 million for the quarter ended December 2021, surpassing the Zacks Consensus Estimate by 5.05%. This compares to year-ago revenues of $121.7 million. The company has topped consensus revenue estimates four times over the last four quarters.
The sustainability of the stock's immediate price movement based on the recently-released numbers and future earnings expectations will mostly depend on management's commentary on the earnings call.
Halozyme Therapeutics shares have lost about 18.6% since the beginning of the year versus the S&P 500's decline of -8.8%.
What's Next for Halozyme Therapeutics?
While Halozyme Therapeutics has underperformed the market so far this year, the question that comes to investors' minds is: what's next for the stock?
There are no easy answers to this key question, but one reliable measure that can help investors address this is the company's earnings outlook. Not only does this include current consensus earnings expectations for the coming quarter(s), but also how these expectations have changed lately.
Empirical research shows a strong correlation between near-term stock movements and trends in earnings estimate revisions. Investors can track such revisions by themselves or rely on a tried-and-tested rating tool like the Zacks Rank, which has an impressive track record of harnessing the power of earnings estimate revisions.
Ahead of this earnings release, the estimate revisions trend for Halozyme Therapeutics: unfavorable. While the magnitude and direction of estimate revisions could change following the company's just-released earnings report, the current status translates into a Zacks Rank #5 (Strong Sell) for the stock. So, the shares are expected to underperform the market in the near future. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here.
It will be interesting to see how estimates for the coming quarters and current fiscal year change in the days ahead. The current consensus EPS estimate is $0.49 on $126.92 million in revenues for the coming quarter and $2.15 on $546.17 million in revenues for the current fiscal year.
Investors should be mindful of the fact that the outlook for the industry can have a material impact on the performance of the stock as well. In terms of the Zacks Industry Rank, Medical - Biomedical and Genetics is currently in the bottom 43% of the 250 plus Zacks industries. Our research shows that the top 50% of the Zacks-ranked industries outperform the bottom 50% by a factor of more than 2 to 1.
One other stock from the same industry, Arbutus Biopharma (ABUS), is yet to report results for the quarter ended December 2021. The results are expected to be released on March 3.
This biopharmaceutical company is expected to post quarterly loss of $0.16 per share in its upcoming report, which represents a year-over-year change of +30.4%. The consensus EPS estimate for the quarter has been revised 3.2% higher over the last 30 days to the current level.
Arbutus Biopharma's revenues are expected to be $3.39 million, up 41.6% from the year-ago quarter.
Just Released: Zacks Top 10 Stocks for 2022
In addition to the investment ideas discussed above, would you like to know about our 10 top buy-and-hold tickers for the entirety of 2022?
Last year's 2021 Zacks Top 10 Stocks portfolio returned gains as high as +147.7%. Now a brand-new portfolio has been handpicked from over 4,000 companies covered by the Zacks Rank. Don’t miss your chance to get in on these long-term buys
Access Zacks Top 10 Stocks for 2022 today >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Halozyme Therapeutics, Inc. (HALO): Free Stock Analysis Report
Arbutus Biopharma Corporation (ABUS): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | One other stock from the same industry, Arbutus Biopharma (ABUS), is yet to report results for the quarter ended December 2021. Arbutus Biopharma Corporation (ABUS): Free Stock Analysis Report Empirical research shows a strong correlation between near-term stock movements and trends in earnings estimate revisions. | One other stock from the same industry, Arbutus Biopharma (ABUS), is yet to report results for the quarter ended December 2021. Arbutus Biopharma Corporation (ABUS): Free Stock Analysis Report Halozyme Therapeutics, which belongs to the Zacks Medical - Biomedical and Genetics industry, posted revenues of $102 million for the quarter ended December 2021, surpassing the Zacks Consensus Estimate by 5.05%. | One other stock from the same industry, Arbutus Biopharma (ABUS), is yet to report results for the quarter ended December 2021. Arbutus Biopharma Corporation (ABUS): Free Stock Analysis Report Halozyme Therapeutics (HALO) came out with quarterly earnings of $0.42 per share, beating the Zacks Consensus Estimate of $0.40 per share. | One other stock from the same industry, Arbutus Biopharma (ABUS), is yet to report results for the quarter ended December 2021. Arbutus Biopharma Corporation (ABUS): Free Stock Analysis Report The company has topped consensus revenue estimates four times over the last four quarters. |
34621.0 | 2022-02-08 00:00:00 UTC | Deciphera Pharmaceuticals, Inc. (DCPH) Reports Q4 Loss, Tops Revenue Estimates | ABUS | https://www.nasdaq.com/articles/deciphera-pharmaceuticals-inc.-dcph-reports-q4-loss-tops-revenue-estimates | nan | nan | Deciphera Pharmaceuticals, Inc. (DCPH) came out with a quarterly loss of $1.51 per share versus the Zacks Consensus Estimate of a loss of $1.49. This compares to loss of $1.10 per share a year ago. These figures are adjusted for non-recurring items.
This quarterly report represents an earnings surprise of -1.34%. A quarter ago, it was expected that this company would post a loss of $1.29 per share when it actually produced a loss of $1.37, delivering a surprise of -6.20%.
Over the last four quarters, the company has surpassed consensus EPS estimates just once.
Deciphera Pharmaceuticals, Inc., which belongs to the Zacks Medical - Biomedical and Genetics industry, posted revenues of $24.2 million for the quarter ended December 2021, surpassing the Zacks Consensus Estimate by 3.26%. This compares to year-ago revenues of $19.49 million. The company has topped consensus revenue estimates three times over the last four quarters.
The sustainability of the stock's immediate price movement based on the recently-released numbers and future earnings expectations will mostly depend on management's commentary on the earnings call.
Deciphera Pharmaceuticals, Inc. Shares have lost about 16% since the beginning of the year versus the S&P 500's decline of -5.9%.
What's Next for Deciphera Pharmaceuticals, Inc.
While Deciphera Pharmaceuticals, Inc. Has underperformed the market so far this year, the question that comes to investors' minds is: what's next for the stock?
There are no easy answers to this key question, but one reliable measure that can help investors address this is the company's earnings outlook. Not only does this include current consensus earnings expectations for the coming quarter(s), but also how these expectations have changed lately.
Empirical research shows a strong correlation between near-term stock movements and trends in earnings estimate revisions. Investors can track such revisions by themselves or rely on a tried-and-tested rating tool like the Zacks Rank, which has an impressive track record of harnessing the power of earnings estimate revisions.
Ahead of this earnings release, the estimate revisions trend for Deciphera Pharmaceuticals, Inc. Mixed. While the magnitude and direction of estimate revisions could change following the company's just-released earnings report, the current status translates into a Zacks Rank #3 (Hold) for the stock. So, the shares are expected to perform in line with the market in the near future. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here.
It will be interesting to see how estimates for the coming quarters and current fiscal year change in the days ahead. The current consensus EPS estimate is -$0.61 on $26.8 million in revenues for the coming quarter and -$2.55 on $123.57 million in revenues for the current fiscal year.
Investors should be mindful of the fact that the outlook for the industry can have a material impact on the performance of the stock as well. In terms of the Zacks Industry Rank, Medical - Biomedical and Genetics is currently in the bottom 44% of the 250 plus Zacks industries. Our research shows that the top 50% of the Zacks-ranked industries outperform the bottom 50% by a factor of more than 2 to 1.
One other stock from the same industry, Arbutus Biopharma (ABUS), is yet to report results for the quarter ended December 2021.
This biopharmaceutical company is expected to post quarterly loss of $0.16 per share in its upcoming report, which represents a year-over-year change of +30.4%. The consensus EPS estimate for the quarter has been revised 3.2% higher over the last 30 days to the current level.
Arbutus Biopharma's revenues are expected to be $3.39 million, up 41.6% from the year-ago quarter.
Zacks Names "Single Best Pick to Double"
From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all.
It’s a little-known chemical company that’s up 65% over last year, yet still dirt cheap. With unrelenting demand, soaring 2022 earnings estimates, and $1.5 billion for repurchasing shares, retail investors could jump in at any time.
This company could rival or surpass other recent Zacks’ Stocks Set to Double like Boston Beer Company which shot up +143.0% in little more than 9 months and NVIDIA which boomed +175.9% in one year.
Free: See Our Top Stock and 4 Runners Up >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Deciphera Pharmaceuticals, Inc. (DCPH): Free Stock Analysis Report
Arbutus Biopharma Corporation (ABUS): Free Stock Analysis Report
To read this article on Zacks.com click here.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | One other stock from the same industry, Arbutus Biopharma (ABUS), is yet to report results for the quarter ended December 2021. Arbutus Biopharma Corporation (ABUS): Free Stock Analysis Report While the magnitude and direction of estimate revisions could change following the company's just-released earnings report, the current status translates into a Zacks Rank #3 (Hold) for the stock. | One other stock from the same industry, Arbutus Biopharma (ABUS), is yet to report results for the quarter ended December 2021. Arbutus Biopharma Corporation (ABUS): Free Stock Analysis Report Deciphera Pharmaceuticals, Inc., which belongs to the Zacks Medical - Biomedical and Genetics industry, posted revenues of $24.2 million for the quarter ended December 2021, surpassing the Zacks Consensus Estimate by 3.26%. | One other stock from the same industry, Arbutus Biopharma (ABUS), is yet to report results for the quarter ended December 2021. Arbutus Biopharma Corporation (ABUS): Free Stock Analysis Report Deciphera Pharmaceuticals, Inc. (DCPH) came out with a quarterly loss of $1.51 per share versus the Zacks Consensus Estimate of a loss of $1.49. | One other stock from the same industry, Arbutus Biopharma (ABUS), is yet to report results for the quarter ended December 2021. Arbutus Biopharma Corporation (ABUS): Free Stock Analysis Report The company has topped consensus revenue estimates three times over the last four quarters. |
34622.0 | 2022-02-05 00:00:00 UTC | What's the Outlook for Arbutus Biopharma? | ABUS | https://www.nasdaq.com/articles/whats-the-outlook-for-arbutus-biopharma | nan | nan | Like many biotech stocks, Arbutus Biopharma (NASDAQ: ABUS) has been a loser for investors over the past 12 months. In this Motley Fool Live video, recorded on Jan. 26, Fool contributors Keith Speights and Brian Orelli address a viewer's question about the stock.
10 stocks we like better than Arbutus Biopharma
When our award-winning analyst team has a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor, has tripled the market.*
They just revealed what they believe are the ten best stocks for investors to buy right now... and Arbutus Biopharma wasn't one of them! That's right -- they think these 10 stocks are even better buys.
See the 10 stocks
*Stock Advisor returns as of January 10, 2022
Keith Speights: "Good morning, Keith and Brian. I'm with you about your opening remarks. Question: What's your opinion about Arbutus Biopharma?" The ticker there is ABUS.
Brian Orelli: Yeah, they have hepatitis drugs, I believe, and they're in early to mid-stage. It's not one that I follow that closely, but obviously, I guess, they're doing hepatitis B versus hepatitis C.
Potentially, there's less competition there in hepatitis B versus hepatitis C. I think that's probably a better place to be looking than in companies that are developing drugs for hepatitis C just because the current medications work so well in hepatitis C, and hepatitis B, I'm not even sure that there's an actual cure for hepatitis B. I think it just knocks down the virus enough so that it's not replicating, but you basically have to take those drugs for as long as you live.
I think if they could develop a cure, it'd be great. One thing that's great about virus developers is that Phase 3 data often looks exactly like Phase 2 data because it's a virus and so you're not dealing with the difference of patient's genetic background.
That's the main reason why drugs have worked for some people and don't work for other people is because the genetic background of the patients are different, but the genetic background of the hepatitis B virus is the same. And so in general, if you have successful Phase 2 data, there's a high likelihood that that's going to translate into successful Phase 3 data.
Brian Orelli, PhD has no position in any of the stocks mentioned. Keith Speights has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Like many biotech stocks, Arbutus Biopharma (NASDAQ: ABUS) has been a loser for investors over the past 12 months. The ticker there is ABUS. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor, has tripled the market. | Like many biotech stocks, Arbutus Biopharma (NASDAQ: ABUS) has been a loser for investors over the past 12 months. The ticker there is ABUS. In this Motley Fool Live video, recorded on Jan. 26, Fool contributors Keith Speights and Brian Orelli address a viewer's question about the stock. | Like many biotech stocks, Arbutus Biopharma (NASDAQ: ABUS) has been a loser for investors over the past 12 months. The ticker there is ABUS. In this Motley Fool Live video, recorded on Jan. 26, Fool contributors Keith Speights and Brian Orelli address a viewer's question about the stock. | Like many biotech stocks, Arbutus Biopharma (NASDAQ: ABUS) has been a loser for investors over the past 12 months. The ticker there is ABUS. In this Motley Fool Live video, recorded on Jan. 26, Fool contributors Keith Speights and Brian Orelli address a viewer's question about the stock. |
34623.0 | 2022-02-02 00:00:00 UTC | Pre-market Movers: MDJH, ELMS, EXC, PYPL, PHAR… | ABUS | https://www.nasdaq.com/articles/pre-market-movers%3A-mdjh-elms-exc-pypl-phar... | nan | nan | (RTTNews) - The following are some of the stocks making big moves in Wednesday's pre-market trading (as of 07.05 A.M. ET).
In the Green
MDJM Ltd (MDJH) is up over 73% at $2.92 Pharming Group N.V. (PHAR) is up over 13% at $10.01 Advanced Micro Devices, Inc. (AMD) is up over 11% at $129.86 Entasis Therapeutics Holdings Inc. (ETTX) is up over 11% at $1.61 Alphabet Inc. (GOOG) is up over 10% at $3038 Xilinx, Inc. (XLNX) is up over 10% at $219.49 Helbiz, Inc. (HLBZ) is up over 10% at $3.37 IceCure Medical Ltd (ICCM) is up over 10% at $2.85 Arbutus Biopharma Corporation (ABUS) is up over 9% at $3.19 Epizyme, Inc. (EPZM) is up over 9% at $1.35 Abeona Therapeutics Inc. (ABEO) is up over 7% at $0.30 AgriFORCE Growing Systems, Ltd. (AGRI) is up over 6% at $1.55
In the Red
Electric Last Mile Solutions, Inc. (ELMS) is down over 31% at $3.81 Exelon Corporation (EXC) is down over 27% at $41.79 PayPal Holdings, Inc. (PYPL) is down over 16% at $146.79 ION Geophysical Corporation (IO) is down over 11% at $0.53 BRF S.A. (BRFS) is down over 9% at $3.72 Indonesia Energy Corporation Limited (INDO) is down over 8% at $4.05 Encompass Health Corporation (EHC) is down over 7% at $57.00 FGI Industries Ltd. (FGI) is down over 7% at $4.44
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | In the Green MDJM Ltd (MDJH) is up over 73% at $2.92 Pharming Group N.V. (PHAR) is up over 13% at $10.01 Advanced Micro Devices, Inc. (AMD) is up over 11% at $129.86 Entasis Therapeutics Holdings Inc. (ETTX) is up over 11% at $1.61 Alphabet Inc. (GOOG) is up over 10% at $3038 Xilinx, Inc. (XLNX) is up over 10% at $219.49 Helbiz, Inc. (HLBZ) is up over 10% at $3.37 IceCure Medical Ltd (ICCM) is up over 10% at $2.85 Arbutus Biopharma Corporation (ABUS) is up over 9% at $3.19 Epizyme, Inc. (EPZM) is up over 9% at $1.35 Abeona Therapeutics Inc. (ABEO) is up over 7% at $0.30 AgriFORCE Growing Systems, Ltd. (AGRI) is up over 6% at $1.55 In the Red Electric Last Mile Solutions, Inc. (ELMS) is down over 31% at $3.81 Exelon Corporation (EXC) is down over 27% at $41.79 PayPal Holdings, Inc. (PYPL) is down over 16% at $146.79 ION Geophysical Corporation (IO) is down over 11% at $0.53 BRF S.A. (BRFS) is down over 9% at $3.72 Indonesia Energy Corporation Limited (INDO) is down over 8% at $4.05 Encompass Health Corporation (EHC) is down over 7% at $57.00 FGI Industries Ltd. (FGI) is down over 7% at $4.44 The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. (RTTNews) - The following are some of the stocks making big moves in Wednesday's pre-market trading (as of 07.05 A.M. ET). | In the Green MDJM Ltd (MDJH) is up over 73% at $2.92 Pharming Group N.V. (PHAR) is up over 13% at $10.01 Advanced Micro Devices, Inc. (AMD) is up over 11% at $129.86 Entasis Therapeutics Holdings Inc. (ETTX) is up over 11% at $1.61 Alphabet Inc. (GOOG) is up over 10% at $3038 Xilinx, Inc. (XLNX) is up over 10% at $219.49 Helbiz, Inc. (HLBZ) is up over 10% at $3.37 IceCure Medical Ltd (ICCM) is up over 10% at $2.85 Arbutus Biopharma Corporation (ABUS) is up over 9% at $3.19 Epizyme, Inc. (EPZM) is up over 9% at $1.35 Abeona Therapeutics Inc. (ABEO) is up over 7% at $0.30 AgriFORCE Growing Systems, Ltd. (AGRI) is up over 6% at $1.55 In the Red Electric Last Mile Solutions, Inc. (ELMS) is down over 31% at $3.81 Exelon Corporation (EXC) is down over 27% at $41.79 PayPal Holdings, Inc. (PYPL) is down over 16% at $146.79 ION Geophysical Corporation (IO) is down over 11% at $0.53 BRF S.A. (BRFS) is down over 9% at $3.72 Indonesia Energy Corporation Limited (INDO) is down over 8% at $4.05 Encompass Health Corporation (EHC) is down over 7% at $57.00 FGI Industries Ltd. (FGI) is down over 7% at $4.44 The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. (RTTNews) - The following are some of the stocks making big moves in Wednesday's pre-market trading (as of 07.05 A.M. ET). | In the Green MDJM Ltd (MDJH) is up over 73% at $2.92 Pharming Group N.V. (PHAR) is up over 13% at $10.01 Advanced Micro Devices, Inc. (AMD) is up over 11% at $129.86 Entasis Therapeutics Holdings Inc. (ETTX) is up over 11% at $1.61 Alphabet Inc. (GOOG) is up over 10% at $3038 Xilinx, Inc. (XLNX) is up over 10% at $219.49 Helbiz, Inc. (HLBZ) is up over 10% at $3.37 IceCure Medical Ltd (ICCM) is up over 10% at $2.85 Arbutus Biopharma Corporation (ABUS) is up over 9% at $3.19 Epizyme, Inc. (EPZM) is up over 9% at $1.35 Abeona Therapeutics Inc. (ABEO) is up over 7% at $0.30 AgriFORCE Growing Systems, Ltd. (AGRI) is up over 6% at $1.55 In the Red Electric Last Mile Solutions, Inc. (ELMS) is down over 31% at $3.81 Exelon Corporation (EXC) is down over 27% at $41.79 PayPal Holdings, Inc. (PYPL) is down over 16% at $146.79 ION Geophysical Corporation (IO) is down over 11% at $0.53 BRF S.A. (BRFS) is down over 9% at $3.72 Indonesia Energy Corporation Limited (INDO) is down over 8% at $4.05 Encompass Health Corporation (EHC) is down over 7% at $57.00 FGI Industries Ltd. (FGI) is down over 7% at $4.44 The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. (RTTNews) - The following are some of the stocks making big moves in Wednesday's pre-market trading (as of 07.05 A.M. ET). | In the Green MDJM Ltd (MDJH) is up over 73% at $2.92 Pharming Group N.V. (PHAR) is up over 13% at $10.01 Advanced Micro Devices, Inc. (AMD) is up over 11% at $129.86 Entasis Therapeutics Holdings Inc. (ETTX) is up over 11% at $1.61 Alphabet Inc. (GOOG) is up over 10% at $3038 Xilinx, Inc. (XLNX) is up over 10% at $219.49 Helbiz, Inc. (HLBZ) is up over 10% at $3.37 IceCure Medical Ltd (ICCM) is up over 10% at $2.85 Arbutus Biopharma Corporation (ABUS) is up over 9% at $3.19 Epizyme, Inc. (EPZM) is up over 9% at $1.35 Abeona Therapeutics Inc. (ABEO) is up over 7% at $0.30 AgriFORCE Growing Systems, Ltd. (AGRI) is up over 6% at $1.55 In the Red Electric Last Mile Solutions, Inc. (ELMS) is down over 31% at $3.81 Exelon Corporation (EXC) is down over 27% at $41.79 PayPal Holdings, Inc. (PYPL) is down over 16% at $146.79 ION Geophysical Corporation (IO) is down over 11% at $0.53 BRF S.A. (BRFS) is down over 9% at $3.72 Indonesia Energy Corporation Limited (INDO) is down over 8% at $4.05 Encompass Health Corporation (EHC) is down over 7% at $57.00 FGI Industries Ltd. (FGI) is down over 7% at $4.44 The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. (RTTNews) - The following are some of the stocks making big moves in Wednesday's pre-market trading (as of 07.05 A.M. ET). |
34624.0 | 2022-01-31 00:00:00 UTC | Pre-market Movers: FGI, IMPP, KSCP, WKEY, HAPP… | ABUS | https://www.nasdaq.com/articles/pre-market-movers%3A-fgi-impp-kscp-wkey-happ... | nan | nan | (RTTNews) - The following are some of the stocks making big moves in Monday's pre-market trading (as of 07.20 A.M. ET).
In the Green
FGI Industries Ltd. (FGI) is up over 62% at $6.12 Knightscope, Inc. (KSCP) is up over 20% at $19.60 WISeKey International Holding AG (WKEY) is up over 16% at $3.80 Cian PLC (CIAN) is up over 9% at $7.66 Happiness Development Group Limited (HAPP) is up over 9% at $0.45 180 Life Sciences Corp. (ATNF) is up over 7% at $2.88 Arbutus Biopharma Corporation (ABUS) is up over 7% at $2.71 Corbus Pharmaceuticals Holdings, Inc. (CRBP) is up over 7% at $0.45
In the Red
Imperial Petroleum Inc. (IMPP) is down over 24% at $1.65 Marine Petroleum Trust (MARPS) is down over 7% at $4.75 ObsEva SA (OBSV) is down over 7% at $1.46 Indonesia Energy Corporation Limited (INDO) is down over 6% at $5.19
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | In the Green FGI Industries Ltd. (FGI) is up over 62% at $6.12 Knightscope, Inc. (KSCP) is up over 20% at $19.60 WISeKey International Holding AG (WKEY) is up over 16% at $3.80 Cian PLC (CIAN) is up over 9% at $7.66 Happiness Development Group Limited (HAPP) is up over 9% at $0.45 180 Life Sciences Corp. (ATNF) is up over 7% at $2.88 Arbutus Biopharma Corporation (ABUS) is up over 7% at $2.71 Corbus Pharmaceuticals Holdings, Inc. (CRBP) is up over 7% at $0.45 In the Red Imperial Petroleum Inc. (IMPP) is down over 24% at $1.65 Marine Petroleum Trust (MARPS) is down over 7% at $4.75 ObsEva SA (OBSV) is down over 7% at $1.46 Indonesia Energy Corporation Limited (INDO) is down over 6% at $5.19 The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. (RTTNews) - The following are some of the stocks making big moves in Monday's pre-market trading (as of 07.20 A.M. ET). | In the Green FGI Industries Ltd. (FGI) is up over 62% at $6.12 Knightscope, Inc. (KSCP) is up over 20% at $19.60 WISeKey International Holding AG (WKEY) is up over 16% at $3.80 Cian PLC (CIAN) is up over 9% at $7.66 Happiness Development Group Limited (HAPP) is up over 9% at $0.45 180 Life Sciences Corp. (ATNF) is up over 7% at $2.88 Arbutus Biopharma Corporation (ABUS) is up over 7% at $2.71 Corbus Pharmaceuticals Holdings, Inc. (CRBP) is up over 7% at $0.45 In the Red Imperial Petroleum Inc. (IMPP) is down over 24% at $1.65 Marine Petroleum Trust (MARPS) is down over 7% at $4.75 ObsEva SA (OBSV) is down over 7% at $1.46 Indonesia Energy Corporation Limited (INDO) is down over 6% at $5.19 The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. (RTTNews) - The following are some of the stocks making big moves in Monday's pre-market trading (as of 07.20 A.M. ET). | In the Green FGI Industries Ltd. (FGI) is up over 62% at $6.12 Knightscope, Inc. (KSCP) is up over 20% at $19.60 WISeKey International Holding AG (WKEY) is up over 16% at $3.80 Cian PLC (CIAN) is up over 9% at $7.66 Happiness Development Group Limited (HAPP) is up over 9% at $0.45 180 Life Sciences Corp. (ATNF) is up over 7% at $2.88 Arbutus Biopharma Corporation (ABUS) is up over 7% at $2.71 Corbus Pharmaceuticals Holdings, Inc. (CRBP) is up over 7% at $0.45 In the Red Imperial Petroleum Inc. (IMPP) is down over 24% at $1.65 Marine Petroleum Trust (MARPS) is down over 7% at $4.75 ObsEva SA (OBSV) is down over 7% at $1.46 Indonesia Energy Corporation Limited (INDO) is down over 6% at $5.19 The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. (RTTNews) - The following are some of the stocks making big moves in Monday's pre-market trading (as of 07.20 A.M. ET). | In the Green FGI Industries Ltd. (FGI) is up over 62% at $6.12 Knightscope, Inc. (KSCP) is up over 20% at $19.60 WISeKey International Holding AG (WKEY) is up over 16% at $3.80 Cian PLC (CIAN) is up over 9% at $7.66 Happiness Development Group Limited (HAPP) is up over 9% at $0.45 180 Life Sciences Corp. (ATNF) is up over 7% at $2.88 Arbutus Biopharma Corporation (ABUS) is up over 7% at $2.71 Corbus Pharmaceuticals Holdings, Inc. (CRBP) is up over 7% at $0.45 In the Red Imperial Petroleum Inc. (IMPP) is down over 24% at $1.65 Marine Petroleum Trust (MARPS) is down over 7% at $4.75 ObsEva SA (OBSV) is down over 7% at $1.46 Indonesia Energy Corporation Limited (INDO) is down over 6% at $5.19 The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. (RTTNews) - The following are some of the stocks making big moves in Monday's pre-market trading (as of 07.20 A.M. ET). |
34625.0 | 2021-12-13 00:00:00 UTC | Arbutus, Qilu To Develop, Commercialize AB-729 In Mainland China, Hong Kong, Macau And Taiwan | ABUS | https://www.nasdaq.com/articles/arbutus-qilu-to-develop-commercialize-ab-729-in-mainland-china-hong-kong-macau-and-taiwan | nan | nan | (RTTNews) - Arbutus Biopharma Corp. (ABUS) and Qilu Pharmaceutical announced an exclusive licensing agreement and strategic partnership to develop and commercialize AB-729 for the treatment or prevention of hepatitis B in mainland China, Hong Kong, Macau and Taiwan.
As per the agreement, Arbutus would receive a $40 million upfront payment and would be entitled to additional payments of up to $245 million upon reaching certain development, regulatory and sales milestones.
Further, Qilu would be responsible for funding all development and commercialization activities for mainland China, Hong Kong, Macau and Taiwan. Arbutus is also entitled to receive double-digit tiered royalties up to the low twenties percent on annual net sales.
In addition, Qilu would make a $15 million equity investment in Arbutus common shares at a price of $4.19 per share, a 15% premium of Arbutus' previous 30-day average closing stock price calculated from December 10, 2021.
AB-729 is Arbutus's lead RNA interference or RNAi therapeutic that is currently in multiple Phase 2a proof-of-concept clinical trials designed to evaluate it in combination with other approved or investigational agents.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | (RTTNews) - Arbutus Biopharma Corp. (ABUS) and Qilu Pharmaceutical announced an exclusive licensing agreement and strategic partnership to develop and commercialize AB-729 for the treatment or prevention of hepatitis B in mainland China, Hong Kong, Macau and Taiwan. Further, Qilu would be responsible for funding all development and commercialization activities for mainland China, Hong Kong, Macau and Taiwan. AB-729 is Arbutus's lead RNA interference or RNAi therapeutic that is currently in multiple Phase 2a proof-of-concept clinical trials designed to evaluate it in combination with other approved or investigational agents. | (RTTNews) - Arbutus Biopharma Corp. (ABUS) and Qilu Pharmaceutical announced an exclusive licensing agreement and strategic partnership to develop and commercialize AB-729 for the treatment or prevention of hepatitis B in mainland China, Hong Kong, Macau and Taiwan. As per the agreement, Arbutus would receive a $40 million upfront payment and would be entitled to additional payments of up to $245 million upon reaching certain development, regulatory and sales milestones. Further, Qilu would be responsible for funding all development and commercialization activities for mainland China, Hong Kong, Macau and Taiwan. | (RTTNews) - Arbutus Biopharma Corp. (ABUS) and Qilu Pharmaceutical announced an exclusive licensing agreement and strategic partnership to develop and commercialize AB-729 for the treatment or prevention of hepatitis B in mainland China, Hong Kong, Macau and Taiwan. As per the agreement, Arbutus would receive a $40 million upfront payment and would be entitled to additional payments of up to $245 million upon reaching certain development, regulatory and sales milestones. In addition, Qilu would make a $15 million equity investment in Arbutus common shares at a price of $4.19 per share, a 15% premium of Arbutus' previous 30-day average closing stock price calculated from December 10, 2021. | (RTTNews) - Arbutus Biopharma Corp. (ABUS) and Qilu Pharmaceutical announced an exclusive licensing agreement and strategic partnership to develop and commercialize AB-729 for the treatment or prevention of hepatitis B in mainland China, Hong Kong, Macau and Taiwan. As per the agreement, Arbutus would receive a $40 million upfront payment and would be entitled to additional payments of up to $245 million upon reaching certain development, regulatory and sales milestones. Further, Qilu would be responsible for funding all development and commercialization activities for mainland China, Hong Kong, Macau and Taiwan. |
34626.0 | 2021-12-09 00:00:00 UTC | Keep on Buying Arbutus Stock Before It Jumps 80%, Says Analyst | ABUS | https://www.nasdaq.com/articles/keep-on-buying-arbutus-stock-before-it-jumps-80-says-analyst | nan | nan | The fight against the coronavirus is an ongoing concern and is being tackled on many fronts. Arbutus Biopharma (ABUS) is another company in the hunt for solutions, and on Tuesday, the biotech announced it had achieved the first milestone based on its agreement with X-Chem and Proteros biostructures on the road to advancing an oral pan-coronavirus treatment.
The company disclosed that it has identified a number of potent and selective small molecules which inhibit the SARS-CoV-2 nsp5 main protease (Mpro), an essential protein needed for viral replication and a validated target for the treatment of Covid-19 and possible future outbreaks of the coronavirus.
Given this milestone has been reached, Arbutus is set to gain the exclusive worldwide license to the identified molecules but in exchange must make an undisclosed but nominal milestone payment to X-Chem and Proteros.
The collaborators have concluded the screening process of X-Chem's considerable Mpro inhibitor library. Now, making use of Proteros' state-of-the-art structure guided methods, they are now advancing into the lead optimization stage. Following which, Arbutus will look to further develop a promising candidate – or candidates - including moving forward to clinical studies.
“We expect more guidance from the company on the timeline for this important program in January 2022,” said H.C. Wainwright analyst Ed Arce. “While this program is still quite early, we are encouraged by the rapid progress and continue to recognize the significant potential value of an oral pan-coronavirus treatment, even several years from now.”
The announcement follows on from another recent positive development. Earlier this month, the company released preliminary data from the ongoing Phase 1a/1b clinical study of AB-836, Arbutus’ next-generation oral capsid inhibitor and indicated as a therapy for chronic hepatitis B viru B virus (cHBV). The data showed the drug was generally safe and well-tolerated, while indicating strong antiviral activity. Arce believes the early signs are “very promising.”
“While this is preliminary data and the sample size (n=4) is quite small,” the analyst said, “We believe that if this robust antiviral activity at a relatively low dose is confirmed at the final result (n=10) and in other higher-dose cohorts, AB-836 may emerge with a clinical profile that is not only generally safe and well-tolerated, but also strongly efficacious and highly competitive with other HBV capsid/core inhibitors.”
These developments underpin Arce’s Buy rating and $8 price target, suggesting room for ~8`0% share appreciation form current levels. (To watch Arce’s track record, click here)
3 other analysts have been tracking ABUS’ progress with 2 imploring to Buy and 1 saying Hold, all adding up to a Strong Buy consensus rating. According to the $7 average price target, shares will be changing hands for a 60% premium a year from now. (See ABUS stock analysis on TipRanks)
To find good ideas for penny stocks trading at attractive valuations, visit TipRanks’ Penny Stocks Screener.
Disclaimer: The opinions expressed in this article are solely those of the featured analyst. The content is intended to be used for informational purposes only. It is very important to do your own analysis before making any investment.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Arbutus Biopharma (ABUS) is another company in the hunt for solutions, and on Tuesday, the biotech announced it had achieved the first milestone based on its agreement with X-Chem and Proteros biostructures on the road to advancing an oral pan-coronavirus treatment. (To watch Arce’s track record, click here) 3 other analysts have been tracking ABUS’ progress with 2 imploring to Buy and 1 saying Hold, all adding up to a Strong Buy consensus rating. (See ABUS stock analysis on TipRanks) To find good ideas for penny stocks trading at attractive valuations, visit TipRanks’ Penny Stocks Screener. | Arbutus Biopharma (ABUS) is another company in the hunt for solutions, and on Tuesday, the biotech announced it had achieved the first milestone based on its agreement with X-Chem and Proteros biostructures on the road to advancing an oral pan-coronavirus treatment. (To watch Arce’s track record, click here) 3 other analysts have been tracking ABUS’ progress with 2 imploring to Buy and 1 saying Hold, all adding up to a Strong Buy consensus rating. (See ABUS stock analysis on TipRanks) To find good ideas for penny stocks trading at attractive valuations, visit TipRanks’ Penny Stocks Screener. | Arbutus Biopharma (ABUS) is another company in the hunt for solutions, and on Tuesday, the biotech announced it had achieved the first milestone based on its agreement with X-Chem and Proteros biostructures on the road to advancing an oral pan-coronavirus treatment. (To watch Arce’s track record, click here) 3 other analysts have been tracking ABUS’ progress with 2 imploring to Buy and 1 saying Hold, all adding up to a Strong Buy consensus rating. (See ABUS stock analysis on TipRanks) To find good ideas for penny stocks trading at attractive valuations, visit TipRanks’ Penny Stocks Screener. | Arbutus Biopharma (ABUS) is another company in the hunt for solutions, and on Tuesday, the biotech announced it had achieved the first milestone based on its agreement with X-Chem and Proteros biostructures on the road to advancing an oral pan-coronavirus treatment. (To watch Arce’s track record, click here) 3 other analysts have been tracking ABUS’ progress with 2 imploring to Buy and 1 saying Hold, all adding up to a Strong Buy consensus rating. (See ABUS stock analysis on TipRanks) To find good ideas for penny stocks trading at attractive valuations, visit TipRanks’ Penny Stocks Screener. |
34627.0 | 2021-12-07 00:00:00 UTC | Pre-Market Most Active for Dec 7, 2021 : SQQQ, INTC, ABUS, SRC, NIO, AAPL, PROG, F, TWTR, TQQQ, UBER, BABA | ABUS | https://www.nasdaq.com/articles/pre-market-most-active-for-dec-7-2021-%3A-sqqq-intc-abus-src-nio-aapl-prog-f-twtr-tqqq-uber | nan | nan | The NASDAQ 100 Pre-Market Indicator is up 15.52 to 16,341.18. The total Pre-Market volume is currently 67,436,463 shares traded.
The following are the most active stocks for the pre-market session:
ProShares UltraPro Short QQQ (SQQQ) is -0.35 at $6.31, with 7,621,929 shares traded. This represents a 10.9% increase from its 52 Week Low.
Intel Corporation (INTC) is +3.67 at $54.66, with 6,484,326 shares traded. INTC's current last sale is 99.38% of the target price of $55.
Arbutus Biopharma Corporation (ABUS) is +0.26 at $3.97, with 5,904,729 shares traded. As reported by Zacks, the current mean recommendation for ABUS is in the "buy range".
Spirit Realty Capital, Inc. (SRC) is -0.46 at $45.51, with 2,197,437 shares traded. SRC's current last sale is 84.28% of the target price of $54.
NIO Inc. (NIO) is +2.01 at $34.35, with 2,019,259 shares traded. As reported by Zacks, the current mean recommendation for NIO is in the "buy range".
Apple Inc. (AAPL) is +3.68 at $169.00, with 1,886,641 shares traded., following a 52-week high recorded in prior regular session.
Progenity, Inc. (PROG) is +0.18 at $3.00, with 1,678,484 shares traded. PROG's current last sale is 150% of the target price of $2.
Ford Motor Company (F) is +0.46 at $19.68, with 1,600,056 shares traded. F's current last sale is 115.76% of the target price of $17.
Twitter, Inc. (TWTR) is +0.65 at $45.12, with 1,527,106 shares traded. TWTR's current last sale is 64.46% of the target price of $70.
ProShares UltraPro QQQ (TQQQ) is +8.49 at $162.08, with 1,516,896 shares traded. This represents a 116.02% increase from its 52 Week Low.
Uber Technologies, Inc. (UBER) is +0.84 at $39.33, with 1,482,914 shares traded. As reported by Zacks, the current mean recommendation for UBER is in the "buy range".
Alibaba Group Holding Limited (BABA) is +5.23 at $128.83, with 1,428,646 shares traded. As reported by Zacks, the current mean recommendation for BABA is in the "buy range".
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Arbutus Biopharma Corporation (ABUS) is +0.26 at $3.97, with 5,904,729 shares traded. As reported by Zacks, the current mean recommendation for ABUS is in the "buy range". ProShares UltraPro Short QQQ (SQQQ) is -0.35 at $6.31, with 7,621,929 shares traded. | As reported by Zacks, the current mean recommendation for ABUS is in the "buy range". Arbutus Biopharma Corporation (ABUS) is +0.26 at $3.97, with 5,904,729 shares traded. As reported by Zacks, the current mean recommendation for NIO is in the "buy range". | Arbutus Biopharma Corporation (ABUS) is +0.26 at $3.97, with 5,904,729 shares traded. As reported by Zacks, the current mean recommendation for ABUS is in the "buy range". The total Pre-Market volume is currently 67,436,463 shares traded. | Arbutus Biopharma Corporation (ABUS) is +0.26 at $3.97, with 5,904,729 shares traded. As reported by Zacks, the current mean recommendation for ABUS is in the "buy range". SRC's current last sale is 84.28% of the target price of $54. |
34628.0 | 2021-12-07 00:00:00 UTC | Pre-Market Most Active for Dec 7, 2021 : SQQQ, ABUS, INTC, TWTR, UBER, AAPL, KO, BABA, LCID, TQQQ, NIO, OWL | ABUS | https://www.nasdaq.com/articles/pre-market-most-active-for-dec-7-2021-%3A-sqqq-abus-intc-twtr-uber-aapl-ko-baba-lcid-tqqq | nan | nan | The NASDAQ 100 Pre-Market Indicator is up 303.33 to 16,149.49. The total Pre-Market volume is currently 36,658,262 shares traded.
The following are the most active stocks for the pre-market session:
ProShares UltraPro Short QQQ (SQQQ) is -0.36 at $6.30, with 5,188,191 shares traded. This represents a 10.72% increase from its 52 Week Low.
Arbutus Biopharma Corporation (ABUS) is +0.37 at $4.08, with 4,239,304 shares traded. As reported by Zacks, the current mean recommendation for ABUS is in the "buy range".
Intel Corporation (INTC) is +3.87 at $54.86, with 3,006,204 shares traded. INTC's current last sale is 99.75% of the target price of $55.
Twitter, Inc. (TWTR) is +1.36 at $45.83, with 1,414,399 shares traded. TWTR's current last sale is 65.47% of the target price of $70.
Uber Technologies, Inc. (UBER) is +1.21 at $39.70, with 1,323,244 shares traded. As reported by Zacks, the current mean recommendation for UBER is in the "buy range".
Apple Inc. (AAPL) is +3.77 at $169.09, with 1,080,028 shares traded. As reported by Zacks, the current mean recommendation for AAPL is in the "buy range".
Coca-Cola Company (The) (KO) is +0.21 at $55.12, with 1,071,955 shares traded. KO's current last sale is 91.87% of the target price of $60.
Alibaba Group Holding Limited (BABA) is +5.93 at $129.53, with 1,033,723 shares traded. As reported by Zacks, the current mean recommendation for BABA is in the "buy range".
Lucid Group, Inc. (LCID) is +1.83 at $46.69, with 998,779 shares traded. As reported by Zacks, the current mean recommendation for LCID is in the "strong buy range".
ProShares UltraPro QQQ (TQQQ) is +8.46 at $162.05, with 952,250 shares traded. This represents a 115.98% increase from its 52 Week Low.
NIO Inc. (NIO) is +1.6 at $33.94, with 919,526 shares traded. As reported by Zacks, the current mean recommendation for NIO is in the "buy range".
Blue Owl Capital Inc. (OWL) is -0.42 at $15.00, with 878,255 shares traded. OWL's current last sale is 90.91% of the target price of $16.5.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Arbutus Biopharma Corporation (ABUS) is +0.37 at $4.08, with 4,239,304 shares traded. As reported by Zacks, the current mean recommendation for ABUS is in the "buy range". ProShares UltraPro Short QQQ (SQQQ) is -0.36 at $6.30, with 5,188,191 shares traded. | As reported by Zacks, the current mean recommendation for ABUS is in the "buy range". Arbutus Biopharma Corporation (ABUS) is +0.37 at $4.08, with 4,239,304 shares traded. As reported by Zacks, the current mean recommendation for UBER is in the "buy range". | Arbutus Biopharma Corporation (ABUS) is +0.37 at $4.08, with 4,239,304 shares traded. As reported by Zacks, the current mean recommendation for ABUS is in the "buy range". The total Pre-Market volume is currently 36,658,262 shares traded. | Arbutus Biopharma Corporation (ABUS) is +0.37 at $4.08, with 4,239,304 shares traded. As reported by Zacks, the current mean recommendation for ABUS is in the "buy range". The NASDAQ 100 Pre-Market Indicator is up 303.33 to 16,149.49. |
34629.0 | 2021-12-06 00:00:00 UTC | Why Vaccine Stocks Like BioNTech and Novavax Are Crashing Today | ABUS | https://www.nasdaq.com/articles/why-vaccine-stocks-like-biontech-and-novavax-are-crashing-today | nan | nan | What happened
Shares of COVID-19 vaccine developers Novavax (NASDAQ: NVAX) and BioNTech (NASDAQ: BNTX) are down 9.2% and 16.1%, respectively, as of 1:19 p.m. ET Monday. Most other makers of COVID-19 vaccines are also under pressure after Moderna (NASDAQ: MRNA) President Stephen Hoge cautioned the world in an interview on Sunday that the existing vaccines may be relatively ineffective in preventing the spread of the new Omicron variant of the coronavirus.
Then there's the fact that pill-based treatments for the disease are nearing their commercial availability.
So what
In an interview with George Stephanopoulos on ABC's This Week, Hoge commented there's a "real risk" that COVID-19's Omicron strain won't be particularly responsive to vaccines that began development even before the Delta variant emerged. It's possible that existing formulations may need to be updated in order to combat the spread of COVID-19. These changes could take weeks to complete, assuming that doing so would produce effective treatments.
Hoge's warning mirrors a similar warning from Moderna CEO Stéphane Bancel a week earlier which didn't upend vaccine manufacturers' stocks. But much has changed in the meantime. As of the end of last week, Omicron infections have been confirmed in 17 different states as well as in several parts of the world. The latest variant may be on track to becoming COVID-19's dominant strain.
The advent of the Omicron variant isn't the only factor contributing to the sharp decline of vaccine stocks today.
Pharmaceutical giants Merck (NYSE: MRK) and Pfizer (NYSE: PFE) have only recently reached key milestones in their development of oral antiviral treatments for COVID-19. A week ago, a U.S. Food and Drug Administration (FDA) advisory committee recommended the FDA approve Merck's antiviral drug molnupiravir as an emergency-use treatment for existing COVID cases in high-risk adults. Pfizer is still waiting for the same green light from the FDA for its Paxlovid. The government has already committed to purchasing 10 million doses of the drug if and when it is approved.
While neither treatment has been specifically tested as a treatment for Omicron infections, both companies say their pills should prove effective against the new strain. The need for these options may have just exploded if Hoge's and Bancel's concern is justified.
Image source: Getty Images.
Monday's multifaceted shake-up on the COVID-19 front rattled more biopharma names than just Novavax and BioNTech. The sell-off dragged down many vaccine-related stocks, including small caps like Arbutus Biopharma (NASDAQ: ABUS) and VBI Vaccines (NASDAQ: VBIV), which are down 13.1% and 8%, respectively, as of midday. Arbutus claims Moderna is using some of its intellectual property with its Moderna vaccine -- an argument the U.S. Court of Appeals bolstered after it rejected Moderna's effort to invalidate two of Arbutus's patents. VBI Vaccines is developing an alternative COVID vaccine of its own. While its VBI-2901 is being designed to target several known strains of the virus, none of those targets are the Omicron variant.
Now what
The knee-jerk sell-off is understandable given the circumstances. Veteran investors can attest to the idea that the time to buy a stock is when it's beaten down. It's possible that the aforementioned vaccine stocks will rebound eventually. Many of the most common ones can possibly be adapted for the Omicron strain.
In a bigger sense, Monday's sell-off underscores a risk that's been in place since any of these companies began working on a COVID-19 vaccine; they're all just one mutation away from being upended. That's why today's sharp sell-offs aren't necessarily a buying opportunity, particularly for buy-and-hold investors.
Certainly, speculators will be interested in positioning for an equally brisk rebound. Given all the new unknowns and variables in play here, however, that sort of trading is more like casino-based gambling and less about true long-term investing. In other words, it can pay off, but the risk of significant near-term loss may be too great for many investors. If you're stepping in for the long haul, just be sure the company has something in the hopper besides a COVID-facing product.
10 stocks we like better than Novavax
When our award-winning analyst team has a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor, has tripled the market.*
They just revealed what they believe are the ten best stocks for investors to buy right now... and Novavax wasn't one of them! That's right -- they think these 10 stocks are even better buys.
See the 10 stocks
*Stock Advisor returns as of November 10, 2021
James Brumley has no position in any of the stocks mentioned. The Motley Fool recommends Moderna Inc. The Motley Fool has a disclosure policy.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | The sell-off dragged down many vaccine-related stocks, including small caps like Arbutus Biopharma (NASDAQ: ABUS) and VBI Vaccines (NASDAQ: VBIV), which are down 13.1% and 8%, respectively, as of midday. So what In an interview with George Stephanopoulos on ABC's This Week, Hoge commented there's a "real risk" that COVID-19's Omicron strain won't be particularly responsive to vaccines that began development even before the Delta variant emerged. The advent of the Omicron variant isn't the only factor contributing to the sharp decline of vaccine stocks today. | The sell-off dragged down many vaccine-related stocks, including small caps like Arbutus Biopharma (NASDAQ: ABUS) and VBI Vaccines (NASDAQ: VBIV), which are down 13.1% and 8%, respectively, as of midday. What happened Shares of COVID-19 vaccine developers Novavax (NASDAQ: NVAX) and BioNTech (NASDAQ: BNTX) are down 9.2% and 16.1%, respectively, as of 1:19 p.m. Hoge's warning mirrors a similar warning from Moderna CEO Stéphane Bancel a week earlier which didn't upend vaccine manufacturers' stocks. | The sell-off dragged down many vaccine-related stocks, including small caps like Arbutus Biopharma (NASDAQ: ABUS) and VBI Vaccines (NASDAQ: VBIV), which are down 13.1% and 8%, respectively, as of midday. Most other makers of COVID-19 vaccines are also under pressure after Moderna (NASDAQ: MRNA) President Stephen Hoge cautioned the world in an interview on Sunday that the existing vaccines may be relatively ineffective in preventing the spread of the new Omicron variant of the coronavirus. So what In an interview with George Stephanopoulos on ABC's This Week, Hoge commented there's a "real risk" that COVID-19's Omicron strain won't be particularly responsive to vaccines that began development even before the Delta variant emerged. | The sell-off dragged down many vaccine-related stocks, including small caps like Arbutus Biopharma (NASDAQ: ABUS) and VBI Vaccines (NASDAQ: VBIV), which are down 13.1% and 8%, respectively, as of midday. Most other makers of COVID-19 vaccines are also under pressure after Moderna (NASDAQ: MRNA) President Stephen Hoge cautioned the world in an interview on Sunday that the existing vaccines may be relatively ineffective in preventing the spread of the new Omicron variant of the coronavirus. A week ago, a U.S. Food and Drug Administration (FDA) advisory committee recommended the FDA approve Merck's antiviral drug molnupiravir as an emergency-use treatment for existing COVID cases in high-risk adults. |
34630.0 | 2021-12-03 00:00:00 UTC | Pre-market Movers: DOCU, ESPR, NAPA, LGVN, OLLI… | ABUS | https://www.nasdaq.com/articles/pre-market-movers%3A-docu-espr-napa-lgvn-olli... | nan | nan | (RTTNews) - The following are some of the stocks making big moves in Friday's pre-market trading (as of 07.00 A.M. ET).
In the Green
The Duckhorn Portfolio, Inc. (NAPA) is up over 28% at $24.00 Longeveron Inc. (LGVN) is up over 28% at $23.20 Marvell Technology, Inc. (MRVL) is up over 19% at $84.93 BIOLASE, Inc. (BIOL) is up over 16% at $0.48 Smartsheet Inc. (SMAR) is up over 15% at $70.60 Celyad Oncology SA (CYAD) is up over 12% at $4.02 890 5th Avenue Partners, Inc. (ENFA) is up over 11% at $11 ReNew Energy Global plc (RNW) is up over 10% at $8.90 Petros Pharmaceuticals, Inc. (PTPI) is up over 10% at $2.85 Zillow Group, Inc. (Z) is up over 9% at $59.35 Marpai, Inc. (MRAI) is up over 8% at $4.80 ReTo Eco-Solutions, Inc. (RETO) is up over 6% at $0.80 Syros Pharmaceuticals, Inc. (SYRS) is up over 5% at $4.04
In the Red
DocuSign, Inc. (DOCU) is down over 31% at $160.47 Esperion Therapeutics, Inc. (ESPR) is down over 30% at $6.20 Ollie's Bargain Outlet Holdings, Inc. (OLLI) is down over 22% at $48.88 Smith & Wesson Brands, Inc. (SWBI) is down over 18% at $18.77 Asana, Inc. (ASAN) is down over 14% at $78 Pioneer Power Solutions, Inc. (PPSI) is down over 10% at $7.58 Valneva SE (VALN) is down over 8% at $57.33 Arbutus Biopharma Corporation (ABUS) is down over 3% at $4.14
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | In the Green The Duckhorn Portfolio, Inc. (NAPA) is up over 28% at $24.00 Longeveron Inc. (LGVN) is up over 28% at $23.20 Marvell Technology, Inc. (MRVL) is up over 19% at $84.93 BIOLASE, Inc. (BIOL) is up over 16% at $0.48 Smartsheet Inc. (SMAR) is up over 15% at $70.60 Celyad Oncology SA (CYAD) is up over 12% at $4.02 890 5th Avenue Partners, Inc. (ENFA) is up over 11% at $11 ReNew Energy Global plc (RNW) is up over 10% at $8.90 Petros Pharmaceuticals, Inc. (PTPI) is up over 10% at $2.85 Zillow Group, Inc. (Z) is up over 9% at $59.35 Marpai, Inc. (MRAI) is up over 8% at $4.80 ReTo Eco-Solutions, Inc. (RETO) is up over 6% at $0.80 Syros Pharmaceuticals, Inc. (SYRS) is up over 5% at $4.04 In the Red DocuSign, Inc. (DOCU) is down over 31% at $160.47 Esperion Therapeutics, Inc. (ESPR) is down over 30% at $6.20 Ollie's Bargain Outlet Holdings, Inc. (OLLI) is down over 22% at $48.88 Smith & Wesson Brands, Inc. (SWBI) is down over 18% at $18.77 Asana, Inc. (ASAN) is down over 14% at $78 Pioneer Power Solutions, Inc. (PPSI) is down over 10% at $7.58 Valneva SE (VALN) is down over 8% at $57.33 Arbutus Biopharma Corporation (ABUS) is down over 3% at $4.14 The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. (RTTNews) - The following are some of the stocks making big moves in Friday's pre-market trading (as of 07.00 A.M. ET). | In the Green The Duckhorn Portfolio, Inc. (NAPA) is up over 28% at $24.00 Longeveron Inc. (LGVN) is up over 28% at $23.20 Marvell Technology, Inc. (MRVL) is up over 19% at $84.93 BIOLASE, Inc. (BIOL) is up over 16% at $0.48 Smartsheet Inc. (SMAR) is up over 15% at $70.60 Celyad Oncology SA (CYAD) is up over 12% at $4.02 890 5th Avenue Partners, Inc. (ENFA) is up over 11% at $11 ReNew Energy Global plc (RNW) is up over 10% at $8.90 Petros Pharmaceuticals, Inc. (PTPI) is up over 10% at $2.85 Zillow Group, Inc. (Z) is up over 9% at $59.35 Marpai, Inc. (MRAI) is up over 8% at $4.80 ReTo Eco-Solutions, Inc. (RETO) is up over 6% at $0.80 Syros Pharmaceuticals, Inc. (SYRS) is up over 5% at $4.04 In the Red DocuSign, Inc. (DOCU) is down over 31% at $160.47 Esperion Therapeutics, Inc. (ESPR) is down over 30% at $6.20 Ollie's Bargain Outlet Holdings, Inc. (OLLI) is down over 22% at $48.88 Smith & Wesson Brands, Inc. (SWBI) is down over 18% at $18.77 Asana, Inc. (ASAN) is down over 14% at $78 Pioneer Power Solutions, Inc. (PPSI) is down over 10% at $7.58 Valneva SE (VALN) is down over 8% at $57.33 Arbutus Biopharma Corporation (ABUS) is down over 3% at $4.14 The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. (RTTNews) - The following are some of the stocks making big moves in Friday's pre-market trading (as of 07.00 A.M. ET). | In the Green The Duckhorn Portfolio, Inc. (NAPA) is up over 28% at $24.00 Longeveron Inc. (LGVN) is up over 28% at $23.20 Marvell Technology, Inc. (MRVL) is up over 19% at $84.93 BIOLASE, Inc. (BIOL) is up over 16% at $0.48 Smartsheet Inc. (SMAR) is up over 15% at $70.60 Celyad Oncology SA (CYAD) is up over 12% at $4.02 890 5th Avenue Partners, Inc. (ENFA) is up over 11% at $11 ReNew Energy Global plc (RNW) is up over 10% at $8.90 Petros Pharmaceuticals, Inc. (PTPI) is up over 10% at $2.85 Zillow Group, Inc. (Z) is up over 9% at $59.35 Marpai, Inc. (MRAI) is up over 8% at $4.80 ReTo Eco-Solutions, Inc. (RETO) is up over 6% at $0.80 Syros Pharmaceuticals, Inc. (SYRS) is up over 5% at $4.04 In the Red DocuSign, Inc. (DOCU) is down over 31% at $160.47 Esperion Therapeutics, Inc. (ESPR) is down over 30% at $6.20 Ollie's Bargain Outlet Holdings, Inc. (OLLI) is down over 22% at $48.88 Smith & Wesson Brands, Inc. (SWBI) is down over 18% at $18.77 Asana, Inc. (ASAN) is down over 14% at $78 Pioneer Power Solutions, Inc. (PPSI) is down over 10% at $7.58 Valneva SE (VALN) is down over 8% at $57.33 Arbutus Biopharma Corporation (ABUS) is down over 3% at $4.14 The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. (RTTNews) - The following are some of the stocks making big moves in Friday's pre-market trading (as of 07.00 A.M. ET). | In the Green The Duckhorn Portfolio, Inc. (NAPA) is up over 28% at $24.00 Longeveron Inc. (LGVN) is up over 28% at $23.20 Marvell Technology, Inc. (MRVL) is up over 19% at $84.93 BIOLASE, Inc. (BIOL) is up over 16% at $0.48 Smartsheet Inc. (SMAR) is up over 15% at $70.60 Celyad Oncology SA (CYAD) is up over 12% at $4.02 890 5th Avenue Partners, Inc. (ENFA) is up over 11% at $11 ReNew Energy Global plc (RNW) is up over 10% at $8.90 Petros Pharmaceuticals, Inc. (PTPI) is up over 10% at $2.85 Zillow Group, Inc. (Z) is up over 9% at $59.35 Marpai, Inc. (MRAI) is up over 8% at $4.80 ReTo Eco-Solutions, Inc. (RETO) is up over 6% at $0.80 Syros Pharmaceuticals, Inc. (SYRS) is up over 5% at $4.04 In the Red DocuSign, Inc. (DOCU) is down over 31% at $160.47 Esperion Therapeutics, Inc. (ESPR) is down over 30% at $6.20 Ollie's Bargain Outlet Holdings, Inc. (OLLI) is down over 22% at $48.88 Smith & Wesson Brands, Inc. (SWBI) is down over 18% at $18.77 Asana, Inc. (ASAN) is down over 14% at $78 Pioneer Power Solutions, Inc. (PPSI) is down over 10% at $7.58 Valneva SE (VALN) is down over 8% at $57.33 Arbutus Biopharma Corporation (ABUS) is down over 3% at $4.14 The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. (RTTNews) - The following are some of the stocks making big moves in Friday's pre-market trading (as of 07.00 A.M. ET). |
34631.0 | 2021-12-02 00:00:00 UTC | Arbutus: Still Plenty of Upside Left Following Favorable Court Decision | ABUS | https://www.nasdaq.com/articles/arbutus%3A-still-plenty-of-upside-left-following-favorable-court-decision | nan | nan | Wednesday’s session started off promisingly but quickly deteriorated with all three indexes seeing out the trading activity in the red. However, that was of little concern to Arbutus Biopharma (ABUS) investors.
Arbutus shares took the up escalator, given a 44% boost following a favorable court of appeals decision. In direct relation to Arbutus’ surge, on the other side of the equation, Moderna shares lost 12%. So, how are these two connected?
A Federal Circuit Court of Appeals looking into the Patent Trial and Appeals Board’s (PTAB) decision to back Arbutus over the lipid nanoparticle (LNP) technology which Moderna has utilized in its Covid-19 vaccine, rejected the vaccine giant’s claims. Although Moderna had in the past licensed the LNPs from Arbutus for other uses, it argued they aren’t patentable. The court disagreed and upheld Arbutus’ patent claims.
LNPs are the minute fat bubbles that coat RNA-based vaccines and enable the vaccine to flow through the bloodstream to the target. Part of Arbutus’s business strategy is based on licensing the tech.
The court’s decision could put ABUS in line for royalties from the sales of Moderna’s Covid-19 vaccine or otherwise it stands to receive a notable one-off fee, which as JMP’s Roy Buchanan notes, could go toward the company’s pipeline development.
“Our main takeaway is that this is obviously positive for Arbutus and may eventually provide funding for the company's HBV programs (and could today if the company utilizes its ATM equity facility),” the analyst said. “Affirmation of the PTAB decisions a clear win for Arbutus' LNP IP.”
The shares might have seen out Wednesday carrying a mighty haul, but Buchanan sees plenty more upside ahead. The analyst reiterated an Outperform (i.e. Buy) rating, backed by a $9 price target, suggesting shares will climb by another 108% over the coming months. (To watch Buchanan’s track record, click here)
Looking at the consensus breakdown, the rest of the Street is on the same page more or less. 3 Buys and 1 Hold add up to a Strong Buy consensus rating. The $6.63 average price target puts the upside potential at ~55%. (See ABUS stock analysis on TipRanks)
To find good ideas for stocks trading at attractive valuations, visit TipRanks’ Best Stocks to Buy, a newly launched tool that unites all of TipRanks’ equity insights.
Disclaimer: The opinions expressed in this article are solely those of the featured analyst. The content is intended to be used for informational purposes only. It is very important to do your own analysis before making any investment.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | The court’s decision could put ABUS in line for royalties from the sales of Moderna’s Covid-19 vaccine or otherwise it stands to receive a notable one-off fee, which as JMP’s Roy Buchanan notes, could go toward the company’s pipeline development. However, that was of little concern to Arbutus Biopharma (ABUS) investors. (See ABUS stock analysis on TipRanks) To find good ideas for stocks trading at attractive valuations, visit TipRanks’ Best Stocks to Buy, a newly launched tool that unites all of TipRanks’ equity insights. | However, that was of little concern to Arbutus Biopharma (ABUS) investors. The court’s decision could put ABUS in line for royalties from the sales of Moderna’s Covid-19 vaccine or otherwise it stands to receive a notable one-off fee, which as JMP’s Roy Buchanan notes, could go toward the company’s pipeline development. (See ABUS stock analysis on TipRanks) To find good ideas for stocks trading at attractive valuations, visit TipRanks’ Best Stocks to Buy, a newly launched tool that unites all of TipRanks’ equity insights. | (See ABUS stock analysis on TipRanks) To find good ideas for stocks trading at attractive valuations, visit TipRanks’ Best Stocks to Buy, a newly launched tool that unites all of TipRanks’ equity insights. However, that was of little concern to Arbutus Biopharma (ABUS) investors. The court’s decision could put ABUS in line for royalties from the sales of Moderna’s Covid-19 vaccine or otherwise it stands to receive a notable one-off fee, which as JMP’s Roy Buchanan notes, could go toward the company’s pipeline development. | However, that was of little concern to Arbutus Biopharma (ABUS) investors. The court’s decision could put ABUS in line for royalties from the sales of Moderna’s Covid-19 vaccine or otherwise it stands to receive a notable one-off fee, which as JMP’s Roy Buchanan notes, could go toward the company’s pipeline development. (See ABUS stock analysis on TipRanks) To find good ideas for stocks trading at attractive valuations, visit TipRanks’ Best Stocks to Buy, a newly launched tool that unites all of TipRanks’ equity insights. |
34632.0 | 2021-12-02 00:00:00 UTC | Pre-market Movers: TANH, GRAB, DWAC, VIR, SNOW… | ABUS | https://www.nasdaq.com/articles/pre-market-movers%3A-tanh-grab-dwac-vir-snow... | nan | nan | (RTTNews) - The following are some of the stocks making big moves in Thursday's pre-market trading (as of 07.30 A.M. ET).
In the Green
Grab Holdings Limited Class A Ordinary Shares (GRAB) is up over 42% at $15.65 Digital World Acquisition Corp. (DWAC) is up over 20% at $53.58 Vir Biotechnology, Inc. (VIR) is up over 19% at $56.01 Phunware, Inc. (PHUN) is up over 19% at $3.87 Snowflake Inc. (SNOW) is up over 15% at $358.00 4D pharma plc (LBPS) is up over 15% at $6.98 Arbutus Biopharma Corporation (ABUS) is up over 15% at $5.32 Remark Holdings, Inc. (MARK) is up over 15% at $1.38 RLX Technology Inc. (RLX) is up over 11% at $4.60 Outlook Therapeutics, Inc. (OTLK) is up over 9% at $1.41 Abeona Therapeutics Inc. (ABEO) is up over 8% at $0.65 Express, Inc. (EXPR) is up over 7% at $3.65 T2 Biosystems, Inc. (TTOO) is up over 7% at $0.64 trivago N.V. (TRVG) is up over 6% at $2.20
In the Red
Tantech Holdings Ltd (TANH) is down over 47% at $0.79 180 Life Sciences Corp. (ATNF) is down over 15% at $4.25 MDJM Ltd (MDJH) is down over 15% at $2.55 OceanPal Inc. (OP) is down over 14% at $5.60 NLS Pharmaceutics AG (NLSP) is down over 10% at $1.80 Cumberland Pharmaceuticals Inc. (CPIX) is down over 8% at $3.77 Skylight Health Group Inc. (SLHG) is down over 8% at $1.55 Palatin Technologies, Inc. (PTN) is down over 5% at $0.54 Clarus Therapeutics Holdings, Inc. (CRXT) is down over 4% at $4.75
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | In the Green Grab Holdings Limited Class A Ordinary Shares (GRAB) is up over 42% at $15.65 Digital World Acquisition Corp. (DWAC) is up over 20% at $53.58 Vir Biotechnology, Inc. (VIR) is up over 19% at $56.01 Phunware, Inc. (PHUN) is up over 19% at $3.87 Snowflake Inc. (SNOW) is up over 15% at $358.00 4D pharma plc (LBPS) is up over 15% at $6.98 Arbutus Biopharma Corporation (ABUS) is up over 15% at $5.32 Remark Holdings, Inc. (MARK) is up over 15% at $1.38 RLX Technology Inc. (RLX) is up over 11% at $4.60 Outlook Therapeutics, Inc. (OTLK) is up over 9% at $1.41 Abeona Therapeutics Inc. (ABEO) is up over 8% at $0.65 Express, Inc. (EXPR) is up over 7% at $3.65 T2 Biosystems, Inc. (TTOO) is up over 7% at $0.64 trivago N.V. (TRVG) is up over 6% at $2.20 In the Red Tantech Holdings Ltd (TANH) is down over 47% at $0.79 180 Life Sciences Corp. (ATNF) is down over 15% at $4.25 MDJM Ltd (MDJH) is down over 15% at $2.55 OceanPal Inc. (OP) is down over 14% at $5.60 NLS Pharmaceutics AG (NLSP) is down over 10% at $1.80 Cumberland Pharmaceuticals Inc. (CPIX) is down over 8% at $3.77 Skylight Health Group Inc. (SLHG) is down over 8% at $1.55 Palatin Technologies, Inc. (PTN) is down over 5% at $0.54 Clarus Therapeutics Holdings, Inc. (CRXT) is down over 4% at $4.75 The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. (RTTNews) - The following are some of the stocks making big moves in Thursday's pre-market trading (as of 07.30 A.M. ET). | In the Green Grab Holdings Limited Class A Ordinary Shares (GRAB) is up over 42% at $15.65 Digital World Acquisition Corp. (DWAC) is up over 20% at $53.58 Vir Biotechnology, Inc. (VIR) is up over 19% at $56.01 Phunware, Inc. (PHUN) is up over 19% at $3.87 Snowflake Inc. (SNOW) is up over 15% at $358.00 4D pharma plc (LBPS) is up over 15% at $6.98 Arbutus Biopharma Corporation (ABUS) is up over 15% at $5.32 Remark Holdings, Inc. (MARK) is up over 15% at $1.38 RLX Technology Inc. (RLX) is up over 11% at $4.60 Outlook Therapeutics, Inc. (OTLK) is up over 9% at $1.41 Abeona Therapeutics Inc. (ABEO) is up over 8% at $0.65 Express, Inc. (EXPR) is up over 7% at $3.65 T2 Biosystems, Inc. (TTOO) is up over 7% at $0.64 trivago N.V. (TRVG) is up over 6% at $2.20 In the Red Tantech Holdings Ltd (TANH) is down over 47% at $0.79 180 Life Sciences Corp. (ATNF) is down over 15% at $4.25 MDJM Ltd (MDJH) is down over 15% at $2.55 OceanPal Inc. (OP) is down over 14% at $5.60 NLS Pharmaceutics AG (NLSP) is down over 10% at $1.80 Cumberland Pharmaceuticals Inc. (CPIX) is down over 8% at $3.77 Skylight Health Group Inc. (SLHG) is down over 8% at $1.55 Palatin Technologies, Inc. (PTN) is down over 5% at $0.54 Clarus Therapeutics Holdings, Inc. (CRXT) is down over 4% at $4.75 The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. (RTTNews) - The following are some of the stocks making big moves in Thursday's pre-market trading (as of 07.30 A.M. ET). | In the Green Grab Holdings Limited Class A Ordinary Shares (GRAB) is up over 42% at $15.65 Digital World Acquisition Corp. (DWAC) is up over 20% at $53.58 Vir Biotechnology, Inc. (VIR) is up over 19% at $56.01 Phunware, Inc. (PHUN) is up over 19% at $3.87 Snowflake Inc. (SNOW) is up over 15% at $358.00 4D pharma plc (LBPS) is up over 15% at $6.98 Arbutus Biopharma Corporation (ABUS) is up over 15% at $5.32 Remark Holdings, Inc. (MARK) is up over 15% at $1.38 RLX Technology Inc. (RLX) is up over 11% at $4.60 Outlook Therapeutics, Inc. (OTLK) is up over 9% at $1.41 Abeona Therapeutics Inc. (ABEO) is up over 8% at $0.65 Express, Inc. (EXPR) is up over 7% at $3.65 T2 Biosystems, Inc. (TTOO) is up over 7% at $0.64 trivago N.V. (TRVG) is up over 6% at $2.20 In the Red Tantech Holdings Ltd (TANH) is down over 47% at $0.79 180 Life Sciences Corp. (ATNF) is down over 15% at $4.25 MDJM Ltd (MDJH) is down over 15% at $2.55 OceanPal Inc. (OP) is down over 14% at $5.60 NLS Pharmaceutics AG (NLSP) is down over 10% at $1.80 Cumberland Pharmaceuticals Inc. (CPIX) is down over 8% at $3.77 Skylight Health Group Inc. (SLHG) is down over 8% at $1.55 Palatin Technologies, Inc. (PTN) is down over 5% at $0.54 Clarus Therapeutics Holdings, Inc. (CRXT) is down over 4% at $4.75 The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. (RTTNews) - The following are some of the stocks making big moves in Thursday's pre-market trading (as of 07.30 A.M. ET). | In the Green Grab Holdings Limited Class A Ordinary Shares (GRAB) is up over 42% at $15.65 Digital World Acquisition Corp. (DWAC) is up over 20% at $53.58 Vir Biotechnology, Inc. (VIR) is up over 19% at $56.01 Phunware, Inc. (PHUN) is up over 19% at $3.87 Snowflake Inc. (SNOW) is up over 15% at $358.00 4D pharma plc (LBPS) is up over 15% at $6.98 Arbutus Biopharma Corporation (ABUS) is up over 15% at $5.32 Remark Holdings, Inc. (MARK) is up over 15% at $1.38 RLX Technology Inc. (RLX) is up over 11% at $4.60 Outlook Therapeutics, Inc. (OTLK) is up over 9% at $1.41 Abeona Therapeutics Inc. (ABEO) is up over 8% at $0.65 Express, Inc. (EXPR) is up over 7% at $3.65 T2 Biosystems, Inc. (TTOO) is up over 7% at $0.64 trivago N.V. (TRVG) is up over 6% at $2.20 In the Red Tantech Holdings Ltd (TANH) is down over 47% at $0.79 180 Life Sciences Corp. (ATNF) is down over 15% at $4.25 MDJM Ltd (MDJH) is down over 15% at $2.55 OceanPal Inc. (OP) is down over 14% at $5.60 NLS Pharmaceutics AG (NLSP) is down over 10% at $1.80 Cumberland Pharmaceuticals Inc. (CPIX) is down over 8% at $3.77 Skylight Health Group Inc. (SLHG) is down over 8% at $1.55 Palatin Technologies, Inc. (PTN) is down over 5% at $0.54 Clarus Therapeutics Holdings, Inc. (CRXT) is down over 4% at $4.75 The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. (RTTNews) - The following are some of the stocks making big moves in Thursday's pre-market trading (as of 07.30 A.M. ET). |
34633.0 | 2021-12-02 00:00:00 UTC | Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursday | ABUS | https://www.nasdaq.com/articles/todays-biggest-pre-market-stock-movers%3A-10-top-gainers-and-losers-on-thursday-0 | nan | nan | InvestorPlace - Stock Market News, Stock Advice & Trading Tips
Good morning, trader! We’re gearing up for another busy day of trading with the biggest pre-market stock movers for Thursday!
Source: ventdusud / Shutterstock.com
News moving stocks today include earnings reports, social media chatter, Omicron, and more.
Let’s get into that news below!
Pre-Market Stock Movers: 10 Top Gainers
Digital World Acquisition (NASDAQ:DWAC) stock is soaring more than 21% on reports the SPAC plans to raise $1 billion in fundraising for its merger with former President Donald Trump’s social media company.
Phunware (NASDAQ:PHUN) shares are heading over 18% higher due to its possible connection to Digital World Acquisition.
Abeona Therapeutics (NASDAQ:ABEO) stock is surging more than 16% on social media buzz from retail traders.
Arbutus Biopharma (NASDAQ:ABUS) shares are rising over 14% as it continues to rally on court ruling news.
Snowflake (NYSE:SNOW) stock is sitting almost 14% higher thanks to the release of its Q3 earnings report.
RLX Technology (NYSE:RLX) shares are climbing more than 12% as China prepares new regulations for e-ciggarettes.
Remark (NASDAQ:MARK) stock is gaining over 11% despite a lack of news this morning.
Express (NYSE:EXPR) shares are increasing nearly 11% with the release of its most recent earnings report.
T2 Biosystems (NASDAQ:TTOO) stock is getting a more than 10% boost after announcing its test can detect Covid-19 variant Omicron.
Vir Biotechnology (NASDAQ:VIR) shares are up over 9% on news that sotrovimab is still effective against Omicron.
7 Stocks to Buy to Hedge Against Rising Oil Prices
10 Top Losers
Tantech (NASDAQ:TANH) stock is plummeting 42% after announcing a proposed public offering.
MDJM (NASDAQ:MDJH) shares are diving more than 16% on no apparent news today.
180 Life Sciences (NASDAQ:ATNF) stock is taking an over 13% beating following a presentation including clinical data yesterday.
OceanPal (NASDAQ:OP) shares are pulling back more than 11% following a recent rally on their public debut.
Clarus Therapeutics (NASDAQ:CRXT) stock is falling over 10% as shares retreat after a rally earlier this week on patent news.
Cumberland (NASDAQ:CPIX) shares are decreasing more than 9% after rallying recently on FDA news.
NLS Pharmaceutics (NASDAQ:NLSP) stock is slipping over 9% following a recent rally on preclinical results.
Skylight Health Group (NASDAQ:SLHG) shares are dropping more than 9% after announcing the pricing for a public offering of its stock.
Pasithea Therapeutics (NASDAQ:KTTA) stock is dipping over 8% after closing its private placement.
Palatin Technologies (NYSEAMERICAN:PTN) shares close out our pre-market stock movers down more than 8% as they settle from a rally at the start of the week.
On the date of publication, William White did not have (either directly or indirectly) any positions in the securities mentioned in this article. The opinions expressed in this article are those of the writer, subject to the InvestorPlace.com Publishing Guidelines.
The post Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursday appeared first on InvestorPlace.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Arbutus Biopharma (NASDAQ:ABUS) shares are rising over 14% as it continues to rally on court ruling news. Source: ventdusud / Shutterstock.com News moving stocks today include earnings reports, social media chatter, Omicron, and more. Clarus Therapeutics (NASDAQ:CRXT) stock is falling over 10% as shares retreat after a rally earlier this week on patent news. | Arbutus Biopharma (NASDAQ:ABUS) shares are rising over 14% as it continues to rally on court ruling news. Source: ventdusud / Shutterstock.com News moving stocks today include earnings reports, social media chatter, Omicron, and more. Pre-Market Stock Movers: 10 Top Gainers Digital World Acquisition (NASDAQ:DWAC) stock is soaring more than 21% on reports the SPAC plans to raise $1 billion in fundraising for its merger with former President Donald Trump’s social media company. | Arbutus Biopharma (NASDAQ:ABUS) shares are rising over 14% as it continues to rally on court ruling news. Pre-Market Stock Movers: 10 Top Gainers Digital World Acquisition (NASDAQ:DWAC) stock is soaring more than 21% on reports the SPAC plans to raise $1 billion in fundraising for its merger with former President Donald Trump’s social media company. 7 Stocks to Buy to Hedge Against Rising Oil Prices 10 Top Losers Tantech (NASDAQ:TANH) stock is plummeting 42% after announcing a proposed public offering. | Arbutus Biopharma (NASDAQ:ABUS) shares are rising over 14% as it continues to rally on court ruling news. Source: ventdusud / Shutterstock.com News moving stocks today include earnings reports, social media chatter, Omicron, and more. Let’s get into that news below! |
34634.0 | 2021-12-02 00:00:00 UTC | Arbutus Biopharma (NASDAQ:ABUS) delivers shareholders notable 7.6% CAGR over 5 years, surging 45% in the last week alone | ABUS | https://www.nasdaq.com/articles/arbutus-biopharma-nasdaq%3Aabus-delivers-shareholders-notable-7.6-cagr-over-5-years-surging | nan | nan | When you buy and hold a stock for the long term, you definitely want it to provide a positive return. Furthermore, you'd generally like to see the share price rise faster than the market. Unfortunately for shareholders, while the Arbutus Biopharma Corporation (NASDAQ:ABUS) share price is up 44% in the last five years, that's less than the market return. Looking at the last year alone, the stock is up 17%.
After a strong gain in the past week, it's worth seeing if longer term returns have been driven by improving fundamentals.
Arbutus Biopharma wasn't profitable in the last twelve months, it is unlikely we'll see a strong correlation between its share price and its earnings per share (EPS). Arguably revenue is our next best option. Shareholders of unprofitable companies usually expect strong revenue growth. That's because fast revenue growth can be easily extrapolated to forecast profits, often of considerable size.
For the last half decade, Arbutus Biopharma can boast revenue growth at a rate of 2.8% per year. Put simply, that growth rate fails to impress. Like its revenue, its share price gained over the period. The increase of 8% per year probably reflects the modest revenue growth. It seems likely that we'll have to zoom in on the data, including profits, to understand if there is an opportunity here.
The company's revenue and earnings (over time) are depicted in the image below (click to see the exact numbers).
NasdaqGS:ABUS Earnings and Revenue Growth December 2nd 2021
Balance sheet strength is crucial. It might be well worthwhile taking a look at our free report on how its financial position has changed over time.
A Different Perspective
Arbutus Biopharma provided a TSR of 17% over the last twelve months. But that return falls short of the market. The silver lining is that the gain was actually better than the average annual return of 8% per year over five year. This could indicate that the company is winning over new investors, as it pursues its strategy. It's always interesting to track share price performance over the longer term. But to understand Arbutus Biopharma better, we need to consider many other factors. Even so, be aware that Arbutus Biopharma is showing 3 warning signs in our investment analysis , and 1 of those doesn't sit too well with us...
Of course Arbutus Biopharma may not be the best stock to buy. So you may wish to see this free collection of growth stocks.
Please note, the market returns quoted in this article reflect the market weighted average returns of stocks that currently trade on US exchanges.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Unfortunately for shareholders, while the Arbutus Biopharma Corporation (NASDAQ:ABUS) share price is up 44% in the last five years, that's less than the market return. NasdaqGS:ABUS Earnings and Revenue Growth December 2nd 2021 Balance sheet strength is crucial. After a strong gain in the past week, it's worth seeing if longer term returns have been driven by improving fundamentals. | Unfortunately for shareholders, while the Arbutus Biopharma Corporation (NASDAQ:ABUS) share price is up 44% in the last five years, that's less than the market return. NasdaqGS:ABUS Earnings and Revenue Growth December 2nd 2021 Balance sheet strength is crucial. Arbutus Biopharma wasn't profitable in the last twelve months, it is unlikely we'll see a strong correlation between its share price and its earnings per share (EPS). | Unfortunately for shareholders, while the Arbutus Biopharma Corporation (NASDAQ:ABUS) share price is up 44% in the last five years, that's less than the market return. NasdaqGS:ABUS Earnings and Revenue Growth December 2nd 2021 Balance sheet strength is crucial. Even so, be aware that Arbutus Biopharma is showing 3 warning signs in our investment analysis , and 1 of those doesn't sit too well with us... Of course Arbutus Biopharma may not be the best stock to buy. | Unfortunately for shareholders, while the Arbutus Biopharma Corporation (NASDAQ:ABUS) share price is up 44% in the last five years, that's less than the market return. NasdaqGS:ABUS Earnings and Revenue Growth December 2nd 2021 Balance sheet strength is crucial. When you buy and hold a stock for the long term, you definitely want it to provide a positive return. |
34635.0 | 2021-12-01 00:00:00 UTC | Why Moderna Stock Plunged Today | ABUS | https://www.nasdaq.com/articles/why-moderna-stock-plunged-today | nan | nan | What happened
Shares of Moderna (NASDAQ: MRNA) fell 12% on Wednesday after a court ruling placed a portion of the biotech's blockbuster COVID-19 vaccine proceeds at risk.
So what
A U.S. Court of Appeals for the Federal Circuit panel affirmed a previous ruling by the U.S. Patent and Trademark Office's Patent Trial and Appeal Board. The decision blocked Moderna's attempts to invalidate two of Arbutus Biopharma's (NASDAQ: ABUS) patents on its lipid nanoparticle (LNP) drug-delivery technology.
Moderna uses LNP to deliver its messenger RNA (mRNA) COVID-19 vaccine safely and effectively into patients.
Moderna's stock price fell sharply on Wednesday following an unfavorable legal decision. Image source: Getty Images.
The court ruling could expose Moderna to a patent infringement lawsuit if Arbutus chooses to bring one against it. However, analysts say it's more likely that the two companies will work out a royalty agreement, with Moderna passing a small percentage of its COVID-19 vaccine sales on to Arbutus.
Now what
Moderna's shares were already under pressure after CEO Stéphane Bancel warned of a sharp decline in the effectiveness of the drugmaker's vaccine in the wake of the emergence of the omicron variant. That could result in reduced demand for its vaccine, which accounts for nearly all of Moderna's revenue.
Still, Moderna President Stephen Hoge expects the company to develop a booster shot that specifically targets the new coronavirus strain. He believes Moderna could file for regulatory authorization for the shots as early as March. Thus, any near-term hit to its COVID-19 vaccine revenue could be offset by sales of boosters beginning early next year.
With the long-term impact of the omicron variant and the recent appeals court ruling likely to be minor, today's sell-off in Moderna's share price could prove to be an overreaction on the part of investors.
10 stocks we like better than Moderna Inc.
When our award-winning analyst team has a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor, has tripled the market.*
They just revealed what they believe are the ten best stocks for investors to buy right now... and Moderna Inc. wasn't one of them! That's right -- they think these 10 stocks are even better buys.
See the 10 stocks
*Stock Advisor returns as of November 10, 2021
Joe Tenebruso has no position in any of the stocks mentioned. The Motley Fool recommends Moderna Inc. The Motley Fool has a disclosure policy.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | The decision blocked Moderna's attempts to invalidate two of Arbutus Biopharma's (NASDAQ: ABUS) patents on its lipid nanoparticle (LNP) drug-delivery technology. What happened Shares of Moderna (NASDAQ: MRNA) fell 12% on Wednesday after a court ruling placed a portion of the biotech's blockbuster COVID-19 vaccine proceeds at risk. Now what Moderna's shares were already under pressure after CEO Stéphane Bancel warned of a sharp decline in the effectiveness of the drugmaker's vaccine in the wake of the emergence of the omicron variant. | The decision blocked Moderna's attempts to invalidate two of Arbutus Biopharma's (NASDAQ: ABUS) patents on its lipid nanoparticle (LNP) drug-delivery technology. What happened Shares of Moderna (NASDAQ: MRNA) fell 12% on Wednesday after a court ruling placed a portion of the biotech's blockbuster COVID-19 vaccine proceeds at risk. Moderna's stock price fell sharply on Wednesday following an unfavorable legal decision. | The decision blocked Moderna's attempts to invalidate two of Arbutus Biopharma's (NASDAQ: ABUS) patents on its lipid nanoparticle (LNP) drug-delivery technology. What happened Shares of Moderna (NASDAQ: MRNA) fell 12% on Wednesday after a court ruling placed a portion of the biotech's blockbuster COVID-19 vaccine proceeds at risk. 10 stocks we like better than Moderna Inc. | The decision blocked Moderna's attempts to invalidate two of Arbutus Biopharma's (NASDAQ: ABUS) patents on its lipid nanoparticle (LNP) drug-delivery technology. What happened Shares of Moderna (NASDAQ: MRNA) fell 12% on Wednesday after a court ruling placed a portion of the biotech's blockbuster COVID-19 vaccine proceeds at risk. With the long-term impact of the omicron variant and the recent appeals court ruling likely to be minor, today's sell-off in Moderna's share price could prove to be an overreaction on the part of investors. |
34636.0 | 2021-12-01 00:00:00 UTC | Health Care Sector Update for 12/01/2021: ABUS,MRNA,ARDX,BHG,BYSI | ABUS | https://www.nasdaq.com/articles/health-care-sector-update-for-12-01-2021%3A-abusmrnaardxbhgbysi | nan | nan | Health care stocks escaped the brunt of Wednesday's late selloff, with the NYSE Health Care Index still rising 0.8% while the Health Care Select Sector SPDR ETF (XLV) gained 0.3%.
The Nasdaq Biotechnology index fell 1.7%.
In company news, Arbutus Biopharma (ABUS) was nearly 46% higher after a US appeals court rejected Moderna's (MRNA) appeal of a decision upholding disputed Arbutus patents, potentially paving the way for patent infriingement claims against mRNA vaccine makers. Moderna shares plunged nearly 12%.
Arbutus also said its AB-836 drug candidate provided robust antiviral activity in patients with chronic hepatitis B in a phase 1a/1b trial. The next-generation capsid inhibitor also was generally safe and well-tolerated in healthy subjects in either single and multiple doses and in hepatitis B patients receiving once-daily injections of up to 100 milligrams, the company said.
Ardelyx (ARDX) shares climbed almost 7.5% after the drug maker announced plans for the commercial launch of its Isbrela treatment for irritable bowel syndrome in adults with constipation during the second quarter of 2022. The company is expecting Isbrela to generate as much as $500 million in annual sales. | In company news, Arbutus Biopharma (ABUS) was nearly 46% higher after a US appeals court rejected Moderna's (MRNA) appeal of a decision upholding disputed Arbutus patents, potentially paving the way for patent infriingement claims against mRNA vaccine makers. Arbutus also said its AB-836 drug candidate provided robust antiviral activity in patients with chronic hepatitis B in a phase 1a/1b trial. The next-generation capsid inhibitor also was generally safe and well-tolerated in healthy subjects in either single and multiple doses and in hepatitis B patients receiving once-daily injections of up to 100 milligrams, the company said. | In company news, Arbutus Biopharma (ABUS) was nearly 46% higher after a US appeals court rejected Moderna's (MRNA) appeal of a decision upholding disputed Arbutus patents, potentially paving the way for patent infriingement claims against mRNA vaccine makers. Health care stocks escaped the brunt of Wednesday's late selloff, with the NYSE Health Care Index still rising 0.8% while the Health Care Select Sector SPDR ETF (XLV) gained 0.3%. Moderna shares plunged nearly 12%. | In company news, Arbutus Biopharma (ABUS) was nearly 46% higher after a US appeals court rejected Moderna's (MRNA) appeal of a decision upholding disputed Arbutus patents, potentially paving the way for patent infriingement claims against mRNA vaccine makers. Health care stocks escaped the brunt of Wednesday's late selloff, with the NYSE Health Care Index still rising 0.8% while the Health Care Select Sector SPDR ETF (XLV) gained 0.3%. Ardelyx (ARDX) shares climbed almost 7.5% after the drug maker announced plans for the commercial launch of its Isbrela treatment for irritable bowel syndrome in adults with constipation during the second quarter of 2022. | In company news, Arbutus Biopharma (ABUS) was nearly 46% higher after a US appeals court rejected Moderna's (MRNA) appeal of a decision upholding disputed Arbutus patents, potentially paving the way for patent infriingement claims against mRNA vaccine makers. Health care stocks escaped the brunt of Wednesday's late selloff, with the NYSE Health Care Index still rising 0.8% while the Health Care Select Sector SPDR ETF (XLV) gained 0.3%. The Nasdaq Biotechnology index fell 1.7%. |
34637.0 | 2021-12-01 00:00:00 UTC | Noteworthy Wednesday Option Activity: ABUS, AMZN, GOOGL | ABUS | https://www.nasdaq.com/articles/noteworthy-wednesday-option-activity%3A-abus-amzn-googl | nan | nan | Among the underlying components of the Russell 3000 index, we saw noteworthy options trading volume today in Arbutus Biopharma Corp (Symbol: ABUS), where a total of 152,984 contracts have traded so far, representing approximately 15.3 million underlying shares. That amounts to about 1068.4% of ABUS's average daily trading volume over the past month of 1.4 million shares. Particularly high volume was seen for the $7.50 strike call option expiring December 17, 2021, with 38,742 contracts trading so far today, representing approximately 3.9 million underlying shares of ABUS. Below is a chart showing ABUS's trailing twelve month trading history, with the $7.50 strike highlighted in orange:
Amazon.com Inc (Symbol: AMZN) options are showing a volume of 259,213 contracts thus far today. That number of contracts represents approximately 25.9 million underlying shares, working out to a sizeable 718.2% of AMZN's average daily trading volume over the past month, of 3.6 million shares. Particularly high volume was seen for the $3600 strike call option expiring December 03, 2021, with 19,316 contracts trading so far today, representing approximately 1.9 million underlying shares of AMZN. Below is a chart showing AMZN's trailing twelve month trading history, with the $3600 strike highlighted in orange:
And Alphabet Inc (Symbol: GOOGL) options are showing a volume of 55,626 contracts thus far today. That number of contracts represents approximately 5.6 million underlying shares, working out to a sizeable 396.3% of GOOGL's average daily trading volume over the past month, of 1.4 million shares. Particularly high volume was seen for the $2950 strike call option expiring December 03, 2021, with 5,338 contracts trading so far today, representing approximately 533,800 underlying shares of GOOGL. Below is a chart showing GOOGL's trailing twelve month trading history, with the $2950 strike highlighted in orange:
For the various different available expirations for ABUS options, AMZN options, or GOOGL options, visit StockOptionsChannel.com.
Today's Most Active Call & Put Options of the S&P 500 »
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Particularly high volume was seen for the $7.50 strike call option expiring December 17, 2021, with 38,742 contracts trading so far today, representing approximately 3.9 million underlying shares of ABUS. Among the underlying components of the Russell 3000 index, we saw noteworthy options trading volume today in Arbutus Biopharma Corp (Symbol: ABUS), where a total of 152,984 contracts have traded so far, representing approximately 15.3 million underlying shares. That amounts to about 1068.4% of ABUS's average daily trading volume over the past month of 1.4 million shares. | Below is a chart showing ABUS's trailing twelve month trading history, with the $7.50 strike highlighted in orange: Amazon.com Inc (Symbol: AMZN) options are showing a volume of 259,213 contracts thus far today. Among the underlying components of the Russell 3000 index, we saw noteworthy options trading volume today in Arbutus Biopharma Corp (Symbol: ABUS), where a total of 152,984 contracts have traded so far, representing approximately 15.3 million underlying shares. That amounts to about 1068.4% of ABUS's average daily trading volume over the past month of 1.4 million shares. | Among the underlying components of the Russell 3000 index, we saw noteworthy options trading volume today in Arbutus Biopharma Corp (Symbol: ABUS), where a total of 152,984 contracts have traded so far, representing approximately 15.3 million underlying shares. Particularly high volume was seen for the $7.50 strike call option expiring December 17, 2021, with 38,742 contracts trading so far today, representing approximately 3.9 million underlying shares of ABUS. That amounts to about 1068.4% of ABUS's average daily trading volume over the past month of 1.4 million shares. | Particularly high volume was seen for the $7.50 strike call option expiring December 17, 2021, with 38,742 contracts trading so far today, representing approximately 3.9 million underlying shares of ABUS. Below is a chart showing GOOGL's trailing twelve month trading history, with the $2950 strike highlighted in orange: For the various different available expirations for ABUS options, AMZN options, or GOOGL options, visit StockOptionsChannel.com. Among the underlying components of the Russell 3000 index, we saw noteworthy options trading volume today in Arbutus Biopharma Corp (Symbol: ABUS), where a total of 152,984 contracts have traded so far, representing approximately 15.3 million underlying shares. |
34638.0 | 2021-12-01 00:00:00 UTC | ABUS Stock Alert: The Moderna News That Has Arbutus Biopharma Shares Rocketing Today | ABUS | https://www.nasdaq.com/articles/abus-stock-alert%3A-the-moderna-news-that-has-arbutus-biopharma-shares-rocketing-today | nan | nan | InvestorPlace - Stock Market News, Stock Advice & Trading Tips
Arbutus Biopharma (NASDAQ:ABUS) stock is taking off on Wednesday thanks to a court ruling in its favor in a case against Moderna (NASDAQ:MRNA).
Source: Shutterstock
The good news for Arbutus Biopharma today is that a court of appeals is backing up the U.S. Patent and Trademark Office in supporting the company’s LNP patents. LNP’s are used in RNA-based vaccines to get the treatment where it needs to go.
Moderna has been fighting against the patents held by Arbutus Biopharma as it uses LNPs in its vaccine for Covid-19. The company is arguing that LNPs aren’t patentable, despite having previously licensed them from Arbutus Biopharma for other uses.
To put it in simple terms, this ruling has Arbutus Biopharma one step closer to collecting royalties from Moderna for its Covid-19 vaccine. Genevant, a company that Arbutus Biopharma spun off, currently owns the patents. However, ABUS still owns a 16% stake in the business, reports The Motley Fool.
7 Tech Stocks That Could Rally In December
The court news today is bringing extra attention to ABUS stock, which is seeing heavy trading as a result. That has some 251 million shares of the stock changing hands as of this writing. That’s a massive surge compared to the company’s daily average trading volume of about 2.5 million shares.
ABUS stock is up 66% as of Wednesday afternoon and is up 45.6% since the start of the year. MRNA stock is down 6.6% as of this afternoon.
There’s morestock market newsfor investors to take a look at below!
We’ve got all the most recentstock newsthat traders need to know about for Wednesday. Among that is the earnings news sending Box (NYSE:BOX) stock higher, the layoff reports hitting iQIYI (NASDAQ:IQ) stock, as well as the FDA update sending BeyondSpring Pharmaceuticals (NASDAQ:BYSI) shares lower today. You can get all of that news from the following links!
More Stock Market News for Wednesday
BOX Stock: The Good News That Has Box, Inc. Shares Bounding Higher Today
iQIYI Layoffs: 10 Things for IQ Stock Investors to Know About the Massive Job Cuts
BYSI Stock Alert: Bad News From the FDA Has BeyondSpring Tanking Today
On the date of publication, William White did not have (either directly or indirectly) any positions in the securities mentioned in this article. The opinions expressed in this article are those of the writer, subject to the InvestorPlace.com Publishing Guidelines.
With only the rarest exceptions, InvestorPlace does not publish commentary about companies that have a market cap of less than $100 million or trade less than 100,000 shares each day. That’s because these “penny stocks” are frequently the playground for scam artists and market manipulators. If we ever do publish commentary on a low-volume stock that may be affected by our commentary, we demand that InvestorPlace.com’s writers disclose this fact and warn readers of the risks.
Read More: Penny Stocks — How to Profit Without Getting Scammed
The post ABUS Stock Alert: The Moderna News That Has Arbutus Biopharma Shares Rocketing Today appeared first on InvestorPlace.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | InvestorPlace - Stock Market News, Stock Advice & Trading Tips Arbutus Biopharma (NASDAQ:ABUS) stock is taking off on Wednesday thanks to a court ruling in its favor in a case against Moderna (NASDAQ:MRNA). However, ABUS still owns a 16% stake in the business, reports The Motley Fool. 7 Tech Stocks That Could Rally In December The court news today is bringing extra attention to ABUS stock, which is seeing heavy trading as a result. | InvestorPlace - Stock Market News, Stock Advice & Trading Tips Arbutus Biopharma (NASDAQ:ABUS) stock is taking off on Wednesday thanks to a court ruling in its favor in a case against Moderna (NASDAQ:MRNA). However, ABUS still owns a 16% stake in the business, reports The Motley Fool. 7 Tech Stocks That Could Rally In December The court news today is bringing extra attention to ABUS stock, which is seeing heavy trading as a result. | InvestorPlace - Stock Market News, Stock Advice & Trading Tips Arbutus Biopharma (NASDAQ:ABUS) stock is taking off on Wednesday thanks to a court ruling in its favor in a case against Moderna (NASDAQ:MRNA). Read More: Penny Stocks — How to Profit Without Getting Scammed The post ABUS Stock Alert: The Moderna News That Has Arbutus Biopharma Shares Rocketing Today appeared first on InvestorPlace. However, ABUS still owns a 16% stake in the business, reports The Motley Fool. | InvestorPlace - Stock Market News, Stock Advice & Trading Tips Arbutus Biopharma (NASDAQ:ABUS) stock is taking off on Wednesday thanks to a court ruling in its favor in a case against Moderna (NASDAQ:MRNA). However, ABUS still owns a 16% stake in the business, reports The Motley Fool. 7 Tech Stocks That Could Rally In December The court news today is bringing extra attention to ABUS stock, which is seeing heavy trading as a result. |
34639.0 | 2021-12-01 00:00:00 UTC | Moderna could be sued over vaccines as court upholds patents | ABUS | https://www.nasdaq.com/articles/moderna-could-be-sued-over-vaccines-as-court-upholds-patents | nan | nan | By Brendan Pierson
Dec 1 (Reuters) - Moderna Inc MRNA.O could face a patent infringement lawsuit over its COVID-19 vaccine after a federal appeals court rejected its challenge to patents belonging to Arbutus Biopharma Corp ABUS.O.
The Federal Circuit U.S. Court of Appeals said Arbutus' patents, which may cover technology used in the vaccines, were not obvious, upholding rulings last year by an administrative panel.
Arbutus shares were up $1.22, or 38% higher, at $4.42. Moderna shares fell about 7%.
Moderna and Arbutus did not immediately respond to requests for comment.
Moderna previously said in court filings that it believes Arbutus could bring a lawsuit demanding royalties from its COVID-19 vaccine if the patents are upheld.
(Reporting By Brendan Pierson in New York; Editing by Bill Berkrot)
((Brendan.Pierson@thomsonreuters.com; 646-223-6017 (desk); 646-306-0235 (cell);))
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | By Brendan Pierson Dec 1 (Reuters) - Moderna Inc MRNA.O could face a patent infringement lawsuit over its COVID-19 vaccine after a federal appeals court rejected its challenge to patents belonging to Arbutus Biopharma Corp ABUS.O. The Federal Circuit U.S. Court of Appeals said Arbutus' patents, which may cover technology used in the vaccines, were not obvious, upholding rulings last year by an administrative panel. Moderna previously said in court filings that it believes Arbutus could bring a lawsuit demanding royalties from its COVID-19 vaccine if the patents are upheld. | By Brendan Pierson Dec 1 (Reuters) - Moderna Inc MRNA.O could face a patent infringement lawsuit over its COVID-19 vaccine after a federal appeals court rejected its challenge to patents belonging to Arbutus Biopharma Corp ABUS.O. The Federal Circuit U.S. Court of Appeals said Arbutus' patents, which may cover technology used in the vaccines, were not obvious, upholding rulings last year by an administrative panel. Arbutus shares were up $1.22, or 38% higher, at $4.42. | By Brendan Pierson Dec 1 (Reuters) - Moderna Inc MRNA.O could face a patent infringement lawsuit over its COVID-19 vaccine after a federal appeals court rejected its challenge to patents belonging to Arbutus Biopharma Corp ABUS.O. The Federal Circuit U.S. Court of Appeals said Arbutus' patents, which may cover technology used in the vaccines, were not obvious, upholding rulings last year by an administrative panel. Moderna previously said in court filings that it believes Arbutus could bring a lawsuit demanding royalties from its COVID-19 vaccine if the patents are upheld. | By Brendan Pierson Dec 1 (Reuters) - Moderna Inc MRNA.O could face a patent infringement lawsuit over its COVID-19 vaccine after a federal appeals court rejected its challenge to patents belonging to Arbutus Biopharma Corp ABUS.O. Arbutus shares were up $1.22, or 38% higher, at $4.42. Moderna shares fell about 7%. |
34640.0 | 2021-12-01 00:00:00 UTC | Moderna loses appeal challenging Arbutus vaccine patents | ABUS | https://www.nasdaq.com/articles/moderna-loses-appeal-challenging-arbutus-vaccine-patents | nan | nan | Dec 1 (Reuters) - A federal appeals court on Wednesday rejected Moderna Inc's bid to invalidate patents belonging to Arbutus Biopharma Corp that could be crucial in the development of future vaccines against COVID-19 and other illnesses.
The Federal Circuit U.S. Court of Appeals said Arbutus' patents were not obvious, upholding rulings last year by an administrative panel.
(Reporting By Brendan Pierson in New York)
((Brendan.Pierson@thomsonreuters.com; 646-223-6017 (desk); 646-306-0235 (cell);))
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Dec 1 (Reuters) - A federal appeals court on Wednesday rejected Moderna Inc's bid to invalidate patents belonging to Arbutus Biopharma Corp that could be crucial in the development of future vaccines against COVID-19 and other illnesses. The Federal Circuit U.S. Court of Appeals said Arbutus' patents were not obvious, upholding rulings last year by an administrative panel. (Reporting By Brendan Pierson in New York) ((Brendan.Pierson@thomsonreuters.com; 646-223-6017 (desk); 646-306-0235 (cell);)) The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Dec 1 (Reuters) - A federal appeals court on Wednesday rejected Moderna Inc's bid to invalidate patents belonging to Arbutus Biopharma Corp that could be crucial in the development of future vaccines against COVID-19 and other illnesses. The Federal Circuit U.S. Court of Appeals said Arbutus' patents were not obvious, upholding rulings last year by an administrative panel. (Reporting By Brendan Pierson in New York) ((Brendan.Pierson@thomsonreuters.com; 646-223-6017 (desk); 646-306-0235 (cell);)) The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Dec 1 (Reuters) - A federal appeals court on Wednesday rejected Moderna Inc's bid to invalidate patents belonging to Arbutus Biopharma Corp that could be crucial in the development of future vaccines against COVID-19 and other illnesses. The Federal Circuit U.S. Court of Appeals said Arbutus' patents were not obvious, upholding rulings last year by an administrative panel. (Reporting By Brendan Pierson in New York) ((Brendan.Pierson@thomsonreuters.com; 646-223-6017 (desk); 646-306-0235 (cell);)) The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Dec 1 (Reuters) - A federal appeals court on Wednesday rejected Moderna Inc's bid to invalidate patents belonging to Arbutus Biopharma Corp that could be crucial in the development of future vaccines against COVID-19 and other illnesses. The Federal Circuit U.S. Court of Appeals said Arbutus' patents were not obvious, upholding rulings last year by an administrative panel. (Reporting By Brendan Pierson in New York) ((Brendan.Pierson@thomsonreuters.com; 646-223-6017 (desk); 646-306-0235 (cell);)) The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. |
34641.0 | 2021-11-04 00:00:00 UTC | Arbutus Biopharma (ABUS) Q3 2021 Earnings Call Transcript | ABUS | https://www.nasdaq.com/articles/arbutus-biopharma-abus-q3-2021-earnings-call-transcript-2021-11-05 | nan | nan | Image source: The Motley Fool.
Arbutus Biopharma (NASDAQ: ABUS)
Q3 2021 Earnings Call
Nov 04, 2021, 8:45 a.m. ET
Contents:
Prepared Remarks
Questions | Arbutus Biopharma (NASDAQ: ABUS) Q3 2021 Earnings Call Nov 04, 2021, 8:45 a.m. Image source: The Motley Fool. ET Contents: Prepared Remarks Questions | Arbutus Biopharma (NASDAQ: ABUS) Q3 2021 Earnings Call Nov 04, 2021, 8:45 a.m. Image source: The Motley Fool. ET Contents: Prepared Remarks Questions | Arbutus Biopharma (NASDAQ: ABUS) Q3 2021 Earnings Call Nov 04, 2021, 8:45 a.m. Image source: The Motley Fool. ET Contents: Prepared Remarks Questions | Arbutus Biopharma (NASDAQ: ABUS) Q3 2021 Earnings Call Nov 04, 2021, 8:45 a.m. Image source: The Motley Fool. ET Contents: Prepared Remarks Questions |
34642.0 | 2021-10-18 00:00:00 UTC | Pre-market Movers: JCS, VALN, RVNC, HX, AVDL… | ABUS | https://www.nasdaq.com/articles/pre-market-movers%3A-jcs-valn-rvnc-hx-avdl...-2021-10-18 | nan | nan | (RTTNews) - The following are some of the stocks making big moves in Monday's pre-market trading (as of 06.30 A.M. EDT).
In the Green
Valneva SE (VALN) is up over 39% at $39.00
Xiaobai Maimai Inc. (HX) is up over 24% at $7.37
Agile Therapeutics, Inc. (AGRX) is up over 16% at $0.89
Sonnet BioTherapeutics Holdings, Inc. (SONN) is up over 9% at $0.72
Dynavax Technologies Corporation (DVAX) is up over 8% at $18.44
FuelCell Energy, Inc. (FCEL) is up over 7% at $7.91
Bitfarms Ltd. (BITF) is up over 5% at $5.66
Camber Energy, Inc. (CEI) is up over 5% at $1.45
Arbutus Biopharma Corporation (ABUS) is up over 4% at $4.27
In the Red
Communications Systems, Inc. (JCS) is down over 42% at $4.87
Revance Therapeutics, Inc. (RVNC) is down over 31% at $15.47
Avadel Pharmaceuticals plc (AVDL) is down over 21% at $7.87
Ocugen, Inc. (OCGN) is down over 11% at $7.64
UP Fintech Holding Limited (TIGR) is down over 9% at $7.15
Futu Holdings Limited (FUTU) is down over 8% at $58.50
LM Funding America, Inc. (LMFA) is down over 8% at $4.37
Zillow Group, Inc. (Z) is down over 6% at $89.00
Aemetis, Inc. (AMTX) is down over 4% at $17.13
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | In the Green Valneva SE (VALN) is up over 39% at $39.00 Xiaobai Maimai Inc. (HX) is up over 24% at $7.37 Agile Therapeutics, Inc. (AGRX) is up over 16% at $0.89 Sonnet BioTherapeutics Holdings, Inc. (SONN) is up over 9% at $0.72 Dynavax Technologies Corporation (DVAX) is up over 8% at $18.44 FuelCell Energy, Inc. (FCEL) is up over 7% at $7.91 Bitfarms Ltd. (BITF) is up over 5% at $5.66 Camber Energy, Inc. (CEI) is up over 5% at $1.45 Arbutus Biopharma Corporation (ABUS) is up over 4% at $4.27 In the Red Communications Systems, Inc. (JCS) is down over 42% at $4.87 Revance Therapeutics, Inc. (RVNC) is down over 31% at $15.47 Avadel Pharmaceuticals plc (AVDL) is down over 21% at $7.87 Ocugen, Inc. (OCGN) is down over 11% at $7.64 UP Fintech Holding Limited (TIGR) is down over 9% at $7.15 Futu Holdings Limited (FUTU) is down over 8% at $58.50 LM Funding America, Inc. (LMFA) is down over 8% at $4.37 Zillow Group, Inc. (Z) is down over 6% at $89.00 Aemetis, Inc. (AMTX) is down over 4% at $17.13 The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. (RTTNews) - The following are some of the stocks making big moves in Monday's pre-market trading (as of 06.30 A.M. EDT). | In the Green Valneva SE (VALN) is up over 39% at $39.00 Xiaobai Maimai Inc. (HX) is up over 24% at $7.37 Agile Therapeutics, Inc. (AGRX) is up over 16% at $0.89 Sonnet BioTherapeutics Holdings, Inc. (SONN) is up over 9% at $0.72 Dynavax Technologies Corporation (DVAX) is up over 8% at $18.44 FuelCell Energy, Inc. (FCEL) is up over 7% at $7.91 Bitfarms Ltd. (BITF) is up over 5% at $5.66 Camber Energy, Inc. (CEI) is up over 5% at $1.45 Arbutus Biopharma Corporation (ABUS) is up over 4% at $4.27 In the Red Communications Systems, Inc. (JCS) is down over 42% at $4.87 Revance Therapeutics, Inc. (RVNC) is down over 31% at $15.47 Avadel Pharmaceuticals plc (AVDL) is down over 21% at $7.87 Ocugen, Inc. (OCGN) is down over 11% at $7.64 UP Fintech Holding Limited (TIGR) is down over 9% at $7.15 Futu Holdings Limited (FUTU) is down over 8% at $58.50 LM Funding America, Inc. (LMFA) is down over 8% at $4.37 Zillow Group, Inc. (Z) is down over 6% at $89.00 Aemetis, Inc. (AMTX) is down over 4% at $17.13 The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. (RTTNews) - The following are some of the stocks making big moves in Monday's pre-market trading (as of 06.30 A.M. EDT). | In the Green Valneva SE (VALN) is up over 39% at $39.00 Xiaobai Maimai Inc. (HX) is up over 24% at $7.37 Agile Therapeutics, Inc. (AGRX) is up over 16% at $0.89 Sonnet BioTherapeutics Holdings, Inc. (SONN) is up over 9% at $0.72 Dynavax Technologies Corporation (DVAX) is up over 8% at $18.44 FuelCell Energy, Inc. (FCEL) is up over 7% at $7.91 Bitfarms Ltd. (BITF) is up over 5% at $5.66 Camber Energy, Inc. (CEI) is up over 5% at $1.45 Arbutus Biopharma Corporation (ABUS) is up over 4% at $4.27 In the Red Communications Systems, Inc. (JCS) is down over 42% at $4.87 Revance Therapeutics, Inc. (RVNC) is down over 31% at $15.47 Avadel Pharmaceuticals plc (AVDL) is down over 21% at $7.87 Ocugen, Inc. (OCGN) is down over 11% at $7.64 UP Fintech Holding Limited (TIGR) is down over 9% at $7.15 Futu Holdings Limited (FUTU) is down over 8% at $58.50 LM Funding America, Inc. (LMFA) is down over 8% at $4.37 Zillow Group, Inc. (Z) is down over 6% at $89.00 Aemetis, Inc. (AMTX) is down over 4% at $17.13 The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. (RTTNews) - The following are some of the stocks making big moves in Monday's pre-market trading (as of 06.30 A.M. EDT). | In the Green Valneva SE (VALN) is up over 39% at $39.00 Xiaobai Maimai Inc. (HX) is up over 24% at $7.37 Agile Therapeutics, Inc. (AGRX) is up over 16% at $0.89 Sonnet BioTherapeutics Holdings, Inc. (SONN) is up over 9% at $0.72 Dynavax Technologies Corporation (DVAX) is up over 8% at $18.44 FuelCell Energy, Inc. (FCEL) is up over 7% at $7.91 Bitfarms Ltd. (BITF) is up over 5% at $5.66 Camber Energy, Inc. (CEI) is up over 5% at $1.45 Arbutus Biopharma Corporation (ABUS) is up over 4% at $4.27 In the Red Communications Systems, Inc. (JCS) is down over 42% at $4.87 Revance Therapeutics, Inc. (RVNC) is down over 31% at $15.47 Avadel Pharmaceuticals plc (AVDL) is down over 21% at $7.87 Ocugen, Inc. (OCGN) is down over 11% at $7.64 UP Fintech Holding Limited (TIGR) is down over 9% at $7.15 Futu Holdings Limited (FUTU) is down over 8% at $58.50 LM Funding America, Inc. (LMFA) is down over 8% at $4.37 Zillow Group, Inc. (Z) is down over 6% at $89.00 Aemetis, Inc. (AMTX) is down over 4% at $17.13 The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. (RTTNews) - The following are some of the stocks making big moves in Monday's pre-market trading (as of 06.30 A.M. EDT). |
34643.0 | 2021-10-07 00:00:00 UTC | Why Moderna Stock Is Rebounding Today | ABUS | https://www.nasdaq.com/articles/why-moderna-stock-is-rebounding-today-2021-10-07 | nan | nan | What happened
Shares of Moderna (NASDAQ: MRNA) were rebounding somewhat on Thursday after several days of declines. The stock was up 4.6% as of 10:59 a.m. EDT today.
Moderna actually had more bad news today. Finland joined Denmark and Sweden in pausing the use of the company's COVID-19 vaccine for some individuals due to concerns about a rare heart inflammation issue. Finland's pause applies to men under age 30, the demographic with the highest risk for the cardiovascular problems.
However, Moderna also announced plans to build a new facility in Africa that will be able to produce up to 500 million doses of its messenger RNA (mRNA) vaccine each year.
In addition, the company's appeal to a Federal Circuit Court to invalidate two of Arbutus Biopharma's (NASDAQ: ABUS) patents is underway. Some investors appear to be cautiously optimistic about Moderna's chances with this case, although the most likely outcome is a settlement.
Image source: Getty Images.
So what
Why would the news about the African manufacturing facility and the federal court appeal have a bigger impact on the vaccine stock than Finland's pause of giving Moderna's vaccine to young men? Politics seems to be a likely factor with the former matter.
Politico reported earlier today that Moderna has been at odds with the Biden administration over producing more doses for use internationally. So the company's announcement about its plans to build the facility in Africa could help reduce the tensions with the White House.
As for the federal case, anything that emerges from the hearing that indicates a scenario where Moderna would pay less to Arbutus could be a positive sign for the biotech.
Now what
Moderna didn't provide any details about when construction would begin for its facility in Africa. The company also stated that it "expects to begin a process for country and site selection soon." That might not be enough to satisfy U.S. government officials.
Again, the odds seem stacked against Moderna in the patent case. However, the company could reach a settlement with Arbutus that investors like.
As for the heart inflammation issues, so far only Scandinavian countries have paused the use of Moderna's vaccine for some groups. If more nations follow suit, this could become a bigger problem for the company.
10 stocks we like better than Moderna Inc.
When our award-winning analyst team has a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor, has tripled the market.*
They just revealed what they believe are the ten best stocks for investors to buy right now... and Moderna Inc. wasn't one of them! That's right -- they think these 10 stocks are even better buys.
See the 10 stocks
*Stock Advisor returns as of September 17, 2021
Keith Speights has no position in any of the stocks mentioned. The Motley Fool recommends Moderna Inc. The Motley Fool has a disclosure policy.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | In addition, the company's appeal to a Federal Circuit Court to invalidate two of Arbutus Biopharma's (NASDAQ: ABUS) patents is underway. Finland joined Denmark and Sweden in pausing the use of the company's COVID-19 vaccine for some individuals due to concerns about a rare heart inflammation issue. However, Moderna also announced plans to build a new facility in Africa that will be able to produce up to 500 million doses of its messenger RNA (mRNA) vaccine each year. | In addition, the company's appeal to a Federal Circuit Court to invalidate two of Arbutus Biopharma's (NASDAQ: ABUS) patents is underway. However, Moderna also announced plans to build a new facility in Africa that will be able to produce up to 500 million doses of its messenger RNA (mRNA) vaccine each year. So what Why would the news about the African manufacturing facility and the federal court appeal have a bigger impact on the vaccine stock than Finland's pause of giving Moderna's vaccine to young men? | In addition, the company's appeal to a Federal Circuit Court to invalidate two of Arbutus Biopharma's (NASDAQ: ABUS) patents is underway. So what Why would the news about the African manufacturing facility and the federal court appeal have a bigger impact on the vaccine stock than Finland's pause of giving Moderna's vaccine to young men? 10 stocks we like better than Moderna Inc. | In addition, the company's appeal to a Federal Circuit Court to invalidate two of Arbutus Biopharma's (NASDAQ: ABUS) patents is underway. So what Why would the news about the African manufacturing facility and the federal court appeal have a bigger impact on the vaccine stock than Finland's pause of giving Moderna's vaccine to young men? Now what Moderna didn't provide any details about when construction would begin for its facility in Africa. |
34644.0 | 2021-10-07 00:00:00 UTC | Pre-market Movers: CYRN, CEI, OSMT, NURO, TTM… | ABUS | https://www.nasdaq.com/articles/pre-market-movers%3A-cyrn-cei-osmt-nuro-ttm...-2021-10-07 | nan | nan | (RTTNews) - The following are some of the stocks making big moves in Thursday's pre-market trading (as of 6.05 A.M. EDT).
In the Green
Cyren Ltd. (CYRN) is up over 58% at $0.77
Camber Energy, Inc. (CEI) is up over 34% at 1.22
NeuroMetrix, Inc. (NURO) is up over 23% at $10.67
Tata Motors Limited (TTM) is up over 11% at $24.88
Rocket Lab USA, Inc. (RKLB) is up over 9% at $15.28
Arbutus Biopharma Corporation (ABUS) is up over 7% at $4.29
Progenity, Inc. (PROG) is up over 6% at $1.52
Stem, Inc. (STEM) is up over 5% at $22.72
In the Red
Osmotica Pharmaceuticals plc (OSMT) is down over 31% at $2.10
Gran Tierra Energy Inc. (GTE) is down over 11% at $0.80
NRx Pharmaceuticals, Inc. (NRXP) is down over 6% at $7.89
NextPlay Technologies, Inc. (NXTP) is down over 6% at $1.57
Vermilion Energy Inc. (VET) is down over 5% at $10.22
Borr Drilling Limited (BORR) is down over 4% at $0.95
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | In the Green Cyren Ltd. (CYRN) is up over 58% at $0.77 Camber Energy, Inc. (CEI) is up over 34% at 1.22 NeuroMetrix, Inc. (NURO) is up over 23% at $10.67 Tata Motors Limited (TTM) is up over 11% at $24.88 Rocket Lab USA, Inc. (RKLB) is up over 9% at $15.28 Arbutus Biopharma Corporation (ABUS) is up over 7% at $4.29 Progenity, Inc. (PROG) is up over 6% at $1.52 Stem, Inc. (STEM) is up over 5% at $22.72 In the Red Osmotica Pharmaceuticals plc (OSMT) is down over 31% at $2.10 Gran Tierra Energy Inc. (GTE) is down over 11% at $0.80 NRx Pharmaceuticals, Inc. (NRXP) is down over 6% at $7.89 NextPlay Technologies, Inc. (NXTP) is down over 6% at $1.57 Vermilion Energy Inc. (VET) is down over 5% at $10.22 Borr Drilling Limited (BORR) is down over 4% at $0.95 The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. (RTTNews) - The following are some of the stocks making big moves in Thursday's pre-market trading (as of 6.05 A.M. EDT). | In the Green Cyren Ltd. (CYRN) is up over 58% at $0.77 Camber Energy, Inc. (CEI) is up over 34% at 1.22 NeuroMetrix, Inc. (NURO) is up over 23% at $10.67 Tata Motors Limited (TTM) is up over 11% at $24.88 Rocket Lab USA, Inc. (RKLB) is up over 9% at $15.28 Arbutus Biopharma Corporation (ABUS) is up over 7% at $4.29 Progenity, Inc. (PROG) is up over 6% at $1.52 Stem, Inc. (STEM) is up over 5% at $22.72 In the Red Osmotica Pharmaceuticals plc (OSMT) is down over 31% at $2.10 Gran Tierra Energy Inc. (GTE) is down over 11% at $0.80 NRx Pharmaceuticals, Inc. (NRXP) is down over 6% at $7.89 NextPlay Technologies, Inc. (NXTP) is down over 6% at $1.57 Vermilion Energy Inc. (VET) is down over 5% at $10.22 Borr Drilling Limited (BORR) is down over 4% at $0.95 The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. (RTTNews) - The following are some of the stocks making big moves in Thursday's pre-market trading (as of 6.05 A.M. EDT). | In the Green Cyren Ltd. (CYRN) is up over 58% at $0.77 Camber Energy, Inc. (CEI) is up over 34% at 1.22 NeuroMetrix, Inc. (NURO) is up over 23% at $10.67 Tata Motors Limited (TTM) is up over 11% at $24.88 Rocket Lab USA, Inc. (RKLB) is up over 9% at $15.28 Arbutus Biopharma Corporation (ABUS) is up over 7% at $4.29 Progenity, Inc. (PROG) is up over 6% at $1.52 Stem, Inc. (STEM) is up over 5% at $22.72 In the Red Osmotica Pharmaceuticals plc (OSMT) is down over 31% at $2.10 Gran Tierra Energy Inc. (GTE) is down over 11% at $0.80 NRx Pharmaceuticals, Inc. (NRXP) is down over 6% at $7.89 NextPlay Technologies, Inc. (NXTP) is down over 6% at $1.57 Vermilion Energy Inc. (VET) is down over 5% at $10.22 Borr Drilling Limited (BORR) is down over 4% at $0.95 The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. (RTTNews) - The following are some of the stocks making big moves in Thursday's pre-market trading (as of 6.05 A.M. EDT). | In the Green Cyren Ltd. (CYRN) is up over 58% at $0.77 Camber Energy, Inc. (CEI) is up over 34% at 1.22 NeuroMetrix, Inc. (NURO) is up over 23% at $10.67 Tata Motors Limited (TTM) is up over 11% at $24.88 Rocket Lab USA, Inc. (RKLB) is up over 9% at $15.28 Arbutus Biopharma Corporation (ABUS) is up over 7% at $4.29 Progenity, Inc. (PROG) is up over 6% at $1.52 Stem, Inc. (STEM) is up over 5% at $22.72 In the Red Osmotica Pharmaceuticals plc (OSMT) is down over 31% at $2.10 Gran Tierra Energy Inc. (GTE) is down over 11% at $0.80 NRx Pharmaceuticals, Inc. (NRXP) is down over 6% at $7.89 NextPlay Technologies, Inc. (NXTP) is down over 6% at $1.57 Vermilion Energy Inc. (VET) is down over 5% at $10.22 Borr Drilling Limited (BORR) is down over 4% at $0.95 The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. (RTTNews) - The following are some of the stocks making big moves in Thursday's pre-market trading (as of 6.05 A.M. EDT). |
34645.0 | 2021-10-03 00:00:00 UTC | What Kind Of Investors Own Most Of Arbutus Biopharma Corporation (NASDAQ:ABUS)? | ABUS | https://www.nasdaq.com/articles/what-kind-of-investors-own-most-of-arbutus-biopharma-corporation-nasdaq%3Aabus-2021-10-03 | nan | nan | Every investor in Arbutus Biopharma Corporation (NASDAQ:ABUS) should be aware of the most powerful shareholder groups. Generally speaking, as a company grows, institutions will increase their ownership. Conversely, insiders often decrease their ownership over time. We also tend to see lower insider ownership in companies that were previously publicly owned.
Arbutus Biopharma is a smaller company with a market capitalization of US$424m, so it may still be flying under the radar of many institutional investors. Our analysis of the ownership of the company, below, shows that institutions own shares in the company. Let's take a closer look to see what the different types of shareholders can tell us about Arbutus Biopharma.
NasdaqGS:ABUS Ownership Breakdown October 3rd 2021
What Does The Institutional Ownership Tell Us About Arbutus Biopharma?
Institutional investors commonly compare their own returns to the returns of a commonly followed index. So they generally do consider buying larger companies that are included in the relevant benchmark index.
As you can see, institutional investors have a fair amount of stake in Arbutus Biopharma. This suggests some credibility amongst professional investors. But we can't rely on that fact alone since institutions make bad investments sometimes, just like everyone does. When multiple institutions own a stock, there's always a risk that they are in a 'crowded trade'. When such a trade goes wrong, multiple parties may compete to sell stock fast. This risk is higher in a company without a history of growth. You can see Arbutus Biopharma's historic earnings and revenue below, but keep in mind there's always more to the story.
NasdaqGS:ABUS Earnings and Revenue Growth October 3rd 2021
Our data indicates that hedge funds own 6.0% of Arbutus Biopharma. That catches my attention because hedge funds sometimes try to influence management, or bring about changes that will create near term value for shareholders. The company's largest shareholder is Roivant Sciences Ltd., with ownership of 16%. In comparison, the second and third largest shareholders hold about 6.0% and 5.9% of the stock.
A deeper look at our ownership data shows that the top 25 shareholders collectively hold less than half of the register, suggesting a large group of small holders where no single shareholder has a majority.
While it makes sense to study institutional ownership data for a company, it also makes sense to study analyst sentiments to know which way the wind is blowing. There are plenty of analysts covering the stock, so it might be worth seeing what they are forecasting, too.
Insider Ownership Of Arbutus Biopharma
The definition of an insider can differ slightly between different countries, but members of the board of directors always count. Management ultimately answers to the board. However, it is not uncommon for managers to be executive board members, especially if they are a founder or the CEO.
Most consider insider ownership a positive because it can indicate the board is well aligned with other shareholders. However, on some occasions too much power is concentrated within this group.
I can report that insiders do own shares in Arbutus Biopharma Corporation. In their own names, insiders own US$14m worth of stock in the US$424m company. Some would say this shows alignment of interests between shareholders and the board. But it might be worth checking if those insiders have been selling.
General Public Ownership
The general public -- including retail investors -- own 51% of Arbutus Biopharma. This size of ownership gives investors from the general public some collective power. They can and probably do influence decisions on executive compensation, dividend policies and proposed business acquisitions.
Private Company Ownership
It seems that Private Companies own 16%, of the Arbutus Biopharma stock. It might be worth looking deeper into this. If related parties, such as insiders, have an interest in one of these private companies, that should be disclosed in the annual report. Private companies may also have a strategic interest in the company.
Next Steps:
I find it very interesting to look at who exactly owns a company. But to truly gain insight, we need to consider other information, too. To that end, you should be aware of the 3 warning signs we've spotted with Arbutus Biopharma .
But ultimately it is the future, not the past, that will determine how well the owners of this business will do. Therefore we think it advisable to take a look at this free report showing whether analysts are predicting a brighter future.
NB: Figures in this article are calculated using data from the last twelve months, which refer to the 12-month period ending on the last date of the month the financial statement is dated. This may not be consistent with full year annual report figures.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Every investor in Arbutus Biopharma Corporation (NASDAQ:ABUS) should be aware of the most powerful shareholder groups. NasdaqGS:ABUS Earnings and Revenue Growth October 3rd 2021 Our data indicates that hedge funds own 6.0% of Arbutus Biopharma. NasdaqGS:ABUS Ownership Breakdown October 3rd 2021 What Does The Institutional Ownership Tell Us About Arbutus Biopharma? | NasdaqGS:ABUS Earnings and Revenue Growth October 3rd 2021 Our data indicates that hedge funds own 6.0% of Arbutus Biopharma. Every investor in Arbutus Biopharma Corporation (NASDAQ:ABUS) should be aware of the most powerful shareholder groups. NasdaqGS:ABUS Ownership Breakdown October 3rd 2021 What Does The Institutional Ownership Tell Us About Arbutus Biopharma? | NasdaqGS:ABUS Ownership Breakdown October 3rd 2021 What Does The Institutional Ownership Tell Us About Arbutus Biopharma? Every investor in Arbutus Biopharma Corporation (NASDAQ:ABUS) should be aware of the most powerful shareholder groups. NasdaqGS:ABUS Earnings and Revenue Growth October 3rd 2021 Our data indicates that hedge funds own 6.0% of Arbutus Biopharma. | Every investor in Arbutus Biopharma Corporation (NASDAQ:ABUS) should be aware of the most powerful shareholder groups. NasdaqGS:ABUS Ownership Breakdown October 3rd 2021 What Does The Institutional Ownership Tell Us About Arbutus Biopharma? NasdaqGS:ABUS Earnings and Revenue Growth October 3rd 2021 Our data indicates that hedge funds own 6.0% of Arbutus Biopharma. |
34646.0 | 2021-09-10 00:00:00 UTC | Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday | ABUS | https://www.nasdaq.com/articles/todays-biggest-pre-market-stock-movers%3A-10-top-gainers-and-losers-on-friday-2021-09-10 | nan | nan | InvestorPlace - Stock Market News, Stock Advice & Trading Tips
Good morning, investor! We’re back at it again with one last day of trading this week and we’re kicking it off with a dive into Friday’s biggest pre-market stock movers.
Source: Shutterstock
There’s plenty of news moving stocks during today’s pre-market hours. That includes earnings reports, clinical trial results, as well as COVID-19 news.
Let’s jump into those pre-market stock movers below!
Pre-Market Stock Movers: 10 Top Gainers
IVERIC bio (NASDAQ:ISEE) stock is soaring nearly 40 % this morning after Stifel initiated coverage of the company with a buy rating.
Affirm Holdings (NASDAQ:AFRM) shares are rising more than 24% following the release of its fiscal Q4 earnings report.
T2 Biosystems (NASDAQ:TTOO) stock is gaining over 23% after revealing that its novel coronavirus test can detect new variants.
Arbutus Biopharma (NASDAQ:ABUS) shares are sitting more than 20% higher on talk it could win a patent battle against Moderna (NASDAQ:MRNA).
Endo International (NASDAQ:ENDP) stock is climbing over 19% after settling an opioid case in New York.
Concord Medical Services (NYSE:CCM) shares are increasing 17% after announcing a new sale of its Proteus Plus tech.
Katapult Holdings (NASDAQ:KPLT) stock is getting a more than 16% boost three months after going public via a SPAC merger.
So-Young International (NASDAQ:SY) shares are jumping over 15% with the release of its Q2 earnings report.
Vince Holding (NYSE:VNCE) stock is running more than 14% higher after releasing its Q2 earnings report.
S&W Seed (NASDAQ:SANW) shares are up over 14% after announcing a production agreement with Ingredion Incorporated (NYSE:INGR).
7 of the Best Large-Cap Stocks to Buy Now
10 Top Losers
Apellis Pharmaceuticals (NASDAQ:APLS) stock is diving more than 32% after revealing results from a recent clinical trial.
Impel NeuroPharma (NASDAQ:IMPL) shares are taking an over 14% beating following its reveal of pricing for a public offering.
Traeger (NYSE:COOK) stock is dropping more than 13% with the release of its first earnings report since going public.
Sumo Logic (NASDAQ:SUMO) shares are falling over 13% after releasing its earnings report for the second quarter of fiscal 2021.
Kaival Brands Innovations (NASDAQ:KAVL) stock is slipping more than 10% after a rally on Thursday.
Creative Realities (NASDAQ:CREX) shares are declining over 7% on no apparent news this morning.
Novavax (NASDAQ:NVAX) stock is decreasing more than 4% as it continues to fall on reports that its vaccine launch could take more time in India.
Direxion Daily FTSE China Bear 3x Shares (NYSEARCA:YANG) are losing over 4% of their value this morning.
Maravai LifeSciences (NASDAQ:MRVI) stock is dipping more than 4% after announcing pricing for a secondary stock offering.
Calliditas Therapeutics (NASDAQ:CALT) shares close out our pre-market stock movers down about 4% after a strong rally yesterday.
On the date of publication, William White did not have (either directly or indirectly) any positions in the securities mentioned in this article. The opinions expressed in this article are those of the writer, subject to the InvestorPlace.com Publishing Guidelines.
The post Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday appeared first on InvestorPlace.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Arbutus Biopharma (NASDAQ:ABUS) shares are sitting more than 20% higher on talk it could win a patent battle against Moderna (NASDAQ:MRNA). Novavax (NASDAQ:NVAX) stock is decreasing more than 4% as it continues to fall on reports that its vaccine launch could take more time in India. Calliditas Therapeutics (NASDAQ:CALT) shares close out our pre-market stock movers down about 4% after a strong rally yesterday. | Arbutus Biopharma (NASDAQ:ABUS) shares are sitting more than 20% higher on talk it could win a patent battle against Moderna (NASDAQ:MRNA). 7 of the Best Large-Cap Stocks to Buy Now 10 Top Losers Apellis Pharmaceuticals (NASDAQ:APLS) stock is diving more than 32% after revealing results from a recent clinical trial. Sumo Logic (NASDAQ:SUMO) shares are falling over 13% after releasing its earnings report for the second quarter of fiscal 2021. | Arbutus Biopharma (NASDAQ:ABUS) shares are sitting more than 20% higher on talk it could win a patent battle against Moderna (NASDAQ:MRNA). Pre-Market Stock Movers: 10 Top Gainers IVERIC bio (NASDAQ:ISEE) stock is soaring nearly 40 % this morning after Stifel initiated coverage of the company with a buy rating. 7 of the Best Large-Cap Stocks to Buy Now 10 Top Losers Apellis Pharmaceuticals (NASDAQ:APLS) stock is diving more than 32% after revealing results from a recent clinical trial. | Arbutus Biopharma (NASDAQ:ABUS) shares are sitting more than 20% higher on talk it could win a patent battle against Moderna (NASDAQ:MRNA). Let’s jump into those pre-market stock movers below! So-Young International (NASDAQ:SY) shares are jumping over 15% with the release of its Q2 earnings report. |
34647.0 | 2021-08-07 00:00:00 UTC | Arbutus Biopharma (ABUS) Q2 2021 Earnings Call Transcript | ABUS | https://www.nasdaq.com/articles/arbutus-biopharma-abus-q2-2021-earnings-call-transcript-2021-08-07 | nan | nan | Image source: The Motley Fool.
Arbutus Biopharma (NASDAQ: ABUS)
Q2 2021 Earnings Call
Aug 05, 2021, 8:45 a.m. ET
Contents:
Prepared Remarks
Questions and Answers
Call Participants
Prepared Remarks:
Operator
Good day, and thank you for standing by. Welcome to the Arbutus Biopharma Corporation 2021 second-quarter financial results and corporate update conference call. At this time, all participants are in a listen-only mode. After the speakers' presentation, there will be a question-and-answer session.
[Operator instructions] Please be advised that today's conference is being recorded. [Operator instructions] I would now like to hand the conference over to your speaker today, Ms. Pam Murphy. Please go ahead.
Pam Murphy -- Investor Relations
Good morning, everyone. On the call from the Arbutus executive team are Bill Collier, president and chief executive officer; Dave Hastings, chief financial officer; Dr. Gaston Picchio, chief development officer; and Dr. Mike Sofia, chief scientific officer.
Bill will begin with a review of the second quarter and first-half accomplishments, clinical development, and remaining 2021 corporate objectives, followed by Dave Hastings who will provide a review of the company's second-quarter financial results. We'll then open up the call for Q&A, and Mike and Gaston will be available to address research and clinical development-related questions. Before we begin, we'd like to remind you that some of the statements made during the call today are forward-looking statements, including statements regarding expectations for Arbutus' proprietary HBV pipeline, and HBV and pan-coronavirus discovery programs, including potential clinical results and timelines for AB-729, AB-836, and future compounds. Our expected cash runway and the potential for our drug candidates to improve upon the standard of care and contribute to a curative combination regimen for HBV.
10 stocks we like better than Arbutus Biopharma
When our award-winning analyst team has a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor, has tripled the market.*
They just revealed what they believe are the ten best stocks for investors to buy right now... and Arbutus Biopharma wasn't one of them! That's right -- they think these 10 stocks are even better buys.
See the 10 stocks
*Stock Advisor returns as of June 7, 2021
These forward-looking statements are subject to a number of risks and uncertainties that may cause our actual results to differ materially, including those described in the most recent annual report on 10-K, quarterly report on Form 10-Q, and other specific reports filed with the SEC from time to time. Bill?
Bill Collier -- President and Chief Executive Officer
Thank you, Pam, and good morning, everybody. Thank you for joining us today. We appreciate your interest in Arbutus Biopharma. I'm very pleased to report on our significant progress so far this year and to outline our objectives for the rest of 2021.
We continue to drive toward our goal at Arbutus, which is to focus primarily on developing a portfolio of products with different mechanisms of action, that when used in combination results in a functional cure for patients living with chronic HBV. During the first half of this year, we established a strong foundation toward achieving that goal by accomplishing the following: We continue to report compelling data on AB-729, with four abstracts at EASL, including a late-breaker oral presentation that showed substantial declines in hepatitis B surface antigen in subjects with chronic HBV. Importantly, 729 continues to have a favorable safety and tolerability profile, and all four of these abstracts were selected for best of EASL conference. Notably, in addition to reporting significant drops in surface antigen, we saw that in three out of five evaluable subjects, and increased HBV-specific immune response, providing support for combination therapy, including immunomodulatory agents.
This compelling 729 data derived from up to one year of dosing supports our view that 60 milligrams every eight weeks is an appropriate dose in our phase 2a clinical trials. And I'll discuss these trials in just a moment. Looking forward, we expect to provide additional data in the second half of 2021, including initial data for a 90-milligram every 12-week cohort in HBV DNA negative subjects and initial data on a 90-milligram every eight-week cohort in HBV DNA positive subjects. As we've discussed in the past, we believe that 729 has the potential to be a cornerstone therapeutic in future HBV combination regimens.
Therefore, our strategy has been to enter several clinical collaborations to evaluate 729 in combination with other agents with potential complementary mechanisms of action. And so I'm pleased to report significant progress toward this goal with our previously announced collaborations with Assembly Biosciences, Antios Therapeutics, and Vaccitech, and also the authorization from the FDA to proceed with our IND application for 729 in a clinical trial in combination with a nucleoside analog and short courses of peginterferon. Now the Antios collaboration will evaluate a triple combination of 729, the Antios proprietary active site polymerase inhibitor nucleoside, which is called ATI-2173, and VIREAD, for the treatment of subjects with chronic HBV. The Vaccitech collaboration will evaluate a triple combination of 729 with Vaccitech's proprietary immunotherapeutic VTP-300 and standard-of-care nucleoside analog therapy for the treatment of subjects with chronic HBV.
The clinical trials evaluating 729 with interferon and Antios' ATI-2173 are expected to initiate in the second half of 2021. We expect to file the CTA for the clinical trial with Vaccitech's VTP-300 in the second half of 2021 and expect to initiate the clinical trial in early 2022. In addition to the substantial progress that we've made with AB-729, I'm also gratified with the initiation of a phase 1a/1b clinical trial with AB-836, our next-generation oral capsid inhibitor. This is an important program as it will allow us to potentially have our own proprietary combination therapy to treat patients with chronic HBV.
At the recent EASL conference, Arbutus presented preclinical 836 data suggesting the potential for increased efficacy and an enhanced resistance profile, relative to previous generation capsid inhibitors. Initial data from healthy volunteers and HBV subjects is expected in the second half of this year. We continue to make progress in all of our discovery programs. We're focused on generating lead nomination candidates for our oral PD-L1 inhibitor and RNA destabilizer programs.
In addition, our internal research program to identify new small-molecule antiviral medicines to treat COVID-19 and future coronavirus outbreaks continues to progress. And so with that summary, I'll now turn the call over to Dave Hastings for a brief financial update.
Dave Hastings -- Chief Financial Officer
Thanks, Bill, and good morning, everybody. As I've mentioned in the past, our key financial metric is cash and financial runway. Our cash, cash equivalents, and investments was $121.3 million as of June 30, 2021, as compared to $123.3 million as of December 31, 2020. Our cash use from operations for the first half of 2021 was $31.9 million, which was offset by $30.7 million of net proceeds on an issuance of common shares under Arbutus' ATM program.
For all of 2021, we expect our cash use to range from $70 million to $75 million, and therefore we expect our current cash runway is sufficient to fund operations through the third quarter of 2022. So with that, Bill, I'll turn the call back to you.
Bill Collier -- President and Chief Executive Officer
Thanks very much, Dave. So, operator, let's now open up the lines for Q&A, please.
Questions & Answers:
Operator
[Operator instructions] Your first question comes from the line of Ed Arce with H.C. Wainwright.
Thomas Yip -- H.C. Wainwright & Co. -- Analyst
Hi. Good morning everyone. This is Thomas Yip asking a couple of questions for Ed. First, about the new phase 2a study with 729, specifically regarding the dosing choice.
In the press release, you indicated that you've already selected 60-milligram every eighth week as the dose to go forward. Just wondering, will the study include only one dose? Or is there -- possible to include additional doses with the 90-milligram dose data that are expected in the second half this year?
Bill Collier -- President and Chief Executive Officer
Yes. Good question. Thank you very much. Good morning.
Gaston, would you like to take that one?
Gaston Picchio -- Chief Development Officer
Sure. Hi. Good morning, Thomas. For now, the decision has been made to include a season dose.
But since we are in the early stages of preparation of the file. And our 90-milligram data will come later this year, there's always an opportunity to reconsider that decision; that includes the doses. But right now, we're going with one dose.
Thomas Yip -- H.C. Wainwright & Co. -- Analyst
OK. Sounds good. And then, perhaps for 836, for also the phase 1a/b study that's ongoing. You mentioned that data from both have the volunteers and HBV patients will be included in at least second half of this year.
Just wondering, will this be a single data readout? And what should we expect from this readout beyond safety data?
Bill Collier -- President and Chief Executive Officer
Yes. Gaston, you want that, too?
Gaston Picchio -- Chief Development Officer
Sure. So we expect, obviously, safety data and tolerability, as well as some HBV DNA data coming from the current hepatitis B cohorts. We may be able to also deliver some HBV RNA data as well. Sorry, let me just add one thing.
We will, as usual, measure as antigen, pending whether, as you know, 836, potentially it's much more effective, but targeting the second mechanism. So we will be measuring as antigen as well and see what happens in that front.
Thomas Yip -- H.C. Wainwright & Co. -- Analyst
All right. So perhaps somewhat comparable to 729 earlier data releases?
Gaston Picchio -- Chief Development Officer
Yes, correct.
Thomas Yip -- H.C. Wainwright & Co. -- Analyst
Great. OK. And then one final question from us. Just wondering, you mentioned the progress for 729 combination studies.
I wonder if -- have you report enrollment progress for the 729 combo study with Assembly, I recall here? And if not, what should we expect from the study mix.
Bill Collier -- President and Chief Executive Officer
Yes. Gaston, want to -- again?
Gaston Picchio -- Chief Development Officer
So I mean, it's a little bit premature yet, the study is recruiting, and pending the progress in terms of enrolling this study, we will make a later announcement regarding what data can we share before the end of the year. But the study is enrolling as planned as we speak.
Thomas Yip -- H.C. Wainwright & Co. -- Analyst
OK. So we should expect a new update by the end of the year?
Gaston Picchio -- Chief Development Officer
Again, I think it's going to be dependent on how successful the enrollment process moves forward. There's challenges around the world right now in terms of COVID. So, so far, so good. The study is enrolling.
The sites are opening, but it's very difficult to predict the pace of enrollment anywhere around the world.
Bill Collier -- President and Chief Executive Officer
Yes. So we haven't guided to having results by the end of the year in that assembly collaboration. What we have said, in conjunction with our partners at Assembly, is that the study has initiated and is recruiting.
Thomas Yip -- H.C. Wainwright & Co. -- Analyst
OK. Understood. And completely understandable given what's going on around the world. Thank you so much for taking the questions, and we look forward to the multiple payer releases in the second half this year.
Bill Collier -- President and Chief Executive Officer
Thank you very much.
Operator
Your next question comes from the line of Brian Skorney with Baird.
Luke Herrmann -- Baird -- Analyst
Hi. This is Luke on for Brian. So regarding the peginterferon alpha combo study, beyond safety, could you maybe talk about what you're hoping to see regarding biomarkers? I know it's still kind of early here, but also, when do you think we could see initial data?
Bill Collier -- President and Chief Executive Officer
Well, on that study, we said that we will initiate in the second half of this year as to the study design. I'll let Gaston answer that.
Gaston Picchio -- Chief Development Officer
Yes. Thanks for the question. So basically, as you know, we presented data at EASL, showing that there is reawakening of HBV-specific immunity after around 20 weeks of dosing with the 729. So we think this provides a great opportunity to add on another agent such as the immunomodulatory agents such as interferon.
So we expect basically to see at the time of the addition of interferon, we expect to see a probably a faster and deeper decline in S-antigen. We also plan to measure T cell responses. And we obviously potentially expect to see that decent responses in the presence of interferon are stronger and potentially broader. Then obviously, we have other biomarker, biomarkers such as HBV RNA, but that will depend on whether the initial baseline HBV RNA level is susceptible, as you know, not in all patients is susceptible.
So really, it's going to be around that. And hopefully, we may see also an increase in antibodies. That's another possibility in the presence of interferon, which we haven't seen so far in the ongoing studies.
Luke Herrmann -- Baird -- Analyst
Great. Thanks.
Bill Collier -- President and Chief Executive Officer
Thank you, Luke.
Operator
Your next question comes from the line of Roy Buchanan with JMP Securities.
Roy Buchanan -- JMP Securities -- Analyst
Hi. Great. Thanks for taking the questions. The first one, I want to ask about the Vaccitech approach? And just what made that approach still appealing for use as a therapeutic vaccine? For example, why not use that approved potent vaccine like Heplisav-B or something as a possible option?
Bill Collier -- President and Chief Executive Officer
Yes. Thanks for the question. We've always had a strategy that a combination of drugs is likely to be the -- like the -- there's actually a slide that we've had in our corporate deck for, it seems like many, many years now, which has got all the different potential combinations in kind of up arrows and down arrows. So I think we've also always recognized that vaccines play a part in that.
And so we were intrigued and interested in the Vaccitech collaboration. I'll let Gaston expand further.
Gaston Picchio -- Chief Development Officer
Yes. Thanks for the question. So it's a little bit along the lines of what we just discussed on the previous questions. So now we have evidence, I think for the first time, I would believe we've been the first ones in showing that, that with an siRNA, you're able to, reawaken HBV specific immune responses.
So I think this provides an excellent opportunity to ask the question of enhancing the HBV-specific immune response in different ways. One could be with a broad immunomodulator such as interferon, the other would be with HBV-specific lectins. Now specifically, so I think the data that we have gathered in the 729 programs, especially the immunology data, it really provides a very good foundation and justification to do this study with Vaccitech. So Vaccitech's platform, we believe, provides a much stronger HBV-specific immune response than existing prophylactic HBV backings.
So I mean, I think you should discuss with them directly their data. But based on what we learned, we believe their therapeutic vaccine with the adeno platform, as well as NDA provides a much better opportunity at enhancing HBV-specific responses compared to prophylactic HBV vaccines that may be in the market.
Roy Buchanan -- JMP Securities -- Analyst
OK, great. And I had a question on Antios' ATI-2173. How does that -- so clinically, how does that differ in targeting versus the background with, which is tenofovir in this case? And is the goal to replace the background news with a more potent nuke? Or what's the goal of the combination?
Bill Collier -- President and Chief Executive Officer
Yes. Good question. It's set up in the study with a nuclear sign. Maybe, Mike Sofia, do you want to chime in on that?
Mike Sofia -- Chief Scientific Officer
Sure. So, I mean, if you look at clonidine as a nucleotide, nucleoside, it shows very interesting profile in, in vivo studies, even if some of the earlier historic clinical trials, which you saw was this longer duration of effect compared to a typical nucleoside, whether tenofovir or entecavir. It also has a slightly different mechanism of action, although it does target the polymerase, it does bind to the active site, it's not what they call a chain terminator. So it doesn't function as a tenofovir or entecavir does.
So that differentiates it in some way. So that combination of interesting observations made it an interesting experiment to do, to combine it with an agent like 729, which reduces S-antigen, can we then bring in something like the Antios molecule with another nucleoside and see very deep suppression of viral replication that is more sustained over time than with a single nucleoside. So that was sort of the rationale for an interest level in bringing in the Antios molecule into the mix.
Roy Buchanan -- JMP Securities -- Analyst
OK. Great. That's helpful. Thanks.
And then last couple of questions on the interferon program. Vir has presented some preliminary results for their combo with the RNAi plus interferon, just anything that you've learned from that program that can be applied to 729, anything that you're doing differently with 729 that might differentiate it from the other candidates, or maybe you don't need to differentiate? And then, what do you guys expect to be the baseline, functional cure rate for the interferon, plus a move? If have the number for interferon, can look in the slide deck. But I'm not clear if interferon numbers, the combos, just interferon itself. Thanks.
Bill Collier -- President and Chief Executive Officer
Gaston, do you want to take that one?
Gaston Picchio -- Chief Development Officer
Sure. So let me start from the last question. So the expectation in terms of functional cure, I don't think we are in a position to provide a number of, what's our expectation of functional cure. So we just let the data speak for itself.
When it comes to what did we learn? Well, the approach that Vir took actually was -- in the part of the study that they showed data on, at EASL was having interferon at the beginning. So from the get-go, they would add their RNAi plus interferon. So that resulted, I believe, if I remember correctly, with 12 in an increase in the decay of S-antigen. So we have a little -- a different approach.
Again, in line with the finance that we have. There were some immunology studies that we presented at EASL. We believe that it's better to first drop S-antigen and allow that immune response to come back and then add the interferon. So I believe -- again, I mean, don't take my word for it, but I believe that based on the data, I believe I have seen that Vir will be testing that as well.
They will be adding interferon later. But we are only exploring adding the interferon later. So as you may see, you can see the design of the starting clinical trials are comped right now. We're going to be adding interferon after 24 weeks of 729 treatment.
So we believe that S-antigen already would have gone down by probably somewhere around 1.8 to two locks, on average, across the entire population. So what we expect, as I said before, is that after having interferon, obviously, the S-antigen will continue to decay. We may see some sort of conversion. We may see also, because we're going to measure that, better HBV-specific immune reawakening compared to subjects that did not receive interferon.
Roy Buchanan -- JMP Securities -- Analyst
OK. Great. Thank you.
Operator
Your next question comes from the line of Keay Nakae with Chardan.
Keay Nakae -- Chardan Capital Markets -- Analyst
Hi. Keay Nakae from Chardan. Just back on that same topic with the time to the interferon in your study. Is there a threshold drop in S-antigen before you'll advance the patient to the interferon? Or is it just simply the 24-week duration standpoint?
Gaston Picchio -- Chief Development Officer
There is no threshold. We are very confident that by week 24, all subjects have achieved at least a lot. And for the vast majority more than a log and a half of S-antigen drug. So in response to your question, there's no minimum threshold that they need to meet, but very confident that everyone is going to be in excess of one log decay of -- in S-antigen.
Keay Nakae -- Chardan Capital Markets -- Analyst
OK. And then how long is the course of interferon?
Gaston Picchio -- Chief Development Officer
Yes. Great question. We're testing two courses: 24 weeks, as well as 12 weeks.
Keay Nakae -- Chardan Capital Markets -- Analyst
OK.
Bill Collier -- President and Chief Executive Officer
Again, may I remind everyone, yes, the details are in clinical trials. I'll go for it right now.
Keay Nakae -- Chardan Capital Markets -- Analyst
OK. All right. Great. That's all I have.
Bill Collier -- President and Chief Executive Officer
Thank you. Yes.
Operator
There are no additional questions at this time. I'd like to turn it back over to management -- I'm sorry, there is a question. There is from Kelechi Chikere with Jefferies.
Bill Collier -- President and Chief Executive Officer
Kelechi.
Kelechi Chikere -- Jefferies -- Analyst
Yes. Hey, how is it going? Thanks for fitting me in here. Just a couple of questions on my end. I guess, on a high level, are there any competitor data sets over the coming quarters that you'll specifically be looking at for a read-through or to inform the design or to provide with any information for your own clinical studies?
Bill Collier -- President and Chief Executive Officer
Hey, good question. I mean, we've just had, obviously, the EASL conference. And as always, we had our highest field for interesting data from, actually any source. And then as you think about the second half of the year, the typical event is AASLD, which is in November.
I don't know that I would single out any particular data set. I'm just racking my brain here. Gaston or Mike, can you think of anything that, other than obviously staying, like you guys, the rest of what all the major companies are doing in the area. So, Gaston?
Kelechi Chikere -- Jefferies -- Analyst
Got it.
Gaston Picchio -- Chief Development Officer
I think the one -- so it's interesting because, at EASL, we pretty much showed one year of dosing with AB-729. And we were expecting to see one year of dosing coming in from Janssen that was presented from their [Inaudible] study. So I would say it will be interesting to see if that data gets presented at ASMD later this year, as well as in that study, I believe they also have a triple combination. So that would be also interesting to see.
Kelechi Chikere -- Jefferies -- Analyst
Yes. Great. Great. Thank you.
That's great color there. And I guess, lastly, I guess in respect to your earlier-stage programs, is there any additional color you can provide around when you might be able to enter the clinic with those, so your destabilizer, as well as the PD-L1?
Bill Collier -- President and Chief Executive Officer
Yes. Mike, you want to take that one?
Mike Sofia -- Chief Scientific Officer
Yes. So we're very close. We're kind of in the latter stages of our candidate selection process. So I think we'll be able to update and -- when we expect to be in the clinic.
Bill Collier -- President and Chief Executive Officer
Perfect. And thank you.
Operator
There are no additional questions at this time.
Bill Collier -- President and Chief Executive Officer
All right. Well, thank you very much, everyone, for joining us this morning. We appreciate your interest and your questions, actually. So we look forward to a productive remainder of 2021, and we continue to be confident with further data from the 729 phase 1a/1b trial.
Our progression of 729 into two additional phase 2a proof-of-concept studies, and data from our 836 clinical trial, as well as continued progress in our HBV discovery programs, that we'll be building on a strong foundation to achieve a functional cure for people with chronic HBV. And of course, we're also looking forward to leveraging our antiviral discovery and research efforts in progressing our pan-coronavirus discovery program. So with that being said, thank you again for your time. And, operator, that concludes our call this morning.
Operator
[Operator signoff]
Duration: 30 minutes
Call participants:
Pam Murphy -- Investor Relations
Bill Collier -- President and Chief Executive Officer
Dave Hastings -- Chief Financial Officer
Thomas Yip -- H.C. Wainwright & Co. -- Analyst
Gaston Picchio -- Chief Development Officer
Luke Herrmann -- Baird -- Analyst
Roy Buchanan -- JMP Securities -- Analyst
Mike Sofia -- Chief Scientific Officer
Keay Nakae -- Chardan Capital Markets -- Analyst
Kelechi Chikere -- Jefferies -- Analyst
More ABUS analysis
All earnings call transcripts
This article is a transcript of this conference call produced for The Motley Fool. While we strive for our Foolish Best, there may be errors, omissions, or inaccuracies in this transcript. As with all our articles, The Motley Fool does not assume any responsibility for your use of this content, and we strongly encourage you to do your own research, including listening to the call yourself and reading the company's SEC filings. Please see our Terms and Conditions for additional details, including our Obligatory Capitalized Disclaimers of Liability.
The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Arbutus Biopharma (NASDAQ: ABUS) Q2 2021 Earnings Call Aug 05, 2021, 8:45 a.m. Operator [Operator signoff] Duration: 30 minutes Call participants: Pam Murphy -- Investor Relations Bill Collier -- President and Chief Executive Officer Dave Hastings -- Chief Financial Officer Thomas Yip -- H.C. Wainwright & Co. -- Analyst Gaston Picchio -- Chief Development Officer Luke Herrmann -- Baird -- Analyst Roy Buchanan -- JMP Securities -- Analyst Mike Sofia -- Chief Scientific Officer Keay Nakae -- Chardan Capital Markets -- Analyst Kelechi Chikere -- Jefferies -- Analyst More ABUS analysis All earnings call transcripts This article is a transcript of this conference call produced for The Motley Fool. During the first half of this year, we established a strong foundation toward achieving that goal by accomplishing the following: We continue to report compelling data on AB-729, with four abstracts at EASL, including a late-breaker oral presentation that showed substantial declines in hepatitis B surface antigen in subjects with chronic HBV. | Operator [Operator signoff] Duration: 30 minutes Call participants: Pam Murphy -- Investor Relations Bill Collier -- President and Chief Executive Officer Dave Hastings -- Chief Financial Officer Thomas Yip -- H.C. Wainwright & Co. -- Analyst Gaston Picchio -- Chief Development Officer Luke Herrmann -- Baird -- Analyst Roy Buchanan -- JMP Securities -- Analyst Mike Sofia -- Chief Scientific Officer Keay Nakae -- Chardan Capital Markets -- Analyst Kelechi Chikere -- Jefferies -- Analyst More ABUS analysis All earnings call transcripts This article is a transcript of this conference call produced for The Motley Fool. Arbutus Biopharma (NASDAQ: ABUS) Q2 2021 Earnings Call Aug 05, 2021, 8:45 a.m. On the call from the Arbutus executive team are Bill Collier, president and chief executive officer; Dave Hastings, chief financial officer; Dr. Gaston Picchio, chief development officer; and Dr. Mike Sofia, chief scientific officer. | Operator [Operator signoff] Duration: 30 minutes Call participants: Pam Murphy -- Investor Relations Bill Collier -- President and Chief Executive Officer Dave Hastings -- Chief Financial Officer Thomas Yip -- H.C. Wainwright & Co. -- Analyst Gaston Picchio -- Chief Development Officer Luke Herrmann -- Baird -- Analyst Roy Buchanan -- JMP Securities -- Analyst Mike Sofia -- Chief Scientific Officer Keay Nakae -- Chardan Capital Markets -- Analyst Kelechi Chikere -- Jefferies -- Analyst More ABUS analysis All earnings call transcripts This article is a transcript of this conference call produced for The Motley Fool. Arbutus Biopharma (NASDAQ: ABUS) Q2 2021 Earnings Call Aug 05, 2021, 8:45 a.m. On the call from the Arbutus executive team are Bill Collier, president and chief executive officer; Dave Hastings, chief financial officer; Dr. Gaston Picchio, chief development officer; and Dr. Mike Sofia, chief scientific officer. | Operator [Operator signoff] Duration: 30 minutes Call participants: Pam Murphy -- Investor Relations Bill Collier -- President and Chief Executive Officer Dave Hastings -- Chief Financial Officer Thomas Yip -- H.C. Wainwright & Co. -- Analyst Gaston Picchio -- Chief Development Officer Luke Herrmann -- Baird -- Analyst Roy Buchanan -- JMP Securities -- Analyst Mike Sofia -- Chief Scientific Officer Keay Nakae -- Chardan Capital Markets -- Analyst Kelechi Chikere -- Jefferies -- Analyst More ABUS analysis All earnings call transcripts This article is a transcript of this conference call produced for The Motley Fool. Arbutus Biopharma (NASDAQ: ABUS) Q2 2021 Earnings Call Aug 05, 2021, 8:45 a.m. Bill Collier -- President and Chief Executive Officer Well, on that study, we said that we will initiate in the second half of this year as to the study design. |
34648.0 | 2021-08-04 00:00:00 UTC | Companies Like Arbutus Biopharma (NASDAQ:ABUS) Are In A Position To Invest In Growth | ABUS | https://www.nasdaq.com/articles/companies-like-arbutus-biopharma-nasdaq%3Aabus-are-in-a-position-to-invest-in-growth-2021-08 | nan | nan | There's no doubt that money can be made by owning shares of unprofitable businesses. For example, biotech and mining exploration companies often lose money for years before finding success with a new treatment or mineral discovery. But while the successes are well known, investors should not ignore the very many unprofitable companies that simply burn through all their cash and collapse.
Given this risk, we thought we'd take a look at whether Arbutus Biopharma (NASDAQ:ABUS) shareholders should be worried about its cash burn. In this article, we define cash burn as its annual (negative) free cash flow, which is the amount of money a company spends each year to fund its growth. Let's start with an examination of the business' cash, relative to its cash burn.
Does Arbutus Biopharma Have A Long Cash Runway?
A company's cash runway is the amount of time it would take to burn through its cash reserves at its current cash burn rate. In March 2021, Arbutus Biopharma had US$132m in cash, and was debt-free. Looking at the last year, the company burnt through US$54m. So it had a cash runway of about 2.4 years from March 2021. That's decent, giving the company a couple years to develop its business. You can see how its cash balance has changed over time in the image below.
NasdaqGS:ABUS Debt to Equity History August 4th 2021
How Well Is Arbutus Biopharma Growing?
We reckon the fact that Arbutus Biopharma managed to shrink its cash burn by 23% over the last year is rather encouraging. And operating revenue was up by 10% too. Considering the factors above, the company doesn’t fare badly when it comes to assessing how it is changing over time. Clearly, however, the crucial factor is whether the company will grow its business going forward. For that reason, it makes a lot of sense to take a look at our analyst forecasts for the company.
How Hard Would It Be For Arbutus Biopharma To Raise More Cash For Growth?
Even though it seems like Arbutus Biopharma is developing its business nicely, we still like to consider how easily it could raise more money to accelerate growth. Issuing new shares, or taking on debt, are the most common ways for a listed company to raise more money for its business. Commonly, a business will sell new shares in itself to raise cash and drive growth. By looking at a company's cash burn relative to its market capitalisation, we gain insight on how much shareholders would be diluted if the company needed to raise enough cash to cover another year's cash burn.
Since it has a market capitalisation of US$265m, Arbutus Biopharma's US$54m in cash burn equates to about 20% of its market value. That's not insignificant, and if the company had to sell enough shares to fund another year's growth at the current share price, you'd likely witness fairly costly dilution.
How Risky Is Arbutus Biopharma's Cash Burn Situation?
On this analysis of Arbutus Biopharma's cash burn, we think its cash runway was reassuring, while its cash burn relative to its market cap has us a bit worried. Cash burning companies are always on the riskier side of things, but after considering all of the factors discussed in this short piece, we're not too worried about its rate of cash burn. On another note, we conducted an in-depth investigation of the company, and identified 4 warning signs for Arbutus Biopharma (1 is significant!) that you should be aware of before investing here.
Of course, you might find a fantastic investment by looking elsewhere. So take a peek at this free list of companies insiders are buying, and this list of stocks growth stocks (according to analyst forecasts)
This article by Simply Wall St is general in nature. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Given this risk, we thought we'd take a look at whether Arbutus Biopharma (NASDAQ:ABUS) shareholders should be worried about its cash burn. NasdaqGS:ABUS Debt to Equity History August 4th 2021 How Well Is Arbutus Biopharma Growing? For example, biotech and mining exploration companies often lose money for years before finding success with a new treatment or mineral discovery. | Given this risk, we thought we'd take a look at whether Arbutus Biopharma (NASDAQ:ABUS) shareholders should be worried about its cash burn. NasdaqGS:ABUS Debt to Equity History August 4th 2021 How Well Is Arbutus Biopharma Growing? How Risky Is Arbutus Biopharma's Cash Burn Situation? | Given this risk, we thought we'd take a look at whether Arbutus Biopharma (NASDAQ:ABUS) shareholders should be worried about its cash burn. NasdaqGS:ABUS Debt to Equity History August 4th 2021 How Well Is Arbutus Biopharma Growing? A company's cash runway is the amount of time it would take to burn through its cash reserves at its current cash burn rate. | Given this risk, we thought we'd take a look at whether Arbutus Biopharma (NASDAQ:ABUS) shareholders should be worried about its cash burn. NasdaqGS:ABUS Debt to Equity History August 4th 2021 How Well Is Arbutus Biopharma Growing? A company's cash runway is the amount of time it would take to burn through its cash reserves at its current cash burn rate. |
34649.0 | 2021-06-28 00:00:00 UTC | Pre-Market Most Active for Jun 28, 2021 : MRIN, SOFI, SPCE, NOK, AMC, NTLA, ABUS, WISH, MNKD, CCL, EXPR, AHT | ABUS | https://www.nasdaq.com/articles/pre-market-most-active-for-jun-28-2021-%3A-mrin-sofi-spce-nok-amc-ntla-abus-wish-mnkd-ccl | nan | nan | The NASDAQ 100 Pre-Market Indicator is up 42.97 to 14,388.15. The total Pre-Market volume is currently 31,653,441 shares traded.
The following are the most active stocks for the pre-market session:
Marin Software Incorporated (MRIN) is +1.4601 at $5.27, with 10,153,940 shares traded.
SoFi Technologies, Inc. (SOFI) is -0.21 at $18.29, with 5,228,538 shares traded. As reported by Zacks, the current mean recommendation for SOFI is in the "strong buy range".
Virgin Galactic Holdings, Inc. (SPCE) is +2.9055 at $58.82, with 3,308,648 shares traded. As reported by Zacks, the current mean recommendation for SPCE is in the "buy range".
Nokia Corporation (NOK) is +0.02 at $5.47, with 2,493,635 shares traded. NOK's current last sale is 95.96% of the target price of $5.7.
AMC Entertainment Holdings, Inc. (AMC) is +1.33 at $55.39, with 1,736,291 shares traded. AMC's current last sale is 963.3% of the target price of $5.75.
Intellia Therapeutics, Inc. (NTLA) is +48.07 at $136.90, with 1,176,382 shares traded. As reported by Zacks, the current mean recommendation for NTLA is in the "buy range".
Arbutus Biopharma Corporation (ABUS) is +0.51 at $3.88, with 1,096,145 shares traded. As reported by Zacks, the current mean recommendation for ABUS is in the "buy range".
ContextLogic Inc. (WISH) is +0.06 at $14.10, with 1,039,161 shares traded. As reported by Zacks, the current mean recommendation for WISH is in the "buy range".
MannKind Corporation (MNKD) is +0.58 at $5.32, with 945,969 shares traded. As reported in the last short interest update the days to cover for MNKD is 8.797978; this calculation is based on the average trading volume of the stock.
Carnival Corporation (CCL) is -0.48 at $27.65, with 777,521 shares traded. CCL's current last sale is 92.17% of the target price of $30.
Express, Inc. (EXPR) is unchanged at $7.10, with 514,339 shares traded. EXPR's current last sale is 157.78% of the target price of $4.5.
Ashford Hospitality Trust Inc (AHT) is +0.28 at $5.48, with 424,197 shares traded. AHT's current last sale is 137% of the target price of $4.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | As reported by Zacks, the current mean recommendation for ABUS is in the "buy range". Arbutus Biopharma Corporation (ABUS) is +0.51 at $3.88, with 1,096,145 shares traded. As reported by Zacks, the current mean recommendation for SOFI is in the "strong buy range". | Arbutus Biopharma Corporation (ABUS) is +0.51 at $3.88, with 1,096,145 shares traded. As reported by Zacks, the current mean recommendation for ABUS is in the "buy range". The total Pre-Market volume is currently 31,653,441 shares traded. | Arbutus Biopharma Corporation (ABUS) is +0.51 at $3.88, with 1,096,145 shares traded. As reported by Zacks, the current mean recommendation for ABUS is in the "buy range". The total Pre-Market volume is currently 31,653,441 shares traded. | Arbutus Biopharma Corporation (ABUS) is +0.51 at $3.88, with 1,096,145 shares traded. As reported by Zacks, the current mean recommendation for ABUS is in the "buy range". As reported by Zacks, the current mean recommendation for SOFI is in the "strong buy range". |
34650.0 | 2021-06-28 00:00:00 UTC | Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday | ABUS | https://www.nasdaq.com/articles/todays-biggest-pre-market-stock-movers%3A-10-top-gainers-and-losers-on-monday-2021-06-28 | nan | nan | InvestorPlace - Stock Market News, Stock Advice & Trading Tips
Good morning! Let’s get ready for trading to start off strong this week with a look at the biggest pre-market stock movers for Monday!
Source: Eric Urquhart/Shutterstock.com
We’re seeing a lot of medical stocks making the lists today with plenty of them being winners and losers.
Let’s dive into those pre-market stock movers below to see why!
Pre-Market Stock Movers: 10 Top Gainers
Intellia Therapeutics (NASDAQ:NTLA) stock is roaring nearly 44% higher after revealing positive interim data from a Phase 1 gene editing study.
Marin Software (NASDAQ:MRIN) shares are continuing to rally almost 24% from Instacart news last week.
Reshape Lifesciences (NASDAQ:RSLS) stock is soaring more than 20% this morning after shares started to rally after-hours Friday.
Mexco Energy (NYSEAMERICAN:MXC) shares are rising over 17% after releasing earnings for its fiscal full-year o 2021.
Arbutus Biopharma (NASDAQ:ABUS) stock is heading close to 14% higher after revealing new data from studies over the weekend.
Beam Therapeutics (NASDAQ:BEAM) shares are recovering about 13% after dipping on Friday.
Editas Medicine (NASDAQ:EDIT) stock continues to increase after a rally on clinical trial data last week with shares up roughly 11% this morning.
Oncternal Therapeutics (NASDAQ:ONCT) shares are jumping more than 10% this morning as shares started to rally late on Friday.
Perion Network (NASDAQ:PERI) stock is getting an over 9% boost after releasing preliminary results for its second quarter.
CRISPR Therapeutics (NASDAQ:CRSP) shares are up more than 8% in pre-market trading.
10 Best Stocks to Buy to Build Up Passive Income Streams
10 Top Losers
CoStar Group (NASDAQ:CSGP) stock is down almost 90% after enacting a 10-for-one stock split today.
Greenland Technologies (NASDAQ:GTEC) shares are diving more than 10% after revealing a proposed underwritten public offering of its stock.
Trevena (NASDAQ:TRVN) stock is retreating over 9% this morning after a rally on Friday.
Atossa Therapeutics (NASDAQ:ATOS) shares are pulling back nearly 9% after rallying last week.
Acurx Pharmaceuticals (NASDAQ:ACXP) stock is taking a more than 8% beating after going public last week.
Ikonics (NASDAQ:IKNX) shares are decreasing over 8% after announcing merger plans that will turn it into a crypto mining company.
Missfresh (NASDAQ:MF) stock is dipping more than 7% after its initial public offering last week.
Osmotica Pharmaceuticals (NASDAQ:OSMT) shares are declining over 7% after a divesture deal sent shares flying on Friday.
Motus GI Holdings (NASDAQ:MOTS) stock is dropping more than 7% this morning.
BurgerFi International (NASDAQ:BFI) shares close out the pre-market movers list down over 6% as it continues a fall that started on Friday.
On the date of publication, William White did not have (either directly or indirectly) any positions in the securities mentioned in this article. The opinions expressed in this article are those of the writer, subject to the InvestorPlace.com Publishing Guidelines.
The post Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday appeared first on InvestorPlace.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Arbutus Biopharma (NASDAQ:ABUS) stock is heading close to 14% higher after revealing new data from studies over the weekend. Editas Medicine (NASDAQ:EDIT) stock continues to increase after a rally on clinical trial data last week with shares up roughly 11% this morning. BurgerFi International (NASDAQ:BFI) shares close out the pre-market movers list down over 6% as it continues a fall that started on Friday. | Arbutus Biopharma (NASDAQ:ABUS) stock is heading close to 14% higher after revealing new data from studies over the weekend. Pre-Market Stock Movers: 10 Top Gainers Intellia Therapeutics (NASDAQ:NTLA) stock is roaring nearly 44% higher after revealing positive interim data from a Phase 1 gene editing study. Beam Therapeutics (NASDAQ:BEAM) shares are recovering about 13% after dipping on Friday. | Arbutus Biopharma (NASDAQ:ABUS) stock is heading close to 14% higher after revealing new data from studies over the weekend. Pre-Market Stock Movers: 10 Top Gainers Intellia Therapeutics (NASDAQ:NTLA) stock is roaring nearly 44% higher after revealing positive interim data from a Phase 1 gene editing study. Editas Medicine (NASDAQ:EDIT) stock continues to increase after a rally on clinical trial data last week with shares up roughly 11% this morning. | Arbutus Biopharma (NASDAQ:ABUS) stock is heading close to 14% higher after revealing new data from studies over the weekend. Let’s dive into those pre-market stock movers below to see why! Oncternal Therapeutics (NASDAQ:ONCT) shares are jumping more than 10% this morning as shares started to rally late on Friday. |
34651.0 | 2021-06-05 00:00:00 UTC | Reflecting on Arbutus Biopharma's (NASDAQ:ABUS) Share Price Returns Over The Last Three Years | ABUS | https://www.nasdaq.com/articles/reflecting-on-arbutus-biopharmas-nasdaq%3Aabus-share-price-returns-over-the-last-three-years | nan | nan | If you are building a properly diversified stock portfolio, the chances are some of your picks will perform badly. But the last three years have been particularly tough on longer term Arbutus Biopharma Corporation (NASDAQ:ABUS) shareholders. So they might be feeling emotional about the 51% share price collapse, in that time. Furthermore, it's down 11% in about a quarter. That's not much fun for holders.
Given that Arbutus Biopharma didn't make a profit in the last twelve months, we'll focus on revenue growth to form a quick view of its business development. When a company doesn't make profits, we'd generally expect to see good revenue growth. That's because it's hard to be confident a company will be sustainable if revenue growth is negligible, and it never makes a profit.
Over the last three years, Arbutus Biopharma's revenue dropped 14% per year. That is not a good result. The share price decline of 15% compound, over three years, is understandable given the company doesn't have profits to boast of, and revenue is moving in the wrong direction. Of course, it's the future that will determine whether today's price is a good one. We don't generally like to own companies that lose money and can't grow revenues. But any company is worth looking at when it makes a maiden profit.
You can see how earnings and revenue have changed over time in the image below (click on the chart to see the exact values).
NasdaqGS:ABUS Earnings and Revenue Growth June 5th 2021
If you are thinking of buying or selling Arbutus Biopharma stock, you should check out this FREE detailed report on its balance sheet.
A Different Perspective
It's nice to see that Arbutus Biopharma shareholders have received a total shareholder return of 43% over the last year. Notably the five-year annualised TSR loss of 3% per year compares very unfavourably with the recent share price performance. We generally put more weight on the long term performance over the short term, but the recent improvement could hint at a (positive) inflection point within the business. I find it very interesting to look at share price over the long term as a proxy for business performance. But to truly gain insight, we need to consider other information, too. To that end, you should learn about the 4 warning signs we've spotted with Arbutus Biopharma (including 1 which can't be ignored) .
For those who like to find winning investments this free list of growing companies with recent insider purchasing, could be just the ticket.
Please note, the market returns quoted in this article reflect the market weighted average returns of stocks that currently trade on US exchanges.
This article by Simply Wall St is general in nature. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | NasdaqGS:ABUS Earnings and Revenue Growth June 5th 2021 If you are thinking of buying or selling Arbutus Biopharma stock, you should check out this FREE detailed report on its balance sheet. But the last three years have been particularly tough on longer term Arbutus Biopharma Corporation (NASDAQ:ABUS) shareholders. Given that Arbutus Biopharma didn't make a profit in the last twelve months, we'll focus on revenue growth to form a quick view of its business development. | But the last three years have been particularly tough on longer term Arbutus Biopharma Corporation (NASDAQ:ABUS) shareholders. NasdaqGS:ABUS Earnings and Revenue Growth June 5th 2021 If you are thinking of buying or selling Arbutus Biopharma stock, you should check out this FREE detailed report on its balance sheet. When a company doesn't make profits, we'd generally expect to see good revenue growth. | But the last three years have been particularly tough on longer term Arbutus Biopharma Corporation (NASDAQ:ABUS) shareholders. NasdaqGS:ABUS Earnings and Revenue Growth June 5th 2021 If you are thinking of buying or selling Arbutus Biopharma stock, you should check out this FREE detailed report on its balance sheet. Given that Arbutus Biopharma didn't make a profit in the last twelve months, we'll focus on revenue growth to form a quick view of its business development. | But the last three years have been particularly tough on longer term Arbutus Biopharma Corporation (NASDAQ:ABUS) shareholders. NasdaqGS:ABUS Earnings and Revenue Growth June 5th 2021 If you are thinking of buying or selling Arbutus Biopharma stock, you should check out this FREE detailed report on its balance sheet. Given that Arbutus Biopharma didn't make a profit in the last twelve months, we'll focus on revenue growth to form a quick view of its business development. |
34652.0 | 2021-05-06 00:00:00 UTC | Arbutus Biopharma (ABUS) Q1 2021 Earnings Call Transcript | ABUS | https://www.nasdaq.com/articles/arbutus-biopharma-abus-q1-2021-earnings-call-transcript-2021-05-06 | nan | nan | Image source: The Motley Fool.
Arbutus Biopharma (NASDAQ: ABUS)
Q1 2021 Earnings Call
May 05, 2021, 8:45 a.m. ET
Contents:
Prepared Remarks
Questions and Answers
Call Participants
Prepared Remarks:
Operator
Ladies and gentlemen, thank you for standing by, and welcome to the Arbutus Biopharma Corporation 2021 first-quarter financial results and corporate update conference call. [Operator instructions] Please be advised that today's conference is being recorded. [Operator instructions]. I would now like to hand the conference to your speaker host today, Pam Murphy.
Please go ahead.
Pam Murphy -- Investor Relations Consultant
Thank you, and good morning. On the call from Arbutus executive team are Bill Collier, president and chief executive officer; Dave Hastings, chief financial officer; Dr. Gaston Picchio, chief development officer; and Dr. Mike Sofia, chief scientific officer.
Bill will begin with the review of the first quarter's accomplishment, clinical development, and remaining 2021 corporate objectives; followed by Dave Hastings, who will provide a the review of the company's first quarter financial results. We'll then open up the call for Q&A. Mike and Gaston will be available to address any research and clinical development related questions. Before we begin, we'd like to remind you that some of the statements made during the call today are forward-looking statements, including statements regarding expectations for Arbutus' proprietary HBV pipeline and pan-coronavirus discovery program, including potential clinical results and timelines for AB-729 and AB-836, and any future compound; our expected cash used and cash runway and the potential for our drug candidates to improve upon standard of care and contribute to a curative combination regimen for HBV.
10 stocks we like better than Arbutus Biopharma
When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor, has tripled the market.*
David and Tom just revealed what they believe are the ten best stocks for investors to buy right now... and Arbutus Biopharma wasn't one of them! That's right -- they think these 10 stocks are even better buys.
See the 10 stocks
*Stock Advisor returns as of February 24, 2021
These forward-looking statements are subject to a number of risks and uncertainties that may cause our actual results to differ materially, including those described in our most recent annual report on 10-K, quarterly report on Form 10-Q and other periodic reports filed with the SEC. Bill?
Bill Collier -- President and Chief Executive Officer
Thank you, Pam, and good morning, everybody. Thank you for joining us today. We really do appreciate your interest in Arbutus Biopharma. I am pleased to report on our progress thus far this year, and to outline our objectives for the rest of 2021.
As we've stated in the past, our goal at Arbutus is to focus on developing a portfolio of products with different mechanisms of action, that when used in combination could result in a functional cure for people living with chronic HBV. During the first quarter, we took another significant step toward that goal when AB-836, our proprietary oral capsid inhibitor began a Phase Ia/Ib clinical trial. 836 is from a novel chemical series, differentiated from competitive compounds with potential for increased efficacy and an enhanced resistance profile. And we look forward to having initial data readouts from this trial in the second half of this year.
In addition, AB-729, our proprietary subcutaneously delivered RNAi agent, continues to demonstrate robust and continuous declines in hepatitis B surface antigen in subjects with chronic HBV, with a favorable safety profile in our ongoing Phase Ia/Ib clinical trial. We expect to provide additional data from ongoing cohorts from this Phase Ia trial in the second quarter of this year, including 60-milligram multidose data with dosing every four and eight weeks and 90-milligram multidose data with dosing interval every eight weeks. Separately, data from the 90-milligram every 12 weeks in HBV negative subjects and the 90-milligram every eight weeks in HBV DNA positive subjects is expected in the second half of 2021. Now, we're very encouraged by the clinical results we've seen thus far with 729, as it demonstrates the inhibition of viral replication and reduction of all HBV antigens, including hepatitis B surface antigen.
As you know, reducing surface antigen is thought to be a key prerequisite to enable reawakening of a patient's immune system to respond to the virus. Therefore, our objective is to advance 729 into two additional proof-of-concept Phase II combination clinical trials with one or more approved or investigational agents in the second half of 2021 with dosing of 729 as infrequently as every eight or 12 weeks. Consistent with our belief that multi-drug combinations will be needed to achieve a functional cure for people with hepatitis B, I am pleased that Arbutus and Assembly Biosciences initiated in the first quarter, a Phase II proof-of-concept clinical trial to evaluate 729 in combination with Assembly lead capsid or core inhibitor candidate, Vebicorvir and an NrtI. Approximately 60 virologically suppressed subjects with HBV e-antigen, chronic HBV will be dosed for 48 weeks with 300 milligrams of Vebicorvir orally once-a-day and 60 milligrams of 729 subcutaneously every eight weeks, with a 48-week follow-up period.
Now, I'd like to turn to our HBV discovery programs, where we're making good progress in our research efforts for a next-generation oral HBV-specific RNA destabilizer, as well as a lead oral compound that inhibits PD-L1. So first, our oral RNA destabilizers have shown compelling antiviral effects in multiple HBV preclinical models. And we remain committed to this area of research. Arbutus is now focused on advancing a next-generation oral HBV-specific RNA destabilizer with distinct chemical scaffolds through lead optimization.
Arbutus also has compounds in lead optimization that are potentially capable of reawakening patients' HBV-specific immune response by inhibiting PD-L1. And we look forward to keeping you up-to-date on how these important research programs are progressing. Finally, to advance our efforts to identify a proprietary oral treatment for COVID and potential future coronavirus outbreaks, we recently announced an important Pan-Coronavirus Discovery Research and License Agreement with X-Chem and Proteros biostructures. Now, this collaboration brings together our own expertise in the discovery and development of antiviral agents with X-Chem's industry-leading DNA-Encoded Library technology and Proteros' protein sciences, biophysics and structural biology capabilities.
This collaboration will allow for the rapid screening of one of the largest small module libraries against Mpro, an essential protein for the coronavirus to replicate itself, and also use state-of-the-art structure guided methods to rapidly optimize Mpro inhibitors. So we look forward to keeping you updated on our pan-coronavirus discovery program as we progress throughout the year. And with that said, I'll now turn the call over to Dave Hastings for a brief financial update, and then we'll open up the call for our Q&A. As Pam mentioned, both Gaston and Mike Sofia are both on the call and can take any additional clinical and discovery questions.
So, over to you, Dave.
Dave Hastings -- Chief Financial Officer
Thanks, Bill, and good morning, everybody. As I've mentioned in the past, our key financial metric is cash and financial runway. Our ending cash, cash equivalents and short-term investments was $132 million as of March 31, 2021, as compared to approximately $123 million as of December 31, 2020. Our cash used from operations for the first quarter of 2021 was approximately $18 million, which was offset by approximately $26 million of net proceeds from the issuance of common shares under Arbutus's ATM program.
For 2021, we expect our cash use to range from $70 million to $75 million. And therefore, we expect our current cash runway is sufficient to fund operations through the third quarter of 2022. So with that, operator, would you please open the call for Q&A.
Questions & Answers:
Operator
[Operator instructions] Our first question coming from the line Ed Arce with H.C. Wainwright.
Ed Arce -- H.C. Wainwright -- Analyst
Just a couple for me. As most investors are eager to find out additional data on your next cohorts in the ongoing Phase Ia/Ib study of 729, wondering if you can tell us for the multi-dose data on the 60 and 90 that you're expecting, how many doses or number of weeks we can expect, given the cohorts both include patients that would be on every eight-week dosing. I was hoping to see at least 24 weeks out, if not more. Just wondering what we can expect later this quarter.
Bill Collier -- President and Chief Executive Officer
Yes. Good morning Ed, its Bill. Thank you very much for that great question. Yes.
I think as we've outlined in the past, we've been operating these cohorts very diligently during the COVID situation and really trying to make sure that we can work in areas where we can select patients and move them forward with full follow-up. So we're pleased with the progress that we've made. And I think we've also been cognizant that when we're looking at dose intervals of either four or eight or 12 weeks, we really do need to have a reasonable timeframe in terms of weeks and months to actually make sense of all the data. So we're closing in on that right now with some of the cohorts where we expect data later on this quarter.
But just with those comments, Gaston, if there's anything else that you would like to add?
Gaston Picchio -- Chief Development Officer -- Analyst
Yes. Hi Ed. Good morning. As Bill stated, we'll be hopefully sharing data on three cohorts.
And to your question, the range of weeks that we will be showing is probably depending what the remarks of Bill that we don't know until the last minute, but it's somewhere between 24 weeks to 48 weeks.
Ed Arce -- H.C. Wainwright -- Analyst
Excellent. OK. And then, I guess, the follow-up to this. And I know, Gaston, you mentioned this numerous times in the past, the importance of having sufficient data to fund or at least to predict a level of plateauing on the different doses.
Is this something that you're hoping to determine with this next data set?
Gaston Picchio -- Chief Development Officer -- Analyst
Well, I mean, I will be able to tell you that once we see the final data. But, yes, we were hoping that with at least 48 weeks of dosing, we will be able to get a better sense of how S-antigen and other HPV antigens are progressing over time.
Bill Collier -- President and Chief Executive Officer
Thank you, Ed. Thank you so much.
Operator
Our next question coming from the line of Kelechi Chikere with Jefferies. Your line is open.
Kelechi Chikere -- Jefferies -- Analyst
Yes. Good morning. Thank you for taking my questions. Just a couple on my end.
I was hoping, can you speak to the preliminary data you'll have for 836 in the second half? What will that be? And I guess, in the big picture, on what metrics are you hoping to see differentiation compared to the other capsid and core inhibitors in development? And I have a follow-up question after that.
Bill Collier -- President and Chief Executive Officer
OK. Good morning Kelly. Yes, I think in our corporate update, we've got the structure of the 836 Phase Ia/Ib study, so it's, I think, a fairly usual clinical structure with healthy volunteers and then single doses in HBV patients and then multiple doses. We are unlikely to get all of that data by the end of the year, but we do expect to have enough to give us confidence to move forward with 836.
So, again, I'll let Gaston add if you've got any further comments to make.
Gaston Picchio -- Chief Development Officer -- Analyst
Yes. So as it can be seen in the corporate deck, I believe its Slide 23 in the corporate deck, you can see the structure, the design of the 836-001 study that has three parts: single ascending, multiple sending and chronic hepatitis B subjects. The study has initiated, as we've stated before. And in the second half, I think, we'll have sufficient data already in chronic hepatitis B subjects provided everything continues as planned, to be able to move 836 forward in combinations.
I cannot give you any more specifics, because it's an ongoing study. Still, as you know, were impacted by the effects of COVID around the world. And, therefore, there's always a certain degree of uncertainty as to whether we can complete everything that we planned. But the study is ongoing and is on track.
Kelechi Chikere -- Jefferies -- Analyst
Thank you. That's very helpful, and that's a great segue to my next question. Just wondering if you can speak to enrollment in your various trials, the 836 study as well as the combo study with 729 and Assembly's core inhibitor. I guess, how is enrollment been going in? What steps have you implemented to ensure you're able to enroll patients in those studies, given everything that's going on?
Bill Collier -- President and Chief Executive Officer
Yes. Gaston, do you want to handle that one?
Gaston Picchio -- Chief Development Officer -- Analyst
Yes. Sorry, can you repeat the first part? were you talking about specifically about the 836 study? Or you were talking about AB-729 by itself or the combo study? I missed that part.
Kelechi Chikere -- Jefferies -- Analyst
Yes, both studies. So 729 combo study that was recently initiated with Assembly, as well as the 836 study that was just initiated. How is enrollment going there?
Gaston Picchio -- Chief Development Officer -- Analyst
Well, we haven't commented. And, obviously, we can't comment on that without our partners at this point in time. But I mean, our partner, Assembly in the combo study has done everything possible to really to speed up enrollment and ensure the timelines are met. So, so far, I mean, we haven't provided any additional guidance on enrollment other than I can reassure that every step has been taken to accelerate enrollment.
And as I said before, the 836 study it's on track and the 729-001 study actually it's fully enrolled, we're following the subjects now.
Bill Collier -- President and Chief Executive Officer
OK. Thank you very much Kelechi.
Operator
And our next question coming from the line of Brian Skorney with Baird.
Brian Skorney -- Baird -- Analyst
Good morning everyone. Thank you for taking the question. On 729, you've seen some really good reductions in S-antigen levels below thresholds that, at least in some Asian countries, it wouldn't be unusual to stop NUC therapy. And we sort of discussed the potential for evaluating what it would look like to take patients off all NUC therapy here.
Could you just speak to your current thinking there? Is that still something on the potential near or medium term horizon? And do you sort of have stopping criteria in mind to look at a value of eight patients off therapy?
Bill Collier -- President and Chief Executive Officer
Yes, Brian, thank you very much. Good question. I think our belief is that we need to get multiple drugs onboard before we start reaching criteria where we can start peeling some of those drugs away, so really understand the basis for the question. Gaston, do you want to comment further on?
Gaston Picchio -- Chief Development Officer -- Analyst
Yes, sure. Thank you. Thanks for the question. So we continue to consider the multiple options that there are in terms of stopping criteria.
Also, those need to be aligned with the recommendations from regulatory agencies around the world, including, obviously, the FDA. So at this point in time, we haven't stopped anyone, and that it's always a possibility. But we haven't done that. Certainly, we continue to consider the 100 IU per ml threshold for service antigen.
The question, I think, that remains is how long that sustained decrease in S-antigen needs to persist before you consider whether stopping the investigational drugs or stopping all therapies, so that would be the NUC. So I mean, we continue to consider multiple options. I think there's no single way of stopping patients right now. Everyone has a different opinion on how it should be done in a safe way.
And, obviously, safety is we're driving force there, just make sure that we don't do anything that results unsafe for the patients.
Operator
Thank you. [Operator instructions] Our next question coming from the line of Roy Buchanan with JMP Securities. Your line is open.
Roy Buchanan -- JMP Securities -- Analyst
Great. Thanks for taking the question. So the first one I wanted to ask about the collaboration, you guys recently announced for SARS-CoV-2 with X-Chem and Proteros. It seems like the DNA-encoded library is kind of a burgeoning space.
I just wondered if you could speak a little bit more in detail about what makes X-Chem's approach industry-leading, how it's differentiated from other libraries? And then I had a financial question for Dave.
Bill Collier -- President and Chief Executive Officer
Yes. OK. So on the X-Chem, Proteros deal, maybe Mike Sofia, so you take that one?
Mike Sofia -- Chief Scientific Officer
Sure. So as we sort of scour the landscape for sort of DEL screening technology, DNA-encoded library technology companies to evaluate who we wanted to partner with. And really X-Chem stood out among all of them, not only because we felt that their expertise was industry leading, they clearly have demonstrated through many, many collaborations they've had with other pharma partners the ability to deliver using their libraries. They probably also have the largest library set out there in the DNA-encoded library arena, including multiple different kinds of libraries that would include both reversible, as well as covalent attachment libraries that we were interested in.
So, overall, we thought that from their level of expertise, their track record that they were the ideal partner to move forward with here. They also had this strategic relationship with Proteros and because Mpro is a nonstructural protein. Its structure is known. It provided a real ideal target to use structured biology, biophysical methods to guide subsequent structure-activity relationship studies and lead optimization studies that we were going to do.
So when you look at the whole package together, it brings together the three companies with really industry-leading expertise and capability to tackle this target and buying new chemical matter that we hope will ultimately lead to clinical candidates that will benefit patients.
Roy Buchanan -- JMP Securities -- Analyst
OK. Great. That's helpful. I mean, just any idea on timing from that partnership for when we could see the first results?
Bill Collier -- President and Chief Executive Officer
Well, obviously, we all agree that the coronavirus issue is front and center on everyone's mind globally. We are driving this as aggressively as we possibly can. And our partners know that. They're fully committed.
This is really a collaboration. It's not a typical CRO relationship. So we hope to have something sooner rather than later, but it's a little early to comment on that right now.
Roy Buchanan -- JMP Securities -- Analyst
Yes. Great. OK. Thank you.
And then just a quick one for Dave, has there been any ATM use since the end of the first quarter? Thanks.
Dave Hastings -- Chief Financial Officer
Yes, Hi Roy. So our typical policy is to disclose ATM sales through sort of the end of the prior quarter. So we'll update everybody on next call for the ATM activity this quarter, Roy.
Roy Buchanan -- JMP Securities -- Analyst
Thank you.
Operator
Our next question coming from line of Mayank Mamtani with B. Riley Securities. Your line is open.
Mayank Mamtani -- B. Riley Securities -- Analyst
Good morning Dave. Thanks for taking my questions. Yes. So on the Assembly trial, if I could clarify, I believe you're starting with the 60 mg dose.
So could you maybe talk about the 90 mg data that you continue to generate? And what, if any, implications you could have to the protocol as you think about balancing S-antigen reduction and maybe safety?
Bill Collier -- President and Chief Executive Officer
Hey, thank you very much for the question. Good morning to you. The Assembly collaboration trial, we've set that dosage for 729 at 60 milligrams every eight weeks. But as you know, we're continuing to look at 90 milligram, eight and 12 weeks, which would potentially allow us to look at that dosage, dependent upon the data in our other Phase II studies.
But, again, Gaston thoughts?
Gaston Picchio -- Chief Development Officer -- Analyst
Yes. Hi. Good morning, Mayank. We felt comfortable with the 60 milligram every eight-week dosing schedule to initiate the collaboration with Assembly, and that's how that study is moving forward.
We don't anticipate having to make any changes to the ongoing study, but that doesn't preclude us from opening other cohorts within this collaboration at different doses or different dosing schedules. But just to be clear that the ongoing study its 60 milligrams every eight weeks.
Mayank Mamtani -- B. Riley Securities -- Analyst
Got it. And sorry, if I missed this on 836. As you're thinking about just longer-term developing this agent and maybe sort of differentiating on the enhanced resistance profile that you have good preclinical data. How, if at all, this program could be developed maybe differently than how current programs are going, combination based RNA plus core capsid? Any insights there beyond 2021?
Bill Collier -- President and Chief Executive Officer
Yes. Mike Sofia, do you want to just talk briefly about what we've shared on the resistance front.
Mike Sofia -- Chief Scientific Officer
Sure, Bill. So yes, I think when you look at 836, it has a number of different differentiating characteristics, right? One is the resistance profile that addresses a number of the emerging resistance issues in the capsid field. The other issue is related to the sort of second mechanism, right. That being able to engage the second mechanism in a clinically relevant dose, which we believe 836 is going to be able to do.
Now with that characteristic, we have the potential of seeing some differentiating profile when we put it in combination with 729. But, I think, everyone should understand that our objective in this combination strategy is ultimately to do the three things that we've said from day one, which is shut down viral replication, which capsid plus NUC will achieve; start the DNA pool with hopefully the capsid will also achieve in association with, I think, our RNAi. And then with the RNAi agent, knocking down the S-antigen to help to reinvigorate the immune system. The other piece of the puzzle here really is the immune modulation piece, which, as Bill had mentioned, we're very excited about our PD-L1 program, which is really maturing very nicely.
And we hope to see great things out of it. And bringing that together does round out the whole picture and strategy that we've been sort of discussing for a number of years now. And so, when you look at our capsid asset, it does have differentiating profile from other competitor compounds, but is a central part of the overall strategy that we set out several years ago.
Mayank Mamtani -- B. Riley Securities -- Analyst
Great. Thanks. Thank you for the comprehensive answer and maybe just if I can squeeze one in for Dave on the IP situation with Moderna. At least from public filings from Moderna it seems like they are taking a relatively different approach from before.
Anything you guys can comment from your end or from Genevant's perspective that gives any color on the lawsuit or the possibility of settlement?
Dave Hastings -- Chief Financial Officer
Well No. We can't comment. We would not lead that effort, Genevant would. But I would say, look, we take our IP very seriously but in terms of sort of the play-by-play with the interactions of the companies, we can't comment on that.
Mayank Mamtani -- B. Riley Securities -- Analyst
Understood. Thanks for taking our questions.
Bill Collier -- President and Chief Executive Officer
Thanks so much Mayank.
Operator
I'm showing no further questions at this time. I would like to turn the call back over to Mr. Bill Collier for any closing remarks.
Bill Collier -- President and Chief Executive Officer
Well, thank you very much for all of your questions and for joining us this morning. We really do appreciate your interest in the company. We look forward to a productive and value building 2021. And I think as you've just heard, we're confident that with further data from our 729 clinical trial, progression of the 729 compound into two Phase II proof-of-concept clinical trials, data from our 836 Phase Ia/Ib clinical trial and continued progress in our HBV discovery programs, that we really have established a strong foundation on our mission to achieve a functional cure for people with chronic HBV.
And also, obviously, looking forward to leveraging our antiviral discovery and research efforts in progressing our pan-coronavirus discovery program. So again, thank you for your interest. And operator, that concludes our call. Thank you.
Operator
[Operator signoff]
Duration: 38 minutes
Call participants:
Pam Murphy -- Investor Relations Consultant
Bill Collier -- President and Chief Executive Officer
Dave Hastings -- Chief Financial Officer
Ed Arce -- H.C. Wainwright -- Analyst
Gaston Picchio -- Chief Development Officer -- Analyst
Kelechi Chikere -- Jefferies -- Analyst
Brian Skorney -- Baird -- Analyst
Roy Buchanan -- JMP Securities -- Analyst
Mike Sofia -- Chief Scientific Officer
Mayank Mamtani -- B. Riley Securities -- Analyst
More ABUS analysis
All earnings call transcripts
This article is a transcript of this conference call produced for The Motley Fool. While we strive for our Foolish Best, there may be errors, omissions, or inaccuracies in this transcript. As with all our articles, The Motley Fool does not assume any responsibility for your use of this content, and we strongly encourage you to do your own research, including listening to the call yourself and reading the company's SEC filings. Please see our Terms and Conditions for additional details, including our Obligatory Capitalized Disclaimers of Liability.
The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Arbutus Biopharma (NASDAQ: ABUS) Q1 2021 Earnings Call May 05, 2021, 8:45 a.m. Operator [Operator signoff] Duration: 38 minutes Call participants: Pam Murphy -- Investor Relations Consultant Bill Collier -- President and Chief Executive Officer Dave Hastings -- Chief Financial Officer Ed Arce -- H.C. Wainwright -- Analyst Gaston Picchio -- Chief Development Officer -- Analyst Kelechi Chikere -- Jefferies -- Analyst Brian Skorney -- Baird -- Analyst Roy Buchanan -- JMP Securities -- Analyst Mike Sofia -- Chief Scientific Officer Mayank Mamtani -- B. Riley Securities -- Analyst More ABUS analysis All earnings call transcripts This article is a transcript of this conference call produced for The Motley Fool. As we've stated in the past, our goal at Arbutus is to focus on developing a portfolio of products with different mechanisms of action, that when used in combination could result in a functional cure for people living with chronic HBV. | Operator [Operator signoff] Duration: 38 minutes Call participants: Pam Murphy -- Investor Relations Consultant Bill Collier -- President and Chief Executive Officer Dave Hastings -- Chief Financial Officer Ed Arce -- H.C. Wainwright -- Analyst Gaston Picchio -- Chief Development Officer -- Analyst Kelechi Chikere -- Jefferies -- Analyst Brian Skorney -- Baird -- Analyst Roy Buchanan -- JMP Securities -- Analyst Mike Sofia -- Chief Scientific Officer Mayank Mamtani -- B. Riley Securities -- Analyst More ABUS analysis All earnings call transcripts This article is a transcript of this conference call produced for The Motley Fool. Arbutus Biopharma (NASDAQ: ABUS) Q1 2021 Earnings Call May 05, 2021, 8:45 a.m. On the call from Arbutus executive team are Bill Collier, president and chief executive officer; Dave Hastings, chief financial officer; Dr. Gaston Picchio, chief development officer; and Dr. Mike Sofia, chief scientific officer. | Operator [Operator signoff] Duration: 38 minutes Call participants: Pam Murphy -- Investor Relations Consultant Bill Collier -- President and Chief Executive Officer Dave Hastings -- Chief Financial Officer Ed Arce -- H.C. Wainwright -- Analyst Gaston Picchio -- Chief Development Officer -- Analyst Kelechi Chikere -- Jefferies -- Analyst Brian Skorney -- Baird -- Analyst Roy Buchanan -- JMP Securities -- Analyst Mike Sofia -- Chief Scientific Officer Mayank Mamtani -- B. Riley Securities -- Analyst More ABUS analysis All earnings call transcripts This article is a transcript of this conference call produced for The Motley Fool. Arbutus Biopharma (NASDAQ: ABUS) Q1 2021 Earnings Call May 05, 2021, 8:45 a.m. On the call from Arbutus executive team are Bill Collier, president and chief executive officer; Dave Hastings, chief financial officer; Dr. Gaston Picchio, chief development officer; and Dr. Mike Sofia, chief scientific officer. | Operator [Operator signoff] Duration: 38 minutes Call participants: Pam Murphy -- Investor Relations Consultant Bill Collier -- President and Chief Executive Officer Dave Hastings -- Chief Financial Officer Ed Arce -- H.C. Wainwright -- Analyst Gaston Picchio -- Chief Development Officer -- Analyst Kelechi Chikere -- Jefferies -- Analyst Brian Skorney -- Baird -- Analyst Roy Buchanan -- JMP Securities -- Analyst Mike Sofia -- Chief Scientific Officer Mayank Mamtani -- B. Riley Securities -- Analyst More ABUS analysis All earnings call transcripts This article is a transcript of this conference call produced for The Motley Fool. Arbutus Biopharma (NASDAQ: ABUS) Q1 2021 Earnings Call May 05, 2021, 8:45 a.m. As Pam mentioned, both Gaston and Mike Sofia are both on the call and can take any additional clinical and discovery questions. |
34653.0 | 2021-03-17 00:00:00 UTC | Arbutus Gets Go Ahead To Kick Off Phase 1a/1b Clinical Trial Of AB-836 | ABUS | https://www.nasdaq.com/articles/arbutus-gets-go-ahead-to-kick-off-phase-1a-1b-clinical-trial-of-ab-836-2021-03-17 | nan | nan | Arbutus Biopharma, a biopharmaceutical company, received the go ahead to commence the Phase 1a/1b clinical trial of AB-836, its proprietary oral capsid inhibitor for the treatment of Hepatitis B virus (HBV) infection.
Hepatitis B is a life-threatening liver infection caused by HBV. As per the data released by the World Health Organization (WHO), more than 250 million people are infected by chronic HBV globally, while other estimates specify that around 2 million people in the US are chronic HBV infection sufferers.
AB-836 is expected to treat HBV after combining with other drugs that have different mechanisms of action, including AB-729, with a single dose daily, Arbutus (ABUS) said.
Arbutus’ Chief Scientific Officer Dr. Michael Sofia said, “Based on pre-clinical studies with AB-836, which is derived from a novel chemical series in this class, we believe it has the potential for improved clinical efficacy and safety as well as a favorable resistance profile relative to earlier generation capsid inhibitors.” (See Arbutus stock analysis on TipRanks)
In response to this development, H.C. Wainwright analyst Ed Arce maintained a Buy rating and a price target of $10 (162.5% upside potential).
Arce said, “AB-836 could become a key component in HBV combination therapies as Arbutus continues its progress with AB-729, its proprietary GalNAc-delivered RNAi therapeutic candidate for HBV.”
The rest of the Street is cautiously optimistic about the stock with a Moderate Buy consensus rating. That’s based on 5 analysts suggesting a Buy and 2 analysts recommending a Hold. The average analyst price target of $6.43 implies 68.8% upside potential to current levels. Shares have gained about 28% over the past six months.
Related News:
Jabil’s Sales Guidance Tops Estimates After 2Q Beat; Shares Jump Pre-Market
Southwest Airlines Provides Operational And Financial Business Update; Shares Gain
Johnson & Johnson’s Single-Dose COVID-19 Vaccine Granted Emergency Use Listing By WHO
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | AB-836 is expected to treat HBV after combining with other drugs that have different mechanisms of action, including AB-729, with a single dose daily, Arbutus (ABUS) said. Arbutus Biopharma, a biopharmaceutical company, received the go ahead to commence the Phase 1a/1b clinical trial of AB-836, its proprietary oral capsid inhibitor for the treatment of Hepatitis B virus (HBV) infection. Arbutus’ Chief Scientific Officer Dr. Michael Sofia said, “Based on pre-clinical studies with AB-836, which is derived from a novel chemical series in this class, we believe it has the potential for improved clinical efficacy and safety as well as a favorable resistance profile relative to earlier generation capsid inhibitors.” (See Arbutus stock analysis on TipRanks) In response to this development, H.C. Wainwright analyst Ed Arce maintained a Buy rating and a price target of $10 (162.5% upside potential). | AB-836 is expected to treat HBV after combining with other drugs that have different mechanisms of action, including AB-729, with a single dose daily, Arbutus (ABUS) said. As per the data released by the World Health Organization (WHO), more than 250 million people are infected by chronic HBV globally, while other estimates specify that around 2 million people in the US are chronic HBV infection sufferers. Arbutus’ Chief Scientific Officer Dr. Michael Sofia said, “Based on pre-clinical studies with AB-836, which is derived from a novel chemical series in this class, we believe it has the potential for improved clinical efficacy and safety as well as a favorable resistance profile relative to earlier generation capsid inhibitors.” (See Arbutus stock analysis on TipRanks) In response to this development, H.C. Wainwright analyst Ed Arce maintained a Buy rating and a price target of $10 (162.5% upside potential). | AB-836 is expected to treat HBV after combining with other drugs that have different mechanisms of action, including AB-729, with a single dose daily, Arbutus (ABUS) said. As per the data released by the World Health Organization (WHO), more than 250 million people are infected by chronic HBV globally, while other estimates specify that around 2 million people in the US are chronic HBV infection sufferers. Arbutus’ Chief Scientific Officer Dr. Michael Sofia said, “Based on pre-clinical studies with AB-836, which is derived from a novel chemical series in this class, we believe it has the potential for improved clinical efficacy and safety as well as a favorable resistance profile relative to earlier generation capsid inhibitors.” (See Arbutus stock analysis on TipRanks) In response to this development, H.C. Wainwright analyst Ed Arce maintained a Buy rating and a price target of $10 (162.5% upside potential). | AB-836 is expected to treat HBV after combining with other drugs that have different mechanisms of action, including AB-729, with a single dose daily, Arbutus (ABUS) said. Arbutus Biopharma, a biopharmaceutical company, received the go ahead to commence the Phase 1a/1b clinical trial of AB-836, its proprietary oral capsid inhibitor for the treatment of Hepatitis B virus (HBV) infection. Hepatitis B is a life-threatening liver infection caused by HBV. |
34654.0 | 2021-03-04 00:00:00 UTC | Arbutus Biopharma (ABUS) Q4 2020 Earnings Call Transcript | ABUS | https://www.nasdaq.com/articles/arbutus-biopharma-abus-q4-2020-earnings-call-transcript-2021-03-05 | nan | nan | Image source: The Motley Fool.
Arbutus Biopharma (NASDAQ: ABUS)
Q4 2020 Earnings Call
Mar 04, 2021, 8:45 a.m. ET
Contents:
Prepared Remarks
Questions and Answers
Call Participants
Prepared Remarks:
Operator
Ladies and gentlemen, thank you for standing by, and welcome to the Arbutus Biopharma Corporation fourth-quarter and year-end 2020 financial results and corporate update conference call. [Operator instructions] Please be advised that today's conference is being recorded. [Operator instructions] I would now like to hand the conference over to your speaker today, Pam Murphy. Thank you.
Please go ahead, ma'am.
Pam Murphy -- Investor Relations Consultant
Good morning, and thank you for joining the Arbutus Biopharma fourth-quarter 2020 conference call and webcast. On the call today are Bill Collier, president and chief executive officer; Dr. Gaston Picchio, chief development officer; Dr. Michael Sofia, chief scientific officer; and Dave Hastings, chief financial officer.
Bill will begin with a summary of recent accomplishments and upcoming events and a review of Arbutus' 2021 corporate objective, followed by Gaston, Mike Sofia, and Dave Hastings, who will provide clinical drug discovery and financial updates, respectively. Please note Gaston will be using a few clinical slides, which can be viewed on the webcast. After the speakers, we'll then open up the call for Q&A. Before we begin, we'd like to remind you that some of the statements made during the call today are forward-looking statements, including statements regarding expectations, timelines, and clinical results for Arbutus' proprietary HBV pipeline and COVID-19 preclinical research efforts, the company's 2021 objective and expected cash use and cash runway.
10 stocks we like better than Arbutus Biopharma
When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor, has tripled the market.*
David and Tom just revealed what they believe are the ten best stocks for investors to buy right now... and Arbutus Biopharma wasn't one of them! That's right -- they think these 10 stocks are even better buys.
See the 10 stocks
*Stock Advisor returns as of February 24, 2021
These forward-looking statements are subject to a number of risks and uncertainties that may cause our actual results to differ, including those described in our most recent annual report on 10-K, quarterly report on Form 10-Q, and other periodic reports filed with the SEC. I would now like to turn the call over to Bill. Bill?
Bill Collier -- President and Chief Executive Officer
Thank you, Pam, and good morning, everybody. Thank you for joining us today. As I approach my two-year anniversary with Arbutus, I'd like to use the next few minutes to summarize the progress that we have made and why I believe that Arbutus is well-positioned to execute on our mission to develop a cure for people with chronic hepatitis B, as well as advance new proprietary therapies to treat coronaviruses. First of all, and Gaston Picchio will describe in more detail, our lead product, AB-729, a subcutaneously delivered RNAi agent, has demonstrated the potential to be a cornerstone drug in future HBV combination regimens.
We've reported in 2020 a significant body of compelling safety and efficacy data from an ongoing Phase 1a/1b clinical trial. And this data strongly supports our plans to initiate two Phase 2 trials for 729 in combination with one or more approved or investigational agents in the second half of 2021. In addition, Arbutus and Assembly have initiated screening of our proof-of-concept Phase 2 clinical trial combining 729 with Assembly Biosciences capsid inhibitor, vebicorvir, and a nucleoside reverse transcriptase inhibitor. Secondly, we've completed the IND-, CTA-enabling studies for AB-836, our next-generation oral capsid inhibitor.
836 is from a novel chemical series, which we believe is differentiated from competitor compounds and offers the potential for increased efficacy and an enhanced resistance profile. We expect to begin the Phase 1a/1b clinical trial for 836 in the first half of 2021. Thirdly, as Mike Sofia will describe, we have a number of active drug discovery efforts in the HBV field, as well as discovery efforts for potential oral therapies to treat coronaviruses. Given our experienced chemistry and biology teams, and the investments we're making in the oral PD-L1 inhibitor and RNA destabilizer programs, we believe these programs have the potential to lead to future proprietary combination regimens to treat HBV.
Furthermore, we're confident that the proven expertise in virology that resides within our discovery team could lead to new oral therapies to treat coronaviruses. And finally, as Dave Hastings will describe in a moment, we have a solid financial position with a cash runway that now extends through the third quarter of 2022 and a demonstrated track record of efficiently raising capital. So with that, let me now turn the call over to Gaston Picchio, our chief development officer. Gaston?
Gaston Picchio -- Chief Development Officer
Thanks, Bill, and good morning, everyone. Today, I will focus my time on describing our current perspectives on AB-729 and our 2021 plans and objectives at as it relates to our lead clinical asset. As part of my discussion today, I will refer to a few slides that are available as part of our webcast and can also be found in our current corporate presentation located on the Arbutus website. First, let me reiterate Bill's confidence in the growing clinical data that has already emerged from our ongoing Phase 1a/1b clinical trial for AB-729.
Now, you can see in the first slide, the design of our Phase 1a/1b single- and multiple-dose clinical trial and the current status of the cohorts that have been completed and reported on, and these are in dark red and dark blue. Notably, this represents a significant data set and allow us to begin to put in perspective the potential of this drug, which I will address momentarily. We expect to report additional data from the ongoing cohorts from this trial in the first half of 2021, except for the 90-milligram every-12-week cohort, which is expected in the second half of 2021. In the next slide, No.
6, you can see that a single dose of AB-729 provided impressive and comparable mean S-antigen declines across all three doses, namely 60, 90, and 180 milligrams. Moving to Slide No. 7. Importantly, as demonstrated, repeat 60-milligram dosing of AB-729 every four weeks resulted in continuous mean S-antigen declines beyond week 12.
Now, as the next slide shows, repeat dosing using 60 milligrams every eight weeks resulted in comparable mean S-antigen declines relative to the 60-milligram dose every four weeks at week 16, or with minus 1.87 log10 versus minus 1.44 log10. Moving to the next slide, No. 9, you can see that in HBV DNA-positive chronic hepatitis subjects, a single 90-milligram AB-729 dose resulted in a robust mean S-antigen decline of minus 1.02 log10, similar to what has been seen in HBV DNA undetectable subjects. Notably, HBV DNA also declined at week 12 with a mean decline of minus 1.53 log10, as well as HBV RNA and core-related antigens, which are not shown here, supporting complete target engagement by AB-729.
Finally, Slide No. 10. AB-729 continues to be safe and well-tolerated. We have not seen any treatment-emerging grade 3 or 4 adverse events or discontinuations in any cohort to date.
In cohort F, two subjects had symptomatic ALT elevations; one subject with a history of grade 1 ALT elevation prior to trial entry had a transient grade 2 elevation, which evolved back to grade 1; while another subject had a transient grade 1 elevation. Further, in cohort E, the two subjects previously reported with grade 2 and two subjects with grade 1 ALT elevations have improved to grade 1 and grade 0, respectively, after week 24. All seven subjects in the cohort have consented to continue dosing with AB-729 for an additional six months. So stepping back with the totality of data we have seen thus far, we believe AB-729 can serve a vital role in our future proprietary combination regimens, both in lowering HBV replication and S-antigen concentrations.
Not only does AB-729 provide an efficacy and safety profile competitive with other programs, but it also potentially represents a competitive advantage in frequency of dosing. This gives me great confidence in our plans to aggressively advance AB-729 into several Phase 2 trials this year. We plan on initiating two Phase 2 combination trials with one or more approved or investigational agents in the second half of this year. In addition, we have initiated screening in our Phase 2 clinical trial combining AB-729 with Assembly Biosciences' lead core inhibitor, also known as capsid inhibitor, vebicorvir.
This proof-of-concept trial is a randomized, multicenter, open-label Phase 2 clinical trial that will explore the safety, pharmacokinetics, and antiviral activity of the triple combination of AB-729, vebicorvir, and an NrtI compared to the double combinations of vebicorvir with an NrtI and AB-729 and an NrtI.This trial is expected to enroll approximately 60 virologically suppressed patients with chronic HBV infection. So with that, I turn the call over to Mike. Mike?
Mike Sofia -- Chief Scientific Officer
Thanks, Gaston, and good morning, everybody. I want to briefly review our drug discovery objectives and strategies as we progress on the HBV and coronavirus research fronts. As you know, we are focused on developing proprietary combination regimens that have the power to functionally cure people with HBV. We have progressed compounds into development that target two critical pieces of our strategy: stopping viral replication and reduce S-antigen levels.
The other pillar of our strategy envisions addressing the immune component of the disease. To that end, we believe our oral PD-L1 program has the potential to reawaken the immune system in HBV patients. Highly functional HBV-specific T cells within our immune system are believed to be required for long-term HBV viral resolution. However, HBV-specific T cells become functionally defective and greatly reduced in their frequency during chronic HBV infection.
One approach to boost HBV-specific T cells is to target the PD-L1/PD-1 axis to release the brakes on the immune system and lead to removal of infected hepatocytes. We are in lead optimization with oral compounds, which are potentially capable of reawakening patients' HBV-specific immune response by inhibiting PD-L1 interactions. In addition, we believe that an all-oral proprietary combination of agents remains an objective for us. We continue to optimize HBV RNA destabilizers that are small-molecule, orally available agents that cause the destabilization and ultimate degradation of HBV RNAs.
Currently, we are advancing several promising next-generation oral HBV RNA destabilizers through lead optimization and candidate selection. Finally, we believe it is important to leverage our virology expertise in the battle against coronaviruses. Our effort is focused on the discovery and development of new molecular entities that address specific viral targets, including the nsp12 viral polymerase and the nsp5 viral protease. These targets are essential viral proteins, which have the potential for delivering pan coronavirus therapies, which Arbutus has experience in targeting.
As all of you know, predicting hard and fast timelines in drug discovery is not possible. Therefore, we are not yet giving specific guidance regarding when we will nominate lead candidates in these three areas. That said, we have a capable and experienced drug discovery team, and I look forward to updating you on our progress throughout the year. With that, I'll turn the call over to Dave.
Dave?
Dave Hastings -- Chief Financial Officer
Thanks, Mike. Good morning, everybody. Our ending cash, cash equivalents, and short-term investments was approximately $123 million as of December 31, 2020, compared to approximately $91 million as of December 31, 2019. Our cash used from operations for the year ended December 31, 2020, was approximately $51 million.
We made a $2.5 million equity investment in Genevant in July. These cash outflows were offset by approximately $86 million of net proceeds from the issuance of common shares under the Arbutus ATM program. Additionally, thus far, during the first quarter of 2021, we have received $24 million of net proceeds from our ATM program. We expect a net cash burn of between $70 million and $75 million in 2021.
And therefore, we believe our cash runway now extends through the third quarter of 2022. Finally, as a reminder, Arbutus owns approximately 16% of the common equity of Genevant Sciences, a company Arbutus launched with Roivant Sciences and to which Arbutus licensed exclusive rights to its LNP delivery technologies for RNA-based applications outside of HBV. We are entitled to receive tiered, low single-digit royalties on future sales of Genevant products covered by the licensed patents. If Genevant sublicenses the intellectual property, licensed by us to Genevant, we are entitled to receive upon the commercialization of a product developed by such sublicensee the lesser of 20% of the revenue received by Genevant for sublicensing and tiered, low single-digit royalties on product sales by the sublicensee.
So with that, Bill, I'll turn the call back to you.
Bill Collier -- President and Chief Executive Officer
All right. Thank you, Dave, and to Gaston and Mike. And I think at this point, operator, can you please open up the lines for questions and answers, please?
Questions & Answers:
Operator
[Operator instructions] And your first question Ed Arce with H. C. Wainwright.
Ed Arce -- H.C. Wainwright -- Analyst
Great. Good morning, and thanks for taking my questions. Congrats on a productive year. A couple questions from me.
You mentioned with 729, two trials that you're intending to start, I think you said in the second half of the year, sort of combination trials. I'm wondering if you could give us a little more detail on the intended design with those. In particular, have you chosen one or more doses, perhaps the 60- or 90-milligram? At least, in one of those committed to a dosing interval, I know that you're very interested in going with once every 12 weeks. And any other sort of details around the trial designs there would be helpful.
Thank you.
Bill Collier -- President and Chief Executive Officer
Thank you for the question, Ed. Just a couple of comments, and then I'll let Gaston answer with any additional detail. I mean, I think what we're trying to communicate today is our confidence in 729 going forward, where, in total, we will kick off three Phase 2 studies this year. The first one, obviously, being the Assembly study, which has initiated.
We did that press release last week. And then today, we're talking about an additional two Phase 2 combination studies. We've not released too much detail about those at this stage. But I think you can see that by kicking off three Phase 2 studies, we clearly feel very confident about 729 moving forward.
And with that, let me hand it over to Gaston.
Gaston Picchio -- Chief Development Officer
Yes. Thanks, Bill, and thanks, Ed, for the question. So as Bill explained, we haven't released the details at this point of what those two additional Phase 2 studies may look like. But obviously, we are exploring potential combinations with both investigational and other approved agents and, obviously, try to exceed the number of drugs there by two.
So we're looking at three or more drugs in those studies. In terms of the dosing schedule, as you may already know, we are confident enough, based on the data that we presented toward the end of last year to use the every-eight-weeks in the Phase 2 in collaboration with Assembly. So I'll just reiterate what was included, Ed, in the press release, announced recently by Assembly on the start of the screening of the study that the dosing of AB-729 would include 60-milligram dose every eight weeks. So we're waiting, obviously, for the results of the other cohorts, especially the every-12-weeks, to decide whether it may be also worth exploring a dosing frequency of every 12, but that data is pending.
Ed Arce -- H.C. Wainwright -- Analyst
Great. That's helpful. And then just one other question from me. Just to remind us, for this year, are you expecting to release any new data of results from any ongoing studies?
Bill Collier -- President and Chief Executive Officer
Yes. So this is Bill. And I will refer everyone to the last slide in our corporate deck, which was refreshed and updated, is on our website, went up this morning. There we list out what we expect to deliver this year.
So we're talking about additional data from the 60-milligram multi-dose cohorts every four and every eight weeks in the first half, additional data from the 90-milligram multi-dose eight-week cohort in the first half, the 90-milligram 12-week data in the second half. We also expect to have some 90-milligram multi-dose eight-week dosing interval in HBV DNA positive subjects in the first half. I've already mentioned the two Phase 2 clinical studies we hope to kick off in the second half. And then as we already mentioned on this call, we expect to kick off the 836 Phase 1a/1b clinical study in the first half of the year.
Ed Arce -- H.C. Wainwright -- Analyst
Great. Thank you, Bill. Sounds like you have your hands full this year with a lot of clinical activity.
Bill Collier -- President and Chief Executive Officer
We do.
Ed Arce -- H.C. Wainwright -- Analyst
Thanks. Thank you, guys, for the questions.
Bill Collier -- President and Chief Executive Officer
Right. Operator, do we have additional questions?
Operator
Your next question comes from Brian Skorney with Baird.
Brian Skorney -- Baird -- Analyst
Hey, good morning, everyone. Thank you for taking my questions. I guess more of a big-picture, long-term question on 729. I mean, we have a pretty good idea in terms of early data, the impact that RNAi interference targeting can have on some of the biomarkers.
But as you kind of think about long-term development plan, what sort of data would you be looking to achieve on a biomarker basis to challenge patients to complete antiviral therapy withdrawal? And I mean, what sort of stopping criteria do you think are reasonable to use?
Bill Collier -- President and Chief Executive Officer
Good question. Thank you very much. Maybe Mike and Gaston, Gaston first, perhaps, to answer that one. I mean, we're talking hypothetically here because we have no plans at the moment to get into this.
But Gaston?
Gaston Picchio -- Chief Development Officer
Yes. Thank you, Brian. In terms of -- let me just go to the -- summarize what we've seen with RNAi so far. So I think RNAi have been shown to, obviously, lower S-antigen also, HBV RNA core-related antigen, E-antigen.
And I think we probably have one of the most robust data showing that 729 can also reduce HBV DNA in a very robust and rapid way. So the big question, I mean, obviously, is going to be should we continue treating and wait until S-antigen becomes undetectable, or can we before stop -- consider stopping patients, or could we stop patients earlier and see whether the immune system has sufficiently reawakened to continue the job and clear all S-antigens and obviously infect hepatocytes and so forth? And that's a question obviously that I don't think anyone has answered so far. What is clear, based on the Assembly study, is that stopping patients with undetectable HBV RNA and HBV DNA, even with a more sensitive assay, was not sufficient to achieve functional cure, defined as loss of S-antigen six months after end of therapy. So they saw relapse very quickly.
So in that sense, obviously, that study did not include an RNAi agent. And lowering S-antigen may favorably impact the immune system in such a way that upon stopping therapy, things may look a little bit different. But really, this is all speculation because nobody has stopped all therapies in RNAi subjects and see after a long dosing period of at least a year, in combination with other agents and see what happens. So we may be in a position to do that later this year in some of our cohorts and see what the turnout is.
But I can't give you a definitive answer what's going to happen. But certainly, that's one of the most important questions in the field right now.
Brian Skorney -- Baird -- Analyst
Right. Thank you.
Bill Collier -- President and Chief Executive Officer
And, Gaston, do you want to just briefly mention because on our corporate deck on our slides, we do show how many subjects get below either 100 or 10 international units per ml for surface antigen. Do you just want to comment on those numbers?
Gaston Picchio -- Chief Development Officer
Yes. So, yes, that's a great point. As you know, in some countries in Asia, especially, there's a tendency for subjects who have been on NUC therapy for a number of years, either S-antigen drops below 100 to actually stop the NUC and follow them very closely. And in some occasions, the subjects who achieve less than 100, which is a threshold that's used, I would say, clinically, most frequently, they tend to seroconvert, so lose S-antigen and some of them even develop anti-S-antibodies, which is the definition of functional cure.
So in our studies, we have pretty much, so far, the vast majority, like six out of seven have reached less than 100 in cohort E and even a couple of them have reached less than 10. So the big question is: In the setting of one year of duration of therapy, is that going to be sufficient? So these are questions that obviously, we're trying to decide whether achieving S-antigen below those thresholds, which have shown in other instances to be clinically relevant, would they be equally relevant toward functional cure when using RNAi agents, in this case, AB-729. So this is still evolving. We're evolving our thinking and trying to decide what would be the best approach to stopping therapy in patients who have received at least one year of AB-729 combination with NUC.
But those are some encouraging pieces of information that a large proportion of these have already crossed that 100 IU per ml threshold.
Brian Skorney -- Baird -- Analyst
Great. Thank you.
Operator
Your next question comes from Mayank Mamtani with B. Riley.
Mayank Mamtani -- B. Riley FBR -- Analyst
Thanks, team, for taking my question, and congrats on the progress. So maybe on the same line of thinking on the triple therapy, just two things stood out to me that you are doing an open-label study, and also the number of subjects 60, just looking at other trials, look different. So I'm just curious how you think about data disclosures here. And again, the off-treatment cure rate that's specifically your program, but also, like as we look externally, there are different approaches, core/capsid inhibitor approach, there's the immunomodulator approach.
Can you comment like, just at a high level, what's your perspective on one versus the other, your confidence level, and just given like the challenging off-treatment cure rates we've seen so far?
Bill Collier -- President and Chief Executive Officer
Yes. Thank you for the question. I think you started just by making reference to the clinical collaboration with Assembly. And you correctly pointed out that that's a Phase 2 study with 60 virologically suppressed subjects with HPV.
And essentially, it's comparing the triple, 729 plus vebicorvir plus a NUC versus 729 plus a NUC versus vebicorvir plus a NUC. The only thing that we have communicated with our partners, Assembly, on that is that the study has started. That was the press release last week. We've not indicated when we will have data available from that study.
Although it is an open-label study. So we will be able to track progress as we go. As to the second part of your question, perhaps, Gaston, I can throw that to you.
Gaston Picchio -- Chief Development Officer
Yes. And so hi, Mayank. It's difficult to say because, to be absolutely honest, we're not sure what the details of other studies are. I mean, I can just reiterate what our study, in collaboration with Assembly, is going to be looking at.
So basically, we're looking at E-antigen negative subjects who are being suppressed for at least six months with NUC therapy, and they're going to be enrolling into -- sorry, randomized into three different arms. So obviously, there are two arms would function as controls, and there's a third arm, which is the exciting arm, which is the combination of the three agents. So as to exactly the differences with other studies that may be looking at similar but not identical approaches, I can't really comment because I don't know the details behind their models and what you can find in clinical trials or goals. So I think it's always important, I mean, at least based on my experience, that despite the fact that there is a reiteration of mechanisms of action.
I think at least I've learned over the years that it's always important to see what different assets within a class can provide. So I wouldn't discount the fact that we're testing three drugs that other companies may be testing as less exciting because I think we've seen some interesting data coming out of 729. And also, vebicorvir has been well established in further suppressing HBV DNA and pgRNA. So the combination of those three in the population that we selected may play out differently than in other regimens.
So I think we have to wait for the results, in short.
Mayank Mamtani -- B. Riley FBR -- Analyst
Understood. And then just two more quick follow-ups. PD-L1 oral inhibitor, any color you could provide on time to IND? And just a high level, why to scale out the use in cancer, for example, maybe by a partner if you don't want to do oncology?
Bill Collier -- President and Chief Executive Officer
Mike, do you want to take that one?
Mike Sofia -- Chief Scientific Officer
Yes. Yes. Hi, Mayank. So look, we've made great progress in that program, and I'm very excited and optimistic about achieving a clinical candidate nomination in the foreseeable future.
And as I said, from discovery, it's hard to give a specific timeline. We want to make sure we bring forward the very best compounds. So we're clearly doing all the relevant studies that need to be done. And those need to be done before, I think, we're comfortable saying we have the candidate that's going to go into the clinic and give any guidance there.
On the cancer issue, look, we're fully aware of the potential for an agent like a PD-L1 inhibitor in other therapeutic areas, specifically cancer. And I think we will look at all options on how to exploit these other areas in the future. But right now, we're really focused on hepatitis B applications for these PD-L1 inhibitors.
Mayank Mamtani -- B. Riley FBR -- Analyst
Great. Thank you for that color. And lastly, on the Genevant-Moderna litigation, can you just remind us what's the next step there on the appeal to PTAB decision that was in July last year? What should we watch out for next?
Bill Collier -- President and Chief Executive Officer
Yes. Let me tackle that one. And then, Dave, you can chime in with any additional color as well. But you're referring back to the patent case that was announced last year where there was a challenge against one of Arbutus patents and was found in our favor.
And I think as we described at the time and subsequently in our various listings, that patent is one of those that has been licensed out to Genevant, which Dave described in his comments this morning. So, unfortunately, it's really not possible for us at Arbutus to comment on what Genevant may or may not be doing. Suffice to say that as part of that license-out arrangement, we've got some very clear terms for any sublicensing that Genevant may do, which is what Dave summarized in his comments. So I think that's about all that we can say.
Dave, unless there's any other additional comments you can think of.
Dave Hastings -- Chief Financial Officer
No, I think you covered it, Bill. Thanks.
Bill Collier -- President and Chief Executive Officer
OK. Great.
Mayank Mamtani -- B. Riley FBR -- Analyst
Thank you.
Operator
Your next question comes from Kelechi Chikere with Jefferies.
Bill Collier -- President and Chief Executive Officer
Good morning.
Kelechi Chikere -- Jefferies -- Analyst
Good morning and thank you for taking my question. I guess in the set of two Phase 2 combo studies slated to start later this year, can I actually speculate on what are some of the investigational or approved agents you're thinking you could potentially cure with 729? I think we're all aware interferon maybe something. What are some of the other agents you're thinking of? Any color there would be great. Thank you.
Bill Collier -- President and Chief Executive Officer
Yes. Good question. I mean, I can say that we want these three studies to be somewhat different so that we're exploring different combinations going forward. I mean, clearly, we have not said today what those compounds are going to be or could be, we've just said either marketed or investigational.
And I think the best way to answer that is with reference to our overall hypothesis that we want to be able to suppress DNA, we want to be able to suppress surface antigen and we want to be able to boost the immune system. That's our model and our strategy here at Arbutus for the way we can try and construct a combination therapy to achieve this functional cure for hepatitis B. I think that's about all we can say at the moment. So, Gaston, anything you want to add?
Gaston Picchio -- Chief Development Officer
No. Thank you. I mean, I think as you pointed out, that's how much we can say. But again, just reiterate our thinking, which is the importance of, first, lowering S-antigen to give the immune system, using different approaches, as Bill outlined, to reawaken and continue the job of clearing the effect of hepatocytes.
But we really believe that that lowering of S-antigen is critical to achieve that goal of functional cure and then intervene with other modalities after that is achieved. So keeping that in mind, I think you can imagine the different modalities that we're considering.
Kelechi Chikere -- Jefferies -- Analyst
Got it. That's helpful. Thank you.
Operator
Your next question comes from Roy Buchanan with JMP Securities.
Roy Buchanan -- JMP Securities -- Analyst
Hi. Thanks for taking the question. Just a quick one. Sorry if I missed this.
Any additional details on the RNA destabilizing you can provide? I mean, are you targeting the HBV RNA itself? Are you targeting a host protein? Any additional details? Thanks.
Bill Collier -- President and Chief Executive Officer
Mike?
Mike Sofia -- Chief Scientific Officer
HI. Mike Sofia. Hi, Roy. So we've actually described pretty extensively some of the mechanistic features of how the molecules that we are working with work.
Look, they do specifically target HBV RNA, and they target it via a mechanism that engages a host protein that's critical for stabilizing the HBV RNA poly (A) tail. And so by inhibiting that host protein interaction with a complex associated with HBV RNA, the PRE region of HBV RNA, we're able to destabilize HBV RNA and lead to the degradation of poly (A) tail or truncating of the poly (A) tail that ultimately leads to degradation of HBV RNA. So it is an HBV RNA-targeting modality, but it goes via a host protein that's critical for maintaining the stability of HBV RNA.
Roy Buchanan -- JMP Securities -- Analyst
OK, great. Thank you.
Operator
Our next question comes from Keay Nakae with Chardan.
Keay Nakae -- Chardan -- Analyst
Yes, thanks. So with the upcoming data, from the 60-milligram multi-dose at eight-week intervals and the 90 at eight- and 12-week interval, can you just tee up for us how many doses you expect to report on in each of those cohorts?
Bill Collier -- President and Chief Executive Officer
Yes. Gaston, maybe you can take that one. I don't want to be vague in the sense that we haven't released that in our guidance. But some of those cohorts have been ongoing for quite some time.
I think we just need to make sure that we have an effective and a realistic time frame to comment on. And by that, all I mean is that if you give something monthly, then within six months, you've got six doses. But if you could give something every 12 weeks within that same time frame, you've got many fewer doses. So we just want to make sure that we've got an appropriate number of doses to comment on.
Keay Nakae -- Chardan -- Analyst
OK.
Bill Collier -- President and Chief Executive Officer
But, Gaston, anything else you want to add?
Gaston Picchio -- Chief Development Officer
Well, I mean, let me just, I mean, articulate the question again. I mean, how many doses we're planning to report for both the 60-milligram every four and 60-milligram every eight weeks. As we pointed out in our guidance, so I mean, without counting the doses, I mean, the goal will be to be able to report end of therapy for both. So 48 weeks of treatment.
Keay Nakae -- Chardan -- Analyst
OK. Yes, that's helpful because, at some point, you're making the decision of when the math is enough and you're reporting it. So that's simply what we're looking for. It's really how far out do you want to go before you report.
Gaston Picchio -- Chief Development Officer
That would be the goal: to report end of therapy. And then obviously, pending decision around, as we were discussing earlier, and decisions around who can and who cannot stop later on, report on basically what happens off therapy in those that may qualify to stop. And that will be the structure, let's say, of every cohort that we're doing right now in the Phase 1a/1b study. So just to reiterate that.
The study was originally meant to have six months of duration in terms of dosing, with different doses and dose frequencies. The study was amended in such a way that patients on reaching the end of the six months can reconsent if they decide and the investigator decides, toward continuation for an additional six months, so that makes it basically a total of 48 weeks. And then after that, a decision will have to be made regarding stopping, either stopping completely all therapy or stopping just 729 and remaining on the NUC. So as all of these cohorts mature and they progress, specifically to your question, for cohorts E and F being the 60 every four and 60 every eight, the next goal will be to be able to report end of therapy.
Keay Nakae -- Chardan -- Analyst
OK.
Gaston Picchio -- Chief Development Officer
Is that helpful?
Keay Nakae -- Chardan -- Analyst
Yes, because you had pushed out the expected reporting of the 90 at 12 weeks. So just trying to understand what's behind that thinking.
Bill Collier -- President and Chief Executive Officer
Yes. OK. There's not so much. So I think we pushed that out.
That was one of the later cohorts to start. So it's just taken longer to go through, OK?
Keay Nakae -- Chardan -- Analyst
OK. Thanks.
Operator
I'm showing no further questions at this time. I would now like to turn the conference back to Bill Collier.
Bill Collier -- President and Chief Executive Officer
Thank you very much, and thank you all for your questions. Just to close out, I'll quickly review, once again, the key objectives for the company for 2021. So as you've heard on this call, we've already initiated the Phase 2 combination clinical trial to evaluate 729 in combination with the Assembly Biosciences core or capsid inhibitor, vebicorvir, and a nucleoside reverse transcriptase inhibitor. Secondly, we also expect to provide additional data from ongoing cohorts of the Phase 1a/1b clinical trial of 729 in the first half of 2021.
And as we also just mentioned, the 90-milligram every-12-week cohort will actually be expected in the second half of this year. We're also excited and expect to initiate two Phase 2 combination clinical trials in HBV subjects, including 729 with one or more approved or investigational agents. Again, that's slated for the second half of 2021. And we also expect to initiate a Phase 1a/1b clinical trial of 836, our next-generation capsid inhibitor, in the first half of 2021.
So I'd like to close out by thanking all of the staff at Arbutus. But importantly, this morning, all of you for joining us today, and we look forward to sharing our progress throughout the coming year. So thank you very much, and operator, that concludes our call.
Operator
[Operator signoff]
Duration: 50 minutes
Call participants:
Pam Murphy -- Investor Relations Consultant
Bill Collier -- President and Chief Executive Officer
Gaston Picchio -- Chief Development Officer
Mike Sofia -- Chief Scientific Officer
Dave Hastings -- Chief Financial Officer
Ed Arce -- H.C. Wainwright -- Analyst
Brian Skorney -- Baird -- Analyst
Mayank Mamtani -- B. Riley FBR -- Analyst
Kelechi Chikere -- Jefferies -- Analyst
Roy Buchanan -- JMP Securities -- Analyst
Keay Nakae -- Chardan -- Analyst
More ABUS analysis
All earnings call transcripts
This article is a transcript of this conference call produced for The Motley Fool. While we strive for our Foolish Best, there may be errors, omissions, or inaccuracies in this transcript. As with all our articles, The Motley Fool does not assume any responsibility for your use of this content, and we strongly encourage you to do your own research, including listening to the call yourself and reading the company's SEC filings. Please see our Terms and Conditions for additional details, including our Obligatory Capitalized Disclaimers of Liability.
Motley Fool Transcribing has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Arbutus Biopharma (NASDAQ: ABUS) Q4 2020 Earnings Call Mar 04, 2021, 8:45 a.m. Operator [Operator signoff] Duration: 50 minutes Call participants: Pam Murphy -- Investor Relations Consultant Bill Collier -- President and Chief Executive Officer Gaston Picchio -- Chief Development Officer Mike Sofia -- Chief Scientific Officer Dave Hastings -- Chief Financial Officer Ed Arce -- H.C. Wainwright -- Analyst Brian Skorney -- Baird -- Analyst Mayank Mamtani -- B. Riley FBR -- Analyst Kelechi Chikere -- Jefferies -- Analyst Roy Buchanan -- JMP Securities -- Analyst Keay Nakae -- Chardan -- Analyst More ABUS analysis All earnings call transcripts This article is a transcript of this conference call produced for The Motley Fool. Bill will begin with a summary of recent accomplishments and upcoming events and a review of Arbutus' 2021 corporate objective, followed by Gaston, Mike Sofia, and Dave Hastings, who will provide clinical drug discovery and financial updates, respectively. | Operator [Operator signoff] Duration: 50 minutes Call participants: Pam Murphy -- Investor Relations Consultant Bill Collier -- President and Chief Executive Officer Gaston Picchio -- Chief Development Officer Mike Sofia -- Chief Scientific Officer Dave Hastings -- Chief Financial Officer Ed Arce -- H.C. Wainwright -- Analyst Brian Skorney -- Baird -- Analyst Mayank Mamtani -- B. Riley FBR -- Analyst Kelechi Chikere -- Jefferies -- Analyst Roy Buchanan -- JMP Securities -- Analyst Keay Nakae -- Chardan -- Analyst More ABUS analysis All earnings call transcripts This article is a transcript of this conference call produced for The Motley Fool. Arbutus Biopharma (NASDAQ: ABUS) Q4 2020 Earnings Call Mar 04, 2021, 8:45 a.m. On the call today are Bill Collier, president and chief executive officer; Dr. Gaston Picchio, chief development officer; Dr. Michael Sofia, chief scientific officer; and Dave Hastings, chief financial officer. | Operator [Operator signoff] Duration: 50 minutes Call participants: Pam Murphy -- Investor Relations Consultant Bill Collier -- President and Chief Executive Officer Gaston Picchio -- Chief Development Officer Mike Sofia -- Chief Scientific Officer Dave Hastings -- Chief Financial Officer Ed Arce -- H.C. Wainwright -- Analyst Brian Skorney -- Baird -- Analyst Mayank Mamtani -- B. Riley FBR -- Analyst Kelechi Chikere -- Jefferies -- Analyst Roy Buchanan -- JMP Securities -- Analyst Keay Nakae -- Chardan -- Analyst More ABUS analysis All earnings call transcripts This article is a transcript of this conference call produced for The Motley Fool. Arbutus Biopharma (NASDAQ: ABUS) Q4 2020 Earnings Call Mar 04, 2021, 8:45 a.m. On the call today are Bill Collier, president and chief executive officer; Dr. Gaston Picchio, chief development officer; Dr. Michael Sofia, chief scientific officer; and Dave Hastings, chief financial officer. | Operator [Operator signoff] Duration: 50 minutes Call participants: Pam Murphy -- Investor Relations Consultant Bill Collier -- President and Chief Executive Officer Gaston Picchio -- Chief Development Officer Mike Sofia -- Chief Scientific Officer Dave Hastings -- Chief Financial Officer Ed Arce -- H.C. Wainwright -- Analyst Brian Skorney -- Baird -- Analyst Mayank Mamtani -- B. Riley FBR -- Analyst Kelechi Chikere -- Jefferies -- Analyst Roy Buchanan -- JMP Securities -- Analyst Keay Nakae -- Chardan -- Analyst More ABUS analysis All earnings call transcripts This article is a transcript of this conference call produced for The Motley Fool. Arbutus Biopharma (NASDAQ: ABUS) Q4 2020 Earnings Call Mar 04, 2021, 8:45 a.m. And then as we already mentioned on this call, we expect to kick off the 836 Phase 1a/1b clinical study in the first half of the year. |
34655.0 | 2020-11-16 00:00:00 UTC | Pre-market Movers In Healthcare Sector: OBSC, CEMI, ABUS, CVAC, ADMP… | ABUS | https://www.nasdaq.com/articles/pre-market-movers-in-healthcare-sector%3A-obsc-cemi-abus-cvac-admp...-2020-11-16 | nan | nan | (RTTNews) - What's moving these stocks in the pre-market hours today?
the Green
1. ObsEva SA (OBSV) is up over 14% at $2.38 in pre-market trading Monday, following positive topline results from its phase IIa proof-of-concept trial of Ebopiprant in preterm labor, dubbed PROLONG. Ebopiprant demonstrated over 50% reduction of pre-term delivery within 48 hrs of treatment in singleton pregnancy.
2. Chembio Diagnostics Inc. (CEMI) is up over 11% at $4.90 in pre-market hours. The company's DPP SARS-CoV-2 Antigen test system was approved by the regulatory authority in Brazil on Friday. The DPP SARS-CoV-2 Antigen test system is designed to detect SARS-CoV-2 antigens in only 20 minutes.
3. Arbutus Biopharma Corporation (ABUS) is up over 12% at $4.09 in pre-market hours today, following encouraging updated clinical data from an ongoing phase Ia/Ib clinical trial with AB-729 in subjects with chronic hepatitis B infection.
4. CureVac N.V. (CVAC) is up more than 8% at $81.90 in pre-market trading Monday on no news. The company's COVID-19 vaccine candidate CVnCoV is under a phase IIa clinical trial in Peru and Panama. A pivotal phase IIb/III clinical study of CVnCoV is expected to be initiated by the end of this year.
5. Acorda Therapeutics Inc. (ACOR) is up over 5% at $0.87 in pre-market hours on no news. The company reported its financial results for the third quarter ended September 30, 2020 on November 3. The total net revenue in Q3, 2020, increased to $53 million from $47.7 million in the year-ago same quarter. However, the product revenue, which comprises of Inbrija and Ampyra, were $34.6 million in Q3, 2020, down from $44.8 million in Q3, 2019.
In the Red
1. Titan Pharmaceuticals Inc. (TTNP) is down more than 5% at $0.11 in pre-market hours today on no news. The company is planning to progress the preclinical development of its ProNeura-based product candidate pipeline in the first half of 2021.
2. Adamis Pharmaceuticals Corporation (ADMP) is down over 3% at $0.66 in pre-market hours. The FDA decision on ZIMHI Injection, proposed for the reversal of opioid overdose, due on November 15, is awaited. ZIMHI is a 5 mg dose of Naloxone.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Arbutus Biopharma Corporation (ABUS) is up over 12% at $4.09 in pre-market hours today, following encouraging updated clinical data from an ongoing phase Ia/Ib clinical trial with AB-729 in subjects with chronic hepatitis B infection. ObsEva SA (OBSV) is up over 14% at $2.38 in pre-market trading Monday, following positive topline results from its phase IIa proof-of-concept trial of Ebopiprant in preterm labor, dubbed PROLONG. The company's DPP SARS-CoV-2 Antigen test system was approved by the regulatory authority in Brazil on Friday. | Arbutus Biopharma Corporation (ABUS) is up over 12% at $4.09 in pre-market hours today, following encouraging updated clinical data from an ongoing phase Ia/Ib clinical trial with AB-729 in subjects with chronic hepatitis B infection. ObsEva SA (OBSV) is up over 14% at $2.38 in pre-market trading Monday, following positive topline results from its phase IIa proof-of-concept trial of Ebopiprant in preterm labor, dubbed PROLONG. The company's DPP SARS-CoV-2 Antigen test system was approved by the regulatory authority in Brazil on Friday. | Arbutus Biopharma Corporation (ABUS) is up over 12% at $4.09 in pre-market hours today, following encouraging updated clinical data from an ongoing phase Ia/Ib clinical trial with AB-729 in subjects with chronic hepatitis B infection. ObsEva SA (OBSV) is up over 14% at $2.38 in pre-market trading Monday, following positive topline results from its phase IIa proof-of-concept trial of Ebopiprant in preterm labor, dubbed PROLONG. Titan Pharmaceuticals Inc. (TTNP) is down more than 5% at $0.11 in pre-market hours today on no news. | Arbutus Biopharma Corporation (ABUS) is up over 12% at $4.09 in pre-market hours today, following encouraging updated clinical data from an ongoing phase Ia/Ib clinical trial with AB-729 in subjects with chronic hepatitis B infection. The company's COVID-19 vaccine candidate CVnCoV is under a phase IIa clinical trial in Peru and Panama. A pivotal phase IIb/III clinical study of CVnCoV is expected to be initiated by the end of this year. |
34656.0 | 2020-11-07 00:00:00 UTC | Earnings Update: Arbutus Biopharma Corporation (NASDAQ:ABUS) Just Reported And Analysts Are Trimming Their Forecasts | ABUS | https://www.nasdaq.com/articles/earnings-update%3A-arbutus-biopharma-corporation-nasdaq%3Aabus-just-reported-and-analysts-are | nan | nan | The analysts might have been a bit too bullish on Arbutus Biopharma Corporation (NASDAQ:ABUS), given that the company fell short of expectations when it released its quarterly results last week. Unfortunately, Arbutus Biopharma delivered a serious earnings miss. Revenues of US$1.5m were 11% below expectations, and statutory losses ballooned 25% to US$0.27 per share. Earnings are an important time for investors, as they can track a company's performance, look at what the analysts are forecasting for next year, and see if there's been a change in sentiment towards the company. We've gathered the most recent statutory forecasts to see whether the analysts have changed their earnings models, following these results.
NasdaqGS:ABUS Earnings and Revenue Growth November 7th 2020
Taking into account the latest results, the current consensus from Arbutus Biopharma's four analysts is for revenues of US$6.72m in 2021, which would reflect a notable 9.4% increase on its sales over the past 12 months. Losses are predicted to fall substantially, shrinking 34% to US$0.80. Before this latest report, the consensus had been expecting revenues of US$10.3m and US$0.78 per share in losses. There's been a definite change in sentiment in this update, with the analysts administering a notable cut to next year's revenue estimates, while at the same time increasing their loss per share forecasts.
There was no major change to the consensus price target of CA$7.88, signalling that the business is performing roughly in line with expectations, despite lower earnings per share forecasts. That's not the only conclusion we can draw from this data however, as some investors also like to consider the spread in estimates when evaluating analyst price targets. Currently, the most bullish analyst values Arbutus Biopharma at CA$8.09 per share, while the most bearish prices it at CA$4.00. There are definitely some different views on the stock, but the range of estimates is not wide enough as to imply that the situation is unforecastable, in our view.
One way to get more context on these forecasts is to look at how they compare to both past performance, and how other companies in the same industry are performing. For example, we noticed that Arbutus Biopharma's rate of growth is expected to accelerate meaningfully, with revenues forecast to grow 9.4%, well above its historical decline of 25% a year over the past five years. Compare this against analyst estimates for the wider industry, which suggest that (in aggregate) industry revenues are expected to grow 20% next year. So although Arbutus Biopharma's revenue growth is expected to improve, it is still expected to grow slower than the industry.
The Bottom Line
The most important thing to take away is that the analysts increased their loss per share estimates for next year. On the negative side, they also downgraded their revenue estimates, and forecasts imply revenues will perform worse than the wider industry. The consensus price target held steady at US$7.88, with the latest estimates not enough to have an impact on their price targets.
Keeping that in mind, we still think that the longer term trajectory of the business is much more important for investors to consider. At Simply Wall St, we have a full range of analyst estimates for Arbutus Biopharma going out to 2024, and you can see them free on our platform here..
However, before you get too enthused, we've discovered 3 warning signs for Arbutus Biopharma that you should be aware of.
This article by Simply Wall St is general in nature. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | The analysts might have been a bit too bullish on Arbutus Biopharma Corporation (NASDAQ:ABUS), given that the company fell short of expectations when it released its quarterly results last week. NasdaqGS:ABUS Earnings and Revenue Growth November 7th 2020 Taking into account the latest results, the current consensus from Arbutus Biopharma's four analysts is for revenues of US$6.72m in 2021, which would reflect a notable 9.4% increase on its sales over the past 12 months. There's been a definite change in sentiment in this update, with the analysts administering a notable cut to next year's revenue estimates, while at the same time increasing their loss per share forecasts. | NasdaqGS:ABUS Earnings and Revenue Growth November 7th 2020 Taking into account the latest results, the current consensus from Arbutus Biopharma's four analysts is for revenues of US$6.72m in 2021, which would reflect a notable 9.4% increase on its sales over the past 12 months. The analysts might have been a bit too bullish on Arbutus Biopharma Corporation (NASDAQ:ABUS), given that the company fell short of expectations when it released its quarterly results last week. There was no major change to the consensus price target of CA$7.88, signalling that the business is performing roughly in line with expectations, despite lower earnings per share forecasts. | NasdaqGS:ABUS Earnings and Revenue Growth November 7th 2020 Taking into account the latest results, the current consensus from Arbutus Biopharma's four analysts is for revenues of US$6.72m in 2021, which would reflect a notable 9.4% increase on its sales over the past 12 months. The analysts might have been a bit too bullish on Arbutus Biopharma Corporation (NASDAQ:ABUS), given that the company fell short of expectations when it released its quarterly results last week. There's been a definite change in sentiment in this update, with the analysts administering a notable cut to next year's revenue estimates, while at the same time increasing their loss per share forecasts. | The analysts might have been a bit too bullish on Arbutus Biopharma Corporation (NASDAQ:ABUS), given that the company fell short of expectations when it released its quarterly results last week. NasdaqGS:ABUS Earnings and Revenue Growth November 7th 2020 Taking into account the latest results, the current consensus from Arbutus Biopharma's four analysts is for revenues of US$6.72m in 2021, which would reflect a notable 9.4% increase on its sales over the past 12 months. Earnings are an important time for investors, as they can track a company's performance, look at what the analysts are forecasting for next year, and see if there's been a change in sentiment towards the company. |
34657.0 | 2020-09-20 00:00:00 UTC | If You Invested $5,000 in Moderna in January, This Is How Much You'd Have Now | ABUS | https://www.nasdaq.com/articles/if-you-invested-%245000-in-moderna-in-january-this-is-how-much-youd-have-now-2020-09-20 | nan | nan | Are you the kind of investor who's leery of buying stocks immediately following their initial public offerings (IPOs)? If so, you might like Moderna's (NASDAQ: MRNA) story.
In December 2018, Moderna conducted the biggest biotech IPO ever. If you had bought shares at the close on the company's first day of trading and held on, your return as of the end of 2019 would have been a piddling 5%. But there's more to the story.
How much would you have today if you'd invested $5,000 in Moderna in January of this year? Your return would be a lot higher than just 5%.
Image source: Getty Images.
Counting the money
Moderna's shares opened on Jan. 2, 2020, the first day of trading this year, at $19.57. An investment of $5,000 would have bought 255 shares. (We'll assume no partial shares were purchased.)
By the end of the third week of February, your investment would be in the red. But then the biotech stock took off. What happened? Moderna announced on Feb. 24 that it had shipped the first batch of coronavirus vaccine candidate mRNA-1273 to the National Institute of Allergy and Infectious Diseases (NIAID) to be used in a planned phase 1 clinical study.
Moderna kept on reporting progress with mRNA-1273. And its shares kept on moving higher.
MRNA data by YCharts
Fast forward to today. Your initial investment of $5,000 would be worth close to $17,820. That's a gain of more than 250% in less than nine months. Moderna has been a much bigger winner than it was immediately after its IPO.
Why it's not even higher
You probably noticed in the stock chart above that Moderna's year-to-date gains were a lot higher in July than they are now. Had you invested $5,000 in January and sold at the peak on July 17, you'd now have nearly $24,190.
Why has Moderna given up some of its impressive gains? One factor was that in July the U.S. Patent Trial and Appeal Board (PTAB) ruled against the company and in favor of Arbutus Biopharma in a patent case involving technology used to deliver messenger RNA (mRNA) to cells. Moderna shrugged off the ruling, stating that its approach and manufacturing processes "have advanced well beyond the technology" in the Arbutus patents. But the PTAB decision rattled investors.
Perhaps the biggest issue, though, was that investors realized they might have gotten the cart before the horse a bit too much. Yes, Moderna's mRNA-1273 is very promising. However, the company still has no approved product on the market yet. It also faces other rivals in the coronavirus vaccine race, including several much larger drugmakers.
Moderna's valuation at its peak likely seemed exceptionally frothy to some. A $37 billion market cap for a clinical-stage biotech did (and still does) sound absurdly high.
Up, up, and away?
You might think that it's too late to buy Moderna shares even after the pullback in recent weeks. My view, though, is that investing $5,000 right now could still pay off in a huge way over time.
To be sure, Moderna isn't the kind of stock that will appeal to some investors. It's very risky. If mRNA-1273 flops, the biotech's shares will crater.
However, I think the chances of success for mRNA-1273 are pretty good. Moderna expects to know in November how well the investigational vaccine works. Positive interim results would almost certainly spark a big gain for the stock.
More importantly, in my view, is that good news for mRNA-1273 would bode well for the rest of Moderna's pipeline. The company has over a dozen other mRNA candidates in clinical testing. It also recently announced plans to develop a seasonal flu vaccine. Success for mRNA-1273 would go a long way toward validating the potential for Moderna's mRNA approach.
Maybe this rosy scenario won't unfold for Moderna. But if it does, an investment of $5,000 is going to turn into a lot more than $17,820 over the next few years.
10 stocks we like better than Moderna INC
When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor, has tripled the market.*
David and Tom just revealed what they believe are the ten best stocks for investors to buy right now... and Moderna INC wasn't one of them! That's right -- they think these 10 stocks are even better buys.
See the 10 stocks
*Stock Advisor returns as of August 1, 2020
Keith Speights has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Are you the kind of investor who's leery of buying stocks immediately following their initial public offerings (IPOs)? Moderna announced on Feb. 24 that it had shipped the first batch of coronavirus vaccine candidate mRNA-1273 to the National Institute of Allergy and Infectious Diseases (NIAID) to be used in a planned phase 1 clinical study. Moderna shrugged off the ruling, stating that its approach and manufacturing processes "have advanced well beyond the technology" in the Arbutus patents. | Are you the kind of investor who's leery of buying stocks immediately following their initial public offerings (IPOs)? If so, you might like Moderna's (NASDAQ: MRNA) story. See the 10 stocks *Stock Advisor returns as of August 1, 2020 Keith Speights has no position in any of the stocks mentioned. | Why it's not even higher You probably noticed in the stock chart above that Moderna's year-to-date gains were a lot higher in July than they are now. 10 stocks we like better than Moderna INC When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. See the 10 stocks *Stock Advisor returns as of August 1, 2020 Keith Speights has no position in any of the stocks mentioned. | If so, you might like Moderna's (NASDAQ: MRNA) story. An investment of $5,000 would have bought 255 shares. To be sure, Moderna isn't the kind of stock that will appeal to some investors. |
34658.0 | 2020-09-15 00:00:00 UTC | BUZZ-U.S. STOCKS ON THE MOVE-General Motors Co, Ocwen Financial Corp, Centrus Energy Corp, Comcast Corp | ABUS | https://www.nasdaq.com/articles/buzz-u.s.-stocks-on-the-move-general-motors-co-ocwen-financial-corp-centrus-energy-corp | nan | nan | Eikon search string for individual stock moves: STXBZ
The Day Ahead newsletter: http://tmsnrt.rs/2ggOmBi
The Morning News Call newsletter: http://tmsnrt.rs/2fwPLTh
Tech stocks pushed Wall Street higher on Tuesday led by Apple shares ahead of a launch event by the company, while investors hoped the Federal Reserve would continue with its dovish stance as the central bank's two-day meeting got underway. .N
At 14:26 ET, the Dow Jones Industrial Average .DJI was up 0.24% at 28,061.44. The S&P 500 .SPX was up 0.66% at 3,405.98 and the Nasdaq Composite .IXIC was up 1.21% at 11,190.233. The top three S&P 500 .PG.INX percentage gainers: ** Kimco Realty Corp , up 5.8% ** SL Green Realty Corp , up 5.8% ** Qorvo Inc , up 5.5% The top three S&P 500 .PL.INX percentage losers: ** Carnival Corp , down 8.8% ** Tapestry Inc , down 4.4% ** Lincoln National Corp , down 4.2% The top three NYSE .PG.N percentage gainers: ** Social Capital Hedosophia Holdings II Corp , up 30.2% ** Ocwen Financial Corp , up 25.6% ** Envela Corp , up 25.1% The top three NYSE .PL.N percentage losers: ** Digital Media Solutions Inc , down 9.9% ** Carnival Corp , down 8.8% ** Carnival Plc , down 8.2% The top three Nasdaq .PG.O percentage gainers: ** Outset Medical Inc , up 117.2% ** Marinus Pharmaceuticals Inc , up 56.9% ** CIM Commercial Trust Corp , up 22.9% The top three Nasdaq .PL.O percentage losers: ** Francesca's Holdings Corp , down 24.7% ** Nano-X Imaging Ltd , down 17% ** Vaxart Inc , down 16.1% ** Marinus Pharmaceuticals Inc MRNS.O: up 56.9%
BUZZ-Surges after genetic epilepsy drug meets late-stage study main goal ** VF Corp VFC.N: up 1.5%
BUZZ-BTIG upgrades to 'buy' on improving demand trends ** iQIYI Inc IQ.O: up 0.7%
BUZZ-Gains on plans to create first FC Barcelona official channel in China ** Lonestar Resources US Inc LONE.O: up 10.3%
BUZZ-Up on entering restructuring support agreement with stakeholders ** Tesla Inc TSLA.O: up 7.0%
BUZZ-Set for fifth straight session of gains ** Novus Therapeutics Inc NVUS.O: up 185.0%
BUZZ-Set for best day after Anelixis acquisition ** Microsoft Corp MSFT.O: up 1.5%
BUZZ-Rises ahead of Xbox cloud gaming service launch ** Nike Inc NKE.N: up 0.4%
BUZZ-Deutsche Bank expects 'impressive' digital growth, hikes PT ** Novavax Inc NVAX.O: up 2.3%
BUZZ-Rises on COVID-19 vaccine deal expansion in India ** Plus Therapeutics Inc PSTV.O: up 20.1%
BUZZ-Soars on FDA 'fast track' tag for brain tumor treatment ** OPKO Health Inc OPK.O: up 0.5%
BUZZ-Up on starting mid-stage study of potential COVID-19 drug ** Carnival Corp CCL.N: down 8.8%
BUZZ-Down on $1 bln equity offering plans ** Aerie Pharmaceuticals Inc AERI.O: up 5.7%
BUZZ-Gains as FDA approves production facility in Ireland ** Arbutus Biopharma Corp ABUS.O: up 9.5%
BUZZ-Rises on positive data from ongoing study of hepatitis B therapy ** Francesca's Holdings Corp FRAN.O: down 24.7%
BUZZ-Plummets on going-concern doubts, plans to explore options ** Kraft Heinz Co KHC.O: up 1.5%
BUZZ-Rises on strong outlook, $2 bln savings target ** Shopify Inc SHOP.N: down 0.5%
BUZZ-Slips after co launches stock, convertible debt deals ** Lennar Corp LEN.N: down 3.8%
BUZZ-Analysts say Q3 order growth below peer rates, shares down ** Equillium Inc EQ.O: up 6.1%
BUZZ-Rises on regulatory pathway for COVID-19 treatment study ** Social Capital Hedosophia II IPOB.N: up 31.4%
BUZZ-Rises on deal to take Opendoor public ** AnPac Bio-Medical Science Co Ltd ANPC.O: up 9.0%
BUZZ-Jumps on immunology testing contract ** Exelixis Inc EXEL.O: up 1.8%
BUZZ-Up as drug for solid tumor shows promise in preclinical study ** NextEra Energy Inc NEE.N: up 4.3%
BUZZ-Surges after co raises guidance, announces stock split ** Nano-X Imaging Ltd NNOX.O: down 17.0%
BUZZ-Falls as short seller Citron sets price target of $0 ** ExlService Holdings Inc EXLS.O: up 9.1%
BUZZ-Rises on better-than-expected 2020 outlook ** Western Union Co WU.N: up 1.1%
BUZZ-Rises after BofA upgrades to 'buy' ** Tupperware Brands Corp TUP.N: up 10.3%
BUZZ-Hits near 17-month peak as D.A. Davidson starts with 'buy' ** JPMorgan Chase & Co JPM.N: down 2.3%
BUZZ-Drops on expectations of weaker net interest income trend into 2021 ** Outset Medical Inc OM.O: up 117.2%
BUZZ-Nearly doubles at open in market debut ** Titan Pharmaceuticals Inc TTNP.O: up 13.9%
BUZZ-Up as partner signs distribution deal for opioid addiction drug ** Delta Air Lines Inc DAL.N: up 2.3%
BUZZ-Rises to over three-month high; set to avoid involuntary furloughs ** Caterpillar Inc CAT.N: down 3.0%
BUZZ-Slips on 20% drop in August total machines retail sales ** Comcast Corp CMCSA.O: up 2.8%
BUZZ-Rises as Peacock streaming rakes in 15 mln users ** Centrus Energy Corp LEU.A: up 20.7%
BUZZ-Rises on partnership with TerraPower ** Skyworks Solutions Inc SWKS.O: up 2.8% ** Qorvo Inc QRVO.O: up 5.5%
BUZZ-Apple suppliers rise ahead of iPhone maker's launch event ** Ocwen Financial Corp OCN.N: up 25.4%
BUZZ-Jumps as August loan originations soar ** Becton Dickinson And Co BDX.N: down 3.8%
BUZZ-Down as co investigates false-positive COVID-19 test results ** General Motors Co GM.N: up 1.5%
BUZZ-Jumps on Reuters report of co exploring entry into aerial taxi market ** Kornit Digital Ltd KRNT.O: down 4.4%
BUZZ-Falls as co, Amazon to sell shares
The 11 major S&P 500 sectors:
Communication Services
.SPLRCL
up 1.86%
Consumer Discretionary
.SPLRCD
up 0.99%
Consumer Staples
.SPLRCS
up 0.10%
Energy
.SPNY
down 0.18%
Financial
.SPSY
down 0.97%
Health
.SPXHC
up 0.37%
Industrial
.SPLRCI
up 0.26%
Information Technology
.SPLRCT
up 0.90%
Materials
.SPLRCM
up 0.85%
Real Estate
.SPLRCR
up 1.85%
Utilities
.SPLRCU
up 0.71%
(Compiled by Shivani Kumaresan in Bengaluru)
((Shivani.Kumaresan@thomsonreuters.com ; +1 646 223 8780))
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | The top three S&P 500 .PG.INX percentage gainers: ** Kimco Realty Corp , up 5.8% ** SL Green Realty Corp , up 5.8% ** Qorvo Inc , up 5.5% The top three S&P 500 .PL.INX percentage losers: ** Carnival Corp , down 8.8% ** Tapestry Inc , down 4.4% ** Lincoln National Corp , down 4.2% The top three NYSE .PG.N percentage gainers: ** Social Capital Hedosophia Holdings II Corp , up 30.2% ** Ocwen Financial Corp , up 25.6% ** Envela Corp , up 25.1% The top three NYSE .PL.N percentage losers: ** Digital Media Solutions Inc , down 9.9% ** Carnival Corp , down 8.8% ** Carnival Plc , down 8.2% The top three Nasdaq .PG.O percentage gainers: ** Outset Medical Inc , up 117.2% ** Marinus Pharmaceuticals Inc , up 56.9% ** CIM Commercial Trust Corp , up 22.9% The top three Nasdaq .PL.O percentage losers: ** Francesca's Holdings Corp , down 24.7% ** Nano-X Imaging Ltd , down 17% ** Vaxart Inc , down 16.1% ** Marinus Pharmaceuticals Inc MRNS.O: up 56.9% BUZZ-Surges after genetic epilepsy drug meets late-stage study main goal ** VF Corp VFC.N: up 1.5% BUZZ-BTIG upgrades to 'buy' on improving demand trends ** iQIYI Inc IQ.O: up 0.7% BUZZ-Gains on plans to create first FC Barcelona official channel in China ** Lonestar Resources US Inc LONE.O: up 10.3% BUZZ-Up on entering restructuring support agreement with stakeholders ** Tesla Inc TSLA.O: up 7.0% BUZZ-Set for fifth straight session of gains ** Novus Therapeutics Inc NVUS.O: up 185.0% BUZZ-Set for best day after Anelixis acquisition ** Microsoft Corp MSFT.O: up 1.5% BUZZ-Rises ahead of Xbox cloud gaming service launch ** Nike Inc NKE.N: up 0.4% BUZZ-Deutsche Bank expects 'impressive' digital growth, hikes PT ** Novavax Inc NVAX.O: up 2.3% BUZZ-Rises on COVID-19 vaccine deal expansion in India ** Plus Therapeutics Inc PSTV.O: up 20.1% BUZZ-Soars on FDA 'fast track' tag for brain tumor treatment ** OPKO Health Inc OPK.O: up 0.5% BUZZ-Up on starting mid-stage study of potential COVID-19 drug ** Carnival Corp CCL.N: down 8.8% BUZZ-Down on $1 bln equity offering plans ** Aerie Pharmaceuticals Inc AERI.O: up 5.7% BUZZ-Gains as FDA approves production facility in Ireland ** Arbutus Biopharma Corp ABUS.O: up 9.5% BUZZ-Rises on positive data from ongoing study of hepatitis B therapy ** Francesca's Holdings Corp FRAN.O: down 24.7% BUZZ-Plummets on going-concern doubts, plans to explore options ** Kraft Heinz Co KHC.O: up 1.5% BUZZ-Rises on strong outlook, $2 bln savings target ** Shopify Inc SHOP.N: down 0.5% BUZZ-Slips after co launches stock, convertible debt deals ** Lennar Corp LEN.N: down 3.8% BUZZ-Analysts say Q3 order growth below peer rates, shares down ** Equillium Inc EQ.O: up 6.1% BUZZ-Rises on regulatory pathway for COVID-19 treatment study ** Social Capital Hedosophia II IPOB.N: up 31.4% BUZZ-Rises on deal to take Opendoor public ** AnPac Bio-Medical Science Co Ltd ANPC.O: up 9.0% BUZZ-Jumps on immunology testing contract ** Exelixis Inc EXEL.O: up 1.8% BUZZ-Up as drug for solid tumor shows promise in preclinical study ** NextEra Energy Inc NEE.N: up 4.3% BUZZ-Surges after co raises guidance, announces stock split ** Nano-X Imaging Ltd NNOX.O: down 17.0% BUZZ-Falls as short seller Citron sets price target of $0 ** ExlService Holdings Inc EXLS.O: up 9.1% BUZZ-Rises on better-than-expected 2020 outlook ** Western Union Co WU.N: up 1.1% BUZZ-Rises after BofA upgrades to 'buy' ** Tupperware Brands Corp TUP.N: up 10.3% BUZZ-Hits near 17-month peak as D.A. Eikon search string for individual stock moves: STXBZ The Day Ahead newsletter: http://tmsnrt.rs/2ggOmBi The Morning News Call newsletter: http://tmsnrt.rs/2fwPLTh Tech stocks pushed Wall Street higher on Tuesday led by Apple shares ahead of a launch event by the company, while investors hoped the Federal Reserve would continue with its dovish stance as the central bank's two-day meeting got underway. Davidson starts with 'buy' ** JPMorgan Chase & Co JPM.N: down 2.3% BUZZ-Drops on expectations of weaker net interest income trend into 2021 ** Outset Medical Inc OM.O: up 117.2% BUZZ-Nearly doubles at open in market debut ** Titan Pharmaceuticals Inc TTNP.O: up 13.9% BUZZ-Up as partner signs distribution deal for opioid addiction drug ** Delta Air Lines Inc DAL.N: up 2.3% BUZZ-Rises to over three-month high; set to avoid involuntary furloughs ** Caterpillar Inc CAT.N: down 3.0% BUZZ-Slips on 20% drop in August total machines retail sales ** Comcast Corp CMCSA.O: up 2.8% BUZZ-Rises as Peacock streaming rakes in 15 mln users ** Centrus Energy Corp LEU.A: up 20.7% BUZZ-Rises on partnership with TerraPower ** Skyworks Solutions Inc SWKS.O: up 2.8% ** Qorvo Inc QRVO.O: up 5.5% BUZZ-Apple suppliers rise ahead of iPhone maker's launch event ** Ocwen Financial Corp OCN.N: up 25.4% BUZZ-Jumps as August loan originations soar ** Becton Dickinson And Co BDX.N: down 3.8% BUZZ-Down as co investigates false-positive COVID-19 test results ** General Motors Co GM.N: up 1.5% BUZZ-Jumps on Reuters report of co exploring entry into aerial taxi market ** Kornit Digital Ltd KRNT.O: down 4.4% BUZZ-Falls as co, Amazon to sell shares The 11 major S&P 500 sectors: Communication Services | The top three S&P 500 .PG.INX percentage gainers: ** Kimco Realty Corp , up 5.8% ** SL Green Realty Corp , up 5.8% ** Qorvo Inc , up 5.5% The top three S&P 500 .PL.INX percentage losers: ** Carnival Corp , down 8.8% ** Tapestry Inc , down 4.4% ** Lincoln National Corp , down 4.2% The top three NYSE .PG.N percentage gainers: ** Social Capital Hedosophia Holdings II Corp , up 30.2% ** Ocwen Financial Corp , up 25.6% ** Envela Corp , up 25.1% The top three NYSE .PL.N percentage losers: ** Digital Media Solutions Inc , down 9.9% ** Carnival Corp , down 8.8% ** Carnival Plc , down 8.2% The top three Nasdaq .PG.O percentage gainers: ** Outset Medical Inc , up 117.2% ** Marinus Pharmaceuticals Inc , up 56.9% ** CIM Commercial Trust Corp , up 22.9% The top three Nasdaq .PL.O percentage losers: ** Francesca's Holdings Corp , down 24.7% ** Nano-X Imaging Ltd , down 17% ** Vaxart Inc , down 16.1% ** Marinus Pharmaceuticals Inc MRNS.O: up 56.9% BUZZ-Surges after genetic epilepsy drug meets late-stage study main goal ** VF Corp VFC.N: up 1.5% BUZZ-BTIG upgrades to 'buy' on improving demand trends ** iQIYI Inc IQ.O: up 0.7% BUZZ-Gains on plans to create first FC Barcelona official channel in China ** Lonestar Resources US Inc LONE.O: up 10.3% BUZZ-Up on entering restructuring support agreement with stakeholders ** Tesla Inc TSLA.O: up 7.0% BUZZ-Set for fifth straight session of gains ** Novus Therapeutics Inc NVUS.O: up 185.0% BUZZ-Set for best day after Anelixis acquisition ** Microsoft Corp MSFT.O: up 1.5% BUZZ-Rises ahead of Xbox cloud gaming service launch ** Nike Inc NKE.N: up 0.4% BUZZ-Deutsche Bank expects 'impressive' digital growth, hikes PT ** Novavax Inc NVAX.O: up 2.3% BUZZ-Rises on COVID-19 vaccine deal expansion in India ** Plus Therapeutics Inc PSTV.O: up 20.1% BUZZ-Soars on FDA 'fast track' tag for brain tumor treatment ** OPKO Health Inc OPK.O: up 0.5% BUZZ-Up on starting mid-stage study of potential COVID-19 drug ** Carnival Corp CCL.N: down 8.8% BUZZ-Down on $1 bln equity offering plans ** Aerie Pharmaceuticals Inc AERI.O: up 5.7% BUZZ-Gains as FDA approves production facility in Ireland ** Arbutus Biopharma Corp ABUS.O: up 9.5% BUZZ-Rises on positive data from ongoing study of hepatitis B therapy ** Francesca's Holdings Corp FRAN.O: down 24.7% BUZZ-Plummets on going-concern doubts, plans to explore options ** Kraft Heinz Co KHC.O: up 1.5% BUZZ-Rises on strong outlook, $2 bln savings target ** Shopify Inc SHOP.N: down 0.5% BUZZ-Slips after co launches stock, convertible debt deals ** Lennar Corp LEN.N: down 3.8% BUZZ-Analysts say Q3 order growth below peer rates, shares down ** Equillium Inc EQ.O: up 6.1% BUZZ-Rises on regulatory pathway for COVID-19 treatment study ** Social Capital Hedosophia II IPOB.N: up 31.4% BUZZ-Rises on deal to take Opendoor public ** AnPac Bio-Medical Science Co Ltd ANPC.O: up 9.0% BUZZ-Jumps on immunology testing contract ** Exelixis Inc EXEL.O: up 1.8% BUZZ-Up as drug for solid tumor shows promise in preclinical study ** NextEra Energy Inc NEE.N: up 4.3% BUZZ-Surges after co raises guidance, announces stock split ** Nano-X Imaging Ltd NNOX.O: down 17.0% BUZZ-Falls as short seller Citron sets price target of $0 ** ExlService Holdings Inc EXLS.O: up 9.1% BUZZ-Rises on better-than-expected 2020 outlook ** Western Union Co WU.N: up 1.1% BUZZ-Rises after BofA upgrades to 'buy' ** Tupperware Brands Corp TUP.N: up 10.3% BUZZ-Hits near 17-month peak as D.A. Eikon search string for individual stock moves: STXBZ The Day Ahead newsletter: http://tmsnrt.rs/2ggOmBi The Morning News Call newsletter: http://tmsnrt.rs/2fwPLTh Tech stocks pushed Wall Street higher on Tuesday led by Apple shares ahead of a launch event by the company, while investors hoped the Federal Reserve would continue with its dovish stance as the central bank's two-day meeting got underway. Davidson starts with 'buy' ** JPMorgan Chase & Co JPM.N: down 2.3% BUZZ-Drops on expectations of weaker net interest income trend into 2021 ** Outset Medical Inc OM.O: up 117.2% BUZZ-Nearly doubles at open in market debut ** Titan Pharmaceuticals Inc TTNP.O: up 13.9% BUZZ-Up as partner signs distribution deal for opioid addiction drug ** Delta Air Lines Inc DAL.N: up 2.3% BUZZ-Rises to over three-month high; set to avoid involuntary furloughs ** Caterpillar Inc CAT.N: down 3.0% BUZZ-Slips on 20% drop in August total machines retail sales ** Comcast Corp CMCSA.O: up 2.8% BUZZ-Rises as Peacock streaming rakes in 15 mln users ** Centrus Energy Corp LEU.A: up 20.7% BUZZ-Rises on partnership with TerraPower ** Skyworks Solutions Inc SWKS.O: up 2.8% ** Qorvo Inc QRVO.O: up 5.5% BUZZ-Apple suppliers rise ahead of iPhone maker's launch event ** Ocwen Financial Corp OCN.N: up 25.4% BUZZ-Jumps as August loan originations soar ** Becton Dickinson And Co BDX.N: down 3.8% BUZZ-Down as co investigates false-positive COVID-19 test results ** General Motors Co GM.N: up 1.5% BUZZ-Jumps on Reuters report of co exploring entry into aerial taxi market ** Kornit Digital Ltd KRNT.O: down 4.4% BUZZ-Falls as co, Amazon to sell shares The 11 major S&P 500 sectors: Communication Services | The top three S&P 500 .PG.INX percentage gainers: ** Kimco Realty Corp , up 5.8% ** SL Green Realty Corp , up 5.8% ** Qorvo Inc , up 5.5% The top three S&P 500 .PL.INX percentage losers: ** Carnival Corp , down 8.8% ** Tapestry Inc , down 4.4% ** Lincoln National Corp , down 4.2% The top three NYSE .PG.N percentage gainers: ** Social Capital Hedosophia Holdings II Corp , up 30.2% ** Ocwen Financial Corp , up 25.6% ** Envela Corp , up 25.1% The top three NYSE .PL.N percentage losers: ** Digital Media Solutions Inc , down 9.9% ** Carnival Corp , down 8.8% ** Carnival Plc , down 8.2% The top three Nasdaq .PG.O percentage gainers: ** Outset Medical Inc , up 117.2% ** Marinus Pharmaceuticals Inc , up 56.9% ** CIM Commercial Trust Corp , up 22.9% The top three Nasdaq .PL.O percentage losers: ** Francesca's Holdings Corp , down 24.7% ** Nano-X Imaging Ltd , down 17% ** Vaxart Inc , down 16.1% ** Marinus Pharmaceuticals Inc MRNS.O: up 56.9% BUZZ-Surges after genetic epilepsy drug meets late-stage study main goal ** VF Corp VFC.N: up 1.5% BUZZ-BTIG upgrades to 'buy' on improving demand trends ** iQIYI Inc IQ.O: up 0.7% BUZZ-Gains on plans to create first FC Barcelona official channel in China ** Lonestar Resources US Inc LONE.O: up 10.3% BUZZ-Up on entering restructuring support agreement with stakeholders ** Tesla Inc TSLA.O: up 7.0% BUZZ-Set for fifth straight session of gains ** Novus Therapeutics Inc NVUS.O: up 185.0% BUZZ-Set for best day after Anelixis acquisition ** Microsoft Corp MSFT.O: up 1.5% BUZZ-Rises ahead of Xbox cloud gaming service launch ** Nike Inc NKE.N: up 0.4% BUZZ-Deutsche Bank expects 'impressive' digital growth, hikes PT ** Novavax Inc NVAX.O: up 2.3% BUZZ-Rises on COVID-19 vaccine deal expansion in India ** Plus Therapeutics Inc PSTV.O: up 20.1% BUZZ-Soars on FDA 'fast track' tag for brain tumor treatment ** OPKO Health Inc OPK.O: up 0.5% BUZZ-Up on starting mid-stage study of potential COVID-19 drug ** Carnival Corp CCL.N: down 8.8% BUZZ-Down on $1 bln equity offering plans ** Aerie Pharmaceuticals Inc AERI.O: up 5.7% BUZZ-Gains as FDA approves production facility in Ireland ** Arbutus Biopharma Corp ABUS.O: up 9.5% BUZZ-Rises on positive data from ongoing study of hepatitis B therapy ** Francesca's Holdings Corp FRAN.O: down 24.7% BUZZ-Plummets on going-concern doubts, plans to explore options ** Kraft Heinz Co KHC.O: up 1.5% BUZZ-Rises on strong outlook, $2 bln savings target ** Shopify Inc SHOP.N: down 0.5% BUZZ-Slips after co launches stock, convertible debt deals ** Lennar Corp LEN.N: down 3.8% BUZZ-Analysts say Q3 order growth below peer rates, shares down ** Equillium Inc EQ.O: up 6.1% BUZZ-Rises on regulatory pathway for COVID-19 treatment study ** Social Capital Hedosophia II IPOB.N: up 31.4% BUZZ-Rises on deal to take Opendoor public ** AnPac Bio-Medical Science Co Ltd ANPC.O: up 9.0% BUZZ-Jumps on immunology testing contract ** Exelixis Inc EXEL.O: up 1.8% BUZZ-Up as drug for solid tumor shows promise in preclinical study ** NextEra Energy Inc NEE.N: up 4.3% BUZZ-Surges after co raises guidance, announces stock split ** Nano-X Imaging Ltd NNOX.O: down 17.0% BUZZ-Falls as short seller Citron sets price target of $0 ** ExlService Holdings Inc EXLS.O: up 9.1% BUZZ-Rises on better-than-expected 2020 outlook ** Western Union Co WU.N: up 1.1% BUZZ-Rises after BofA upgrades to 'buy' ** Tupperware Brands Corp TUP.N: up 10.3% BUZZ-Hits near 17-month peak as D.A. .N At 14:26 ET, the Dow Jones Industrial Average .DJI was up 0.24% at 28,061.44. Davidson starts with 'buy' ** JPMorgan Chase & Co JPM.N: down 2.3% BUZZ-Drops on expectations of weaker net interest income trend into 2021 ** Outset Medical Inc OM.O: up 117.2% BUZZ-Nearly doubles at open in market debut ** Titan Pharmaceuticals Inc TTNP.O: up 13.9% BUZZ-Up as partner signs distribution deal for opioid addiction drug ** Delta Air Lines Inc DAL.N: up 2.3% BUZZ-Rises to over three-month high; set to avoid involuntary furloughs ** Caterpillar Inc CAT.N: down 3.0% BUZZ-Slips on 20% drop in August total machines retail sales ** Comcast Corp CMCSA.O: up 2.8% BUZZ-Rises as Peacock streaming rakes in 15 mln users ** Centrus Energy Corp LEU.A: up 20.7% BUZZ-Rises on partnership with TerraPower ** Skyworks Solutions Inc SWKS.O: up 2.8% ** Qorvo Inc QRVO.O: up 5.5% BUZZ-Apple suppliers rise ahead of iPhone maker's launch event ** Ocwen Financial Corp OCN.N: up 25.4% BUZZ-Jumps as August loan originations soar ** Becton Dickinson And Co BDX.N: down 3.8% BUZZ-Down as co investigates false-positive COVID-19 test results ** General Motors Co GM.N: up 1.5% BUZZ-Jumps on Reuters report of co exploring entry into aerial taxi market ** Kornit Digital Ltd KRNT.O: down 4.4% BUZZ-Falls as co, Amazon to sell shares The 11 major S&P 500 sectors: Communication Services | The top three S&P 500 .PG.INX percentage gainers: ** Kimco Realty Corp , up 5.8% ** SL Green Realty Corp , up 5.8% ** Qorvo Inc , up 5.5% The top three S&P 500 .PL.INX percentage losers: ** Carnival Corp , down 8.8% ** Tapestry Inc , down 4.4% ** Lincoln National Corp , down 4.2% The top three NYSE .PG.N percentage gainers: ** Social Capital Hedosophia Holdings II Corp , up 30.2% ** Ocwen Financial Corp , up 25.6% ** Envela Corp , up 25.1% The top three NYSE .PL.N percentage losers: ** Digital Media Solutions Inc , down 9.9% ** Carnival Corp , down 8.8% ** Carnival Plc , down 8.2% The top three Nasdaq .PG.O percentage gainers: ** Outset Medical Inc , up 117.2% ** Marinus Pharmaceuticals Inc , up 56.9% ** CIM Commercial Trust Corp , up 22.9% The top three Nasdaq .PL.O percentage losers: ** Francesca's Holdings Corp , down 24.7% ** Nano-X Imaging Ltd , down 17% ** Vaxart Inc , down 16.1% ** Marinus Pharmaceuticals Inc MRNS.O: up 56.9% BUZZ-Surges after genetic epilepsy drug meets late-stage study main goal ** VF Corp VFC.N: up 1.5% BUZZ-BTIG upgrades to 'buy' on improving demand trends ** iQIYI Inc IQ.O: up 0.7% BUZZ-Gains on plans to create first FC Barcelona official channel in China ** Lonestar Resources US Inc LONE.O: up 10.3% BUZZ-Up on entering restructuring support agreement with stakeholders ** Tesla Inc TSLA.O: up 7.0% BUZZ-Set for fifth straight session of gains ** Novus Therapeutics Inc NVUS.O: up 185.0% BUZZ-Set for best day after Anelixis acquisition ** Microsoft Corp MSFT.O: up 1.5% BUZZ-Rises ahead of Xbox cloud gaming service launch ** Nike Inc NKE.N: up 0.4% BUZZ-Deutsche Bank expects 'impressive' digital growth, hikes PT ** Novavax Inc NVAX.O: up 2.3% BUZZ-Rises on COVID-19 vaccine deal expansion in India ** Plus Therapeutics Inc PSTV.O: up 20.1% BUZZ-Soars on FDA 'fast track' tag for brain tumor treatment ** OPKO Health Inc OPK.O: up 0.5% BUZZ-Up on starting mid-stage study of potential COVID-19 drug ** Carnival Corp CCL.N: down 8.8% BUZZ-Down on $1 bln equity offering plans ** Aerie Pharmaceuticals Inc AERI.O: up 5.7% BUZZ-Gains as FDA approves production facility in Ireland ** Arbutus Biopharma Corp ABUS.O: up 9.5% BUZZ-Rises on positive data from ongoing study of hepatitis B therapy ** Francesca's Holdings Corp FRAN.O: down 24.7% BUZZ-Plummets on going-concern doubts, plans to explore options ** Kraft Heinz Co KHC.O: up 1.5% BUZZ-Rises on strong outlook, $2 bln savings target ** Shopify Inc SHOP.N: down 0.5% BUZZ-Slips after co launches stock, convertible debt deals ** Lennar Corp LEN.N: down 3.8% BUZZ-Analysts say Q3 order growth below peer rates, shares down ** Equillium Inc EQ.O: up 6.1% BUZZ-Rises on regulatory pathway for COVID-19 treatment study ** Social Capital Hedosophia II IPOB.N: up 31.4% BUZZ-Rises on deal to take Opendoor public ** AnPac Bio-Medical Science Co Ltd ANPC.O: up 9.0% BUZZ-Jumps on immunology testing contract ** Exelixis Inc EXEL.O: up 1.8% BUZZ-Up as drug for solid tumor shows promise in preclinical study ** NextEra Energy Inc NEE.N: up 4.3% BUZZ-Surges after co raises guidance, announces stock split ** Nano-X Imaging Ltd NNOX.O: down 17.0% BUZZ-Falls as short seller Citron sets price target of $0 ** ExlService Holdings Inc EXLS.O: up 9.1% BUZZ-Rises on better-than-expected 2020 outlook ** Western Union Co WU.N: up 1.1% BUZZ-Rises after BofA upgrades to 'buy' ** Tupperware Brands Corp TUP.N: up 10.3% BUZZ-Hits near 17-month peak as D.A. Eikon search string for individual stock moves: STXBZ The Day Ahead newsletter: http://tmsnrt.rs/2ggOmBi The Morning News Call newsletter: http://tmsnrt.rs/2fwPLTh Tech stocks pushed Wall Street higher on Tuesday led by Apple shares ahead of a launch event by the company, while investors hoped the Federal Reserve would continue with its dovish stance as the central bank's two-day meeting got underway. .N At 14:26 ET, the Dow Jones Industrial Average .DJI was up 0.24% at 28,061.44. |
34659.0 | 2020-09-15 00:00:00 UTC | BUZZ-U.S. STOCKS ON THE MOVE-Exelixis Inc, AnPac Bio-Medical, Lennar Corp, Equillium Inc | ABUS | https://www.nasdaq.com/articles/buzz-u.s.-stocks-on-the-move-exelixis-inc-anpac-bio-medical-lennar-corp-equillium-inc-2020 | nan | nan | Eikon search string for individual stock moves: STXBZ
The Day Ahead newsletter: http://tmsnrt.rs/2ggOmBi
The Morning News Call newsletter: http://tmsnrt.rs/2fwPLTh
U.S. stocks opened higher on Tuesday as upbeat data from China revived optimism around an economic rebound, while investors looked for more stimulus from the Federal Reserve as the central bank kicks off a two-day meeting. .N
At 9:30 a.m. ET, the Dow Jones Industrial Average .DJI was up 0.68% at 28,183.36. The S&P 500 .SPX was up 0.91% at 3,414.23 and the Nasdaq Composite .IXIC was up 1.37% at 11,208.015. The top three S&P 500 .PG.INX percentage gainers: ** Occidental PetROleum Corp , up 5% ** Nextera Energy Inc , up 4.3% ** Apache Corp , up 4% The top three S&P 500 .PL.INX percentage losers: ** Carnival Corp , down 7.1% ** Clorox Co , down 3.1% ** Charles Schwab Corp , down 3% The top three NYSE .PG.N percentage gainers: ** Social Capital Hedosophia Holdings II Corp , up 22.5% ** Envela Corp , up 19.7% ** Radiant Logistics Inc , up 10.1% The top three NYSE .PL.N percentage losers: ** Carnival Corp CCL.N, down 7.1% ** Carnival Plc CUK.N, down 6.3% ** Medallia Inc , down 6.3% The top three Nasdaq .PG.O percentage gainers: ** Marinus Pharmaceuticals Inc , up 50.5% ** Plus Therapeutics Inc , up 32.8% ** NextDecade Corp , up 28.6% The top three Nasdaq .PL.O percentage losers: ** Francesca's Holdings Corp , down 24.6% ** AudioEye Inc , down 13.6% ** Cassava Sciences Inc , down 12.5% ** Marinus Pharmaceuticals Inc MRNS.O: up 50.5%
BUZZ-Surges after genetic epilepsy drug meets late-stage study main goal ** VF Corp VFC.N: up 2.0%
BUZZ-BTIG upgrades to 'buy' on improving demand trends ** Lonestar Resources US Inc LONE.O: up 23.6%
BUZZ-Up on entering restructuring support agreement with stakeholders ** Tesla Inc TSLA.O: up 4.4%
BUZZ-Set for fifth straight session of gains ** Novus Therapeutics Inc NVUS.O: up 215.3%
BUZZ-Set for best day after Anelixis acquisition ** Camping World Holdings Inc CWH.N: up 2.4%
BUZZ-Zooms ahead as RV demand prompts upbeat forecast ** 3M Co MMM.N: up 0.1%
BUZZ-Rises after upbeat Q3 sales outlook ** Microsoft Corp MSFT.O: up 1.9%
BUZZ-Rises ahead of Xbox cloud gaming service launch ** BioNTech SE BNTX.O: up 2.2%
BUZZ-Rises on $445 mln German govt funding for COVID-19 vaccine program ** Future FinTech Group Inc FTFT.O: up 7.6%
BUZZ-Rises on proposed deal to buy stake in Sichuan Tema ** Nike Inc NKE.N: up 0.4%
BUZZ-Deutsche Bank expects 'impressive' digital growth, hikes PT ** Novavax Inc NVAX.O: up 5.2%
BUZZ-Rises on COVID-19 vaccine deal expansion in India ** Plus Therapeutics Inc PSTV.O: up 32.8%
BUZZ-Soars on FDA 'fast track' tag for brain tumor treatment ** OPKO Health Inc OPK.O: up 6.2%
BUZZ-Up on starting mid-stage study of potential COVID-19 drug ** Carnival Corp CCL.N: down 7.1%
BUZZ-Down on $1 bln equity offering plans ** Aerie Pharmaceuticals Inc AERI.O: up 2.6%
BUZZ-Gains as FDA approves production facility in Ireland ** Arbutus Biopharma Corp ABUS.O: up 11.1%
BUZZ-Rises on positive data from ongoing study of hepatitis B therapy ** Francesca's Holdings Corp FRAN.O: down 24.6%
BUZZ-Plummets on going-concern doubts, plans to explore options ** Kraft Heinz Co KHC.O: up 2.1%
BUZZ-Rises on strong outlook, $2 bln savings target ** Lennar Corp LEN.N: down 2.6%
BUZZ-Analysts say Q3 order growth below peer rates, shares down ** Equillium Inc EQ.O: up 14.3%
BUZZ-Rises on regulatory pathway for COVID-19 treatment study ** Social Capital Hedosophia II IPOB.N: up 22.5%
BUZZ-Rises on deal to take Opendoor public ** AnPac Bio-Medical Science Co Ltd ANPC.O: up 3.2%
BUZZ-Jumps on immunology testing contract ** Fulgent Genetics Inc FLGT.O: up 0.7%
BUZZ-Up on partnership with Utah for COVID-19 testing ** Exelixis Inc EXEL.O: up 1.1%
BUZZ-Up as drug for solid tumor shows promise in preclinical study
The 11 major S&P 500 sectors:
Communication Services
.SPLRCL
up 1.19%
Consumer Discretionary
.SPLRCD
up 0.89%
Consumer Staples
.SPLRCS
up 0.22%
Energy
.SPNY
up 1.26%
Financial
.SPSY
down 0.10%
Health
.SPXHC
up 0.61%
Industrial
.SPLRCI
up 0.41%
Information Technology
.SPLRCT
up 1.62%
Materials
.SPLRCM
up 0.83%
Real Estate
.SPLRCR
up 0.75%
Utilities
.SPLRCU
up 1.13%
(Compiled by Shivani Kumaresan in Bengaluru)
((Shivani.Kumaresan@thomsonreuters.com ; +1 646 223 8780))
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | The top three S&P 500 .PG.INX percentage gainers: ** Occidental PetROleum Corp , up 5% ** Nextera Energy Inc , up 4.3% ** Apache Corp , up 4% The top three S&P 500 .PL.INX percentage losers: ** Carnival Corp , down 7.1% ** Clorox Co , down 3.1% ** Charles Schwab Corp , down 3% The top three NYSE .PG.N percentage gainers: ** Social Capital Hedosophia Holdings II Corp , up 22.5% ** Envela Corp , up 19.7% ** Radiant Logistics Inc , up 10.1% The top three NYSE .PL.N percentage losers: ** Carnival Corp CCL.N, down 7.1% ** Carnival Plc CUK.N, down 6.3% ** Medallia Inc , down 6.3% The top three Nasdaq .PG.O percentage gainers: ** Marinus Pharmaceuticals Inc , up 50.5% ** Plus Therapeutics Inc , up 32.8% ** NextDecade Corp , up 28.6% The top three Nasdaq .PL.O percentage losers: ** Francesca's Holdings Corp , down 24.6% ** AudioEye Inc , down 13.6% ** Cassava Sciences Inc , down 12.5% ** Marinus Pharmaceuticals Inc MRNS.O: up 50.5% BUZZ-Surges after genetic epilepsy drug meets late-stage study main goal ** VF Corp VFC.N: up 2.0% BUZZ-BTIG upgrades to 'buy' on improving demand trends ** Lonestar Resources US Inc LONE.O: up 23.6% BUZZ-Up on entering restructuring support agreement with stakeholders ** Tesla Inc TSLA.O: up 4.4% BUZZ-Set for fifth straight session of gains ** Novus Therapeutics Inc NVUS.O: up 215.3% BUZZ-Set for best day after Anelixis acquisition ** Camping World Holdings Inc CWH.N: up 2.4% BUZZ-Zooms ahead as RV demand prompts upbeat forecast ** 3M Co MMM.N: up 0.1% BUZZ-Rises after upbeat Q3 sales outlook ** Microsoft Corp MSFT.O: up 1.9% BUZZ-Rises ahead of Xbox cloud gaming service launch ** BioNTech SE BNTX.O: up 2.2% BUZZ-Rises on $445 mln German govt funding for COVID-19 vaccine program ** Future FinTech Group Inc FTFT.O: up 7.6% BUZZ-Rises on proposed deal to buy stake in Sichuan Tema ** Nike Inc NKE.N: up 0.4% BUZZ-Deutsche Bank expects 'impressive' digital growth, hikes PT ** Novavax Inc NVAX.O: up 5.2% BUZZ-Rises on COVID-19 vaccine deal expansion in India ** Plus Therapeutics Inc PSTV.O: up 32.8% BUZZ-Soars on FDA 'fast track' tag for brain tumor treatment ** OPKO Health Inc OPK.O: up 6.2% BUZZ-Up on starting mid-stage study of potential COVID-19 drug ** Carnival Corp CCL.N: down 7.1% BUZZ-Down on $1 bln equity offering plans ** Aerie Pharmaceuticals Inc AERI.O: up 2.6% BUZZ-Gains as FDA approves production facility in Ireland ** Arbutus Biopharma Corp ABUS.O: up 11.1% BUZZ-Rises on positive data from ongoing study of hepatitis B therapy ** Francesca's Holdings Corp FRAN.O: down 24.6% BUZZ-Plummets on going-concern doubts, plans to explore options ** Kraft Heinz Co KHC.O: up 2.1% BUZZ-Rises on strong outlook, $2 bln savings target ** Lennar Corp LEN.N: down 2.6% BUZZ-Analysts say Q3 order growth below peer rates, shares down ** Equillium Inc EQ.O: up 14.3% BUZZ-Rises on regulatory pathway for COVID-19 treatment study ** Social Capital Hedosophia II IPOB.N: up 22.5% BUZZ-Rises on deal to take Opendoor public ** AnPac Bio-Medical Science Co Ltd ANPC.O: up 3.2% BUZZ-Jumps on immunology testing contract ** Fulgent Genetics Inc FLGT.O: up 0.7% BUZZ-Up on partnership with Utah for COVID-19 testing ** Exelixis Inc EXEL.O: up 1.1% BUZZ-Up as drug for solid tumor shows promise in preclinical study The 11 major S&P 500 sectors: Communication Services Eikon search string for individual stock moves: STXBZ The Day Ahead newsletter: http://tmsnrt.rs/2ggOmBi The Morning News Call newsletter: http://tmsnrt.rs/2fwPLTh U.S. stocks opened higher on Tuesday as upbeat data from China revived optimism around an economic rebound, while investors looked for more stimulus from the Federal Reserve as the central bank kicks off a two-day meeting. up 1.13% (Compiled by Shivani Kumaresan in Bengaluru) ((Shivani.Kumaresan@thomsonreuters.com ; +1 646 223 8780)) The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | The top three S&P 500 .PG.INX percentage gainers: ** Occidental PetROleum Corp , up 5% ** Nextera Energy Inc , up 4.3% ** Apache Corp , up 4% The top three S&P 500 .PL.INX percentage losers: ** Carnival Corp , down 7.1% ** Clorox Co , down 3.1% ** Charles Schwab Corp , down 3% The top three NYSE .PG.N percentage gainers: ** Social Capital Hedosophia Holdings II Corp , up 22.5% ** Envela Corp , up 19.7% ** Radiant Logistics Inc , up 10.1% The top three NYSE .PL.N percentage losers: ** Carnival Corp CCL.N, down 7.1% ** Carnival Plc CUK.N, down 6.3% ** Medallia Inc , down 6.3% The top three Nasdaq .PG.O percentage gainers: ** Marinus Pharmaceuticals Inc , up 50.5% ** Plus Therapeutics Inc , up 32.8% ** NextDecade Corp , up 28.6% The top three Nasdaq .PL.O percentage losers: ** Francesca's Holdings Corp , down 24.6% ** AudioEye Inc , down 13.6% ** Cassava Sciences Inc , down 12.5% ** Marinus Pharmaceuticals Inc MRNS.O: up 50.5% BUZZ-Surges after genetic epilepsy drug meets late-stage study main goal ** VF Corp VFC.N: up 2.0% BUZZ-BTIG upgrades to 'buy' on improving demand trends ** Lonestar Resources US Inc LONE.O: up 23.6% BUZZ-Up on entering restructuring support agreement with stakeholders ** Tesla Inc TSLA.O: up 4.4% BUZZ-Set for fifth straight session of gains ** Novus Therapeutics Inc NVUS.O: up 215.3% BUZZ-Set for best day after Anelixis acquisition ** Camping World Holdings Inc CWH.N: up 2.4% BUZZ-Zooms ahead as RV demand prompts upbeat forecast ** 3M Co MMM.N: up 0.1% BUZZ-Rises after upbeat Q3 sales outlook ** Microsoft Corp MSFT.O: up 1.9% BUZZ-Rises ahead of Xbox cloud gaming service launch ** BioNTech SE BNTX.O: up 2.2% BUZZ-Rises on $445 mln German govt funding for COVID-19 vaccine program ** Future FinTech Group Inc FTFT.O: up 7.6% BUZZ-Rises on proposed deal to buy stake in Sichuan Tema ** Nike Inc NKE.N: up 0.4% BUZZ-Deutsche Bank expects 'impressive' digital growth, hikes PT ** Novavax Inc NVAX.O: up 5.2% BUZZ-Rises on COVID-19 vaccine deal expansion in India ** Plus Therapeutics Inc PSTV.O: up 32.8% BUZZ-Soars on FDA 'fast track' tag for brain tumor treatment ** OPKO Health Inc OPK.O: up 6.2% BUZZ-Up on starting mid-stage study of potential COVID-19 drug ** Carnival Corp CCL.N: down 7.1% BUZZ-Down on $1 bln equity offering plans ** Aerie Pharmaceuticals Inc AERI.O: up 2.6% BUZZ-Gains as FDA approves production facility in Ireland ** Arbutus Biopharma Corp ABUS.O: up 11.1% BUZZ-Rises on positive data from ongoing study of hepatitis B therapy ** Francesca's Holdings Corp FRAN.O: down 24.6% BUZZ-Plummets on going-concern doubts, plans to explore options ** Kraft Heinz Co KHC.O: up 2.1% BUZZ-Rises on strong outlook, $2 bln savings target ** Lennar Corp LEN.N: down 2.6% BUZZ-Analysts say Q3 order growth below peer rates, shares down ** Equillium Inc EQ.O: up 14.3% BUZZ-Rises on regulatory pathway for COVID-19 treatment study ** Social Capital Hedosophia II IPOB.N: up 22.5% BUZZ-Rises on deal to take Opendoor public ** AnPac Bio-Medical Science Co Ltd ANPC.O: up 3.2% BUZZ-Jumps on immunology testing contract ** Fulgent Genetics Inc FLGT.O: up 0.7% BUZZ-Up on partnership with Utah for COVID-19 testing ** Exelixis Inc EXEL.O: up 1.1% BUZZ-Up as drug for solid tumor shows promise in preclinical study The 11 major S&P 500 sectors: Communication Services Eikon search string for individual stock moves: STXBZ The Day Ahead newsletter: http://tmsnrt.rs/2ggOmBi The Morning News Call newsletter: http://tmsnrt.rs/2fwPLTh U.S. stocks opened higher on Tuesday as upbeat data from China revived optimism around an economic rebound, while investors looked for more stimulus from the Federal Reserve as the central bank kicks off a two-day meeting. up 1.13% (Compiled by Shivani Kumaresan in Bengaluru) ((Shivani.Kumaresan@thomsonreuters.com ; +1 646 223 8780)) The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | The top three S&P 500 .PG.INX percentage gainers: ** Occidental PetROleum Corp , up 5% ** Nextera Energy Inc , up 4.3% ** Apache Corp , up 4% The top three S&P 500 .PL.INX percentage losers: ** Carnival Corp , down 7.1% ** Clorox Co , down 3.1% ** Charles Schwab Corp , down 3% The top three NYSE .PG.N percentage gainers: ** Social Capital Hedosophia Holdings II Corp , up 22.5% ** Envela Corp , up 19.7% ** Radiant Logistics Inc , up 10.1% The top three NYSE .PL.N percentage losers: ** Carnival Corp CCL.N, down 7.1% ** Carnival Plc CUK.N, down 6.3% ** Medallia Inc , down 6.3% The top three Nasdaq .PG.O percentage gainers: ** Marinus Pharmaceuticals Inc , up 50.5% ** Plus Therapeutics Inc , up 32.8% ** NextDecade Corp , up 28.6% The top three Nasdaq .PL.O percentage losers: ** Francesca's Holdings Corp , down 24.6% ** AudioEye Inc , down 13.6% ** Cassava Sciences Inc , down 12.5% ** Marinus Pharmaceuticals Inc MRNS.O: up 50.5% BUZZ-Surges after genetic epilepsy drug meets late-stage study main goal ** VF Corp VFC.N: up 2.0% BUZZ-BTIG upgrades to 'buy' on improving demand trends ** Lonestar Resources US Inc LONE.O: up 23.6% BUZZ-Up on entering restructuring support agreement with stakeholders ** Tesla Inc TSLA.O: up 4.4% BUZZ-Set for fifth straight session of gains ** Novus Therapeutics Inc NVUS.O: up 215.3% BUZZ-Set for best day after Anelixis acquisition ** Camping World Holdings Inc CWH.N: up 2.4% BUZZ-Zooms ahead as RV demand prompts upbeat forecast ** 3M Co MMM.N: up 0.1% BUZZ-Rises after upbeat Q3 sales outlook ** Microsoft Corp MSFT.O: up 1.9% BUZZ-Rises ahead of Xbox cloud gaming service launch ** BioNTech SE BNTX.O: up 2.2% BUZZ-Rises on $445 mln German govt funding for COVID-19 vaccine program ** Future FinTech Group Inc FTFT.O: up 7.6% BUZZ-Rises on proposed deal to buy stake in Sichuan Tema ** Nike Inc NKE.N: up 0.4% BUZZ-Deutsche Bank expects 'impressive' digital growth, hikes PT ** Novavax Inc NVAX.O: up 5.2% BUZZ-Rises on COVID-19 vaccine deal expansion in India ** Plus Therapeutics Inc PSTV.O: up 32.8% BUZZ-Soars on FDA 'fast track' tag for brain tumor treatment ** OPKO Health Inc OPK.O: up 6.2% BUZZ-Up on starting mid-stage study of potential COVID-19 drug ** Carnival Corp CCL.N: down 7.1% BUZZ-Down on $1 bln equity offering plans ** Aerie Pharmaceuticals Inc AERI.O: up 2.6% BUZZ-Gains as FDA approves production facility in Ireland ** Arbutus Biopharma Corp ABUS.O: up 11.1% BUZZ-Rises on positive data from ongoing study of hepatitis B therapy ** Francesca's Holdings Corp FRAN.O: down 24.6% BUZZ-Plummets on going-concern doubts, plans to explore options ** Kraft Heinz Co KHC.O: up 2.1% BUZZ-Rises on strong outlook, $2 bln savings target ** Lennar Corp LEN.N: down 2.6% BUZZ-Analysts say Q3 order growth below peer rates, shares down ** Equillium Inc EQ.O: up 14.3% BUZZ-Rises on regulatory pathway for COVID-19 treatment study ** Social Capital Hedosophia II IPOB.N: up 22.5% BUZZ-Rises on deal to take Opendoor public ** AnPac Bio-Medical Science Co Ltd ANPC.O: up 3.2% BUZZ-Jumps on immunology testing contract ** Fulgent Genetics Inc FLGT.O: up 0.7% BUZZ-Up on partnership with Utah for COVID-19 testing ** Exelixis Inc EXEL.O: up 1.1% BUZZ-Up as drug for solid tumor shows promise in preclinical study The 11 major S&P 500 sectors: Communication Services ET, the Dow Jones Industrial Average .DJI was up 0.68% at 28,183.36. up 1.19% Consumer Discretionary | The top three S&P 500 .PG.INX percentage gainers: ** Occidental PetROleum Corp , up 5% ** Nextera Energy Inc , up 4.3% ** Apache Corp , up 4% The top three S&P 500 .PL.INX percentage losers: ** Carnival Corp , down 7.1% ** Clorox Co , down 3.1% ** Charles Schwab Corp , down 3% The top three NYSE .PG.N percentage gainers: ** Social Capital Hedosophia Holdings II Corp , up 22.5% ** Envela Corp , up 19.7% ** Radiant Logistics Inc , up 10.1% The top three NYSE .PL.N percentage losers: ** Carnival Corp CCL.N, down 7.1% ** Carnival Plc CUK.N, down 6.3% ** Medallia Inc , down 6.3% The top three Nasdaq .PG.O percentage gainers: ** Marinus Pharmaceuticals Inc , up 50.5% ** Plus Therapeutics Inc , up 32.8% ** NextDecade Corp , up 28.6% The top three Nasdaq .PL.O percentage losers: ** Francesca's Holdings Corp , down 24.6% ** AudioEye Inc , down 13.6% ** Cassava Sciences Inc , down 12.5% ** Marinus Pharmaceuticals Inc MRNS.O: up 50.5% BUZZ-Surges after genetic epilepsy drug meets late-stage study main goal ** VF Corp VFC.N: up 2.0% BUZZ-BTIG upgrades to 'buy' on improving demand trends ** Lonestar Resources US Inc LONE.O: up 23.6% BUZZ-Up on entering restructuring support agreement with stakeholders ** Tesla Inc TSLA.O: up 4.4% BUZZ-Set for fifth straight session of gains ** Novus Therapeutics Inc NVUS.O: up 215.3% BUZZ-Set for best day after Anelixis acquisition ** Camping World Holdings Inc CWH.N: up 2.4% BUZZ-Zooms ahead as RV demand prompts upbeat forecast ** 3M Co MMM.N: up 0.1% BUZZ-Rises after upbeat Q3 sales outlook ** Microsoft Corp MSFT.O: up 1.9% BUZZ-Rises ahead of Xbox cloud gaming service launch ** BioNTech SE BNTX.O: up 2.2% BUZZ-Rises on $445 mln German govt funding for COVID-19 vaccine program ** Future FinTech Group Inc FTFT.O: up 7.6% BUZZ-Rises on proposed deal to buy stake in Sichuan Tema ** Nike Inc NKE.N: up 0.4% BUZZ-Deutsche Bank expects 'impressive' digital growth, hikes PT ** Novavax Inc NVAX.O: up 5.2% BUZZ-Rises on COVID-19 vaccine deal expansion in India ** Plus Therapeutics Inc PSTV.O: up 32.8% BUZZ-Soars on FDA 'fast track' tag for brain tumor treatment ** OPKO Health Inc OPK.O: up 6.2% BUZZ-Up on starting mid-stage study of potential COVID-19 drug ** Carnival Corp CCL.N: down 7.1% BUZZ-Down on $1 bln equity offering plans ** Aerie Pharmaceuticals Inc AERI.O: up 2.6% BUZZ-Gains as FDA approves production facility in Ireland ** Arbutus Biopharma Corp ABUS.O: up 11.1% BUZZ-Rises on positive data from ongoing study of hepatitis B therapy ** Francesca's Holdings Corp FRAN.O: down 24.6% BUZZ-Plummets on going-concern doubts, plans to explore options ** Kraft Heinz Co KHC.O: up 2.1% BUZZ-Rises on strong outlook, $2 bln savings target ** Lennar Corp LEN.N: down 2.6% BUZZ-Analysts say Q3 order growth below peer rates, shares down ** Equillium Inc EQ.O: up 14.3% BUZZ-Rises on regulatory pathway for COVID-19 treatment study ** Social Capital Hedosophia II IPOB.N: up 22.5% BUZZ-Rises on deal to take Opendoor public ** AnPac Bio-Medical Science Co Ltd ANPC.O: up 3.2% BUZZ-Jumps on immunology testing contract ** Fulgent Genetics Inc FLGT.O: up 0.7% BUZZ-Up on partnership with Utah for COVID-19 testing ** Exelixis Inc EXEL.O: up 1.1% BUZZ-Up as drug for solid tumor shows promise in preclinical study The 11 major S&P 500 sectors: Communication Services Eikon search string for individual stock moves: STXBZ The Day Ahead newsletter: http://tmsnrt.rs/2ggOmBi The Morning News Call newsletter: http://tmsnrt.rs/2fwPLTh U.S. stocks opened higher on Tuesday as upbeat data from China revived optimism around an economic rebound, while investors looked for more stimulus from the Federal Reserve as the central bank kicks off a two-day meeting. ET, the Dow Jones Industrial Average .DJI was up 0.68% at 28,183.36. |
34660.0 | 2020-08-25 00:00:00 UTC | Pre-market Movers In Healthcare Sector: OCGN, CERS, IBIO, KMDA, SONN… | ABUS | https://www.nasdaq.com/articles/pre-market-movers-in-healthcare-sector%3A-ocgn-cers-ibio-kmda-sonn...-2020-08-25 | nan | nan | (RTTNews) - What's moving these stocks in the pre-market hours today?
In the Green
1. Ocugen Inc. (OCGN) is up over 31% at $0.53 in pre-market trading Tuesday. The company made a presentation at the World Orphan Drug Congress USA 2020 Conference, highlighting its breakthrough modifier gene therapy platform, on August 24. Ocugen's gene therapy product candidate OCU400 is being explored in the indications of RHO mutation-associated retinal degeneration, CEP290 mutation-associated retinal degeneration, and NR2E3 mutation-associated retinal degeneration. This product is under pre-clinical testing.
2. Tonix Pharmaceuticals Holding Corp. (TNXP) is up more than 17% at $0.98 in pre-market hours today. The company has a couple of catalysts to keep an eye on in the coming months. The interim analysis results for phase III trial of TNX-102 SL for the management of Fibromyalgia, dubbed RELIEF, is expected in September, with topline data anticipated next quarter. The company's TNX-1800, a vaccine candidate to protect against COVID-19, is under preclinical testing, with data anticipated in Q4, 2020.
3. Cerus Corporation (CERS) is up over 13% at $7.75 in pre-market trading. The company, which operates in the blood transfusion space, markets INTERCEPT Blood System, which has earned both CE Mark and FDA approval for pathogen reduction of both platelet and plasma components. It should be noted that it was only as recently as August 23, did the FDA give emergency use approval for the investigational convalescent plasma for the treatment of COVID-19 in hospitalized patients.
4. iBio Inc. (IBIO) is up more than 13% at $2.49 in pre-market trading Tuesday. The company has two vaccine candidates for COVID-19, both of which are under preclinical development. iBio is also investigating an array of adjuvants in combination with its proprietary lichenase carrier molecule ("LicKM") fused to a coronavirus subunit protein ("IBIO-201"). Ten distinct preclinical study arms for the IBIO-201 antigen-adjuvant combinations have been concluded.
5. Kamada Ltd. (KMDA) is up over 6% at $12.46 in pre-market hours, adding to yesterday's gain of more than 17%. This company is developing a plasma-derived hyperimmune IgG therapy for coronavirus disease which is in phase I/II trial.
6. Arbutus Biopharma Corporation (ABUS) is up more than 4% at $3.15 in pre-market hours today.
In the Red
1. NanoVibronix Inc. (NAOV) is down more than 20% at $0.69 in pre-market hours, adding to yesterday's loss of over 10%. Yesterday, the company announced that due to demand, the underwriter has agreed to increase the size of the previously announced public offering and purchase on a firm commitment basis 4.33 million shares of common stock, at a price to the public of $0.75 per share, less underwriting discounts, and commissions. The closing of the offering is expected to occur on or about August 27, 2020, subject to satisfaction of customary closing conditions.
2. Cancer Genetics Inc. (CGIX) is down nearly 17% at $5.19 in pre-market hours today, giving back some of what it gained yesterday. The company's shares had touched a new high of $10.39 in intraday trading yesterday, following a definitive merger agreement with StemoniX Inc. The combined company expects to remain listed on the Nasdaq Stock Market.
3. Sonnet BioTherapeutics Holdings Inc. (SONN) is down more than 13% at $3.38 in pre-market hours, giving back some of what it gained yesterday.
4. Onconova Therapeutics Inc. (ONTX) is down more than 6% at $0.33 in pre-market hours, adding to yesterday's loss. Yesterday, the company announced that its phase III trial of intravenous Rigosertib in patients with myelodysplastic syndromes, dubbed INSPIRE, did not meet its primary endpoint of improved survival. The news had sent the stock plunging 66% to $0.34.
5. EyePoint Pharmaceuticals Inc. (EYPT) is down 2% at $0.59 in pre-market hours. Yesterday, the company announced that it has entered into a purchase and marketing agreement with Vantage Outsourcing for DEXYCU 9%, a marketed intraocular product for the treatment of postoperative inflammation.
6. Vaxart, Inc. (VXRT) is down over 4% at $7 in pre-market trading, adding to yesterday's loss of more than 10%. The stock has lost nearly 60% of its value from its 52-week high of $17.49 set on July 14.
7. Inovio Pharmaceuticals, Inc. (INO) is down more than 3% at $11.77 in pre-market hours today. The company's COVID-19 DNA vaccine INO-4800 is under a phase I study and positive interim data from the first two cohorts in the trial in the U.S. were reported in June. A phase II/III clinical study of INO-4800 in the U.S. is expected to start in September. Yesterday, there were reports that the Trump administration might fast track approval for AstraZeneca's COVID-19 vaccine as early as October.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Arbutus Biopharma Corporation (ABUS) is up more than 4% at $3.15 in pre-market hours today. The company made a presentation at the World Orphan Drug Congress USA 2020 Conference, highlighting its breakthrough modifier gene therapy platform, on August 24. The interim analysis results for phase III trial of TNX-102 SL for the management of Fibromyalgia, dubbed RELIEF, is expected in September, with topline data anticipated next quarter. | Arbutus Biopharma Corporation (ABUS) is up more than 4% at $3.15 in pre-market hours today. Ocugen's gene therapy product candidate OCU400 is being explored in the indications of RHO mutation-associated retinal degeneration, CEP290 mutation-associated retinal degeneration, and NR2E3 mutation-associated retinal degeneration. Kamada Ltd. (KMDA) is up over 6% at $12.46 in pre-market hours, adding to yesterday's gain of more than 17%. | Arbutus Biopharma Corporation (ABUS) is up more than 4% at $3.15 in pre-market hours today. Yesterday, the company announced that due to demand, the underwriter has agreed to increase the size of the previously announced public offering and purchase on a firm commitment basis 4.33 million shares of common stock, at a price to the public of $0.75 per share, less underwriting discounts, and commissions. Cancer Genetics Inc. (CGIX) is down nearly 17% at $5.19 in pre-market hours today, giving back some of what it gained yesterday. | Arbutus Biopharma Corporation (ABUS) is up more than 4% at $3.15 in pre-market hours today. (RTTNews) - What's moving these stocks in the pre-market hours today? Vaxart, Inc. (VXRT) is down over 4% at $7 in pre-market trading, adding to yesterday's loss of more than 10%. |
34661.0 | 2020-08-12 00:00:00 UTC | Pre-Market Most Active for Aug 12, 2020 : ABUS, MRNA, NIO, JMIA, AAL, SQQQ, NOK, GE, CCL, OSTK, QQQ, NCLH | ABUS | https://www.nasdaq.com/articles/pre-market-most-active-for-aug-12-2020-%3A-abus-mrna-nio-jmia-aal-sqqq-nok-ge-ccl-ostk-qqq | nan | nan | The NASDAQ 100 Pre-Market Indicator is up 87.78 to 10,963.86. The total Pre-Market volume is currently 13,545,706 shares traded.
The following are the most active stocks for the pre-market session:
Arbutus Biopharma Corporation (ABUS) is +0.48 at $3.92, with 1,827,096 shares traded. ABUS's current last sale is 87.11% of the target price of $4.5.
Moderna, Inc. (MRNA) is +6.28 at $75.25, with 1,539,185 shares traded. As reported by Zacks, the current mean recommendation for MRNA is in the "buy range".
NIO Inc. (NIO) is +0.36 at $13.35, with 1,340,685 shares traded. NIO's current last sale is 259.22% of the target price of $5.15.
Jumia Technologies AG (JMIA) is -3.05 at $13.32, with 1,295,531 shares traded. Business Wire Reports: Jumia Reports Second Quarter 2020 Results
American Airlines Group, Inc. (AAL) is +0.46 at $14.19, with 1,150,124 shares traded. Over the last four weeks they have had 3 up revisions for the earnings forecast, for the fiscal quarter ending Mar 2021. The consensus EPS forecast is $-1.62. AAL's current last sale is 118.25% of the target price of $12.
ProShares UltraPro Short QQQ (SQQQ) is -0.17 at $5.77, with 751,117 shares traded. This represents a 8.05% increase from its 52 Week Low.
Nokia Corporation (NOK) is +0.08 at $5.04, with 651,212 shares traded. As reported by Zacks, the current mean recommendation for NOK is in the "buy range".
General Electric Company (GE) is +0.08 at $6.81, with 500,324 shares traded. As reported by Zacks, the current mean recommendation for GE is in the "buy range".
Carnival Corporation (CCL) is +0.4401 at $16.26, with 436,653 shares traded. CCL's current last sale is 101.63% of the target price of $16.
Overstock.com, Inc. (OSTK) is -6.15 at $85.85, with 428,649 shares traded. As reported by Zacks, the current mean recommendation for OSTK is in the "strong buy range".
Invesco QQQ Trust, Series 1 (QQQ) is +2.52 at $267.71, with 392,308 shares traded. This represents a 62.32% increase from its 52 Week Low.
Norwegian Cruise Line Holdings Ltd. (NCLH) is +0.61 at $16.25, with 334,583 shares traded. NCLH's current last sale is 101.56% of the target price of $16.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Arbutus Biopharma Corporation (ABUS) is +0.48 at $3.92, with 1,827,096 shares traded. ABUS's current last sale is 87.11% of the target price of $4.5. Over the last four weeks they have had 3 up revisions for the earnings forecast, for the fiscal quarter ending Mar 2021. | Arbutus Biopharma Corporation (ABUS) is +0.48 at $3.92, with 1,827,096 shares traded. ABUS's current last sale is 87.11% of the target price of $4.5. As reported by Zacks, the current mean recommendation for MRNA is in the "buy range". | Arbutus Biopharma Corporation (ABUS) is +0.48 at $3.92, with 1,827,096 shares traded. ABUS's current last sale is 87.11% of the target price of $4.5. The total Pre-Market volume is currently 13,545,706 shares traded. | Arbutus Biopharma Corporation (ABUS) is +0.48 at $3.92, with 1,827,096 shares traded. ABUS's current last sale is 87.11% of the target price of $4.5. NIO's current last sale is 259.22% of the target price of $5.15. |
34662.0 | 2020-08-12 00:00:00 UTC | BUZZ-U.S. STOCKS ON THE MOVE-Sasol, Moderna | ABUS | https://www.nasdaq.com/articles/buzz-u.s.-stocks-on-the-move-sasol-moderna-2020-08-12 | nan | nan | Eikon search string for individual stock moves: STXBZ
The Day Ahead newsletter: http://tmsnrt.rs/2ggOmBi
The Morning News Call newsletter: http://tmsnrt.rs/2fwPLTh
U.S. stock index futures rose on Wednesday following a pullback on Wall Street in the previous session, as resilient fuel demand drove up oil prices, while investors remained on edge due to a stalemate over the next coronavirus federal aid bill..N
At 6:28 a.m. ET, Dow e-minis 1YMc1 were up 1.01% at 27,893. S&P 500 e-minis ESc1 were up 0.83% at 3,357.75 and Nasdaq 100 e-minis NQc1 were up 0.96% at 10,982.5. The top three NYSE percentage gainers premarket .PRPG.NQ: ** K12 Inc , up 7.7% ** Now Inc , up 7.5% ** Transocean Ltd , up 7.3% The top three NYSE percentage losers premarket .PRPL.NQ: ** Lemonade Inc , down 6.8% ** RA Medical Systems Inc , down 6.2% ** Noah Holdings Ltd , down 5.1% The top three Nasdaq percentage gainers premarket .PRPG.O: ** Cyclacel Pharmaceuticals Inc , up 49.2% ** Arbutus Biopharma Corp , up 27.3% ** Pacific Ethanol Inc , up 24.6% The top three Nasdaq percentage losers premarket .PRPL.O: ** Kingold Jewelry Inc , down 32.6% ** Staffing 360 Solutions Inc , down 24.9% ** Synacor Inc , down 16.5% ** Sasol Ltd SSL.N: down 3.3% premarket BUZZ-Slips after annual loss warning as pandemic hits business ** Moderna Inc MRNA.O: up 9% premarket BUZZ-More contracts possible after U.S. COVID-19 vaccine deal - Jefferies
(Compiled by Amal S in Bengaluru)
((Amal.S@thomsonreuters.com; within U.S.+1 646 223 8780; outside U.S. +91 80 6749 3677;))
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Eikon search string for individual stock moves: STXBZ The Day Ahead newsletter: http://tmsnrt.rs/2ggOmBi The Morning News Call newsletter: http://tmsnrt.rs/2fwPLTh U.S. stock index futures rose on Wednesday following a pullback on Wall Street in the previous session, as resilient fuel demand drove up oil prices, while investors remained on edge due to a stalemate over the next coronavirus federal aid bill..N At 6:28 a.m. ET, Dow e-minis 1YMc1 were up 1.01% at 27,893. The top three NYSE percentage gainers premarket .PRPG.NQ: ** K12 Inc , up 7.7% ** Now Inc , up 7.5% ** Transocean Ltd , up 7.3% The top three NYSE percentage losers premarket .PRPL.NQ: ** Lemonade Inc , down 6.8% ** RA Medical Systems Inc , down 6.2% ** Noah Holdings Ltd , down 5.1% The top three Nasdaq percentage gainers premarket .PRPG.O: ** Cyclacel Pharmaceuticals Inc , up 49.2% ** Arbutus Biopharma Corp , up 27.3% ** Pacific Ethanol Inc , up 24.6% The top three Nasdaq percentage losers premarket .PRPL.O: ** Kingold Jewelry Inc , down 32.6% ** Staffing 360 Solutions Inc , down 24.9% ** Synacor Inc , down 16.5% ** Sasol Ltd SSL.N: down 3.3% premarket BUZZ-Slips after annual loss warning as pandemic hits business ** Moderna Inc MRNA.O: up 9% premarket BUZZ-More contracts possible after U.S. COVID-19 vaccine deal - Jefferies (Compiled by Amal S in Bengaluru) ((Amal.S@thomsonreuters.com; within U.S.+1 646 223 8780; outside U.S. +91 80 6749 3677;)) The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Eikon search string for individual stock moves: STXBZ The Day Ahead newsletter: http://tmsnrt.rs/2ggOmBi The Morning News Call newsletter: http://tmsnrt.rs/2fwPLTh U.S. stock index futures rose on Wednesday following a pullback on Wall Street in the previous session, as resilient fuel demand drove up oil prices, while investors remained on edge due to a stalemate over the next coronavirus federal aid bill..N At 6:28 a.m. S&P 500 e-minis ESc1 were up 0.83% at 3,357.75 and Nasdaq 100 e-minis NQc1 were up 0.96% at 10,982.5. The top three NYSE percentage gainers premarket .PRPG.NQ: ** K12 Inc , up 7.7% ** Now Inc , up 7.5% ** Transocean Ltd , up 7.3% The top three NYSE percentage losers premarket .PRPL.NQ: ** Lemonade Inc , down 6.8% ** RA Medical Systems Inc , down 6.2% ** Noah Holdings Ltd , down 5.1% The top three Nasdaq percentage gainers premarket .PRPG.O: ** Cyclacel Pharmaceuticals Inc , up 49.2% ** Arbutus Biopharma Corp , up 27.3% ** Pacific Ethanol Inc , up 24.6% The top three Nasdaq percentage losers premarket .PRPL.O: ** Kingold Jewelry Inc , down 32.6% ** Staffing 360 Solutions Inc , down 24.9% ** Synacor Inc , down 16.5% ** Sasol Ltd SSL.N: down 3.3% premarket BUZZ-Slips after annual loss warning as pandemic hits business ** Moderna Inc MRNA.O: up 9% premarket BUZZ-More contracts possible after U.S. COVID-19 vaccine deal - Jefferies (Compiled by Amal S in Bengaluru) ((Amal.S@thomsonreuters.com; within U.S.+1 646 223 8780; outside U.S. +91 80 6749 3677;)) The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Eikon search string for individual stock moves: STXBZ The Day Ahead newsletter: http://tmsnrt.rs/2ggOmBi The Morning News Call newsletter: http://tmsnrt.rs/2fwPLTh U.S. stock index futures rose on Wednesday following a pullback on Wall Street in the previous session, as resilient fuel demand drove up oil prices, while investors remained on edge due to a stalemate over the next coronavirus federal aid bill..N At 6:28 a.m. S&P 500 e-minis ESc1 were up 0.83% at 3,357.75 and Nasdaq 100 e-minis NQc1 were up 0.96% at 10,982.5. The top three NYSE percentage gainers premarket .PRPG.NQ: ** K12 Inc , up 7.7% ** Now Inc , up 7.5% ** Transocean Ltd , up 7.3% The top three NYSE percentage losers premarket .PRPL.NQ: ** Lemonade Inc , down 6.8% ** RA Medical Systems Inc , down 6.2% ** Noah Holdings Ltd , down 5.1% The top three Nasdaq percentage gainers premarket .PRPG.O: ** Cyclacel Pharmaceuticals Inc , up 49.2% ** Arbutus Biopharma Corp , up 27.3% ** Pacific Ethanol Inc , up 24.6% The top three Nasdaq percentage losers premarket .PRPL.O: ** Kingold Jewelry Inc , down 32.6% ** Staffing 360 Solutions Inc , down 24.9% ** Synacor Inc , down 16.5% ** Sasol Ltd SSL.N: down 3.3% premarket BUZZ-Slips after annual loss warning as pandemic hits business ** Moderna Inc MRNA.O: up 9% premarket BUZZ-More contracts possible after U.S. COVID-19 vaccine deal - Jefferies (Compiled by Amal S in Bengaluru) ((Amal.S@thomsonreuters.com; within U.S.+1 646 223 8780; outside U.S. +91 80 6749 3677;)) The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Eikon search string for individual stock moves: STXBZ The Day Ahead newsletter: http://tmsnrt.rs/2ggOmBi The Morning News Call newsletter: http://tmsnrt.rs/2fwPLTh U.S. stock index futures rose on Wednesday following a pullback on Wall Street in the previous session, as resilient fuel demand drove up oil prices, while investors remained on edge due to a stalemate over the next coronavirus federal aid bill..N At 6:28 a.m. ET, Dow e-minis 1YMc1 were up 1.01% at 27,893. S&P 500 e-minis ESc1 were up 0.83% at 3,357.75 and Nasdaq 100 e-minis NQc1 were up 0.96% at 10,982.5. |
34663.0 | 2020-08-12 00:00:00 UTC | Pre-market Movers In Healthcare Sector: AZRX, ABUS, MRNA, MNK, TRVN… | ABUS | https://www.nasdaq.com/articles/pre-market-movers-in-healthcare-sector%3A-azrx-abus-mrna-mnk-trvn...-2020-08-12 | nan | nan | (RTTNews) - What's moving these stocks in pre-market hours today?
In the Green
1. AzurRx BioPharma Inc. (AZRX) is up over 27% at $1.29 in pre-market trading Wednesday, following positive results from the first five patients in its phase II combination therapy trial of MS1819 for the treatment of severe exocrine pancreatic insufficiency (EPI) in patients with cystic fibrosis. Topline data from the full dataset is expected in the first quarter of next year.
2. Arbutus Biopharma Corporation (ABUS) is up 27% at $4.37 in pre-market trading. In a patent suit with Moderna Inc. (MRNA) over a drug-delivery technology, the U.S. Patent Trial and Appeal Board had ruled in favor of Arbutus last month.
3. Regional Health Properties Inc. (RHE) is up over 13% at $1.98 in pre-market trading today. In the second quarter ended June 30, 2020, net loss shrunk to $1.84 million or $1.09 per share on total revenue of $4.54 million. This compared with a net loss of $3.49 million or $2.07 per share and revenue of $5.30 million in the year-ago quarter.
4. Moderna Inc. (MRNA) is up more than 9% at $75 in premarket hours Wednesday, following a supply agreement with the U.S. Government for initial 100 million doses of mRNA-1273, the company's mRNA vaccine against COVID-19. A phase III study of mRNA-1273, being conducted in collaboration with NIH and BARDA, is expected to complete enrollment in September 2020.
5. iBio Inc. (IBIO) is up over 8% at $2.99 in premarket trading. The company has two vaccine candidates for COVID-19, both of which are under preclinical development. iBio is also investigating an array of adjuvants in combination with its proprietary lichenase carrier molecule ("LicKM") fused to a coronavirus subunit protein ("IBIO-201"). Ten distinct preclinical study arms for the IBIO-201 antigen-adjuvant combinations have been concluded.
6. Mallinckrodt plc (MNK) is up over 6% at $1.49 in premarket trading today. The Biologics License Application for StrataGraft, an investigational regenerative skin tissue therapy in development, for the treatment of adult patients with deep partial-thickness thermal burns, is under FDA review, with a decision expected on February 2, 2021. When reporting its second-quarter results early this month, the company revealed that it been working with external advisors to explore a range of options, including a bankruptcy filing.
7. NovaBay Pharmaceuticals Inc. (NBY) is up over 5% at $1.08 in premarket trading. Last week, the company reported strong financial results for the second quarter with product revenue increasing 122% and operating loss narrowing 21% over the prior-year period, while also improving its cash position.
In the Red
1. Trevena Inc. (TRVN) is down over 14% at $2.35 in premarket trading today, adding to yesterday's loss of more than 12%, following a proposed public offering of common stock. The company secured FDA approval for its OLINVYK in adults for the management of acute pain severe enough to require an IV opioid analgesic on Aug.10.
2. T2 Biosystems Inc. (TTOO) is down over 7% at $1.73 in premarket trading Wednesday, following second-quarter financial results. Although total revenue for the second quarter of 2020 was $2.6 million, an increase of 41% compared to the prior-year period, product revenue was $1.0 million, a decrease of 18% compared to the prior-year period driven by lower instrument sales to international markets.
However, for the full year 2020, T2 Biosystems expects total revenues of between $18.0 million to $20.0 million, including product revenues between $13.0 million to $14.0 million and research and contribution revenues between $5.0 million to $6.0 million. In February, when reporting fourth-quarter 2019 financial results, the company had projected revenue for the full year 2020 to range from $14.0 million to $17.0 million, including product revenue between $8.0 million and $10.0 million and research and grant contribution revenue of $6.0 million to $7.0 million.
3. Sunesis Pharmaceuticals Inc. (SNSS) is down over 7% at $0.30 in premarket trading today. The company reported financial results for the second quarter ended June 30, 2020, yesterday. Last month, the company had announced a 30% reduction in its workforce to focus on the development of SNS-510, which is believed to have potential in both solid and hematologic malignancies. Sunesis is conducting an Investigational New Drug-enabling program for SNS-510.
4. Adamis Pharmaceuticals Corporation (ADMP) is down more than 5% at $1.08, adding to yesterday's loss of over 7%. It was only last week did the company regain compliance with the NASDAQ minimum bid price requirement.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Arbutus Biopharma Corporation (ABUS) is up 27% at $4.37 in pre-market trading. The Biologics License Application for StrataGraft, an investigational regenerative skin tissue therapy in development, for the treatment of adult patients with deep partial-thickness thermal burns, is under FDA review, with a decision expected on February 2, 2021. When reporting its second-quarter results early this month, the company revealed that it been working with external advisors to explore a range of options, including a bankruptcy filing. | Arbutus Biopharma Corporation (ABUS) is up 27% at $4.37 in pre-market trading. Although total revenue for the second quarter of 2020 was $2.6 million, an increase of 41% compared to the prior-year period, product revenue was $1.0 million, a decrease of 18% compared to the prior-year period driven by lower instrument sales to international markets. However, for the full year 2020, T2 Biosystems expects total revenues of between $18.0 million to $20.0 million, including product revenues between $13.0 million to $14.0 million and research and contribution revenues between $5.0 million to $6.0 million. | Arbutus Biopharma Corporation (ABUS) is up 27% at $4.37 in pre-market trading. Although total revenue for the second quarter of 2020 was $2.6 million, an increase of 41% compared to the prior-year period, product revenue was $1.0 million, a decrease of 18% compared to the prior-year period driven by lower instrument sales to international markets. However, for the full year 2020, T2 Biosystems expects total revenues of between $18.0 million to $20.0 million, including product revenues between $13.0 million to $14.0 million and research and contribution revenues between $5.0 million to $6.0 million. | Arbutus Biopharma Corporation (ABUS) is up 27% at $4.37 in pre-market trading. T2 Biosystems Inc. (TTOO) is down over 7% at $1.73 in premarket trading Wednesday, following second-quarter financial results. In February, when reporting fourth-quarter 2019 financial results, the company had projected revenue for the full year 2020 to range from $14.0 million to $17.0 million, including product revenue between $8.0 million and $10.0 million and research and grant contribution revenue of $6.0 million to $7.0 million. |
34664.0 | 2020-08-11 00:00:00 UTC | Moderna says uncertain about coronavirus vaccine patent exclusivity | ABUS | https://www.nasdaq.com/articles/moderna-says-uncertain-about-coronavirus-vaccine-patent-exclusivity-2020-08-11 | nan | nan | Aug 11 (Reuters) - Moderna Inc MRNA.O said there was a possibility it was not the first company to make breakthroughs claimed in its patent applications, including those for its experimental coronavirus vaccine, according to a recent regulatory filing.
The statement by the U.S. drug developer was made in a quarterly filing on Aug. 6 under mandatory disclosures of risks to its business.
Moderna's prior quarterly filings with U.S. regulators did not have the disclosure.
"For this and other reasons, we may be unable to secure desired patent rights, thereby losing exclusivity," the company said. (https://bit.ly/2PISREC)
The company has received funding from the U.S. government to develop its coronavirus vaccine, and in July lost a bid to invalidate a U.S. patent owned by Arbutus Biopharma Corp ABUS.O that poses a potential obstacle to Moderna's efforts to develop next-generation vaccines.
"We cannot be certain that we were the first to make the inventions claimed in our patents or pending patent applications, or that we were the first to file for patent protection of such inventions, including mRNA-1273," the company said.
(Reporting by Manas Mishra in Bengaluru; Editing by Shounak Dasgupta)
((Manas.Mishra@thomsonreuters.com; www.twitter.com/Manasmishra24; within U.S. +1 646 223 8780, outside U.S. +91 806749 2709))
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | (https://bit.ly/2PISREC) The company has received funding from the U.S. government to develop its coronavirus vaccine, and in July lost a bid to invalidate a U.S. patent owned by Arbutus Biopharma Corp ABUS.O that poses a potential obstacle to Moderna's efforts to develop next-generation vaccines. Aug 11 (Reuters) - Moderna Inc MRNA.O said there was a possibility it was not the first company to make breakthroughs claimed in its patent applications, including those for its experimental coronavirus vaccine, according to a recent regulatory filing. The statement by the U.S. drug developer was made in a quarterly filing on Aug. 6 under mandatory disclosures of risks to its business. | (https://bit.ly/2PISREC) The company has received funding from the U.S. government to develop its coronavirus vaccine, and in July lost a bid to invalidate a U.S. patent owned by Arbutus Biopharma Corp ABUS.O that poses a potential obstacle to Moderna's efforts to develop next-generation vaccines. Aug 11 (Reuters) - Moderna Inc MRNA.O said there was a possibility it was not the first company to make breakthroughs claimed in its patent applications, including those for its experimental coronavirus vaccine, according to a recent regulatory filing. Moderna's prior quarterly filings with U.S. regulators did not have the disclosure. | (https://bit.ly/2PISREC) The company has received funding from the U.S. government to develop its coronavirus vaccine, and in July lost a bid to invalidate a U.S. patent owned by Arbutus Biopharma Corp ABUS.O that poses a potential obstacle to Moderna's efforts to develop next-generation vaccines. Aug 11 (Reuters) - Moderna Inc MRNA.O said there was a possibility it was not the first company to make breakthroughs claimed in its patent applications, including those for its experimental coronavirus vaccine, according to a recent regulatory filing. "We cannot be certain that we were the first to make the inventions claimed in our patents or pending patent applications, or that we were the first to file for patent protection of such inventions, including mRNA-1273," the company said. | (https://bit.ly/2PISREC) The company has received funding from the U.S. government to develop its coronavirus vaccine, and in July lost a bid to invalidate a U.S. patent owned by Arbutus Biopharma Corp ABUS.O that poses a potential obstacle to Moderna's efforts to develop next-generation vaccines. Aug 11 (Reuters) - Moderna Inc MRNA.O said there was a possibility it was not the first company to make breakthroughs claimed in its patent applications, including those for its experimental coronavirus vaccine, according to a recent regulatory filing. The statement by the U.S. drug developer was made in a quarterly filing on Aug. 6 under mandatory disclosures of risks to its business. |
34665.0 | 2020-08-07 00:00:00 UTC | Here's Why Arbutus Biopharma Fell Today | ABUS | https://www.nasdaq.com/articles/heres-why-arbutus-biopharma-fell-today-2020-08-07 | nan | nan | What happened
Shares of Arbutus Biopharma (NASDAQ: ABUS) are down 15% at 2:14 p.m. EDT, following the release of the biotech's first-quarter results, although there didn't appear to be anything in the press release to justify the sell-off.
So what
Arbutus is still a clinical-stage biotech, so revenue is minimal and comes from collaborations and licenses. The company also has some noncash royalty revenue that it books each quarter. On the bottom line, the biotech posted a net loss of $17.1 million, which is to be expected with no products on the market.
The more important issue is how much cash Arbutus is burning relative to what it has in the bank. Fortunately, with the help of a capital raise in July, the company was able to extend its cash runway into mid-2022, compared with prior guidance of mid-2021.
Image source: Getty Images.
Today's decline likely has to do with what wasn't in the press release. There was no major update on any of its pipeline candidates -- especially its antiviral program developing drugs to treat COVID-19, which is still in preclinical development but could advance rapidly given the pandemic.
Now what
While short-term investors hit the sell button, long-term investors should view the pullback as a buying opportunity with the caveat that Arbutus is your typical risky-but-cheap biotech. The company's most advanced drug, AB-729, is in phase 1 clinical trials to treat hepatitis B virus infections.
The company also has patents that it's licensed out to partners, which could add to its revenue stream in the future. And last month, Moderna unsuccessfully tried to get one of Arbutus' patents invalidated, potentially setting up a royalty stream on Moderna's coronavirus vaccine.
Finally, Arbutus owns 16% of privately held Genevant, a joint venture started with Roivant Sciences, which could benefit Arbutus if Genevant starts generating revenue or if the company were to go public, allowing Arbutus to easily sell its stake and generate additional capital.
10 stocks we like better than Arbutus Biopharma
When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor, has tripled the market.*
David and Tom just revealed what they believe are the ten best stocks for investors to buy right now... and Arbutus Biopharma wasn't one of them! That's right -- they think these 10 stocks are even better buys.
See the 10 stocks
*Stock Advisor returns as of August 1, 2020
Brian Orelli, PhD and The Motley Fool have no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | What happened Shares of Arbutus Biopharma (NASDAQ: ABUS) are down 15% at 2:14 p.m. EDT, following the release of the biotech's first-quarter results, although there didn't appear to be anything in the press release to justify the sell-off. On the bottom line, the biotech posted a net loss of $17.1 million, which is to be expected with no products on the market. Fortunately, with the help of a capital raise in July, the company was able to extend its cash runway into mid-2022, compared with prior guidance of mid-2021. | What happened Shares of Arbutus Biopharma (NASDAQ: ABUS) are down 15% at 2:14 p.m. EDT, following the release of the biotech's first-quarter results, although there didn't appear to be anything in the press release to justify the sell-off. Finally, Arbutus owns 16% of privately held Genevant, a joint venture started with Roivant Sciences, which could benefit Arbutus if Genevant starts generating revenue or if the company were to go public, allowing Arbutus to easily sell its stake and generate additional capital. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor, has tripled the market. | What happened Shares of Arbutus Biopharma (NASDAQ: ABUS) are down 15% at 2:14 p.m. EDT, following the release of the biotech's first-quarter results, although there didn't appear to be anything in the press release to justify the sell-off. Finally, Arbutus owns 16% of privately held Genevant, a joint venture started with Roivant Sciences, which could benefit Arbutus if Genevant starts generating revenue or if the company were to go public, allowing Arbutus to easily sell its stake and generate additional capital. 10 stocks we like better than Arbutus Biopharma When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. | What happened Shares of Arbutus Biopharma (NASDAQ: ABUS) are down 15% at 2:14 p.m. EDT, following the release of the biotech's first-quarter results, although there didn't appear to be anything in the press release to justify the sell-off. The company also has patents that it's licensed out to partners, which could add to its revenue stream in the future. * David and Tom just revealed what they believe are the ten best stocks for investors to buy right now... and Arbutus Biopharma wasn't one of them! |
34666.0 | 2020-08-07 00:00:00 UTC | Pre-Market Most Active for Aug 7, 2020 : RKT, CNDT, SQQQ, ANPC, NIO, ABUS, AAL, TRUE, BABA, UBER, SPAQ, CCL | ABUS | https://www.nasdaq.com/articles/pre-market-most-active-for-aug-7-2020-%3A-rkt-cndt-sqqq-anpc-nio-abus-aal-true-baba-uber | nan | nan | The NASDAQ 100 Pre-Market Indicator is down -31.45 to 11,235.63. The total Pre-Market volume is currently 20,521,553 shares traded.
The following are the most active stocks for the pre-market session:
Rocket Companies, Inc. (RKT) is +2.79 at $24.30, with 3,471,576 shares traded.
Conduent Incorporated (CNDT) is +1.8 at $4.06, with 2,917,109 shares traded. CNDT's current last sale is 135.33% of the target price of $3.
ProShares UltraPro Short QQQ (SQQQ) is +0.05 at $5.41, with 2,430,893 shares traded., following a 52-week high recorded in prior regular session.
AnPac Bio-Medical Science Co., Ltd. (ANPC) is +5.81 at $11.30, with 1,952,802 shares traded.
NIO Inc. (NIO) is -0.2599 at $13.58, with 1,491,015 shares traded.NIO is scheduled to provide an earnings report on 8/11/2020, for the fiscal quarter ending Jun2020. The consensus earnings per share forecast is -0.35 per share, which represents a -45 percent increase over the EPS one Year Ago
Arbutus Biopharma Corporation (ABUS) is -0.34 at $4.03, with 926,288 shares traded. GlobeNewswire Reports: Arbutus Reports Second Quarter 2020 Financial Results and Provides Corporate Update
American Airlines Group, Inc. (AAL) is -0.19 at $12.85, with 660,747 shares traded. Over the last four weeks they have had 3 up revisions for the earnings forecast, for the fiscal quarter ending Mar 2021. The consensus EPS forecast is $-1.62. AAL's current last sale is 107.08% of the target price of $12.
TrueCar, Inc. (TRUE) is +1.53 at $5.82, with 482,779 shares traded. As reported in the last short interest update the days to cover for TRUE is 14.365711; this calculation is based on the average trading volume of the stock.
Alibaba Group Holding Limited (BABA) is -7.63 at $258.05, with 437,659 shares traded. BABA's current last sale is 93.84% of the target price of $275.
Uber Technologies, Inc. (UBER) is -1.36 at $33.35, with 347,984 shares traded. As reported by Zacks, the current mean recommendation for UBER is in the "buy range".
Spartan Energy Acquisition Corp (SPAQ) is +0.47 at $12.84, with 237,983 shares traded.
Carnival Corporation (CCL) is -0.2 at $13.58, with 230,416 shares traded. CCL's current last sale is 84.88% of the target price of $16.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Arbutus Biopharma Corporation (ABUS) is -0.34 at $4.03, with 926,288 shares traded. ProShares UltraPro Short QQQ (SQQQ) is +0.05 at $5.41, with 2,430,893 shares traded., following a 52-week high recorded in prior regular session. Over the last four weeks they have had 3 up revisions for the earnings forecast, for the fiscal quarter ending Mar 2021. | Arbutus Biopharma Corporation (ABUS) is -0.34 at $4.03, with 926,288 shares traded. The total Pre-Market volume is currently 20,521,553 shares traded. GlobeNewswire Reports: Arbutus Reports Second Quarter 2020 Financial Results and Provides Corporate Update | Arbutus Biopharma Corporation (ABUS) is -0.34 at $4.03, with 926,288 shares traded. The total Pre-Market volume is currently 20,521,553 shares traded. The consensus earnings per share forecast is -0.35 per share, which represents a -45 percent increase over the EPS one Year Ago | Arbutus Biopharma Corporation (ABUS) is -0.34 at $4.03, with 926,288 shares traded. The following are the most active stocks for the pre-market session: GlobeNewswire Reports: Arbutus Reports Second Quarter 2020 Financial Results and Provides Corporate Update |
34667.0 | 2020-08-03 00:00:00 UTC | 3 Healthcare Stocks That Rocketed Higher in July | ABUS | https://www.nasdaq.com/articles/3-healthcare-stocks-that-rocketed-higher-in-july-2020-08-03 | nan | nan | Dismal economic data that pressured the entire market at the end of July rolled right off the backs of some high-flying healthcare stocks. These three more than doubled, all for very different reasons.
Here's what sent their share prices screaming higher.
COMPANY (TICKER) PRICE CHANGE IN JULY 2020 MARKET CAP
Altimmune (NASDAQ: ALT) 148% $851 million
Owens & Minor (NYSE: OMI) 111% $1.0 billion
Arbutus Biopharma (NASDAQ: ABUS) 109% $263 million
Data source: Yahoo! Finance.
Image source: Getty Images.
1. Altimmune: Through the nose
This clinical-stage biotechnology company doesn't have any products to sell yet, but Altimmune's attempt to develop a single-dose intranasal coronavirus vaccine is getting lots of attention. The stock soared last month after a subsidiary of General Dynamics agreed to coordinate government funding efforts for the Maryland-headquartered biotech and its vaccine candidate, AdCOVID.
Altimmune will need all the funding it can find, because the company plans to begin manufacturing AdCOVID before the end of October. The company still hasn't filed an investigational new drug application with the Food and Drug Administration; that would need to be approved before the company could begin a human proof-of-concept trial with its coronavirus vaccine candidate.
Altimmune ended March with just $11 million in cash after losing $3.9 million during the first three months of 2020. Despite the lack of progress thus far with AdCOVID, last month, the company used a value-diluting share offering to add $132 million to its cash cushion.
2. Owens & Minor: Personal protective equipment
This company connects healthcare providers with manufacturers of healthcare products. The stock soared last month after the company reported preliminary results for the second quarter that were much better than expected, thanks to unprecedented demand for personal protective equipment.
The average analyst following Owens & Minor expected the company to lose around $0.03 per share, but COVID-19-related demand was stronger than anyone expected. Instead of a slight loss, the company anticipates adjusted second-quarter earnings of between $0.18 and $0.20 per share.
Sales of gloves, masks, and gowns were so good that Owens & Minor raised its full-year earnings expectations from a range of $0.50 to $0.60 per share to between $1.00 and $1.20 per share.
Image source: Getty Images.
3. Arbutus Biopharma: Patent ruling
This clinical-stage biotechnology company is developing an antiviral treatment for hepatitis B, but that isn't what pushed up its stock price last month. The stock more than doubled because the U.S. Patent Trial and Appeal Board rejected a challenge to three patents that Arbutus has owned for years, regarding messenger RNA (mRNA) delivery technology.
The challenger to Arbutus' patents is Moderna (NASDAQ: MRNA), a company entirely reliant on mRNA drug development. The highest-profile candidate in Moderna's pipeline is a potential coronavirus vaccine called mRNA-1273, and it recently began a phase 3 trial expected to enroll around 30,000 patients.
Moderna argues that its proprietary delivery technology has advanced far beyond anything that appears in Arbutus' patents. If an appeal board doesn't agree, Arbutus could end up receiving royalties from Moderna.
Stocks to buy?
It's probably best to steer clear of all these recent highfliers.
Arbutus could be years from producing sales from an approved drug, and Moderna plans to appeal. Even if Moderna loses on appeal, Arbutus won't receive a dime unless mRNA-1273 or one of the company's other new drug candidates succeeds. Though it's operated for 10 years, mRNA-1273 is the first drug Moderna has advanced into a late-stage clinical trial.
While there's a chance that Altimmune will pick up more funding from the U.S. government to run clinical trials with its experimental coronavirus vaccine, it's far behind the competition. Without any data from human studies, it's much too early to expect success from the AdCOVID program.
And though exploding demand for personal protective equipment will push Owens & Minor into profitability in 2020, investors should know the company lost $62 million last year. Once spiking demand settles down, its stock could tumble.
10 stocks we like better than Owens & Minor
When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor, has tripled the market.*
David and Tom just revealed what they believe are the ten best stocks for investors to buy right now… and Owens & Minor wasn't one of them! That's right -- they think these 10 stocks are even better buys.
See the 10 stocks
*Stock Advisor returns as of June 2, 2020
Cory Renauer has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Altimmune (NASDAQ: ALT) 148% $851 million Owens & Minor (NYSE: OMI) 111% $1.0 billion Arbutus Biopharma (NASDAQ: ABUS) 109% $263 million Data source: Yahoo! The stock soared last month after a subsidiary of General Dynamics agreed to coordinate government funding efforts for the Maryland-headquartered biotech and its vaccine candidate, AdCOVID. Arbutus Biopharma: Patent ruling This clinical-stage biotechnology company is developing an antiviral treatment for hepatitis B, but that isn't what pushed up its stock price last month. | Altimmune (NASDAQ: ALT) 148% $851 million Owens & Minor (NYSE: OMI) 111% $1.0 billion Arbutus Biopharma (NASDAQ: ABUS) 109% $263 million Data source: Yahoo! Owens & Minor: Personal protective equipment This company connects healthcare providers with manufacturers of healthcare products. The challenger to Arbutus' patents is Moderna (NASDAQ: MRNA), a company entirely reliant on mRNA drug development. | Altimmune (NASDAQ: ALT) 148% $851 million Owens & Minor (NYSE: OMI) 111% $1.0 billion Arbutus Biopharma (NASDAQ: ABUS) 109% $263 million Data source: Yahoo! The company still hasn't filed an investigational new drug application with the Food and Drug Administration; that would need to be approved before the company could begin a human proof-of-concept trial with its coronavirus vaccine candidate. Arbutus Biopharma: Patent ruling This clinical-stage biotechnology company is developing an antiviral treatment for hepatitis B, but that isn't what pushed up its stock price last month. | Altimmune (NASDAQ: ALT) 148% $851 million Owens & Minor (NYSE: OMI) 111% $1.0 billion Arbutus Biopharma (NASDAQ: ABUS) 109% $263 million Data source: Yahoo! The stock soared last month after the company reported preliminary results for the second quarter that were much better than expected, thanks to unprecedented demand for personal protective equipment. The stock more than doubled because the U.S. Patent Trial and Appeal Board rejected a challenge to three patents that Arbutus has owned for years, regarding messenger RNA (mRNA) delivery technology. |
34668.0 | 2020-07-29 00:00:00 UTC | 1 Reason to Sell Moderna Now | ABUS | https://www.nasdaq.com/articles/1-reason-to-sell-moderna-now-2020-07-29 | nan | nan | There are multiple bear arguments floating around as reasons to sell Moderna (NASDAQ: MRNA), one of the drugmakers leading the way to develop a coronavirus vaccine.
Most of them don't hold much water.
Executives have sold shares: While it would be great if executives would hold forever, can you blame them for diversifying their portfolios that have become overweighted after the stock has run-up this year?
Moderna lost a petition trying to invalidate patents held by Arbutus Biopharma (NASDAQ: ABUS): The patents are unlikely to keep Moderna's coronavirus vaccine, mRNA-1273, off the market. The biggest impact would be Moderna having to pay royalties to Arbutus on sales of mRNA-1273.
mRNA-1273 has lots of competition: In the short term, this isn't going to be a winner-takes-all market, as companies won't be able to manufacture enough vaccine to meet demand. As long as vaccines are efficacious enough to get approved by regulators, the second- and third-best vaccines will sell out until manufacturing of the best vaccine is able to ramp up to meet demand.
Image source: Getty Images.
But there is one reason to sell Moderna that seems perfectly valid: It's nearly impossible to value the biotech right now.
Moderna's valuation will be determined by the cost of the vaccine (unknown), net margin (unknown and further complicated by the Arbutus patent fight), and the number of doses Moderna can manufacture (the company estimates it can make 500 million doses per year, with the potential to increase the output to 1 billion doses starting in 2021).
Even if all three of those components were known and investors could accurately estimate 2021 profits, Moderna's valuation will ultimately be determined by its multiyear profit potential. If mRNA-1273 produces long-lasting immunity, sales of the coronavirus vaccine will be limited to just one regimen (two doses) per patient, limiting sales to just a couple of years until the world is fully vaccinated.
10 stocks we like better than Moderna
When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor, has tripled the market.*
David and Tom just revealed what they believe are the ten best stocks for investors to buy right now... and Moderna wasn't one of them! That's right -- they think these 10 stocks are even better buys.
See the 10 stocks
*Stock Advisor returns as of June 2, 2020
Brian Orelli, PhD and The Motley Fool have no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Moderna lost a petition trying to invalidate patents held by Arbutus Biopharma (NASDAQ: ABUS): The patents are unlikely to keep Moderna's coronavirus vaccine, mRNA-1273, off the market. There are multiple bear arguments floating around as reasons to sell Moderna (NASDAQ: MRNA), one of the drugmakers leading the way to develop a coronavirus vaccine. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor, has tripled the market. | Moderna lost a petition trying to invalidate patents held by Arbutus Biopharma (NASDAQ: ABUS): The patents are unlikely to keep Moderna's coronavirus vaccine, mRNA-1273, off the market. mRNA-1273 has lots of competition: In the short term, this isn't going to be a winner-takes-all market, as companies won't be able to manufacture enough vaccine to meet demand. Moderna's valuation will be determined by the cost of the vaccine (unknown), net margin (unknown and further complicated by the Arbutus patent fight), and the number of doses Moderna can manufacture (the company estimates it can make 500 million doses per year, with the potential to increase the output to 1 billion doses starting in 2021). | Moderna lost a petition trying to invalidate patents held by Arbutus Biopharma (NASDAQ: ABUS): The patents are unlikely to keep Moderna's coronavirus vaccine, mRNA-1273, off the market. Moderna's valuation will be determined by the cost of the vaccine (unknown), net margin (unknown and further complicated by the Arbutus patent fight), and the number of doses Moderna can manufacture (the company estimates it can make 500 million doses per year, with the potential to increase the output to 1 billion doses starting in 2021). See the 10 stocks *Stock Advisor returns as of June 2, 2020 Brian Orelli, PhD and The Motley Fool have no position in any of the stocks mentioned. | Moderna lost a petition trying to invalidate patents held by Arbutus Biopharma (NASDAQ: ABUS): The patents are unlikely to keep Moderna's coronavirus vaccine, mRNA-1273, off the market. Most of them don't hold much water. Moderna's valuation will be determined by the cost of the vaccine (unknown), net margin (unknown and further complicated by the Arbutus patent fight), and the number of doses Moderna can manufacture (the company estimates it can make 500 million doses per year, with the potential to increase the output to 1 billion doses starting in 2021). |
34669.0 | 2020-07-28 00:00:00 UTC | Pre-market Movers In Healthcare Sector: SPPI, MEDS, OCGN, SRNE, CRMD... | ABUS | https://www.nasdaq.com/articles/pre-market-movers-in-healthcare-sector%3A-sppi-meds-ocgn-srne-crmd...-2020-07-28 | nan | nan | (RTTNews) - What's moving these stocks in pre-market hours today?
In the Green
1. Spectrum Pharmaceuticals Inc. (SPPI) is up more than 66% at $5.39 in pre-market trading Tuesday, following positive results from Cohort 2 of its phase II clinical trial of Poziotinib in previously treated non-small-cell lung cancer patients with HER2 exon 20 insertion mutations, dubbed ZENITH20. According to the trial results, the median duration of response was 5.1 months, with a median follow up of 8.3 months. The disease control rate (DCR) was 70% and the median progression-free survival was 5.5 months.
2. Trxade Group Inc. (MEDS) is up more than 32% at $8.45 in pre-market trading today, following impressive second-quarter financial results. Revenues for the second quarter of 2020 increased 244% to a record $6.6 million, compared to revenue of $1.9 million in the same quarter last year.
3. Ocugen Inc. (OCGN) is up more than 19% $0.74 in pre-market trading, adding to yesterday's gain of more than 66%. The company's gene therapy product candidate ration OCU400 has been granted Orphan Drug Designation by the FDA in the treatment of RHO mutation-associated retinal degeneration. This represents the third Orphan Drug Designation for OCU400. OCU400, under preclinical testing, is being developed for the treatment of RHO mutation-associated retinal degeneration, CEP290 mutation-associated retinal degeneration, and NR2E3 mutation-associated retinal degeneration.
4. Sunesis Pharmaceuticals Inc. (SNSS) is up over 6% at $0.43 in pre-market trading, adding to yesterday's gain of nearly 16%, on no news.
5. Sorrento Therapeutics Inc. (SRNE) is up over 5% at $8.20 in pre-market trading on no news. Last week, the company signed a letter of intent to acquire SmartPharm, a gene-encoded therapeutics company developing non-viral DNA and RNA gene delivery platforms for COVID-19 and rare diseases. Financial terms were not disclosed. The transaction is expected to close in August 2020.
6. Novan Inc. (NOVN) is up over 4% at $1.03 in pre-market hours Tuesday, adding to yesterday's gain of more than 14%, on no news. The company's advanced candidate is SB206 for the treatment of molluscum. The first patient in an additional phase III pivotal trial for SB206 as a treatment for molluscum, dubbed B-SIMPLE4, is expected to be enrolled in September 2020. If all goes well as planned, top-line efficacy results can be expected in the second quarter of 2021.
7. TCR2 Therapeutics Inc. (TCRR), which gained over 25% yesterday, following positive interim data from phase I portion of its phase I/II trial of solid tumor candidate TC-210, is up more than 4% at $17.10 in pre-market trading Tuesday. On Sunday, the company announced that the first five patients treated in the phase I portion of its phase I/II trial of TC-210 for mesothelin-expressing solid tumors showed tumor regression and that clinical benefit was observed in them. Yesterday, TCR2 announced that it has commenced an underwritten public offering of 6 million shares of its common stock.
In the Red
1. CorMedix Inc. (CRMD) is down 20% at $4.80 in pre-market trading Tuesday, following a proposed public offering of its common stock.
2. MediciNova Inc. (MNOV), which gained more than 95% yesterday, is down over 16% at $9.18 in pre-market trading. The shares had soared as much as over 130% yesterday to touch an intraday high of $13.25, following the company's agreement with BioComo and Mie University, Japan, for joint development of a SARS-CoV-2 vaccine.
3. Allena Pharmaceuticals Inc. (ALNA) is down over 14% at $1.32 in pre-market trading. The company entered into an underwriting agreement with H.C. Wainwright & Co., LLC yesterday, under which the underwriter agreed to purchase 5.12 million shares of Allena Pharma's common stock at a price to the public of $1.30 per share, less underwriting discounts and commissions. The closing of the offering is expected to occur on or about July 30, 2020. The gross proceeds from the offering are expected to be $6.7 million.
4. Arbutus Biopharma Corporation (ABUS) is down over 11% at $3.94 in pre-market trading.
5. Tonix Pharmaceuticals Holding Corp. (TNXP) is down more than 5% at $1.23 in pre-market trading. The company is slated to present preclinical results of TNX-1900 (oxytocin solution for intranasal delivery) at the American Academy of Neurology's first-ever Sports Concussion Conference on July 31.
6. iBio Inc. (IBIO), which lost more than 15% in regular trading yesterday, is down more than 5% at $4.41 in pre-market trading today. The company has two vaccine candidates for COVID-19, under preclinical development. The two COVID-19 vaccine candidates are produced in modified tobacco leaves using a plant-based growing system known as "FastPharming." The vaccine candidates are being tested at Texas A&M University System ("TAMUS") laboratories.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Arbutus Biopharma Corporation (ABUS) is down over 11% at $3.94 in pre-market trading. Spectrum Pharmaceuticals Inc. (SPPI) is up more than 66% at $5.39 in pre-market trading Tuesday, following positive results from Cohort 2 of its phase II clinical trial of Poziotinib in previously treated non-small-cell lung cancer patients with HER2 exon 20 insertion mutations, dubbed ZENITH20. The company's gene therapy product candidate ration OCU400 has been granted Orphan Drug Designation by the FDA in the treatment of RHO mutation-associated retinal degeneration. | Arbutus Biopharma Corporation (ABUS) is down over 11% at $3.94 in pre-market trading. OCU400, under preclinical testing, is being developed for the treatment of RHO mutation-associated retinal degeneration, CEP290 mutation-associated retinal degeneration, and NR2E3 mutation-associated retinal degeneration. Novan Inc. (NOVN) is up over 4% at $1.03 in pre-market hours Tuesday, adding to yesterday's gain of more than 14%, on no news. | Arbutus Biopharma Corporation (ABUS) is down over 11% at $3.94 in pre-market trading. Spectrum Pharmaceuticals Inc. (SPPI) is up more than 66% at $5.39 in pre-market trading Tuesday, following positive results from Cohort 2 of its phase II clinical trial of Poziotinib in previously treated non-small-cell lung cancer patients with HER2 exon 20 insertion mutations, dubbed ZENITH20. TCR2 Therapeutics Inc. (TCRR), which gained over 25% yesterday, following positive interim data from phase I portion of its phase I/II trial of solid tumor candidate TC-210, is up more than 4% at $17.10 in pre-market trading Tuesday. | Arbutus Biopharma Corporation (ABUS) is down over 11% at $3.94 in pre-market trading. Sunesis Pharmaceuticals Inc. (SNSS) is up over 6% at $0.43 in pre-market trading, adding to yesterday's gain of nearly 16%, on no news. TCR2 Therapeutics Inc. (TCRR), which gained over 25% yesterday, following positive interim data from phase I portion of its phase I/II trial of solid tumor candidate TC-210, is up more than 4% at $17.10 in pre-market trading Tuesday. |
34670.0 | 2020-07-28 00:00:00 UTC | MRNA, PFE/BNTX COVID-19 Vaccines Move Into Phase 3, CytoDyn On Watch, GNCA To Report Data On Jul.30 | ABUS | https://www.nasdaq.com/articles/mrna-pfe-bntx-covid-19-vaccines-move-into-phase-3-cytodyn-on-watch-gnca-to-report-data-on | nan | nan | (RTTNews) - Today's Daily Dose brings you news about Moderna moving its COVID-19 vaccine candidate into phase III testing, Pfizer/BioNTech selecting BNT162b2 vaccine candidate for SARS COV-2 to advance into phase II/III trial, positive results from TCR2 Therapeutics' phase I/II trial of TC-210 for mesothelin-expressing solid tumors, Spectrum Pharma's non-small cell lung cancer trial results, and MediciNova joining the COVID-19 vaccine fray, among others.
Read on…
1. CytoDyn to Provide COVID-19 Trial Updates On Jul.30
CytoDyn Inc. (CYDY.OB) is scheduled to host a conference call on July 30, 2020, to provide a comprehensive update on its two trials for COVID-19 patients with mild-to-moderate and severe-to-critical indications.
The company is testing Leronlimab in a phase II trial in mild-to-moderate COVID-19 population and in a phase IIb/III trial in severe and critically ill COVID-19 population.
On July 21, the company announced patient safety data from its over-enrolled COVID-19 phase II trial for mild-to-moderate indications.
CYDY.OB closed Monday's trading at $5.55, up 2.78%.
2. Diffusion Pharma Sees Delay in Patient Enrollment in Phase Ib COVID-19 Study
Diffusion Pharmaceuticals Inc. (DFFN) has been asked by the FDA to make some changes in the design of the proposed phase Ib/IIb study to test trans sodium crocetinate in COVID-19 patients.
As a result of the FDA's suggested protocol modifications and other things, the company now expects enrollment of the first patient in the phase Ib part of the study in August and not in July as was previously estimated.
If all goes well as planned, the first clinical data from the COVID-19 trial is expected to be available early in the fourth quarter of 2020.
DFFN closed Monday's trading at $1.14, down 13.64%.
3. Genocea Gathers Momentum
Shares of Genocea Biosciences Inc. (GNCA) are gathering steam in the run-up to the presentation of data from Part B of its phase I/IIa clinical trial of its personalized cancer vaccine candidate GEN-009.
Part B of the study is evaluating the safety, immunogenicity, and preliminary antitumor activity of GEN-009 in adult patients with cutaneous melanoma, non-small cell lung cancer (NSCLC), squamous cell carcinoma of the head and neck (SCCHN), urothelial carcinoma, or renal cell carcinoma. The Company plans to present initial clinical data on the first 5 patients from Part B on July 30.
Data from Part A of the study that evaluated the safety and immunogenicity of GEN-009 as monotherapy in certain solid tumor cancer patients were presented at ASCO20 Virtual Scientific Program.
GNCA touched a new high of $5.74 in intraday trading on Monday, before closing at $5.53, up 23.44%.
4. Lumos Pharma to Get Non-dilutive Capital
Lumos Pharma Inc. (LUMO) has entered into a definitive agreement to sell its Priority Review Voucher, valued at $100 million, to Merck.
The Priority Review Voucher (PRV) was granted in conjunction with the approval by the FDA of ERVEBO, a vaccine developed by Lumos Pharma's licensee, Merck, for the prevention of the Zaire Ebola virus disease.
As per the deal, Lumos Pharma will receive approximately $60 million which represents its 60% interest in the total value of the PRV. The $60 million will be received in two non-contingent payments, $34 million in 2020, and $26 million in the first quarter of 2021.
The sale of the PRV provides an important source of non-dilutive capital to fund additional investment in the pipeline and the evaluation of other assets for potential acquisitions or partnerships, according to Lumos.
As of March 31, 2020, Lumos had cash and cash equivalents totaling $85.8 million.
The company is planning to initiate a phase IIb trial of its lead candidate LUM-201 in pediatric growth hormone deficiency prior to the end of this year.
LUMO closed Monday's trading at $14.81, down 2.89%. In after-hours, the stock was up 20.39% at $17.83.
5. MediciNova Teams Up With BioComo, Mie University to Develop SARS-CoV-2 Vaccine
Shares of MediciNova Inc. (MNOV) touched a new 52-week high of $13.25 in intraday trading after the company announced an agreement with BioComo and Mie University, Japan, for joint development of a SARS-CoV-2 vaccine.
The potential SARS-CoV-2 vaccine uses BC-PIV, a human parainfluenza virus type 2 vector developed by BioComo and Tetsuya Nosaka, professor of the Department of Microbiology and Molecular Genetics, Mie University Graduate School of Medicine.
The development of the novel BC-PIV SARS-CoV-2 vaccine was initiated by BioComo and Mie University in March of this year. BioComo and Mie University have granted MediciNova exclusive worldwide development rights to use BC-PIV for SARS-CoV-2 vaccine development.
BC-PIV SARS-COV-2 vaccine can be developed as an intra-nasal vaccine in addition to an intra-muscular injection because of its high affinity to nasal and upper respiratory tract mucosa, which is the same route of the natural infection of SARS-CoV-2, according to BioComo.
MNOV closed Monday's trading at $11.00, up 95.04%. In after-hours, the stock fell 10.91% to $9.80.
6. Moderna Advances COVID-19 Vaccine Candidate into Phase III Study
Moderna Inc. (MRNA), one of the top contenders in the race to develop a COVID-19 vaccine, has begun its phase III study of mRNA-1273 against the novel coronavirus.
The phase III study, dubbed COVE, is expected to include approximately 30,000 participants in the United States, testing the mRNA-1273 vaccine at a dosage of 100 µg. The primary endpoint will be the prevention of symptomatic COVID-19 disease.
COVE is being conducted in collaboration with the National Institute of Allergy and Infectious Diseases and the Biomedical Advanced Research and Development Authority (BARDA).
Early this month, the company announced that it has completed enrollment of its phase II study of the mRNA-1273 vaccine, which is testing two dose levels - 50 µg and 100 µg.
Only the interim results of phase I study, which tested 25 µg and 100 µg dose levels of the vaccine candidate, have been announced, and they were promising.
Meanwhile, Moderna is involved in a patent dispute with Arbutus Biopharma over a drug-delivery technology. Last week, the U.S. Patent Trial and Appeal Board ruled in favor of Arbutus, sending Moderna's share price down as much as 20%, as investors feared that the mRNA-1273 vaccine could see some patent challenge.
However, Moderna has issued a statement saying that the improved proprietary LNP formula, used to manufacture mRNA-1273, is not covered by the Arbutus patents and that it is not aware of any significant intellectual property impediments for any products it intends to commercialize, including mRNA-1273.
MRNA closed Monday's trading at $79.91, up 9.15%.
7. NGM Biopharma Initiates CATALINA Study
NGM Biopharmaceuticals Inc. (NGM) has initiated a phase II trial of intravitreal injections (IVT) of NGM621 in patients with geographic atrophy secondary to age-related macular degeneration.
The phase II study, dubbed CATALINA, is a multicenter, randomized, double-masked, sham-controlled study evaluating safety and efficacy of intravitreal injections of NGM621 every four or eight weeks for 48 week.
Geographic atrophy, an advanced form of age-related macular degeneration, is a progressive retinal degenerative disease associated with irreversible loss of vision, diminished quality of life, and eventual blindness.
NGM closed Monday's trading at $18.32, up 2.29%.
8. Pfizer/BioNTech Select BNT162b2 to Test in Phase III Trial
Pfizer Inc. (PFE) and BioNTech SE (BNTX) have begun a global phase II/III safety and efficacy clinical study of its modified messenger RNA vaccine candidate BNT162b2.
BNT162b2 is one of the four vaccine candidates in Pfizer/BioNTech's BNT162 mRNA-based vaccine program. During preclinical and clinical studies of the four BNT162 RNA vaccine candidates, BNT162b1 and BNT162b2 emerged as strong candidates based on assessments of safety and immune response.
Of the two, BNT162b2 has been selected to progress to the phase II/III study based on the totality of available data from preclinical and clinical studies, including select immune response and tolerability parameters.
The phase II/III study of BNT162b2 is designed to enroll up to 30,000 participants aged 18 to 85 years and is expected to include approximately 120 sites globally, including 39 states across the United States and countries including Argentina, Brazil, and Germany.
BNTX closed Monday's trading at $86.53, up 2.80%.
9. scPharma To Face FDA In December
scPharmaceuticals Inc.'s (SCPH) resubmitted New Drug Application for FUROSCIX has been accepted for review by the FDA, with a decision date set for December 30, 2020. FUROSCIX, a proprietary, subcutaneously delivered furosemide solution, is proposed as an outpatient alternative for the treatment of worsening heart failure due to congestion.
This is FUROSCIX's second go-around with the FDA. In June 2018, it was turned down by the regulatory agency.
SCPH closed Monday's trading at $7.37, up 0.82%.
10. Spectrum Pharma's Cohort 2 Trial of ZENITH20 Study Achieves Key Goal
Spectrum Pharmaceuticals Inc.'s (SPPI) ZENITH20, a phase II clinical trial of Poziotinib has met the pre-specified primary endpoint in Cohort 2 in which previously treated non-small cell lung cancer (NSCLC) patients with HER2 exon 20 insertion mutations were enrolled.
The Cohort 2 of the ZENITH20 clinical trial was designed to be a registrational study and it enrolled a total of 90 patients who received an oral, once-daily dose of 16 mg of Poziotinib.
According to the trial results, the median duration of response was 5.1 months, with a median follow up of 8.3 months. The disease control rate (DCR) was 70% and the median progression-free survival was 5.5 months.
The ZENITH20 trial is comprised of 7 independent cohorts. In December 2019, the company reported that the primary endpoint for Cohort 1 was not met but clinical activity was seen. The Cohort 1 involved previously treated non-small-cell lung cancer with EGFR exon 20 insertion mutations.
SPPI closed Monday's trading at $3.24, up 3.51%. In after-hours, the stock was up 70.68% at $5.53.
11. TCR2 Therapeutics' Solid Tumor Candidate TC-210 Shows Promising Results
Shares of TCR2 Therapeutics Inc. (TCRR) jumped more than 25 percent on Monday, following positive interim data from the first five patients treated in the phase I portion of its phase I/II trial of TC-210 for mesothelin-expressing solid tumors.
All five patients showed tumor regression and clinical benefit was observed in the heavily pre-treated cancer patients. TC-210 demonstrated a manageable toxicity profile, with only one patient exhibiting TC-210-related non-hematologic grade >2 toxicity and no evidence of neurotoxicity or on-target, off-tumor toxicity, according to the company.
In other news, the company announced that it has commenced an underwritten public offering of 6 million shares of its common stock.
TCRR closed Monday's trading at $16.39, up 25.11%. In after-hours, the stock gained another 3.72% and was at $17.
12. Stocks That Moved On No News
Fulgent Genetics Inc. (FLGT) closed Monday's trading at $26.46, up 35.62%.
Capricor Therapeutics Inc. (CAPR) closed Monday's trading at $9.81, up 27.07%.
Arcturus Therapeutics Holdings Inc. (ARCT) closed Monday's trading at $63.19, up 17.67%.
iBio Inc. (IBIO) closed Monday's trading at $4.66, down 15.27%.
Altimmune Inc. (ALT) closed Monday's trading at $22.43, down 12.49%.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | The Priority Review Voucher (PRV) was granted in conjunction with the approval by the FDA of ERVEBO, a vaccine developed by Lumos Pharma's licensee, Merck, for the prevention of the Zaire Ebola virus disease. The potential SARS-CoV-2 vaccine uses BC-PIV, a human parainfluenza virus type 2 vector developed by BioComo and Tetsuya Nosaka, professor of the Department of Microbiology and Molecular Genetics, Mie University Graduate School of Medicine. However, Moderna has issued a statement saying that the improved proprietary LNP formula, used to manufacture mRNA-1273, is not covered by the Arbutus patents and that it is not aware of any significant intellectual property impediments for any products it intends to commercialize, including mRNA-1273. | (RTTNews) - Today's Daily Dose brings you news about Moderna moving its COVID-19 vaccine candidate into phase III testing, Pfizer/BioNTech selecting BNT162b2 vaccine candidate for SARS COV-2 to advance into phase II/III trial, positive results from TCR2 Therapeutics' phase I/II trial of TC-210 for mesothelin-expressing solid tumors, Spectrum Pharma's non-small cell lung cancer trial results, and MediciNova joining the COVID-19 vaccine fray, among others. NGM Biopharma Initiates CATALINA Study NGM Biopharmaceuticals Inc. (NGM) has initiated a phase II trial of intravitreal injections (IVT) of NGM621 in patients with geographic atrophy secondary to age-related macular degeneration. Spectrum Pharma's Cohort 2 Trial of ZENITH20 Study Achieves Key Goal Spectrum Pharmaceuticals Inc.'s (SPPI) ZENITH20, a phase II clinical trial of Poziotinib has met the pre-specified primary endpoint in Cohort 2 in which previously treated non-small cell lung cancer (NSCLC) patients with HER2 exon 20 insertion mutations were enrolled. | (RTTNews) - Today's Daily Dose brings you news about Moderna moving its COVID-19 vaccine candidate into phase III testing, Pfizer/BioNTech selecting BNT162b2 vaccine candidate for SARS COV-2 to advance into phase II/III trial, positive results from TCR2 Therapeutics' phase I/II trial of TC-210 for mesothelin-expressing solid tumors, Spectrum Pharma's non-small cell lung cancer trial results, and MediciNova joining the COVID-19 vaccine fray, among others. Moderna Advances COVID-19 Vaccine Candidate into Phase III Study Moderna Inc. (MRNA), one of the top contenders in the race to develop a COVID-19 vaccine, has begun its phase III study of mRNA-1273 against the novel coronavirus. Spectrum Pharma's Cohort 2 Trial of ZENITH20 Study Achieves Key Goal Spectrum Pharmaceuticals Inc.'s (SPPI) ZENITH20, a phase II clinical trial of Poziotinib has met the pre-specified primary endpoint in Cohort 2 in which previously treated non-small cell lung cancer (NSCLC) patients with HER2 exon 20 insertion mutations were enrolled. | (RTTNews) - Today's Daily Dose brings you news about Moderna moving its COVID-19 vaccine candidate into phase III testing, Pfizer/BioNTech selecting BNT162b2 vaccine candidate for SARS COV-2 to advance into phase II/III trial, positive results from TCR2 Therapeutics' phase I/II trial of TC-210 for mesothelin-expressing solid tumors, Spectrum Pharma's non-small cell lung cancer trial results, and MediciNova joining the COVID-19 vaccine fray, among others. On July 21, the company announced patient safety data from its over-enrolled COVID-19 phase II trial for mild-to-moderate indications. Spectrum Pharma's Cohort 2 Trial of ZENITH20 Study Achieves Key Goal Spectrum Pharmaceuticals Inc.'s (SPPI) ZENITH20, a phase II clinical trial of Poziotinib has met the pre-specified primary endpoint in Cohort 2 in which previously treated non-small cell lung cancer (NSCLC) patients with HER2 exon 20 insertion mutations were enrolled. |
34671.0 | 2020-07-26 00:00:00 UTC | Moderna gets further $472 million U.S. award for coronavirus vaccine development | ABUS | https://www.nasdaq.com/articles/moderna-gets-further-%24472-million-u.s.-award-for-coronavirus-vaccine-development-2020-07 | nan | nan | Adds details from press release, background
July 26 (Reuters) - Moderna Inc MRNA.O said on Sunday it has received an additional $472 million from the U.S. government's Biomedical Advanced Research and Development Authority (BARDA) to support development of its novel coronavirus vaccine.
The U.S.-based drug maker said the additional funding will support its late-stage clinical development including the expanded Phase 3 study of Moderna's vaccine candidate.
In April, Moderna had received $483 million from the U.S. federal agency that funds disease-fighting technology, when the experimental vaccine was in an early-stage trial conducted by the U.S. National Institutes of Health.
"Encouraged by the Phase 1 data, we believe that our mRNA vaccine may aid in addressing the COVID-19 pandemic and preventing future outbreaks," Chief Executive Officer Stéphane Bancel said in a press release.
BARDA's total funding for the experimental vaccine of Moderna, the first in the United States to begin human trials of a coronavirus vaccine, is now about $955 million.
The vaccine uses synthetic messenger RNA (mRNA) to inoculate against the coronavirus. Such treatments help the body immunize against a virus and can potentially be developed and manufactured more quickly than traditional vaccines.
A Phase 3 study, conducted in collaboration with the National Institute of Allergy and Infectious Diseases, will begin on July 27 and involve about 30,000 participants, according to the company.
Moderna said it remains on track to be able to deliver about 500 million doses per year, and possibly up to 1 billion doses per year, beginning in 2021.
The announcement about further funding came two days after the drug developer said its formula used in developing the vaccine was not covered under patents owned by Arbutus Biopharma ABUS.O
Pfizer Inc PFE.N, Novavax Inc NVAX.O, Britian's AstraZeneca Plc AZN.L are other few drug makers that received funding from BARDA for coronavirus vaccine development.
(Reporting by Maria Ponnezhath in Bengaluru; Editing by Will Dunham)
((Maria.Ponnezhath@thomsonreuters.com; +91 8061822749;))
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | The announcement about further funding came two days after the drug developer said its formula used in developing the vaccine was not covered under patents owned by Arbutus Biopharma ABUS.O Pfizer Inc PFE.N, Novavax Inc NVAX.O, Britian's AstraZeneca Plc AZN.L are other few drug makers that received funding from BARDA for coronavirus vaccine development. The U.S.-based drug maker said the additional funding will support its late-stage clinical development including the expanded Phase 3 study of Moderna's vaccine candidate. In April, Moderna had received $483 million from the U.S. federal agency that funds disease-fighting technology, when the experimental vaccine was in an early-stage trial conducted by the U.S. National Institutes of Health. | The announcement about further funding came two days after the drug developer said its formula used in developing the vaccine was not covered under patents owned by Arbutus Biopharma ABUS.O Pfizer Inc PFE.N, Novavax Inc NVAX.O, Britian's AstraZeneca Plc AZN.L are other few drug makers that received funding from BARDA for coronavirus vaccine development. Adds details from press release, background July 26 (Reuters) - Moderna Inc MRNA.O said on Sunday it has received an additional $472 million from the U.S. government's Biomedical Advanced Research and Development Authority (BARDA) to support development of its novel coronavirus vaccine. The U.S.-based drug maker said the additional funding will support its late-stage clinical development including the expanded Phase 3 study of Moderna's vaccine candidate. | The announcement about further funding came two days after the drug developer said its formula used in developing the vaccine was not covered under patents owned by Arbutus Biopharma ABUS.O Pfizer Inc PFE.N, Novavax Inc NVAX.O, Britian's AstraZeneca Plc AZN.L are other few drug makers that received funding from BARDA for coronavirus vaccine development. Adds details from press release, background July 26 (Reuters) - Moderna Inc MRNA.O said on Sunday it has received an additional $472 million from the U.S. government's Biomedical Advanced Research and Development Authority (BARDA) to support development of its novel coronavirus vaccine. BARDA's total funding for the experimental vaccine of Moderna, the first in the United States to begin human trials of a coronavirus vaccine, is now about $955 million. | The announcement about further funding came two days after the drug developer said its formula used in developing the vaccine was not covered under patents owned by Arbutus Biopharma ABUS.O Pfizer Inc PFE.N, Novavax Inc NVAX.O, Britian's AstraZeneca Plc AZN.L are other few drug makers that received funding from BARDA for coronavirus vaccine development. Adds details from press release, background July 26 (Reuters) - Moderna Inc MRNA.O said on Sunday it has received an additional $472 million from the U.S. government's Biomedical Advanced Research and Development Authority (BARDA) to support development of its novel coronavirus vaccine. The U.S.-based drug maker said the additional funding will support its late-stage clinical development including the expanded Phase 3 study of Moderna's vaccine candidate. |
34672.0 | 2020-07-24 00:00:00 UTC | Stock Alert: Arbutus Biopharma Up 25% After Winning Patent Dispute With Moderna | ABUS | https://www.nasdaq.com/articles/stock-alert%3A-arbutus-biopharma-up-25-after-winning-patent-dispute-with-moderna-2020-07-24 | nan | nan | (RTTNews) - Shares of Arbutus Biopharma Corp. (ABUS) gained over 25% on Friday morning after the U.S. Patent and Trademark Office ruled in favor of the company in a patent dispute with Moderna Inc. (MRNA)
ABUS is currently trading at $7.83, up $1.63 or 26.29%, on the Nasdaq.
The decision will help Arbutus make a royalty claim for products developed by Moderna using lipid nanoparticle delivery technology. This technology is currently being used by Moderna to develop a COVID-19 vaccine, known as MRNA-1273.
Moderna had filed the patent case against Arbutus Biopharma in January last year. Moderna argued that Arbutus patent for lipid nanoparticles, the technology used to deliver messenger RNA to a patients' cells, was unpatentable.
Meanwhile, Moderna shares are trading down 7%.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | (RTTNews) - Shares of Arbutus Biopharma Corp. (ABUS) gained over 25% on Friday morning after the U.S. Patent and Trademark Office ruled in favor of the company in a patent dispute with Moderna Inc. (MRNA) ABUS is currently trading at $7.83, up $1.63 or 26.29%, on the Nasdaq. The decision will help Arbutus make a royalty claim for products developed by Moderna using lipid nanoparticle delivery technology. Moderna argued that Arbutus patent for lipid nanoparticles, the technology used to deliver messenger RNA to a patients' cells, was unpatentable. | (RTTNews) - Shares of Arbutus Biopharma Corp. (ABUS) gained over 25% on Friday morning after the U.S. Patent and Trademark Office ruled in favor of the company in a patent dispute with Moderna Inc. (MRNA) ABUS is currently trading at $7.83, up $1.63 or 26.29%, on the Nasdaq. The decision will help Arbutus make a royalty claim for products developed by Moderna using lipid nanoparticle delivery technology. Moderna argued that Arbutus patent for lipid nanoparticles, the technology used to deliver messenger RNA to a patients' cells, was unpatentable. | (RTTNews) - Shares of Arbutus Biopharma Corp. (ABUS) gained over 25% on Friday morning after the U.S. Patent and Trademark Office ruled in favor of the company in a patent dispute with Moderna Inc. (MRNA) ABUS is currently trading at $7.83, up $1.63 or 26.29%, on the Nasdaq. The decision will help Arbutus make a royalty claim for products developed by Moderna using lipid nanoparticle delivery technology. Moderna argued that Arbutus patent for lipid nanoparticles, the technology used to deliver messenger RNA to a patients' cells, was unpatentable. | (RTTNews) - Shares of Arbutus Biopharma Corp. (ABUS) gained over 25% on Friday morning after the U.S. Patent and Trademark Office ruled in favor of the company in a patent dispute with Moderna Inc. (MRNA) ABUS is currently trading at $7.83, up $1.63 or 26.29%, on the Nasdaq. The decision will help Arbutus make a royalty claim for products developed by Moderna using lipid nanoparticle delivery technology. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. |
34673.0 | 2020-07-24 00:00:00 UTC | Moderna says patent ruling not to affect COVID-19 vaccine development | ABUS | https://www.nasdaq.com/articles/moderna-says-patent-ruling-not-to-affect-covid-19-vaccine-development-2020-07-24 | nan | nan | July 24 (Reuters) - Moderna Inc said on Friday its formula used in developing a COVID-19 vaccine was not covered under patents owned by Arbutus Biopharma .
An administrative court run by the U.S. Patent and Trademark Office on Thursday rejected Moderna's arguments to invalidate a U.S. patent owned by Arbutus, sparking worries over its efforts to develop next-generation vaccines, including a coronavirus vaccine.
Moderna said the court's ruling relates to actions it took in response to "longstanding aggressive posture" taken by Arbutus against developers of nucleic acid-based therapeutics and began well before the development of mRNA-1273, its COVID-19 vaccine candidate.
Moderna shares were up slightly in extended trading, while Arbutus shares closed down 20% on Friday. (Reporting by Vishwadha Chander in Bengaluru; Editing by Anil D'Silva) ((Vishwadha.Chander@thomsonreuters.com; within U.S. +1 646 223 8780, outside U.S. +91 80 6749 6132;)) Keywords: MODERNA PATENT/
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | July 24 (Reuters) - Moderna Inc said on Friday its formula used in developing a COVID-19 vaccine was not covered under patents owned by Arbutus Biopharma . An administrative court run by the U.S. Patent and Trademark Office on Thursday rejected Moderna's arguments to invalidate a U.S. patent owned by Arbutus, sparking worries over its efforts to develop next-generation vaccines, including a coronavirus vaccine. (Reporting by Vishwadha Chander in Bengaluru; Editing by Anil D'Silva) ((Vishwadha.Chander@thomsonreuters.com; within U.S. +1 646 223 8780, outside U.S. +91 80 6749 6132;)) Keywords: MODERNA PATENT/ The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | July 24 (Reuters) - Moderna Inc said on Friday its formula used in developing a COVID-19 vaccine was not covered under patents owned by Arbutus Biopharma . An administrative court run by the U.S. Patent and Trademark Office on Thursday rejected Moderna's arguments to invalidate a U.S. patent owned by Arbutus, sparking worries over its efforts to develop next-generation vaccines, including a coronavirus vaccine. Moderna shares were up slightly in extended trading, while Arbutus shares closed down 20% on Friday. | July 24 (Reuters) - Moderna Inc said on Friday its formula used in developing a COVID-19 vaccine was not covered under patents owned by Arbutus Biopharma . An administrative court run by the U.S. Patent and Trademark Office on Thursday rejected Moderna's arguments to invalidate a U.S. patent owned by Arbutus, sparking worries over its efforts to develop next-generation vaccines, including a coronavirus vaccine. Moderna said the court's ruling relates to actions it took in response to "longstanding aggressive posture" taken by Arbutus against developers of nucleic acid-based therapeutics and began well before the development of mRNA-1273, its COVID-19 vaccine candidate. | July 24 (Reuters) - Moderna Inc said on Friday its formula used in developing a COVID-19 vaccine was not covered under patents owned by Arbutus Biopharma . An administrative court run by the U.S. Patent and Trademark Office on Thursday rejected Moderna's arguments to invalidate a U.S. patent owned by Arbutus, sparking worries over its efforts to develop next-generation vaccines, including a coronavirus vaccine. Moderna said the court's ruling relates to actions it took in response to "longstanding aggressive posture" taken by Arbutus against developers of nucleic acid-based therapeutics and began well before the development of mRNA-1273, its COVID-19 vaccine candidate. |
34674.0 | 2020-07-24 00:00:00 UTC | Health Care Sector Update for 07/24/2020: JNJ,ABUS,LMAT,MGEN,MRNA | ABUS | https://www.nasdaq.com/articles/health-care-sector-update-for-07-24-2020%3A-jnjabuslmatmgenmrna-2020-07-24 | nan | nan | Health care stocks were mostly lower late Friday, with the NYSE Health Care Index declining about 1.0% while the SPDR Health Care Select Sector ETF was down 1.4%.
The Nasdaq Biotechnology index also was off 2.4% this afternoon.
In company news, Johnson & Johnson (JNJ) fell 1.2% on Friday and the health care conglomerate saying a European advisory panel is recommending regulators expand the indication for its Prezista HIV-1 drug treatment to also include children 12 years old or older and weighing at least 40 kilograms. Prezista currently is only approved for adult patients with human immunodeficiency virus infections.
Arbutus Biopharma (ABUS) was 16% lower in recent trade, reversing a 45.5% early advance after the US Patent and Trademark Office late Thursday rejected a bid by Moderna (MRNA) to revoke a vaccine technology patent held by Arbutus that uses lipid nanoparticles to encourage the body to produce therapeutic proteins. Moderna shares slipped nearly 3% on Friday.
To the upside, LeMaitre Vascular (LMAT) was almost 11% higher after the medical device company said it earned $0.17 per share during the three months ended June 30, down from $0.23 per share during the same quarter last year but easily topping the Capital IQ consensus for $0.01. Revenue fell 16% year-over-year to $24.9 million, also surpassing the $17.1 million analyst mean.
Miragen Therapeutics (MGEN) climbed more than 14% after the US Food & Drug Administration designated the company's cobomarsen product candidate as an orphan drug to treat T-cell lymphoma, a rare type of cancer in white blood cells.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Arbutus Biopharma (ABUS) was 16% lower in recent trade, reversing a 45.5% early advance after the US Patent and Trademark Office late Thursday rejected a bid by Moderna (MRNA) to revoke a vaccine technology patent held by Arbutus that uses lipid nanoparticles to encourage the body to produce therapeutic proteins. In company news, Johnson & Johnson (JNJ) fell 1.2% on Friday and the health care conglomerate saying a European advisory panel is recommending regulators expand the indication for its Prezista HIV-1 drug treatment to also include children 12 years old or older and weighing at least 40 kilograms. Miragen Therapeutics (MGEN) climbed more than 14% after the US Food & Drug Administration designated the company's cobomarsen product candidate as an orphan drug to treat T-cell lymphoma, a rare type of cancer in white blood cells. | Arbutus Biopharma (ABUS) was 16% lower in recent trade, reversing a 45.5% early advance after the US Patent and Trademark Office late Thursday rejected a bid by Moderna (MRNA) to revoke a vaccine technology patent held by Arbutus that uses lipid nanoparticles to encourage the body to produce therapeutic proteins. Health care stocks were mostly lower late Friday, with the NYSE Health Care Index declining about 1.0% while the SPDR Health Care Select Sector ETF was down 1.4%. In company news, Johnson & Johnson (JNJ) fell 1.2% on Friday and the health care conglomerate saying a European advisory panel is recommending regulators expand the indication for its Prezista HIV-1 drug treatment to also include children 12 years old or older and weighing at least 40 kilograms. | Arbutus Biopharma (ABUS) was 16% lower in recent trade, reversing a 45.5% early advance after the US Patent and Trademark Office late Thursday rejected a bid by Moderna (MRNA) to revoke a vaccine technology patent held by Arbutus that uses lipid nanoparticles to encourage the body to produce therapeutic proteins. Health care stocks were mostly lower late Friday, with the NYSE Health Care Index declining about 1.0% while the SPDR Health Care Select Sector ETF was down 1.4%. In company news, Johnson & Johnson (JNJ) fell 1.2% on Friday and the health care conglomerate saying a European advisory panel is recommending regulators expand the indication for its Prezista HIV-1 drug treatment to also include children 12 years old or older and weighing at least 40 kilograms. | Arbutus Biopharma (ABUS) was 16% lower in recent trade, reversing a 45.5% early advance after the US Patent and Trademark Office late Thursday rejected a bid by Moderna (MRNA) to revoke a vaccine technology patent held by Arbutus that uses lipid nanoparticles to encourage the body to produce therapeutic proteins. Health care stocks were mostly lower late Friday, with the NYSE Health Care Index declining about 1.0% while the SPDR Health Care Select Sector ETF was down 1.4%. The Nasdaq Biotechnology index also was off 2.4% this afternoon. |
34675.0 | 2020-07-24 00:00:00 UTC | Health Care Sector Update for 07/24/2020: ABUS, MRNA, MGEN, NVAX, XLV, IBB | ABUS | https://www.nasdaq.com/articles/health-care-sector-update-for-07-24-2020%3A-abus-mrna-mgen-nvax-xlv-ibb-2020-07-24 | nan | nan | Health care firms were declining premarket Friday as the Health Care SPDR (XLV) was dropping by 0.10%, while the iShares NASDAQ Biotechnology Index (IBB) was slipping by 0.70% recently.
Moderna's (MRNA) bid to invalidate a US patent on vaccine technology owned by Arbutus Biopharma (ABUS) has been denied by the US Patent and Trademark Office, Reuters reported. The decision could hamper Moderna's efforts to develop next-generation vaccines, including a vaccine for COVID-19, according to the report. Arbutus was up more than 24%, while Moderna was recently declining by more than 6%. | Moderna's (MRNA) bid to invalidate a US patent on vaccine technology owned by Arbutus Biopharma (ABUS) has been denied by the US Patent and Trademark Office, Reuters reported. Health care firms were declining premarket Friday as the Health Care SPDR (XLV) was dropping by 0.10%, while the iShares NASDAQ Biotechnology Index (IBB) was slipping by 0.70% recently. The decision could hamper Moderna's efforts to develop next-generation vaccines, including a vaccine for COVID-19, according to the report. | Moderna's (MRNA) bid to invalidate a US patent on vaccine technology owned by Arbutus Biopharma (ABUS) has been denied by the US Patent and Trademark Office, Reuters reported. Health care firms were declining premarket Friday as the Health Care SPDR (XLV) was dropping by 0.10%, while the iShares NASDAQ Biotechnology Index (IBB) was slipping by 0.70% recently. Arbutus was up more than 24%, while Moderna was recently declining by more than 6%. | Moderna's (MRNA) bid to invalidate a US patent on vaccine technology owned by Arbutus Biopharma (ABUS) has been denied by the US Patent and Trademark Office, Reuters reported. Health care firms were declining premarket Friday as the Health Care SPDR (XLV) was dropping by 0.10%, while the iShares NASDAQ Biotechnology Index (IBB) was slipping by 0.70% recently. The decision could hamper Moderna's efforts to develop next-generation vaccines, including a vaccine for COVID-19, according to the report. | Moderna's (MRNA) bid to invalidate a US patent on vaccine technology owned by Arbutus Biopharma (ABUS) has been denied by the US Patent and Trademark Office, Reuters reported. Health care firms were declining premarket Friday as the Health Care SPDR (XLV) was dropping by 0.10%, while the iShares NASDAQ Biotechnology Index (IBB) was slipping by 0.70% recently. The decision could hamper Moderna's efforts to develop next-generation vaccines, including a vaccine for COVID-19, according to the report. |
34676.0 | 2020-07-24 00:00:00 UTC | Tiny Arbutus Biopharma Wins Patent Litigation Fight with COVID-19 Vaccine Implications | ABUS | https://www.nasdaq.com/articles/tiny-arbutus-biopharma-wins-patent-litigation-fight-with-covid-19-vaccine-implications | nan | nan | Arbutus Biopharma (NASDAQ: ABUS) has for some years owned the rights to a technology that can be used to deliver messenger RNA to a patient's cells. Back in January 2019, Moderna (NASDAQ: MRNA), whose entire drug platform is based upon messenger RNA, filed a petition with the U.S. Patent Office to have the small biotech firm's drug-delivery patent declared invalid. Instead, on Thursday, the agency's Patent Trial and Appeal Board ruled in favor of Arbutus.
The ruling is important as Moderna's COVID-19 vaccine candidate uses technology that's covered by this patent. The experimental vaccines that the company is developing use mRNA to issue instructions to the body's cells to start manufacturing proteins that will trigger an immune system response. But a major issue with this method is the matter of treatment delivery -- how to get these instructions into the body's cells. Several years ago, Moderna licensed its delivery technology -- the use of lipid nanoparticles -- from a small Canadian company called Acuitas. That company, it turns out, had licensed its technology from Arbutus Biopharma -- and it did not have rights to sublicense it.
Image source: Getty Images
With the upholding of the Arbutus patent, it appears that Moderna might have to pay the smaller company some royalties. While Arbutus has yet to sue for those royalties, Moderna's attempt to invalidate the patent was an implicit admission that it was aware that the patent might cover its delivery system. In 2017, then-CEO of Arbutus Mark Murray said, "We have seen no evidence of a Moderna delivery system that is free of our intellectual property. Not in their publications, their presentations, or in the examples in their patent filings. In our view what they are reporting as theirs appears to be dominated by our intellectual property."
After the ruling, Arbutus' stock shot dramatically higher -- as of 12:50 p.m. on Friday, it was up by about 102% from its Wednesday closing price. Meanwhile, Moderna's stock has dropped by 10%, shaving a few billion off its market cap.
10 stocks we like better than Moderna INC
When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor, has tripled the market.*
David and Tom just revealed what they believe are the ten best stocks for investors to buy right now... and Moderna INC wasn't one of them! That's right -- they think these 10 stocks are even better buys.
See the 10 stocks
*Stock Advisor returns as of June 2, 2020
Taylor Carmichael has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Arbutus Biopharma (NASDAQ: ABUS) has for some years owned the rights to a technology that can be used to deliver messenger RNA to a patient's cells. The experimental vaccines that the company is developing use mRNA to issue instructions to the body's cells to start manufacturing proteins that will trigger an immune system response. Several years ago, Moderna licensed its delivery technology -- the use of lipid nanoparticles -- from a small Canadian company called Acuitas. | Arbutus Biopharma (NASDAQ: ABUS) has for some years owned the rights to a technology that can be used to deliver messenger RNA to a patient's cells. The experimental vaccines that the company is developing use mRNA to issue instructions to the body's cells to start manufacturing proteins that will trigger an immune system response. Several years ago, Moderna licensed its delivery technology -- the use of lipid nanoparticles -- from a small Canadian company called Acuitas. | Arbutus Biopharma (NASDAQ: ABUS) has for some years owned the rights to a technology that can be used to deliver messenger RNA to a patient's cells. Back in January 2019, Moderna (NASDAQ: MRNA), whose entire drug platform is based upon messenger RNA, filed a petition with the U.S. Patent Office to have the small biotech firm's drug-delivery patent declared invalid. While Arbutus has yet to sue for those royalties, Moderna's attempt to invalidate the patent was an implicit admission that it was aware that the patent might cover its delivery system. | Arbutus Biopharma (NASDAQ: ABUS) has for some years owned the rights to a technology that can be used to deliver messenger RNA to a patient's cells. Back in January 2019, Moderna (NASDAQ: MRNA), whose entire drug platform is based upon messenger RNA, filed a petition with the U.S. Patent Office to have the small biotech firm's drug-delivery patent declared invalid. While Arbutus has yet to sue for those royalties, Moderna's attempt to invalidate the patent was an implicit admission that it was aware that the patent might cover its delivery system. |
34677.0 | 2020-07-24 00:00:00 UTC | Pre-market Movers In Healthcare Sector: THTX, ABUS, QLGN CNTG, MRNA… | ABUS | https://www.nasdaq.com/articles/pre-market-movers-in-healthcare-sector%3A-thtx-abus-qlgn-cntg-mrna...-2020-07-24 | nan | nan | (RTTNews) - What's moving these stocks in pre-market hours today?
In the Green
1. Theratechnologies Inc. (THTX) is up over 37% at $3.09 in pre-market trading Friday, on new data from a sub-analysis of its phase II study of Tesamorelin on the transcriptome of the liver biopsies in people living with HIV-associated nonalcoholic fatty liver disease (NAFLD). Tesamorelin is approved by the FDA and marketed under the brand name Egrifta for the treatment of excess abdominal fat in HIV patients with lipodystrophy. The data support the clinical relevance for the development of Tesamorelin as a potential treatment for liver diseases, according to the company.
2. Miragen Therapeutics (MGEN) is up more than 29% at $1.42 in pre-market trading. Yesterday, the company's investigational drug Cobomarsen was designated an orphan drug by the FDA for the treatment of T-cell lymphoma. Cobomarsen is under a phase I trial in adult T-cell leukemia/lymphoma and in a global phase II trial in patients with mycosis fungoides, the most common type of cutaneous T-cell lymphoma, dubbed SOLAR. Miragen regained compliance with the applicable NASDAQ minimum bid price continued listing requirement on July 1.
3. Arbutus Biopharma Corporation (ABUS) is up over 20% at $7.50 in pre-market trading, adding to yesterday's surge of over 100%. The shares are rallying on the back of a favorable decision from the Patent Trial and Appeal Board related to '069 patent covering Arbutus' lipid nanoparticle (LNP) technology, which was challenged by Moderna. The coronavirus vaccine candidate mRNA-1653, being developed by Moderna, is based on the LNP technology.
4. AIkido Pharma Inc. (AIKI) is up over 8% at $1.32 in pre-market trading, adding to yesterday's gain of over 14% on no news. The last what we heard from the company was on July 9, 2020, when it announced key progress in computational approaches to identify virus treatments, including the novel coronavirus.
5. Centogene N.V. (CNTG) is up over 9% at $13.31 in pre-market trading Friday, rallying for the second straight day. Yesterday, the company announced that its validated COVID-19 test kit, called CentoKit-19, is now available in Germany on Amazon.de. Centogene is the first provider worldwide to make its innovative and comprehensive testing solution for the detection of SARS-CoV-2 virus RNA available to all individuals in Germany via the online marketplace.
6. Qualigen Therapeutics Inc. (QLGN) is up over 8% at $5.40 in pre-market trading today. An exclusive worldwide license agreement with the University of Louisville (UofL) for the intellectual property covering the "RAS-F" family of RAS oncogene protein-protein interaction inhibitor small molecule drug candidates was signed by the company yesterday. Qualigen will evaluate these patent-pending compounds in order to identify a lead drug candidate for further development against one or more cancers.
7. BioNTech SE (BNTX) is up more than 3% at $92 in pre-market trading. The company and its partner Pfizer executed an agreement with the U.S. Department of Health and Human Services for up to 600 million of BNT162, the COVID-19 vaccine candidate jointly developed by Pfizer and BioNTech. A phase IIb/III safety and efficacy trial of BNT162 is expected to begin later this month, with regulatory review expected as early as October 2020. As per the agreement, the U.S. government will pay the companies $1.95 billion upon the receipt of the first 100 million doses, following FDA authorization or approval. The U.S. government also can acquire up to an additional 500 million dose.
In the Red
1. Heat Biologics Inc. (HTBX) is down more than 5% at $2.60 in pre-market trading on no news. Last month, the Company had said that it remains on track to complete the design and development of its COVID-19 vaccine in July, and initiate manufacturing in early August. The Company is collaborating with Waisman Biomanufacturing to manufacture its COVID-19 vaccine.
2. Milestone Pharmaceuticals Inc. (MIST) is down over 4% at $8.47 in pre-market trading today, giving back some of what it gained yesterday. The shares were up over 160% yesterday, following an update related to Etripamil nasal spray, the company's investigational novel short-acting calcium channel blocker for patients with paroxysmal supraventricular tachycardia. The company had also announced that it has entered into a securities purchase agreement with existing shareholder RTW Investments, LP for a $25 million private placement.
3. Moderna Inc. (MRNA), which lost over 9% in yesterday's trade, is down over 3% in pre-market trading today after losing a patent challenge against Arbutus related to lipid nanoparticle (LNP) technology. The coronoavirus vaccine candidate mRNA-1653, being developed by Moderna, is based on the LNP technology.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Arbutus Biopharma Corporation (ABUS) is up over 20% at $7.50 in pre-market trading, adding to yesterday's surge of over 100%. Centogene is the first provider worldwide to make its innovative and comprehensive testing solution for the detection of SARS-CoV-2 virus RNA available to all individuals in Germany via the online marketplace. An exclusive worldwide license agreement with the University of Louisville (UofL) for the intellectual property covering the "RAS-F" family of RAS oncogene protein-protein interaction inhibitor small molecule drug candidates was signed by the company yesterday. | Arbutus Biopharma Corporation (ABUS) is up over 20% at $7.50 in pre-market trading, adding to yesterday's surge of over 100%. Yesterday, the company's investigational drug Cobomarsen was designated an orphan drug by the FDA for the treatment of T-cell lymphoma. The shares are rallying on the back of a favorable decision from the Patent Trial and Appeal Board related to '069 patent covering Arbutus' lipid nanoparticle (LNP) technology, which was challenged by Moderna. | Arbutus Biopharma Corporation (ABUS) is up over 20% at $7.50 in pre-market trading, adding to yesterday's surge of over 100%. Yesterday, the company's investigational drug Cobomarsen was designated an orphan drug by the FDA for the treatment of T-cell lymphoma. The company and its partner Pfizer executed an agreement with the U.S. Department of Health and Human Services for up to 600 million of BNT162, the COVID-19 vaccine candidate jointly developed by Pfizer and BioNTech. | Arbutus Biopharma Corporation (ABUS) is up over 20% at $7.50 in pre-market trading, adding to yesterday's surge of over 100%. Yesterday, the company's investigational drug Cobomarsen was designated an orphan drug by the FDA for the treatment of T-cell lymphoma. As per the agreement, the U.S. government will pay the companies $1.95 billion upon the receipt of the first 100 million doses, following FDA authorization or approval. |
34678.0 | 2020-07-24 00:00:00 UTC | BUZZ-U.S. STOCKS ON THE MOVE-ChannelAdvisor, PolarityTE, Xerox | ABUS | https://www.nasdaq.com/articles/buzz-u.s.-stocks-on-the-move-channeladvisor-polarityte-xerox-2020-07-24 | nan | nan | Eikon search string for individual stock moves: STXBZ
The Day Ahead newsletter: http://tmsnrt.rs/2ggOmBi
The Morning News Call newsletter: http://tmsnrt.rs/2fwPLTh
Wall Street opened lower on Friday as U.S.-China tensions and fears over mounting COVID-19 cases weighed on investor sentiment, erasing all gains for the benchmark S&P 500 index so far this week. .N
At 9:30 a.m. ET, the Dow Jones Industrial Average .DJI was down 0.55% at 26,506.23. The S&P 500 .SPX was down 0.67% at 3,213.85 and the Nasdaq Composite .IXIC was down 1.50% at 10,305.003. The top three S&P 500 .PG.INX percentage gainers: ** Advanced Micro Devices Inc , up 9.6% ** Everest Re Group Ltd , up 3.7% ** FirstEnergy Corp , up 3.5% The top three S&P 500 .PL.INX percentage losers: ** Intel Corp , down 16.2% ** KLA Corp , down 6.6% ** Applied Materials Inc , down 6.2% The top three NYSE .PG.N percentage gainers: ** ChannelAdvisor Corp , up 18.9% ** Taiwan Semiconductor Manufacturing Co , up 10.5% ** Sogou Inc , up 10.3% The top three NYSE .PL.N percentage losers: ** Veoneer Inc , down 10.6% ** SelectQuote Inc Ord , down 9.7% ** China Distance Education Holdings Ltd , down 9.6% The top three Nasdaq .PG.O percentage gainers: ** Global Eagle Entertainment Inc , up 198.1% ** Arbutus Biopharma Corp , up 39.8% ** PolarityTE Inc , up 27.4% The top three Nasdaq .PL.O percentage losers: ** eHealth Inc , down 21.9% ** Intel Corp , down 16.2% ** Lightbridge Corp , down 15.8% ** Theratechnologies THTX.O: up 23.8%
BUZZ-Surges on positive data from HIV-associated NASH drug ** American Express Co AXP.N: down 1.9%
BUZZ-shares fall as pandemic-related defaults loom, Q2 profit plunges ** Intel Corp INTC.O: down 16.2%
BUZZ-Intel sinks as price targets slashed on chip delay ** CVS Health Corp CVS.N: up 0.5%
BUZZ-Drug stocks in focus ahead of Trump plan to lower drug prices ** Twitter Inc TWTR.N: down 0.9%
BUZZ-Street View: Privacy concerns cloud Twitter's gradual flight to recovery ** Comcast Corp CMCSA.O: up 2.2%
BUZZ-Shares up on launch of tool to track ad effectiveness ** Yamana Gold AUY.N: up 1.9%
BUZZ-Gains on Q2 profit beat, dividend raise ** Tesla Inc TSLA.O: down 6.1%
BUZZ-Short sellers face tightening squeeze - S3 Partners ** AT&T Inc T.N: down 0.3%
BUZZ-Street View:Entertainment trends still struggle, despite solid wireless ** Skechers USA SKX.N: up 5.6%
BUZZ-Gains as online surge drives Q2 sales beat ** Moderna Inc MRNA.O: down 9.8%
BUZZ-Falls on losing challenge to invalidate Arbutus' U.S. patent on vaccine tech ** Goldman Sachs GS.N: up 0.6%
BUZZ-Rises after $3.9 bln settlement over 1MDB dispute USN ** Advanced Micro Devices Inc AMD.O: up 9.6%
BUZZ-AMD gains as Intel falls behind in chip race ** Xerox holdings Corp XRX.N: down 2.2%
BUZZ-J.P.Morgan downgrades, expects pandemic to hammer Q2 results ** Union Pacific Corp UNP.N: up 0.6%
BUZZ-Street View: Union Pacific better positioned than rivals to deal with virus blow ** PolarityTE PTE.O: up 27.4%
BUZZ-Jumps on positive data from diabetic foot ulcer treatment trial ** ChannelAdvisor ECOM.N: up 34.1%
BUZZ-Rises on acquisition of analytics firm BlueBoard ** Bloomin' Brands Inc BLMN.O: up 6.3%
BUZZ-Rises on smaller-than-expected Q2 loss
The 11 major S&P 500 sectors:
Communication Services
.SPLRCL
down 0.56%
Consumer Discretionary
.SPLRCD
down 0.72%
Consumer Staples
.SPLRCS
up 0.61%
Energy
.SPNY
up 0.38%
Financial
.SPSY
up 0.28%
Health
.SPXHC
down 0.82%
Industrial
.SPLRCI
up 0.05%
Information Technology
.SPLRCT
down 1.88%
Materials
.SPLRCM
down 0.48%
Real Estate
.SPLRCR
up 0.20%
Utilities
.SPLRCU
up 0.44%
(Compiled by Shivani Kumaresan in Bengaluru)
((Shivani.Kumaresan@thomsonreuters.com ; +1 646 223 8780))
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Eikon search string for individual stock moves: STXBZ The Day Ahead newsletter: http://tmsnrt.rs/2ggOmBi The Morning News Call newsletter: http://tmsnrt.rs/2fwPLTh Wall Street opened lower on Friday as U.S.-China tensions and fears over mounting COVID-19 cases weighed on investor sentiment, erasing all gains for the benchmark S&P 500 index so far this week. The top three S&P 500 .PG.INX percentage gainers: ** Advanced Micro Devices Inc , up 9.6% ** Everest Re Group Ltd , up 3.7% ** FirstEnergy Corp , up 3.5% The top three S&P 500 .PL.INX percentage losers: ** Intel Corp , down 16.2% ** KLA Corp , down 6.6% ** Applied Materials Inc , down 6.2% The top three NYSE .PG.N percentage gainers: ** ChannelAdvisor Corp , up 18.9% ** Taiwan Semiconductor Manufacturing Co , up 10.5% ** Sogou Inc , up 10.3% The top three NYSE .PL.N percentage losers: ** Veoneer Inc , down 10.6% ** SelectQuote Inc Ord , down 9.7% ** China Distance Education Holdings Ltd , down 9.6% The top three Nasdaq .PG.O percentage gainers: ** Global Eagle Entertainment Inc , up 198.1% ** Arbutus Biopharma Corp , up 39.8% ** PolarityTE Inc , up 27.4% The top three Nasdaq .PL.O percentage losers: ** eHealth Inc , down 21.9% ** Intel Corp , down 16.2% ** Lightbridge Corp , down 15.8% ** Theratechnologies THTX.O: up 23.8% BUZZ-Surges on positive data from HIV-associated NASH drug ** American Express Co AXP.N: down 1.9% BUZZ-shares fall as pandemic-related defaults loom, Q2 profit plunges ** Intel Corp INTC.O: down 16.2% BUZZ-Intel sinks as price targets slashed on chip delay ** CVS Health Corp CVS.N: up 0.5% BUZZ-Drug stocks in focus ahead of Trump plan to lower drug prices ** Twitter Inc TWTR.N: down 0.9% BUZZ-Street View: Privacy concerns cloud Twitter's gradual flight to recovery ** Comcast Corp CMCSA.O: up 2.2% BUZZ-Shares up on launch of tool to track ad effectiveness ** Yamana Gold AUY.N: up 1.9% BUZZ-Gains on Q2 profit beat, dividend raise ** Tesla Inc TSLA.O: down 6.1% BUZZ-Short sellers face tightening squeeze - S3 Partners ** AT&T Inc T.N: down 0.3% BUZZ-Street View:Entertainment trends still struggle, despite solid wireless ** Skechers USA SKX.N: up 5.6% BUZZ-Gains as online surge drives Q2 sales beat ** Moderna Inc MRNA.O: down 9.8% BUZZ-Falls on losing challenge to invalidate Arbutus' U.S. patent on vaccine tech ** Goldman Sachs GS.N: up 0.6% BUZZ-Rises after $3.9 bln settlement over 1MDB dispute USN ** Advanced Micro Devices Inc AMD.O: up 9.6% BUZZ-AMD gains as Intel falls behind in chip race ** Xerox holdings Corp XRX.N: down 2.2% BUZZ-J.P.Morgan downgrades, expects pandemic to hammer Q2 results ** Union Pacific Corp UNP.N: up 0.6% BUZZ-Street View: Union Pacific better positioned than rivals to deal with virus blow ** PolarityTE PTE.O: up 27.4% BUZZ-Jumps on positive data from diabetic foot ulcer treatment trial ** ChannelAdvisor ECOM.N: up 34.1% BUZZ-Rises on acquisition of analytics firm BlueBoard ** Bloomin' Brands Inc BLMN.O: up 6.3% BUZZ-Rises on smaller-than-expected Q2 loss The 11 major S&P 500 sectors: Communication Services up 0.44% (Compiled by Shivani Kumaresan in Bengaluru) ((Shivani.Kumaresan@thomsonreuters.com ; +1 646 223 8780)) The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Eikon search string for individual stock moves: STXBZ The Day Ahead newsletter: http://tmsnrt.rs/2ggOmBi The Morning News Call newsletter: http://tmsnrt.rs/2fwPLTh Wall Street opened lower on Friday as U.S.-China tensions and fears over mounting COVID-19 cases weighed on investor sentiment, erasing all gains for the benchmark S&P 500 index so far this week. The top three S&P 500 .PG.INX percentage gainers: ** Advanced Micro Devices Inc , up 9.6% ** Everest Re Group Ltd , up 3.7% ** FirstEnergy Corp , up 3.5% The top three S&P 500 .PL.INX percentage losers: ** Intel Corp , down 16.2% ** KLA Corp , down 6.6% ** Applied Materials Inc , down 6.2% The top three NYSE .PG.N percentage gainers: ** ChannelAdvisor Corp , up 18.9% ** Taiwan Semiconductor Manufacturing Co , up 10.5% ** Sogou Inc , up 10.3% The top three NYSE .PL.N percentage losers: ** Veoneer Inc , down 10.6% ** SelectQuote Inc Ord , down 9.7% ** China Distance Education Holdings Ltd , down 9.6% The top three Nasdaq .PG.O percentage gainers: ** Global Eagle Entertainment Inc , up 198.1% ** Arbutus Biopharma Corp , up 39.8% ** PolarityTE Inc , up 27.4% The top three Nasdaq .PL.O percentage losers: ** eHealth Inc , down 21.9% ** Intel Corp , down 16.2% ** Lightbridge Corp , down 15.8% ** Theratechnologies THTX.O: up 23.8% BUZZ-Surges on positive data from HIV-associated NASH drug ** American Express Co AXP.N: down 1.9% BUZZ-shares fall as pandemic-related defaults loom, Q2 profit plunges ** Intel Corp INTC.O: down 16.2% BUZZ-Intel sinks as price targets slashed on chip delay ** CVS Health Corp CVS.N: up 0.5% BUZZ-Drug stocks in focus ahead of Trump plan to lower drug prices ** Twitter Inc TWTR.N: down 0.9% BUZZ-Street View: Privacy concerns cloud Twitter's gradual flight to recovery ** Comcast Corp CMCSA.O: up 2.2% BUZZ-Shares up on launch of tool to track ad effectiveness ** Yamana Gold AUY.N: up 1.9% BUZZ-Gains on Q2 profit beat, dividend raise ** Tesla Inc TSLA.O: down 6.1% BUZZ-Short sellers face tightening squeeze - S3 Partners ** AT&T Inc T.N: down 0.3% BUZZ-Street View:Entertainment trends still struggle, despite solid wireless ** Skechers USA SKX.N: up 5.6% BUZZ-Gains as online surge drives Q2 sales beat ** Moderna Inc MRNA.O: down 9.8% BUZZ-Falls on losing challenge to invalidate Arbutus' U.S. patent on vaccine tech ** Goldman Sachs GS.N: up 0.6% BUZZ-Rises after $3.9 bln settlement over 1MDB dispute USN ** Advanced Micro Devices Inc AMD.O: up 9.6% BUZZ-AMD gains as Intel falls behind in chip race ** Xerox holdings Corp XRX.N: down 2.2% BUZZ-J.P.Morgan downgrades, expects pandemic to hammer Q2 results ** Union Pacific Corp UNP.N: up 0.6% BUZZ-Street View: Union Pacific better positioned than rivals to deal with virus blow ** PolarityTE PTE.O: up 27.4% BUZZ-Jumps on positive data from diabetic foot ulcer treatment trial ** ChannelAdvisor ECOM.N: up 34.1% BUZZ-Rises on acquisition of analytics firm BlueBoard ** Bloomin' Brands Inc BLMN.O: up 6.3% BUZZ-Rises on smaller-than-expected Q2 loss The 11 major S&P 500 sectors: Communication Services up 0.44% (Compiled by Shivani Kumaresan in Bengaluru) ((Shivani.Kumaresan@thomsonreuters.com ; +1 646 223 8780)) The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | ET, the Dow Jones Industrial Average .DJI was down 0.55% at 26,506.23. The top three S&P 500 .PG.INX percentage gainers: ** Advanced Micro Devices Inc , up 9.6% ** Everest Re Group Ltd , up 3.7% ** FirstEnergy Corp , up 3.5% The top three S&P 500 .PL.INX percentage losers: ** Intel Corp , down 16.2% ** KLA Corp , down 6.6% ** Applied Materials Inc , down 6.2% The top three NYSE .PG.N percentage gainers: ** ChannelAdvisor Corp , up 18.9% ** Taiwan Semiconductor Manufacturing Co , up 10.5% ** Sogou Inc , up 10.3% The top three NYSE .PL.N percentage losers: ** Veoneer Inc , down 10.6% ** SelectQuote Inc Ord , down 9.7% ** China Distance Education Holdings Ltd , down 9.6% The top three Nasdaq .PG.O percentage gainers: ** Global Eagle Entertainment Inc , up 198.1% ** Arbutus Biopharma Corp , up 39.8% ** PolarityTE Inc , up 27.4% The top three Nasdaq .PL.O percentage losers: ** eHealth Inc , down 21.9% ** Intel Corp , down 16.2% ** Lightbridge Corp , down 15.8% ** Theratechnologies THTX.O: up 23.8% BUZZ-Surges on positive data from HIV-associated NASH drug ** American Express Co AXP.N: down 1.9% BUZZ-shares fall as pandemic-related defaults loom, Q2 profit plunges ** Intel Corp INTC.O: down 16.2% BUZZ-Intel sinks as price targets slashed on chip delay ** CVS Health Corp CVS.N: up 0.5% BUZZ-Drug stocks in focus ahead of Trump plan to lower drug prices ** Twitter Inc TWTR.N: down 0.9% BUZZ-Street View: Privacy concerns cloud Twitter's gradual flight to recovery ** Comcast Corp CMCSA.O: up 2.2% BUZZ-Shares up on launch of tool to track ad effectiveness ** Yamana Gold AUY.N: up 1.9% BUZZ-Gains on Q2 profit beat, dividend raise ** Tesla Inc TSLA.O: down 6.1% BUZZ-Short sellers face tightening squeeze - S3 Partners ** AT&T Inc T.N: down 0.3% BUZZ-Street View:Entertainment trends still struggle, despite solid wireless ** Skechers USA SKX.N: up 5.6% BUZZ-Gains as online surge drives Q2 sales beat ** Moderna Inc MRNA.O: down 9.8% BUZZ-Falls on losing challenge to invalidate Arbutus' U.S. patent on vaccine tech ** Goldman Sachs GS.N: up 0.6% BUZZ-Rises after $3.9 bln settlement over 1MDB dispute USN ** Advanced Micro Devices Inc AMD.O: up 9.6% BUZZ-AMD gains as Intel falls behind in chip race ** Xerox holdings Corp XRX.N: down 2.2% BUZZ-J.P.Morgan downgrades, expects pandemic to hammer Q2 results ** Union Pacific Corp UNP.N: up 0.6% BUZZ-Street View: Union Pacific better positioned than rivals to deal with virus blow ** PolarityTE PTE.O: up 27.4% BUZZ-Jumps on positive data from diabetic foot ulcer treatment trial ** ChannelAdvisor ECOM.N: up 34.1% BUZZ-Rises on acquisition of analytics firm BlueBoard ** Bloomin' Brands Inc BLMN.O: up 6.3% BUZZ-Rises on smaller-than-expected Q2 loss The 11 major S&P 500 sectors: Communication Services down 0.56% Consumer Discretionary | Eikon search string for individual stock moves: STXBZ The Day Ahead newsletter: http://tmsnrt.rs/2ggOmBi The Morning News Call newsletter: http://tmsnrt.rs/2fwPLTh Wall Street opened lower on Friday as U.S.-China tensions and fears over mounting COVID-19 cases weighed on investor sentiment, erasing all gains for the benchmark S&P 500 index so far this week. ET, the Dow Jones Industrial Average .DJI was down 0.55% at 26,506.23. The S&P 500 .SPX was down 0.67% at 3,213.85 and the Nasdaq Composite .IXIC was down 1.50% at 10,305.003. |
34679.0 | 2020-07-23 00:00:00 UTC | After Hours Most Active for Jul 23, 2020 : INTC, BABA, FHB, ABUS, AMD, BAC, CZR, QQQ, T, EBS, SWN, MS | ABUS | https://www.nasdaq.com/articles/after-hours-most-active-for-jul-23-2020-%3A-intc-baba-fhb-abus-amd-bac-czr-qqq-t-ebs-swn-ms | nan | nan | The NASDAQ 100 After Hours Indicator is down -26.08 to 10,554.51. The total After hours volume is currently 87,086,061 shares traded.
The following are the most active stocks for the after hours session:
Intel Corporation (INTC) is -5.02 at $55.38, with 9,406,063 shares traded. Business Wire Reports: Health Discovery Corporation Files Infringement Suit Against Intel Corporation
Alibaba Group Holding Limited (BABA) is -0.55 at $251.33, with 6,117,141 shares traded. BABA's current last sale is 91.39% of the target price of $275.
First Hawaiian, Inc. (FHB) is unchanged at $18.59, with 4,644,215 shares traded.FHB is scheduled to provide an earnings report on 7/24/2020, for the fiscal quarter ending Jun2020. The consensus earnings per share forecast is 0.21 per share, which represents a 54 percent increase over the EPS one Year Ago
Arbutus Biopharma Corporation (ABUS) is +0.32 at $6.52, with 4,444,543 shares traded., following a 52-week high recorded in today's regular session.
Advanced Micro Devices, Inc. (AMD) is +2.93 at $62.50, with 3,974,116 shares traded.AMD is scheduled to provide an earnings report on 7/28/2020, for the fiscal quarter ending Jun2020. The consensus earnings per share forecast is 0.12 per share, which represents a 4 percent increase over the EPS one Year Ago
Bank of America Corporation (BAC) is -0.02 at $24.52, with 3,308,395 shares traded. Over the last four weeks they have had 5 up revisions for the earnings forecast, for the fiscal quarter ending Sep 2020. The consensus EPS forecast is $0.41. BAC's current last sale is 90.81% of the target price of $27.
Caesars Entertainment, Inc. (CZR) is -0.03 at $36.55, with 2,925,141 shares traded. Over the last four weeks they have had 4 up revisions for the earnings forecast, for the fiscal quarter ending Jun 2020. The consensus EPS forecast is $-1.79. As reported by Zacks, the current mean recommendation for CZR is in the "buy range".
Invesco QQQ Trust, Series 1 (QQQ) is -0.68 at $257.33, with 2,327,416 shares traded. This represents a 56.02% increase from its 52 Week Low.
AT&T Inc. (T) is -0.07 at $29.83, with 2,237,212 shares traded. PR Newswire Reports: AT&T 5G. Today Nationwide.
Emergent Biosolutions, Inc. (EBS) is unchanged at $88.97, with 2,008,195 shares traded.EBS is scheduled to provide an earnings report on 7/30/2020, for the fiscal quarter ending Jun2020. The consensus earnings per share forecast is 0.53 per share, which represents a 12 percent increase over the EPS one Year Ago
Southwestern Energy Company (SWN) is unchanged at $2.58, with 1,793,821 shares traded.SWN is scheduled to provide an earnings report on 7/30/2020, for the fiscal quarter ending Jun2020. The consensus earnings per share forecast is -0.03 per share, which represents a 8 percent increase over the EPS one Year Ago
Morgan Stanley (MS) is unchanged at $50.56, with 1,647,309 shares traded. Over the last four weeks they have had 3 up revisions for the earnings forecast, for the fiscal quarter ending Sep 2020. The consensus EPS forecast is $1.1. As reported by Zacks, the current mean recommendation for MS is in the "buy range".
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Arbutus Biopharma Corporation (ABUS) is +0.32 at $6.52, with 4,444,543 shares traded., following a 52-week high recorded in today's regular session. Advanced Micro Devices, Inc. (AMD) is +2.93 at $62.50, with 3,974,116 shares traded.AMD is scheduled to provide an earnings report on 7/28/2020, for the fiscal quarter ending Jun2020. Emergent Biosolutions, Inc. (EBS) is unchanged at $88.97, with 2,008,195 shares traded.EBS is scheduled to provide an earnings report on 7/30/2020, for the fiscal quarter ending Jun2020. | Arbutus Biopharma Corporation (ABUS) is +0.32 at $6.52, with 4,444,543 shares traded., following a 52-week high recorded in today's regular session. The consensus earnings per share forecast is 0.21 per share, which represents a 54 percent increase over the EPS one Year Ago The consensus earnings per share forecast is 0.12 per share, which represents a 4 percent increase over the EPS one Year Ago | Arbutus Biopharma Corporation (ABUS) is +0.32 at $6.52, with 4,444,543 shares traded., following a 52-week high recorded in today's regular session. The consensus earnings per share forecast is 0.21 per share, which represents a 54 percent increase over the EPS one Year Ago The consensus earnings per share forecast is 0.12 per share, which represents a 4 percent increase over the EPS one Year Ago | Arbutus Biopharma Corporation (ABUS) is +0.32 at $6.52, with 4,444,543 shares traded., following a 52-week high recorded in today's regular session. Over the last four weeks they have had 5 up revisions for the earnings forecast, for the fiscal quarter ending Sep 2020. AT&T Inc. (T) is -0.07 at $29.83, with 2,237,212 shares traded. |
34680.0 | 2020-07-23 00:00:00 UTC | Moderna loses challenge to Arbutus patent on vaccine technology | ABUS | https://www.nasdaq.com/articles/moderna-loses-challenge-to-arbutus-patent-on-vaccine-technology-2020-07-23 | nan | nan | By Jan Wolfe
July 23 (Reuters) - Shares of Moderna Inc MRNA.O fell nearly 10% after it lost a bid to invalidate a U.S. patent owned by Arbutus Biopharma ABUS.O that presents an obstacle to Moderna's efforts to develop next-generation flu vaccines.
An administrative court run by the U.S. Patent and Trademark Office rejected arguments by Moderna that an Arbutus patent known as the '069 patent should be revoked because it described obvious concepts.
The '069 patent relates to lipid nanoparticle (LNP) technology that allows the human body to make its own therapeutic proteins or vaccines.
LNP technology is crucial to Moderna's vaccine development efforts, and the patent ruling increases pressure on the Cambridge, Massachusetts-based firm to pay for a license to Arbutus' patent portfolio.
Modern can still appeal the patent office ruling to the U.S. Court of Appeals for the Federal Circuit. But that court often upholds the patent office's determinations.
Moderna has received funding from the U.S. government to develop a coronavirus vaccine.
Arbutus shares soared 56% after the patent board posted its opinion on its electronic docket.
Moderna did not immediately respond to a Reuters request for comment.
(Reporting by Vishwadha Chander in Bengaluru and Jan Wolfe in Boston; Editing by Anil D'Silva and Cynthia Osterman)
((Vishwadha.Chander@thomsonreuters.com; within U.S. +1 646 223 8780, outside U.S. +91 80 6749 6132;))
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | By Jan Wolfe July 23 (Reuters) - Shares of Moderna Inc MRNA.O fell nearly 10% after it lost a bid to invalidate a U.S. patent owned by Arbutus Biopharma ABUS.O that presents an obstacle to Moderna's efforts to develop next-generation flu vaccines. The '069 patent relates to lipid nanoparticle (LNP) technology that allows the human body to make its own therapeutic proteins or vaccines. Arbutus shares soared 56% after the patent board posted its opinion on its electronic docket. | By Jan Wolfe July 23 (Reuters) - Shares of Moderna Inc MRNA.O fell nearly 10% after it lost a bid to invalidate a U.S. patent owned by Arbutus Biopharma ABUS.O that presents an obstacle to Moderna's efforts to develop next-generation flu vaccines. LNP technology is crucial to Moderna's vaccine development efforts, and the patent ruling increases pressure on the Cambridge, Massachusetts-based firm to pay for a license to Arbutus' patent portfolio. Modern can still appeal the patent office ruling to the U.S. Court of Appeals for the Federal Circuit. | By Jan Wolfe July 23 (Reuters) - Shares of Moderna Inc MRNA.O fell nearly 10% after it lost a bid to invalidate a U.S. patent owned by Arbutus Biopharma ABUS.O that presents an obstacle to Moderna's efforts to develop next-generation flu vaccines. An administrative court run by the U.S. Patent and Trademark Office rejected arguments by Moderna that an Arbutus patent known as the '069 patent should be revoked because it described obvious concepts. LNP technology is crucial to Moderna's vaccine development efforts, and the patent ruling increases pressure on the Cambridge, Massachusetts-based firm to pay for a license to Arbutus' patent portfolio. | By Jan Wolfe July 23 (Reuters) - Shares of Moderna Inc MRNA.O fell nearly 10% after it lost a bid to invalidate a U.S. patent owned by Arbutus Biopharma ABUS.O that presents an obstacle to Moderna's efforts to develop next-generation flu vaccines. LNP technology is crucial to Moderna's vaccine development efforts, and the patent ruling increases pressure on the Cambridge, Massachusetts-based firm to pay for a license to Arbutus' patent portfolio. But that court often upholds the patent office's determinations. |
34681.0 | 2020-05-19 00:00:00 UTC | BUZZ-U.S. STOCKS ON THE MOVE-Xenetic Biosciences, Dycom, Dynavax Technologies | ABUS | https://www.nasdaq.com/articles/buzz-u.s.-stocks-on-the-move-xenetic-biosciences-dycom-dynavax-technologies-2020-05-19 | nan | nan | Eikon search string for individual stock moves: STXBZ
The Day Ahead newsletter: http://tmsnrt.rs/2ggOmBi
The Morning News Call newsletter: http://tmsnrt.rs/2fwPLTh
The S&P 500 was largely unchanged on Tuesday, after a strong rally in the prior session, as investors sifted through a mixed batch of results from major retailers including Walmart and Home Depot. .N
At 13:06 ET, the Dow Jones Industrial Average .DJI was down 0.35% at 24,511.51. The S&P 500 .SPX was down 0.03% at 2,953.12 and the Nasdaq Composite .IXIC was up 0.58% at 9,288.802. The top three S&P 500 .PG.INX percentage gainers: ** Advance Auto Parts Inc , up 6.1% ** HP Inc , up 5% ** Lennar Corp , up 4.9% The top three S&P 500 .PL.INX percentage losers: ** Kohl's Corp , down 7.9% ** TechnipFMC Plc , down 6.7% ** Noble Energy Inc , down 6.5% The top three NYSE .PG.N percentage gainers: ** Dycom Industries Inc , up 21.2% ** Puxin Ltd , up 18.9% ** John Hancock Mltfactor Energy ETF , up 15.5% The top three NYSE .PL.N percentage losers: ** Timber Pharmaceuticals Inc , down 31.4% ** Aurora Cannabis Inc , down 14.6% ** Crescent Point Energy Corp CPG.N, down 11.3% The top three Nasdaq .PG.O percentage gainers: ** Nano Dimension Inc , up 401.4% ** Shiftpixy Inc , up 84.8% ** Iterum Therapeutics Plc , up 29% The top three Nasdaq .PL.O percentage losers: ** Gamida Cell Ltd , down 23.1% ** Sorrento Therapeutics Inc , down 21.8% ** Bellerophon Therapeutics Inc , down 18.8% ** Fastly Inc FSLY.N: up 4.3%
BUZZ-Stay-at-home winner Fastly surges ahead of share offering ** Atlas Corp ATCO.N: up 4.2%
BUZZ-Rises as BMO says stock undervalued, upgrades to "outperform" ** L3Harris Technologies Inc LHX.N: up 0.7% ** Lockheed Martin Corp LMT.N: up 0.5% ** Northrop Grumman Corp NOC.N: up 0.4%
BUZZ-Seaport sees good entry point for some undervalued U.S. defense stocks ** Carvana Co CVNA.N: down 8.8%
BUZZ-Skids on stock offering ** Hepion Pharmaceuticals Inc HEPA.O: up 7.1%
BUZZ-Jumps on plans for mid-stage trial of NASH fibrosis treatment ** Xenetic Biosciences Inc XBIO.O: up 16.3%
BUZZ-Rises on blood cancer research deal ** Energous Corp WATT.O: up 3.7%
BUZZ-Rises on deal for wirelessly charged electronic paper display tags ** Dycom Industries Inc DY.N: up 21.5%
BUZZ-Soars after surprise profit ** Adamis Pharmaceuticals Inc ADMP.O: down 15.9%
BUZZ-Drops after Q1 revenue miss ** Tricida Inc TCDA.O: down 13.1%
BUZZ-Falls as kidney disease specialist launches convertible debt deal ** Eagle Materials Inc EXP.N: up 4.8%
BUZZ-Soars to one-month high on Q4 results beat ** PBF Energy Inc PBF.N: down 1.7% BUZZ-Barclays cuts to 'underweight' on constrained FCF outlook, leverage ** Dynavax Technologies Inc DVAX.O: up 26.6% BUZZ-Up after co says partners may begin COVID-19 vaccine trial in July ** Home Depot Inc HD.N: down 2.4% BUZZ-Profit misses estimates; scraps FY outlook ** Tilray Inc TLRY.O: up 6.8% BUZZ-Road to profitability a long haul for pot producer - brokerage ** Arbutus Biopharama Corp ABUS.O: up 23% BUZZ-Jumps on positive data from hepatitis B treatment study ** Moderna Inc MRNA.O: down 6.4% BUZZ-Slips after pricing upsized stock offering to fund COVID-19 vaccine ** Aptiv Plc APTV.N: up 4.0% BUZZ- "Longer pain but sharper recovery" - UBS ** Flotek Industries Inc FTK.N: up 16.8% BUZZ-Rises on acquisition of data and analytics firm ** Baidu Inc BIDU.O: up 5.1% BUZZ-Jefferies sees continued revenue growth in H2, raises PT ** Advance Auto Parts Inc AAP.N: up 6.1% BUZZ-Surges as Q2 same store sales look promising ** Tonix Pharmaceuticals Holding Corp TNXP.O: up 5.6% BUZZ-Up after appointing new exec to advance COVID-19 vaccine program ** Oric Pharmaceuticals Inc ORIC.O: up 2% BUZZ-Guggenheim sees potential in trial cancer drug, starts with 'buy' ** Southwest Airlines Co LUV.N: up 3.6% BUZZ-Rises on improving demand for air travel ** Walmart Inc WMT.N: up 0.1% BUZZ-Set to open at 4-week high as stockpiling drives Q1 beat ** Targa Resources TRGP.N: down 4.8% BUZZ-Down as Mizuho lowers 2020 estimates, cuts PT ** Goldman Sachs Group Inc GS.N: down 0.6% ** JPMorgan Chase & Co JPM.N: down 0.3% ** Citigroup Inc C.N: down 1.3% ** Wells Fargo & Co WFC.N: down 2.5% ** Bank of America Corp BAC.N: down 1.2% ** Morgan Stanley MS.N: down 0.2% BUZZ-U.S. banks slide as yields drop amid risk-off mood ** Danaos Corp DAC.N: up 3.6% BUZZ-Rises on upbeat Q1, says no impact from COVID-19 yet ** Moderna Inc MRNA.O: down 6.4% ** Turning Point Therapeutics Inc TPTX.O: down 8.4% ** Gossamer Bio Inc GOSS.O: down 17.0% ** Krystal Biotech Inc KRYS.O: down 3.6% ** Clovis Oncology Inc CLVS.O: down 12.0% ** Bellerophon Therapeutics Inc BLPH.O: down 18.8% BUZZ-Biotech blitz: Moderna, Bluebird lead $3 bln capital raise wave ** KemPharm Inc KMPH.O: up 11.2% BUZZ-Rises as FDA agrees to review ADHD drug ** Take-Two Interactive Software Inc TTWO.O: up 3.8% BUZZ-Gains as Benchmark raises PT, sees Q4 results beat
The 11 major S&P 500 sectors:
Communication Services
.SPLRCL
up 0.26%
Consumer Discretionary
.SPLRCD
up 0.96%
Consumer Staples
.SPLRCS
down 0.85%
Energy
.SPNY
down 2.03%
Financial
.SPSY
down 0.98%
Health
.SPXHC
down 0.91%
Industrial
.SPLRCI
up 0.39%
Information Technology
.SPLRCT
up 0.88%
Materials
.SPLRCM
down 0.03%
Real Estate
.SPLRCR
down 0.92%
Utilities
.SPLRCU
down 0.96%
(Compiled by Amal S in Bengaluru)
((Amal.S@thomsonreuters.com; within U.S.+1 646 223 8780; outside U.S. +91 80 6749 3677;))
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | The top three S&P 500 .PG.INX percentage gainers: ** Advance Auto Parts Inc , up 6.1% ** HP Inc , up 5% ** Lennar Corp , up 4.9% The top three S&P 500 .PL.INX percentage losers: ** Kohl's Corp , down 7.9% ** TechnipFMC Plc , down 6.7% ** Noble Energy Inc , down 6.5% The top three NYSE .PG.N percentage gainers: ** Dycom Industries Inc , up 21.2% ** Puxin Ltd , up 18.9% ** John Hancock Mltfactor Energy ETF , up 15.5% The top three NYSE .PL.N percentage losers: ** Timber Pharmaceuticals Inc , down 31.4% ** Aurora Cannabis Inc , down 14.6% ** Crescent Point Energy Corp CPG.N, down 11.3% The top three Nasdaq .PG.O percentage gainers: ** Nano Dimension Inc , up 401.4% ** Shiftpixy Inc , up 84.8% ** Iterum Therapeutics Plc , up 29% The top three Nasdaq .PL.O percentage losers: ** Gamida Cell Ltd , down 23.1% ** Sorrento Therapeutics Inc , down 21.8% ** Bellerophon Therapeutics Inc , down 18.8% ** Fastly Inc FSLY.N: up 4.3% BUZZ-Stay-at-home winner Fastly surges ahead of share offering ** Atlas Corp ATCO.N: up 4.2% BUZZ-Rises as BMO says stock undervalued, upgrades to "outperform" ** L3Harris Technologies Inc LHX.N: up 0.7% ** Lockheed Martin Corp LMT.N: up 0.5% ** Northrop Grumman Corp NOC.N: up 0.4% BUZZ-Seaport sees good entry point for some undervalued U.S. defense stocks ** Carvana Co CVNA.N: down 8.8% BUZZ-Skids on stock offering ** Hepion Pharmaceuticals Inc HEPA.O: up 7.1% BUZZ-Jumps on plans for mid-stage trial of NASH fibrosis treatment ** Xenetic Biosciences Inc XBIO.O: up 16.3% BUZZ-Rises on blood cancer research deal ** Energous Corp WATT.O: up 3.7% BUZZ-Rises on deal for wirelessly charged electronic paper display tags ** Dycom Industries Inc DY.N: up 21.5% BUZZ-Soars after surprise profit ** Adamis Pharmaceuticals Inc ADMP.O: down 15.9% BUZZ-Drops after Q1 revenue miss ** Tricida Inc TCDA.O: down 13.1% BUZZ-Falls as kidney disease specialist launches convertible debt deal ** Eagle Materials Inc EXP.N: up 4.8% BUZZ-Soars to one-month high on Q4 results beat ** PBF Energy Inc PBF.N: down 1.7% BUZZ-Barclays cuts to 'underweight' on constrained FCF outlook, leverage ** Dynavax Technologies Inc DVAX.O: up 26.6% BUZZ-Up after co says partners may begin COVID-19 vaccine trial in July ** Home Depot Inc HD.N: down 2.4% BUZZ-Profit misses estimates; scraps FY outlook ** Tilray Inc TLRY.O: up 6.8% BUZZ-Road to profitability a long haul for pot producer - brokerage ** Arbutus Biopharama Corp ABUS.O: up 23% BUZZ-Jumps on positive data from hepatitis B treatment study ** Moderna Inc MRNA.O: down 6.4% BUZZ-Slips after pricing upsized stock offering to fund COVID-19 vaccine ** Aptiv Plc APTV.N: up 4.0% BUZZ- "Longer pain but sharper recovery" - UBS ** Flotek Industries Inc FTK.N: up 16.8% BUZZ-Rises on acquisition of data and analytics firm ** Baidu Inc BIDU.O: up 5.1% BUZZ-Jefferies sees continued revenue growth in H2, raises PT ** Advance Auto Parts Inc AAP.N: up 6.1% BUZZ-Surges as Q2 same store sales look promising ** Tonix Pharmaceuticals Holding Corp TNXP.O: up 5.6% BUZZ-Up after appointing new exec to advance COVID-19 vaccine program ** Oric Pharmaceuticals Inc ORIC.O: up 2% BUZZ-Guggenheim sees potential in trial cancer drug, starts with 'buy' ** Southwest Airlines Co LUV.N: up 3.6% BUZZ-Rises on improving demand for air travel ** Walmart Inc WMT.N: up 0.1% BUZZ-Set to open at 4-week high as stockpiling drives Q1 beat ** Targa Resources TRGP.N: down 4.8% BUZZ-Down as Mizuho lowers 2020 estimates, cuts PT ** Goldman Sachs Group Inc GS.N: down 0.6% ** JPMorgan Chase & Co JPM.N: down 0.3% ** Citigroup Inc C.N: down 1.3% ** Wells Fargo & Co WFC.N: down 2.5% ** Bank of America Corp BAC.N: down 1.2% ** Morgan Stanley MS.N: down 0.2% BUZZ-U.S. banks slide as yields drop amid risk-off mood ** Danaos Corp DAC.N: up 3.6% BUZZ-Rises on upbeat Q1, says no impact from COVID-19 yet ** Moderna Inc MRNA.O: down 6.4% ** Turning Point Therapeutics Inc TPTX.O: down 8.4% ** Gossamer Bio Inc GOSS.O: down 17.0% ** Krystal Biotech Inc KRYS.O: down 3.6% ** Clovis Oncology Inc CLVS.O: down 12.0% ** Bellerophon Therapeutics Inc BLPH.O: down 18.8% BUZZ-Biotech blitz: Moderna, Bluebird lead $3 bln capital raise wave ** KemPharm Inc KMPH.O: up 11.2% BUZZ-Rises as FDA agrees to review ADHD drug ** Take-Two Interactive Software Inc TTWO.O: up 3.8% BUZZ-Gains as Benchmark raises PT, sees Q4 results beat The 11 major S&P 500 sectors: Communication Services Eikon search string for individual stock moves: STXBZ The Day Ahead newsletter: http://tmsnrt.rs/2ggOmBi The Morning News Call newsletter: http://tmsnrt.rs/2fwPLTh The S&P 500 was largely unchanged on Tuesday, after a strong rally in the prior session, as investors sifted through a mixed batch of results from major retailers including Walmart and Home Depot. down 0.96% (Compiled by Amal S in Bengaluru) ((Amal.S@thomsonreuters.com; within U.S.+1 646 223 8780; outside U.S. +91 80 6749 3677;)) The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | The top three S&P 500 .PG.INX percentage gainers: ** Advance Auto Parts Inc , up 6.1% ** HP Inc , up 5% ** Lennar Corp , up 4.9% The top three S&P 500 .PL.INX percentage losers: ** Kohl's Corp , down 7.9% ** TechnipFMC Plc , down 6.7% ** Noble Energy Inc , down 6.5% The top three NYSE .PG.N percentage gainers: ** Dycom Industries Inc , up 21.2% ** Puxin Ltd , up 18.9% ** John Hancock Mltfactor Energy ETF , up 15.5% The top three NYSE .PL.N percentage losers: ** Timber Pharmaceuticals Inc , down 31.4% ** Aurora Cannabis Inc , down 14.6% ** Crescent Point Energy Corp CPG.N, down 11.3% The top three Nasdaq .PG.O percentage gainers: ** Nano Dimension Inc , up 401.4% ** Shiftpixy Inc , up 84.8% ** Iterum Therapeutics Plc , up 29% The top three Nasdaq .PL.O percentage losers: ** Gamida Cell Ltd , down 23.1% ** Sorrento Therapeutics Inc , down 21.8% ** Bellerophon Therapeutics Inc , down 18.8% ** Fastly Inc FSLY.N: up 4.3% BUZZ-Stay-at-home winner Fastly surges ahead of share offering ** Atlas Corp ATCO.N: up 4.2% BUZZ-Rises as BMO says stock undervalued, upgrades to "outperform" ** L3Harris Technologies Inc LHX.N: up 0.7% ** Lockheed Martin Corp LMT.N: up 0.5% ** Northrop Grumman Corp NOC.N: up 0.4% BUZZ-Seaport sees good entry point for some undervalued U.S. defense stocks ** Carvana Co CVNA.N: down 8.8% BUZZ-Skids on stock offering ** Hepion Pharmaceuticals Inc HEPA.O: up 7.1% BUZZ-Jumps on plans for mid-stage trial of NASH fibrosis treatment ** Xenetic Biosciences Inc XBIO.O: up 16.3% BUZZ-Rises on blood cancer research deal ** Energous Corp WATT.O: up 3.7% BUZZ-Rises on deal for wirelessly charged electronic paper display tags ** Dycom Industries Inc DY.N: up 21.5% BUZZ-Soars after surprise profit ** Adamis Pharmaceuticals Inc ADMP.O: down 15.9% BUZZ-Drops after Q1 revenue miss ** Tricida Inc TCDA.O: down 13.1% BUZZ-Falls as kidney disease specialist launches convertible debt deal ** Eagle Materials Inc EXP.N: up 4.8% BUZZ-Soars to one-month high on Q4 results beat ** PBF Energy Inc PBF.N: down 1.7% BUZZ-Barclays cuts to 'underweight' on constrained FCF outlook, leverage ** Dynavax Technologies Inc DVAX.O: up 26.6% BUZZ-Up after co says partners may begin COVID-19 vaccine trial in July ** Home Depot Inc HD.N: down 2.4% BUZZ-Profit misses estimates; scraps FY outlook ** Tilray Inc TLRY.O: up 6.8% BUZZ-Road to profitability a long haul for pot producer - brokerage ** Arbutus Biopharama Corp ABUS.O: up 23% BUZZ-Jumps on positive data from hepatitis B treatment study ** Moderna Inc MRNA.O: down 6.4% BUZZ-Slips after pricing upsized stock offering to fund COVID-19 vaccine ** Aptiv Plc APTV.N: up 4.0% BUZZ- "Longer pain but sharper recovery" - UBS ** Flotek Industries Inc FTK.N: up 16.8% BUZZ-Rises on acquisition of data and analytics firm ** Baidu Inc BIDU.O: up 5.1% BUZZ-Jefferies sees continued revenue growth in H2, raises PT ** Advance Auto Parts Inc AAP.N: up 6.1% BUZZ-Surges as Q2 same store sales look promising ** Tonix Pharmaceuticals Holding Corp TNXP.O: up 5.6% BUZZ-Up after appointing new exec to advance COVID-19 vaccine program ** Oric Pharmaceuticals Inc ORIC.O: up 2% BUZZ-Guggenheim sees potential in trial cancer drug, starts with 'buy' ** Southwest Airlines Co LUV.N: up 3.6% BUZZ-Rises on improving demand for air travel ** Walmart Inc WMT.N: up 0.1% BUZZ-Set to open at 4-week high as stockpiling drives Q1 beat ** Targa Resources TRGP.N: down 4.8% BUZZ-Down as Mizuho lowers 2020 estimates, cuts PT ** Goldman Sachs Group Inc GS.N: down 0.6% ** JPMorgan Chase & Co JPM.N: down 0.3% ** Citigroup Inc C.N: down 1.3% ** Wells Fargo & Co WFC.N: down 2.5% ** Bank of America Corp BAC.N: down 1.2% ** Morgan Stanley MS.N: down 0.2% BUZZ-U.S. banks slide as yields drop amid risk-off mood ** Danaos Corp DAC.N: up 3.6% BUZZ-Rises on upbeat Q1, says no impact from COVID-19 yet ** Moderna Inc MRNA.O: down 6.4% ** Turning Point Therapeutics Inc TPTX.O: down 8.4% ** Gossamer Bio Inc GOSS.O: down 17.0% ** Krystal Biotech Inc KRYS.O: down 3.6% ** Clovis Oncology Inc CLVS.O: down 12.0% ** Bellerophon Therapeutics Inc BLPH.O: down 18.8% BUZZ-Biotech blitz: Moderna, Bluebird lead $3 bln capital raise wave ** KemPharm Inc KMPH.O: up 11.2% BUZZ-Rises as FDA agrees to review ADHD drug ** Take-Two Interactive Software Inc TTWO.O: up 3.8% BUZZ-Gains as Benchmark raises PT, sees Q4 results beat The 11 major S&P 500 sectors: Communication Services Eikon search string for individual stock moves: STXBZ The Day Ahead newsletter: http://tmsnrt.rs/2ggOmBi The Morning News Call newsletter: http://tmsnrt.rs/2fwPLTh The S&P 500 was largely unchanged on Tuesday, after a strong rally in the prior session, as investors sifted through a mixed batch of results from major retailers including Walmart and Home Depot. down 0.96% (Compiled by Amal S in Bengaluru) ((Amal.S@thomsonreuters.com; within U.S.+1 646 223 8780; outside U.S. +91 80 6749 3677;)) The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | The top three S&P 500 .PG.INX percentage gainers: ** Advance Auto Parts Inc , up 6.1% ** HP Inc , up 5% ** Lennar Corp , up 4.9% The top three S&P 500 .PL.INX percentage losers: ** Kohl's Corp , down 7.9% ** TechnipFMC Plc , down 6.7% ** Noble Energy Inc , down 6.5% The top three NYSE .PG.N percentage gainers: ** Dycom Industries Inc , up 21.2% ** Puxin Ltd , up 18.9% ** John Hancock Mltfactor Energy ETF , up 15.5% The top three NYSE .PL.N percentage losers: ** Timber Pharmaceuticals Inc , down 31.4% ** Aurora Cannabis Inc , down 14.6% ** Crescent Point Energy Corp CPG.N, down 11.3% The top three Nasdaq .PG.O percentage gainers: ** Nano Dimension Inc , up 401.4% ** Shiftpixy Inc , up 84.8% ** Iterum Therapeutics Plc , up 29% The top three Nasdaq .PL.O percentage losers: ** Gamida Cell Ltd , down 23.1% ** Sorrento Therapeutics Inc , down 21.8% ** Bellerophon Therapeutics Inc , down 18.8% ** Fastly Inc FSLY.N: up 4.3% BUZZ-Stay-at-home winner Fastly surges ahead of share offering ** Atlas Corp ATCO.N: up 4.2% BUZZ-Rises as BMO says stock undervalued, upgrades to "outperform" ** L3Harris Technologies Inc LHX.N: up 0.7% ** Lockheed Martin Corp LMT.N: up 0.5% ** Northrop Grumman Corp NOC.N: up 0.4% BUZZ-Seaport sees good entry point for some undervalued U.S. defense stocks ** Carvana Co CVNA.N: down 8.8% BUZZ-Skids on stock offering ** Hepion Pharmaceuticals Inc HEPA.O: up 7.1% BUZZ-Jumps on plans for mid-stage trial of NASH fibrosis treatment ** Xenetic Biosciences Inc XBIO.O: up 16.3% BUZZ-Rises on blood cancer research deal ** Energous Corp WATT.O: up 3.7% BUZZ-Rises on deal for wirelessly charged electronic paper display tags ** Dycom Industries Inc DY.N: up 21.5% BUZZ-Soars after surprise profit ** Adamis Pharmaceuticals Inc ADMP.O: down 15.9% BUZZ-Drops after Q1 revenue miss ** Tricida Inc TCDA.O: down 13.1% BUZZ-Falls as kidney disease specialist launches convertible debt deal ** Eagle Materials Inc EXP.N: up 4.8% BUZZ-Soars to one-month high on Q4 results beat ** PBF Energy Inc PBF.N: down 1.7% BUZZ-Barclays cuts to 'underweight' on constrained FCF outlook, leverage ** Dynavax Technologies Inc DVAX.O: up 26.6% BUZZ-Up after co says partners may begin COVID-19 vaccine trial in July ** Home Depot Inc HD.N: down 2.4% BUZZ-Profit misses estimates; scraps FY outlook ** Tilray Inc TLRY.O: up 6.8% BUZZ-Road to profitability a long haul for pot producer - brokerage ** Arbutus Biopharama Corp ABUS.O: up 23% BUZZ-Jumps on positive data from hepatitis B treatment study ** Moderna Inc MRNA.O: down 6.4% BUZZ-Slips after pricing upsized stock offering to fund COVID-19 vaccine ** Aptiv Plc APTV.N: up 4.0% BUZZ- "Longer pain but sharper recovery" - UBS ** Flotek Industries Inc FTK.N: up 16.8% BUZZ-Rises on acquisition of data and analytics firm ** Baidu Inc BIDU.O: up 5.1% BUZZ-Jefferies sees continued revenue growth in H2, raises PT ** Advance Auto Parts Inc AAP.N: up 6.1% BUZZ-Surges as Q2 same store sales look promising ** Tonix Pharmaceuticals Holding Corp TNXP.O: up 5.6% BUZZ-Up after appointing new exec to advance COVID-19 vaccine program ** Oric Pharmaceuticals Inc ORIC.O: up 2% BUZZ-Guggenheim sees potential in trial cancer drug, starts with 'buy' ** Southwest Airlines Co LUV.N: up 3.6% BUZZ-Rises on improving demand for air travel ** Walmart Inc WMT.N: up 0.1% BUZZ-Set to open at 4-week high as stockpiling drives Q1 beat ** Targa Resources TRGP.N: down 4.8% BUZZ-Down as Mizuho lowers 2020 estimates, cuts PT ** Goldman Sachs Group Inc GS.N: down 0.6% ** JPMorgan Chase & Co JPM.N: down 0.3% ** Citigroup Inc C.N: down 1.3% ** Wells Fargo & Co WFC.N: down 2.5% ** Bank of America Corp BAC.N: down 1.2% ** Morgan Stanley MS.N: down 0.2% BUZZ-U.S. banks slide as yields drop amid risk-off mood ** Danaos Corp DAC.N: up 3.6% BUZZ-Rises on upbeat Q1, says no impact from COVID-19 yet ** Moderna Inc MRNA.O: down 6.4% ** Turning Point Therapeutics Inc TPTX.O: down 8.4% ** Gossamer Bio Inc GOSS.O: down 17.0% ** Krystal Biotech Inc KRYS.O: down 3.6% ** Clovis Oncology Inc CLVS.O: down 12.0% ** Bellerophon Therapeutics Inc BLPH.O: down 18.8% BUZZ-Biotech blitz: Moderna, Bluebird lead $3 bln capital raise wave ** KemPharm Inc KMPH.O: up 11.2% BUZZ-Rises as FDA agrees to review ADHD drug ** Take-Two Interactive Software Inc TTWO.O: up 3.8% BUZZ-Gains as Benchmark raises PT, sees Q4 results beat The 11 major S&P 500 sectors: Communication Services up 0.26% Consumer Discretionary up 0.96% Consumer Staples | The top three S&P 500 .PG.INX percentage gainers: ** Advance Auto Parts Inc , up 6.1% ** HP Inc , up 5% ** Lennar Corp , up 4.9% The top three S&P 500 .PL.INX percentage losers: ** Kohl's Corp , down 7.9% ** TechnipFMC Plc , down 6.7% ** Noble Energy Inc , down 6.5% The top three NYSE .PG.N percentage gainers: ** Dycom Industries Inc , up 21.2% ** Puxin Ltd , up 18.9% ** John Hancock Mltfactor Energy ETF , up 15.5% The top three NYSE .PL.N percentage losers: ** Timber Pharmaceuticals Inc , down 31.4% ** Aurora Cannabis Inc , down 14.6% ** Crescent Point Energy Corp CPG.N, down 11.3% The top three Nasdaq .PG.O percentage gainers: ** Nano Dimension Inc , up 401.4% ** Shiftpixy Inc , up 84.8% ** Iterum Therapeutics Plc , up 29% The top three Nasdaq .PL.O percentage losers: ** Gamida Cell Ltd , down 23.1% ** Sorrento Therapeutics Inc , down 21.8% ** Bellerophon Therapeutics Inc , down 18.8% ** Fastly Inc FSLY.N: up 4.3% BUZZ-Stay-at-home winner Fastly surges ahead of share offering ** Atlas Corp ATCO.N: up 4.2% BUZZ-Rises as BMO says stock undervalued, upgrades to "outperform" ** L3Harris Technologies Inc LHX.N: up 0.7% ** Lockheed Martin Corp LMT.N: up 0.5% ** Northrop Grumman Corp NOC.N: up 0.4% BUZZ-Seaport sees good entry point for some undervalued U.S. defense stocks ** Carvana Co CVNA.N: down 8.8% BUZZ-Skids on stock offering ** Hepion Pharmaceuticals Inc HEPA.O: up 7.1% BUZZ-Jumps on plans for mid-stage trial of NASH fibrosis treatment ** Xenetic Biosciences Inc XBIO.O: up 16.3% BUZZ-Rises on blood cancer research deal ** Energous Corp WATT.O: up 3.7% BUZZ-Rises on deal for wirelessly charged electronic paper display tags ** Dycom Industries Inc DY.N: up 21.5% BUZZ-Soars after surprise profit ** Adamis Pharmaceuticals Inc ADMP.O: down 15.9% BUZZ-Drops after Q1 revenue miss ** Tricida Inc TCDA.O: down 13.1% BUZZ-Falls as kidney disease specialist launches convertible debt deal ** Eagle Materials Inc EXP.N: up 4.8% BUZZ-Soars to one-month high on Q4 results beat ** PBF Energy Inc PBF.N: down 1.7% BUZZ-Barclays cuts to 'underweight' on constrained FCF outlook, leverage ** Dynavax Technologies Inc DVAX.O: up 26.6% BUZZ-Up after co says partners may begin COVID-19 vaccine trial in July ** Home Depot Inc HD.N: down 2.4% BUZZ-Profit misses estimates; scraps FY outlook ** Tilray Inc TLRY.O: up 6.8% BUZZ-Road to profitability a long haul for pot producer - brokerage ** Arbutus Biopharama Corp ABUS.O: up 23% BUZZ-Jumps on positive data from hepatitis B treatment study ** Moderna Inc MRNA.O: down 6.4% BUZZ-Slips after pricing upsized stock offering to fund COVID-19 vaccine ** Aptiv Plc APTV.N: up 4.0% BUZZ- "Longer pain but sharper recovery" - UBS ** Flotek Industries Inc FTK.N: up 16.8% BUZZ-Rises on acquisition of data and analytics firm ** Baidu Inc BIDU.O: up 5.1% BUZZ-Jefferies sees continued revenue growth in H2, raises PT ** Advance Auto Parts Inc AAP.N: up 6.1% BUZZ-Surges as Q2 same store sales look promising ** Tonix Pharmaceuticals Holding Corp TNXP.O: up 5.6% BUZZ-Up after appointing new exec to advance COVID-19 vaccine program ** Oric Pharmaceuticals Inc ORIC.O: up 2% BUZZ-Guggenheim sees potential in trial cancer drug, starts with 'buy' ** Southwest Airlines Co LUV.N: up 3.6% BUZZ-Rises on improving demand for air travel ** Walmart Inc WMT.N: up 0.1% BUZZ-Set to open at 4-week high as stockpiling drives Q1 beat ** Targa Resources TRGP.N: down 4.8% BUZZ-Down as Mizuho lowers 2020 estimates, cuts PT ** Goldman Sachs Group Inc GS.N: down 0.6% ** JPMorgan Chase & Co JPM.N: down 0.3% ** Citigroup Inc C.N: down 1.3% ** Wells Fargo & Co WFC.N: down 2.5% ** Bank of America Corp BAC.N: down 1.2% ** Morgan Stanley MS.N: down 0.2% BUZZ-U.S. banks slide as yields drop amid risk-off mood ** Danaos Corp DAC.N: up 3.6% BUZZ-Rises on upbeat Q1, says no impact from COVID-19 yet ** Moderna Inc MRNA.O: down 6.4% ** Turning Point Therapeutics Inc TPTX.O: down 8.4% ** Gossamer Bio Inc GOSS.O: down 17.0% ** Krystal Biotech Inc KRYS.O: down 3.6% ** Clovis Oncology Inc CLVS.O: down 12.0% ** Bellerophon Therapeutics Inc BLPH.O: down 18.8% BUZZ-Biotech blitz: Moderna, Bluebird lead $3 bln capital raise wave ** KemPharm Inc KMPH.O: up 11.2% BUZZ-Rises as FDA agrees to review ADHD drug ** Take-Two Interactive Software Inc TTWO.O: up 3.8% BUZZ-Gains as Benchmark raises PT, sees Q4 results beat The 11 major S&P 500 sectors: Communication Services Eikon search string for individual stock moves: STXBZ The Day Ahead newsletter: http://tmsnrt.rs/2ggOmBi The Morning News Call newsletter: http://tmsnrt.rs/2fwPLTh The S&P 500 was largely unchanged on Tuesday, after a strong rally in the prior session, as investors sifted through a mixed batch of results from major retailers including Walmart and Home Depot. .N At 13:06 ET, the Dow Jones Industrial Average .DJI was down 0.35% at 24,511.51. |
34682.0 | 2020-05-19 00:00:00 UTC | BUZZ-U.S. STOCKS ON THE MOVE-KemPharm, Flotek, Arbutus Biopharama | ABUS | https://www.nasdaq.com/articles/buzz-u.s.-stocks-on-the-move-kempharm-flotek-arbutus-biopharama-2020-05-19 | nan | nan | Eikon search string for individual stock moves: STXBZ
The Day Ahead newsletter: http://tmsnrt.rs/2ggOmBi
The Morning News Call newsletter: http://tmsnrt.rs/2fwPLTh
The S&P 500 was trading flat on Tuesday, handing back some gains from a strong rally in the previous session, as investors digested a mixed set of quarterly results from retailers including Home Depot and Walmart. .N
At 11:01 ET, the Dow Jones Industrial Average .DJI was down 0.35% at 24,512.1. The S&P 500 .SPX was down 0.25% at 2,946.65 and the Nasdaq Composite .IXIC was up 0.62% at 9,292.181. The top three S&P 500 .PG.INX percentage gainers: ** Advance Auto Parts Inc , up 4.7% ** Cadence Design Systems Inc , up 4.2 % ** Take-Two Interactive Software Inc , up 3.9% The top three S&P 500 .PL.INX percentage losers: ** Kohl's Corp , down 9.5% ** Nordstrom Inc , down 5.3% ** TechnipFMC Plc , down 5% The top three NYSE .PG.N percentage gainers: ** Dycom Industries Inc , up 23.5% ** Direxion Daily Consumer Discretionary Bull 3X , up 15.5% ** Direxion Daily Small Cap Bull 2x Shares , up 14.4% The top three NYSE .PL.N percentage losers: ** Timber Pharmaceuticals Inc , down 31.4% ** FTS Internationl Inc , down 10.4% ** Carvana Co , down 9.5% The top three Nasdaq .PG.O percentage gainers: ** Shiftpixy Inc , up 80.9% ** Mercurity Fintech Holdings Inc , up 44.3% ** Dynavax Technologies Corp , up 27% The top three Nasdaq .PL.O percentage losers: ** Gamida Cell Ltd , down 24.2% ** Bellerophon Therapeutics Inc , down 17% ** Sorrento Therapeutics Inc , down 16.6% ** Carvana Co CVNA.N: down 9.6%
BUZZ-Skids on stock offering ** Hepion Pharmaceuticals Inc HEPA.O: up 3.6%
BUZZ-Jumps on plans for mid-stage trial of NASH fibrosis treatment ** Xenetic Biosciences Inc XBIO.O: up 13.4%
BUZZ-Rises on blood cancer research deal ** Energous Corp WATT.O: up 2.7%
BUZZ-Rises on deal for wirelessly charged electronic paper display tags ** Dycom Industries Inc DY.N: up 23.6%
BUZZ-Soars after surprise profit ** Adamis Pharmaceuticals Inc ADMP.O: down 16.4%
BUZZ-Drops after Q1 revenue miss ** Tricida Inc TCDA.O: down 9.1%
BUZZ-Falls as kidney disease specialist launches convertible debt deal ** Oxford Immunotec Global Plc OXFD.O: up 3.5%
BUZZ-Up on releasing test kit to study immune response to COVID-19 ** Eagle Materials Inc EXP.N: up 5.5%
BUZZ-Soars to one-month high on Q4 results beat ** PBF Energy Inc PBF.N: down 2.9% BUZZ-Barclays cuts to 'underweight' on constrained FCF outlook, leverage ** Dynavax Technologies Inc DVAX.O: up 27.0% BUZZ-Up after co says partners may begin COVID-19 vaccine trial in July ** Home Depot Inc HD.N: down 1.8% BUZZ-Profit misses estimates; scraps FY outlook ** Tilray Inc TLRY.O: up 1.8% BUZZ-Road to profitability a long haul for pot producer - brokerage ** Arbutus Biopharama Corp ABUS.O: up 26.7% BUZZ-Jumps on positive data from hepatitis B treatment study ** Moderna Inc MRNA.O: down 4.6% BUZZ-Slips after pricing upsized stock offering to fund COVID-19 vaccine ** Aptiv Plc APTV.N: up 2.8% BUZZ- "Longer pain but sharper recovery" - UBS ** Flotek Industries Inc FTK.N: up 23.3% BUZZ-Rises on acquisition of data and analytics firm ** Tesla Inc TSLA.O: down 0.7% BUZZ-JMP Securities does not expect pre-COVID-19 output soon from Fremont, cuts PT ** Baidu Inc BIDU.O: up 5.5% BUZZ-Jefferies sees continued revenue growth in H2, raises PT ** Advance Auto Parts Inc AAP.N: up 4.8% BUZZ-Surges as Q2 same store sales look promising ** Tonix Pharmaceuticals Holding Corp TNXP.O: up 6.8% BUZZ-Up after appointing new exec to advance COVID-19 vaccine program ** Oric Pharmaceuticals Inc ORIC.O: up 3.4% BUZZ-Guggenheim sees potential in trial cancer drug, starts with 'buy' ** Southwest Airlines Co LUV.N: up 2.2% BUZZ-Rises on improving demand for air travel ** Walmart Inc WMT.N: up 0.9% BUZZ-Set to open at 4-week high as stockpiling drives Q1 beat ** Targa Resources TRGP.N: down 1.4% BUZZ-Down as Mizuho lowers 2020 estimates, cuts PT ** Goldman Sachs Group Inc GS.N: down 0.7% ** JPMorgan Chase & Co JPM.N: down 0.2% ** Citigroup Inc C.N: down 1.3% premarket ** Wells Fargo & Co WFC.N: down 3.0% ** Bank of America Corp BAC.N: down 1.0% ** Morgan Stanley MS.N: down 0.2% BUZZ-U.S. banks slide as yields drop amid risk-off mood ** Danaos Corp DAC.N: up 2.9% BUZZ-Rises on upbeat Q1, says no impact from COVID-19 yet ** KemPharm Inc KMPH.O: up 19.9% BUZZ-Rises as FDA agrees to review ADHD drug ** Take-Two Interactive Software Inc TTWO.O: up 3.9% BUZZ-Gains as Benchmark raises PT, sees Q4 results beat
The 11 major S&P 500 sectors:
Communication Services
.SPLRCL
flat
Consumer Discretionary
.SPLRCD
up 0.59%
Consumer Staples
.SPLRCS
down 0.46%
Energy
.SPNY
down 1.70%
Financial
.SPSY
down 0.94%
Health
.SPXHC
down 0.51%
Industrial
.SPLRCI
up 0.13%
Information Technology
.SPLRCT
up 0.98%
Materials
.SPLRCM
down 0.08%
Real Estate
.SPLRCR
down 1.05%
Utilities
.SPLRCU
down 0.66%
(Compiled by Amal S in Bengaluru)
((Amal.S@thomsonreuters.com; within U.S.+1 646 223 8780; outside U.S. +91 80 6749 3677;))
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | The top three S&P 500 .PG.INX percentage gainers: ** Advance Auto Parts Inc , up 4.7% ** Cadence Design Systems Inc , up 4.2 % ** Take-Two Interactive Software Inc , up 3.9% The top three S&P 500 .PL.INX percentage losers: ** Kohl's Corp , down 9.5% ** Nordstrom Inc , down 5.3% ** TechnipFMC Plc , down 5% The top three NYSE .PG.N percentage gainers: ** Dycom Industries Inc , up 23.5% ** Direxion Daily Consumer Discretionary Bull 3X , up 15.5% ** Direxion Daily Small Cap Bull 2x Shares , up 14.4% The top three NYSE .PL.N percentage losers: ** Timber Pharmaceuticals Inc , down 31.4% ** FTS Internationl Inc , down 10.4% ** Carvana Co , down 9.5% The top three Nasdaq .PG.O percentage gainers: ** Shiftpixy Inc , up 80.9% ** Mercurity Fintech Holdings Inc , up 44.3% ** Dynavax Technologies Corp , up 27% The top three Nasdaq .PL.O percentage losers: ** Gamida Cell Ltd , down 24.2% ** Bellerophon Therapeutics Inc , down 17% ** Sorrento Therapeutics Inc , down 16.6% ** Carvana Co CVNA.N: down 9.6% BUZZ-Skids on stock offering ** Hepion Pharmaceuticals Inc HEPA.O: up 3.6% BUZZ-Jumps on plans for mid-stage trial of NASH fibrosis treatment ** Xenetic Biosciences Inc XBIO.O: up 13.4% BUZZ-Rises on blood cancer research deal ** Energous Corp WATT.O: up 2.7% BUZZ-Rises on deal for wirelessly charged electronic paper display tags ** Dycom Industries Inc DY.N: up 23.6% BUZZ-Soars after surprise profit ** Adamis Pharmaceuticals Inc ADMP.O: down 16.4% BUZZ-Drops after Q1 revenue miss ** Tricida Inc TCDA.O: down 9.1% BUZZ-Falls as kidney disease specialist launches convertible debt deal ** Oxford Immunotec Global Plc OXFD.O: up 3.5% BUZZ-Up on releasing test kit to study immune response to COVID-19 ** Eagle Materials Inc EXP.N: up 5.5% BUZZ-Soars to one-month high on Q4 results beat ** PBF Energy Inc PBF.N: down 2.9% BUZZ-Barclays cuts to 'underweight' on constrained FCF outlook, leverage ** Dynavax Technologies Inc DVAX.O: up 27.0% BUZZ-Up after co says partners may begin COVID-19 vaccine trial in July ** Home Depot Inc HD.N: down 1.8% BUZZ-Profit misses estimates; scraps FY outlook ** Tilray Inc TLRY.O: up 1.8% BUZZ-Road to profitability a long haul for pot producer - brokerage ** Arbutus Biopharama Corp ABUS.O: up 26.7% BUZZ-Jumps on positive data from hepatitis B treatment study ** Moderna Inc MRNA.O: down 4.6% BUZZ-Slips after pricing upsized stock offering to fund COVID-19 vaccine ** Aptiv Plc APTV.N: up 2.8% BUZZ- "Longer pain but sharper recovery" - UBS ** Flotek Industries Inc FTK.N: up 23.3% BUZZ-Rises on acquisition of data and analytics firm ** Tesla Inc TSLA.O: down 0.7% BUZZ-JMP Securities does not expect pre-COVID-19 output soon from Fremont, cuts PT ** Baidu Inc BIDU.O: up 5.5% BUZZ-Jefferies sees continued revenue growth in H2, raises PT ** Advance Auto Parts Inc AAP.N: up 4.8% BUZZ-Surges as Q2 same store sales look promising ** Tonix Pharmaceuticals Holding Corp TNXP.O: up 6.8% BUZZ-Up after appointing new exec to advance COVID-19 vaccine program ** Oric Pharmaceuticals Inc ORIC.O: up 3.4% BUZZ-Guggenheim sees potential in trial cancer drug, starts with 'buy' ** Southwest Airlines Co LUV.N: up 2.2% BUZZ-Rises on improving demand for air travel ** Walmart Inc WMT.N: up 0.9% BUZZ-Set to open at 4-week high as stockpiling drives Q1 beat ** Targa Resources TRGP.N: down 1.4% BUZZ-Down as Mizuho lowers 2020 estimates, cuts PT ** Goldman Sachs Group Inc GS.N: down 0.7% ** JPMorgan Chase & Co JPM.N: down 0.2% ** Citigroup Inc C.N: down 1.3% premarket ** Wells Fargo & Co WFC.N: down 3.0% ** Bank of America Corp BAC.N: down 1.0% ** Morgan Stanley MS.N: down 0.2% BUZZ-U.S. banks slide as yields drop amid risk-off mood ** Danaos Corp DAC.N: up 2.9% BUZZ-Rises on upbeat Q1, says no impact from COVID-19 yet ** KemPharm Inc KMPH.O: up 19.9% BUZZ-Rises as FDA agrees to review ADHD drug ** Take-Two Interactive Software Inc TTWO.O: up 3.9% BUZZ-Gains as Benchmark raises PT, sees Q4 results beat The 11 major S&P 500 sectors: Communication Services Eikon search string for individual stock moves: STXBZ The Day Ahead newsletter: http://tmsnrt.rs/2ggOmBi The Morning News Call newsletter: http://tmsnrt.rs/2fwPLTh The S&P 500 was trading flat on Tuesday, handing back some gains from a strong rally in the previous session, as investors digested a mixed set of quarterly results from retailers including Home Depot and Walmart. down 0.66% (Compiled by Amal S in Bengaluru) ((Amal.S@thomsonreuters.com; within U.S.+1 646 223 8780; outside U.S. +91 80 6749 3677;)) The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | The top three S&P 500 .PG.INX percentage gainers: ** Advance Auto Parts Inc , up 4.7% ** Cadence Design Systems Inc , up 4.2 % ** Take-Two Interactive Software Inc , up 3.9% The top three S&P 500 .PL.INX percentage losers: ** Kohl's Corp , down 9.5% ** Nordstrom Inc , down 5.3% ** TechnipFMC Plc , down 5% The top three NYSE .PG.N percentage gainers: ** Dycom Industries Inc , up 23.5% ** Direxion Daily Consumer Discretionary Bull 3X , up 15.5% ** Direxion Daily Small Cap Bull 2x Shares , up 14.4% The top three NYSE .PL.N percentage losers: ** Timber Pharmaceuticals Inc , down 31.4% ** FTS Internationl Inc , down 10.4% ** Carvana Co , down 9.5% The top three Nasdaq .PG.O percentage gainers: ** Shiftpixy Inc , up 80.9% ** Mercurity Fintech Holdings Inc , up 44.3% ** Dynavax Technologies Corp , up 27% The top three Nasdaq .PL.O percentage losers: ** Gamida Cell Ltd , down 24.2% ** Bellerophon Therapeutics Inc , down 17% ** Sorrento Therapeutics Inc , down 16.6% ** Carvana Co CVNA.N: down 9.6% BUZZ-Skids on stock offering ** Hepion Pharmaceuticals Inc HEPA.O: up 3.6% BUZZ-Jumps on plans for mid-stage trial of NASH fibrosis treatment ** Xenetic Biosciences Inc XBIO.O: up 13.4% BUZZ-Rises on blood cancer research deal ** Energous Corp WATT.O: up 2.7% BUZZ-Rises on deal for wirelessly charged electronic paper display tags ** Dycom Industries Inc DY.N: up 23.6% BUZZ-Soars after surprise profit ** Adamis Pharmaceuticals Inc ADMP.O: down 16.4% BUZZ-Drops after Q1 revenue miss ** Tricida Inc TCDA.O: down 9.1% BUZZ-Falls as kidney disease specialist launches convertible debt deal ** Oxford Immunotec Global Plc OXFD.O: up 3.5% BUZZ-Up on releasing test kit to study immune response to COVID-19 ** Eagle Materials Inc EXP.N: up 5.5% BUZZ-Soars to one-month high on Q4 results beat ** PBF Energy Inc PBF.N: down 2.9% BUZZ-Barclays cuts to 'underweight' on constrained FCF outlook, leverage ** Dynavax Technologies Inc DVAX.O: up 27.0% BUZZ-Up after co says partners may begin COVID-19 vaccine trial in July ** Home Depot Inc HD.N: down 1.8% BUZZ-Profit misses estimates; scraps FY outlook ** Tilray Inc TLRY.O: up 1.8% BUZZ-Road to profitability a long haul for pot producer - brokerage ** Arbutus Biopharama Corp ABUS.O: up 26.7% BUZZ-Jumps on positive data from hepatitis B treatment study ** Moderna Inc MRNA.O: down 4.6% BUZZ-Slips after pricing upsized stock offering to fund COVID-19 vaccine ** Aptiv Plc APTV.N: up 2.8% BUZZ- "Longer pain but sharper recovery" - UBS ** Flotek Industries Inc FTK.N: up 23.3% BUZZ-Rises on acquisition of data and analytics firm ** Tesla Inc TSLA.O: down 0.7% BUZZ-JMP Securities does not expect pre-COVID-19 output soon from Fremont, cuts PT ** Baidu Inc BIDU.O: up 5.5% BUZZ-Jefferies sees continued revenue growth in H2, raises PT ** Advance Auto Parts Inc AAP.N: up 4.8% BUZZ-Surges as Q2 same store sales look promising ** Tonix Pharmaceuticals Holding Corp TNXP.O: up 6.8% BUZZ-Up after appointing new exec to advance COVID-19 vaccine program ** Oric Pharmaceuticals Inc ORIC.O: up 3.4% BUZZ-Guggenheim sees potential in trial cancer drug, starts with 'buy' ** Southwest Airlines Co LUV.N: up 2.2% BUZZ-Rises on improving demand for air travel ** Walmart Inc WMT.N: up 0.9% BUZZ-Set to open at 4-week high as stockpiling drives Q1 beat ** Targa Resources TRGP.N: down 1.4% BUZZ-Down as Mizuho lowers 2020 estimates, cuts PT ** Goldman Sachs Group Inc GS.N: down 0.7% ** JPMorgan Chase & Co JPM.N: down 0.2% ** Citigroup Inc C.N: down 1.3% premarket ** Wells Fargo & Co WFC.N: down 3.0% ** Bank of America Corp BAC.N: down 1.0% ** Morgan Stanley MS.N: down 0.2% BUZZ-U.S. banks slide as yields drop amid risk-off mood ** Danaos Corp DAC.N: up 2.9% BUZZ-Rises on upbeat Q1, says no impact from COVID-19 yet ** KemPharm Inc KMPH.O: up 19.9% BUZZ-Rises as FDA agrees to review ADHD drug ** Take-Two Interactive Software Inc TTWO.O: up 3.9% BUZZ-Gains as Benchmark raises PT, sees Q4 results beat The 11 major S&P 500 sectors: Communication Services Eikon search string for individual stock moves: STXBZ The Day Ahead newsletter: http://tmsnrt.rs/2ggOmBi The Morning News Call newsletter: http://tmsnrt.rs/2fwPLTh The S&P 500 was trading flat on Tuesday, handing back some gains from a strong rally in the previous session, as investors digested a mixed set of quarterly results from retailers including Home Depot and Walmart. flat Consumer Discretionary | The top three S&P 500 .PG.INX percentage gainers: ** Advance Auto Parts Inc , up 4.7% ** Cadence Design Systems Inc , up 4.2 % ** Take-Two Interactive Software Inc , up 3.9% The top three S&P 500 .PL.INX percentage losers: ** Kohl's Corp , down 9.5% ** Nordstrom Inc , down 5.3% ** TechnipFMC Plc , down 5% The top three NYSE .PG.N percentage gainers: ** Dycom Industries Inc , up 23.5% ** Direxion Daily Consumer Discretionary Bull 3X , up 15.5% ** Direxion Daily Small Cap Bull 2x Shares , up 14.4% The top three NYSE .PL.N percentage losers: ** Timber Pharmaceuticals Inc , down 31.4% ** FTS Internationl Inc , down 10.4% ** Carvana Co , down 9.5% The top three Nasdaq .PG.O percentage gainers: ** Shiftpixy Inc , up 80.9% ** Mercurity Fintech Holdings Inc , up 44.3% ** Dynavax Technologies Corp , up 27% The top three Nasdaq .PL.O percentage losers: ** Gamida Cell Ltd , down 24.2% ** Bellerophon Therapeutics Inc , down 17% ** Sorrento Therapeutics Inc , down 16.6% ** Carvana Co CVNA.N: down 9.6% BUZZ-Skids on stock offering ** Hepion Pharmaceuticals Inc HEPA.O: up 3.6% BUZZ-Jumps on plans for mid-stage trial of NASH fibrosis treatment ** Xenetic Biosciences Inc XBIO.O: up 13.4% BUZZ-Rises on blood cancer research deal ** Energous Corp WATT.O: up 2.7% BUZZ-Rises on deal for wirelessly charged electronic paper display tags ** Dycom Industries Inc DY.N: up 23.6% BUZZ-Soars after surprise profit ** Adamis Pharmaceuticals Inc ADMP.O: down 16.4% BUZZ-Drops after Q1 revenue miss ** Tricida Inc TCDA.O: down 9.1% BUZZ-Falls as kidney disease specialist launches convertible debt deal ** Oxford Immunotec Global Plc OXFD.O: up 3.5% BUZZ-Up on releasing test kit to study immune response to COVID-19 ** Eagle Materials Inc EXP.N: up 5.5% BUZZ-Soars to one-month high on Q4 results beat ** PBF Energy Inc PBF.N: down 2.9% BUZZ-Barclays cuts to 'underweight' on constrained FCF outlook, leverage ** Dynavax Technologies Inc DVAX.O: up 27.0% BUZZ-Up after co says partners may begin COVID-19 vaccine trial in July ** Home Depot Inc HD.N: down 1.8% BUZZ-Profit misses estimates; scraps FY outlook ** Tilray Inc TLRY.O: up 1.8% BUZZ-Road to profitability a long haul for pot producer - brokerage ** Arbutus Biopharama Corp ABUS.O: up 26.7% BUZZ-Jumps on positive data from hepatitis B treatment study ** Moderna Inc MRNA.O: down 4.6% BUZZ-Slips after pricing upsized stock offering to fund COVID-19 vaccine ** Aptiv Plc APTV.N: up 2.8% BUZZ- "Longer pain but sharper recovery" - UBS ** Flotek Industries Inc FTK.N: up 23.3% BUZZ-Rises on acquisition of data and analytics firm ** Tesla Inc TSLA.O: down 0.7% BUZZ-JMP Securities does not expect pre-COVID-19 output soon from Fremont, cuts PT ** Baidu Inc BIDU.O: up 5.5% BUZZ-Jefferies sees continued revenue growth in H2, raises PT ** Advance Auto Parts Inc AAP.N: up 4.8% BUZZ-Surges as Q2 same store sales look promising ** Tonix Pharmaceuticals Holding Corp TNXP.O: up 6.8% BUZZ-Up after appointing new exec to advance COVID-19 vaccine program ** Oric Pharmaceuticals Inc ORIC.O: up 3.4% BUZZ-Guggenheim sees potential in trial cancer drug, starts with 'buy' ** Southwest Airlines Co LUV.N: up 2.2% BUZZ-Rises on improving demand for air travel ** Walmart Inc WMT.N: up 0.9% BUZZ-Set to open at 4-week high as stockpiling drives Q1 beat ** Targa Resources TRGP.N: down 1.4% BUZZ-Down as Mizuho lowers 2020 estimates, cuts PT ** Goldman Sachs Group Inc GS.N: down 0.7% ** JPMorgan Chase & Co JPM.N: down 0.2% ** Citigroup Inc C.N: down 1.3% premarket ** Wells Fargo & Co WFC.N: down 3.0% ** Bank of America Corp BAC.N: down 1.0% ** Morgan Stanley MS.N: down 0.2% BUZZ-U.S. banks slide as yields drop amid risk-off mood ** Danaos Corp DAC.N: up 2.9% BUZZ-Rises on upbeat Q1, says no impact from COVID-19 yet ** KemPharm Inc KMPH.O: up 19.9% BUZZ-Rises as FDA agrees to review ADHD drug ** Take-Two Interactive Software Inc TTWO.O: up 3.9% BUZZ-Gains as Benchmark raises PT, sees Q4 results beat The 11 major S&P 500 sectors: Communication Services down 1.70% Financial down 0.08% Real Estate | The top three S&P 500 .PG.INX percentage gainers: ** Advance Auto Parts Inc , up 4.7% ** Cadence Design Systems Inc , up 4.2 % ** Take-Two Interactive Software Inc , up 3.9% The top three S&P 500 .PL.INX percentage losers: ** Kohl's Corp , down 9.5% ** Nordstrom Inc , down 5.3% ** TechnipFMC Plc , down 5% The top three NYSE .PG.N percentage gainers: ** Dycom Industries Inc , up 23.5% ** Direxion Daily Consumer Discretionary Bull 3X , up 15.5% ** Direxion Daily Small Cap Bull 2x Shares , up 14.4% The top three NYSE .PL.N percentage losers: ** Timber Pharmaceuticals Inc , down 31.4% ** FTS Internationl Inc , down 10.4% ** Carvana Co , down 9.5% The top three Nasdaq .PG.O percentage gainers: ** Shiftpixy Inc , up 80.9% ** Mercurity Fintech Holdings Inc , up 44.3% ** Dynavax Technologies Corp , up 27% The top three Nasdaq .PL.O percentage losers: ** Gamida Cell Ltd , down 24.2% ** Bellerophon Therapeutics Inc , down 17% ** Sorrento Therapeutics Inc , down 16.6% ** Carvana Co CVNA.N: down 9.6% BUZZ-Skids on stock offering ** Hepion Pharmaceuticals Inc HEPA.O: up 3.6% BUZZ-Jumps on plans for mid-stage trial of NASH fibrosis treatment ** Xenetic Biosciences Inc XBIO.O: up 13.4% BUZZ-Rises on blood cancer research deal ** Energous Corp WATT.O: up 2.7% BUZZ-Rises on deal for wirelessly charged electronic paper display tags ** Dycom Industries Inc DY.N: up 23.6% BUZZ-Soars after surprise profit ** Adamis Pharmaceuticals Inc ADMP.O: down 16.4% BUZZ-Drops after Q1 revenue miss ** Tricida Inc TCDA.O: down 9.1% BUZZ-Falls as kidney disease specialist launches convertible debt deal ** Oxford Immunotec Global Plc OXFD.O: up 3.5% BUZZ-Up on releasing test kit to study immune response to COVID-19 ** Eagle Materials Inc EXP.N: up 5.5% BUZZ-Soars to one-month high on Q4 results beat ** PBF Energy Inc PBF.N: down 2.9% BUZZ-Barclays cuts to 'underweight' on constrained FCF outlook, leverage ** Dynavax Technologies Inc DVAX.O: up 27.0% BUZZ-Up after co says partners may begin COVID-19 vaccine trial in July ** Home Depot Inc HD.N: down 1.8% BUZZ-Profit misses estimates; scraps FY outlook ** Tilray Inc TLRY.O: up 1.8% BUZZ-Road to profitability a long haul for pot producer - brokerage ** Arbutus Biopharama Corp ABUS.O: up 26.7% BUZZ-Jumps on positive data from hepatitis B treatment study ** Moderna Inc MRNA.O: down 4.6% BUZZ-Slips after pricing upsized stock offering to fund COVID-19 vaccine ** Aptiv Plc APTV.N: up 2.8% BUZZ- "Longer pain but sharper recovery" - UBS ** Flotek Industries Inc FTK.N: up 23.3% BUZZ-Rises on acquisition of data and analytics firm ** Tesla Inc TSLA.O: down 0.7% BUZZ-JMP Securities does not expect pre-COVID-19 output soon from Fremont, cuts PT ** Baidu Inc BIDU.O: up 5.5% BUZZ-Jefferies sees continued revenue growth in H2, raises PT ** Advance Auto Parts Inc AAP.N: up 4.8% BUZZ-Surges as Q2 same store sales look promising ** Tonix Pharmaceuticals Holding Corp TNXP.O: up 6.8% BUZZ-Up after appointing new exec to advance COVID-19 vaccine program ** Oric Pharmaceuticals Inc ORIC.O: up 3.4% BUZZ-Guggenheim sees potential in trial cancer drug, starts with 'buy' ** Southwest Airlines Co LUV.N: up 2.2% BUZZ-Rises on improving demand for air travel ** Walmart Inc WMT.N: up 0.9% BUZZ-Set to open at 4-week high as stockpiling drives Q1 beat ** Targa Resources TRGP.N: down 1.4% BUZZ-Down as Mizuho lowers 2020 estimates, cuts PT ** Goldman Sachs Group Inc GS.N: down 0.7% ** JPMorgan Chase & Co JPM.N: down 0.2% ** Citigroup Inc C.N: down 1.3% premarket ** Wells Fargo & Co WFC.N: down 3.0% ** Bank of America Corp BAC.N: down 1.0% ** Morgan Stanley MS.N: down 0.2% BUZZ-U.S. banks slide as yields drop amid risk-off mood ** Danaos Corp DAC.N: up 2.9% BUZZ-Rises on upbeat Q1, says no impact from COVID-19 yet ** KemPharm Inc KMPH.O: up 19.9% BUZZ-Rises as FDA agrees to review ADHD drug ** Take-Two Interactive Software Inc TTWO.O: up 3.9% BUZZ-Gains as Benchmark raises PT, sees Q4 results beat The 11 major S&P 500 sectors: Communication Services Eikon search string for individual stock moves: STXBZ The Day Ahead newsletter: http://tmsnrt.rs/2ggOmBi The Morning News Call newsletter: http://tmsnrt.rs/2fwPLTh The S&P 500 was trading flat on Tuesday, handing back some gains from a strong rally in the previous session, as investors digested a mixed set of quarterly results from retailers including Home Depot and Walmart. .N At 11:01 ET, the Dow Jones Industrial Average .DJI was down 0.35% at 24,512.1. |
34683.0 | 2020-05-19 00:00:00 UTC | BUZZ-U.S. STOCKS ON THE MOVE-Dynavax Technologies, Arbutus Biopharama, Flotek | ABUS | https://www.nasdaq.com/articles/buzz-u.s.-stocks-on-the-move-dynavax-technologies-arbutus-biopharama-flotek-2020-05-19 | nan | nan | Eikon search string for individual stock moves: STXBZ
The Day Ahead newsletter: http://tmsnrt.rs/2ggOmBi
The Morning News Call newsletter: http://tmsnrt.rs/2fwPLTh
U.S. stock index futures were trading flat on Tuesday, handing back some gains from the S&P 500's best day in six weeks in the previous session, as investors digested a mixed set of quarterly results from retailers including Home Depot and Walmart..N
At 9:01 ET, Dow e-minis 1YMc1 were down 0.06% at 24,493. S&P 500 e-minis ESc1 were down 0.20% at 2,942.25, while Nasdaq 100 e-minis NQc1 were up 0.09% at 9,333.5. The top three NYSE percentage gainers premarket .PRPG.NQ: ** Flotek Industries Inc , up 24.3% ** Armstrong Flooring Inc , up 15.6% ** PAR Technology Corp , up 12.0% The top three NYSE percentage losers premarket .PRPL.NQ: ** Four Seasons Edu Inc , down 22.1% ** Hexo Corp , down 14.2% ** Crescent Point Energy Corp , down 8.4% The top three Nasdaq percentage gainers premarket .PRPG.O: ** Immuron Equity Warrants , up 113.1% ** Nano Dimension Ltd , up 59.8% ** Kirkland's Inc , up 47.2% The top three Nasdaq percentage losers premarket .PRPL.O: ** Gamida Cell Ltd , down 24.4% ** Zions Bancorporation NA , down 19.9% ** Gossamer Bio Inc , down 15.8% ** PBF Energy Inc PBF.N: down 1.8% premarket BUZZ-Barclays cuts to 'underweight' on constrained FCF outlook, leverage ** Dynavax Technologies Inc DVAX.O: up 40.5% premarket BUZZ-Up after co says partners may begin COVID-19 vaccine trial in July ** Home Depot Inc HD.N: down 1.2% premarket BUZZ-Profit misses estimates; scraps FY outlook ** Tilray Inc TLRY.O: up 2.9% premarket BUZZ-Road to profitability a long haul for pot producer - brokerage ** Arbutus Biopharama Corp ABUS.O: up 35.8% premarket BUZZ-Jumps on positive data from hepatitis B treatment study ** Moderna Inc MRNA.O: down 3.9% premarket BUZZ-Slips after pricing upsized stock offering to fund COVID-19 vaccine ** Aptiv Plc APTV.N: up 0.6% premarket BUZZ- "Longer pain but sharper recovery" - UBS ** Flotek Industries Inc FTK.N: up 24.3% premarket BUZZ-Rises on acquisition of data and analytics firm ** Bilibili Inc BILI.O: down 2% premarket BUZZ-Falls on bigger-than-expected Q1 loss as marketing spend soars ** Baidu Inc BIDU.O: up 11% premarket BUZZ-Jefferies sees continued revenue growth in H2, raises PT ** Advance Auto Parts Inc AAP.N: up 7.3% premarket BUZZ-Surges as Q2 same store sales look promising ** Walgreens Boots Alliance Inc WBA.O: up 0.6% premarket BUZZ-Underperformance due to COVID-19 is overdone: Cowen ** Tonix Pharmaceuticals Holding Corp TNXP.O: up 5.5% premarket BUZZ-Up after appointing new exec to advance COVID-19 vaccine program ** Oric Pharmaceuticals Inc ORIC.O: up 1.9% premarket BUZZ-Guggenheim sees potential in trial cancer drug, starts with 'buy' ** Southwest Airlines Co LUV.N: up 4% premarket BUZZ-Rises on improving demand for air travel ** Walmart Inc WMT.N: up 3.8% premarket BUZZ-Set to open at 4-week high as stockpiling drives Q1 beat ** Danaos Corp DAC.N: up 11.1% premarket BUZZ-Rises on upbeat Q1, says no impact from COVID-19 yet ** Moderna Inc MRNA.O: down 3.9% premarket ** Bluebird Bio Inc BLUE.O: down 1% premarket ** Turning Point Therapeutics Inc TPTX.O: down 6.5% premarket ** Gossamer Bio Inc GOSS.O: down 15.8% premarket ** Krystal Biotech Inc KRYS.O: down 3.2% premarket ** Clovis Oncology Inc CLVS.O: down 6.6% premarket ** Bellerophon Therapeutics Inc BLPH.O: down 14.2% premarket BUZZ-Biotech blitz: Moderna, Bluebird lead $3 bln capital raise wave ** KemPharm Inc KMPH.O: up 15.6% premarket BUZZ-Rises as FDA agrees to review ADHD drug ** Take-Two Interactive Software Inc TTWO.O: up 1.2% premarket BUZZ-Gains as Benchmark raises PT, sees Q4 results beat
(Compiled by Amal S in Bengaluru)
((Amal.S@thomsonreuters.com; within U.S.+1 646 223 8780; outside U.S. +91 80 6749 3677;))
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | The top three NYSE percentage gainers premarket .PRPG.NQ: ** Flotek Industries Inc , up 24.3% ** Armstrong Flooring Inc , up 15.6% ** PAR Technology Corp , up 12.0% The top three NYSE percentage losers premarket .PRPL.NQ: ** Four Seasons Edu Inc , down 22.1% ** Hexo Corp , down 14.2% ** Crescent Point Energy Corp , down 8.4% The top three Nasdaq percentage gainers premarket .PRPG.O: ** Immuron Equity Warrants , up 113.1% ** Nano Dimension Ltd , up 59.8% ** Kirkland's Inc , up 47.2% The top three Nasdaq percentage losers premarket .PRPL.O: ** Gamida Cell Ltd , down 24.4% ** Zions Bancorporation NA , down 19.9% ** Gossamer Bio Inc , down 15.8% ** PBF Energy Inc PBF.N: down 1.8% premarket BUZZ-Barclays cuts to 'underweight' on constrained FCF outlook, leverage ** Dynavax Technologies Inc DVAX.O: up 40.5% premarket BUZZ-Up after co says partners may begin COVID-19 vaccine trial in July ** Home Depot Inc HD.N: down 1.2% premarket BUZZ-Profit misses estimates; scraps FY outlook ** Tilray Inc TLRY.O: up 2.9% premarket BUZZ-Road to profitability a long haul for pot producer - brokerage ** Arbutus Biopharama Corp ABUS.O: up 35.8% premarket BUZZ-Jumps on positive data from hepatitis B treatment study ** Moderna Inc MRNA.O: down 3.9% premarket BUZZ-Slips after pricing upsized stock offering to fund COVID-19 vaccine ** Aptiv Plc APTV.N: up 0.6% premarket BUZZ- "Longer pain but sharper recovery" - UBS ** Flotek Industries Inc FTK.N: up 24.3% premarket BUZZ-Rises on acquisition of data and analytics firm ** Bilibili Inc BILI.O: down 2% premarket BUZZ-Falls on bigger-than-expected Q1 loss as marketing spend soars ** Baidu Inc BIDU.O: up 11% premarket BUZZ-Jefferies sees continued revenue growth in H2, raises PT ** Advance Auto Parts Inc AAP.N: up 7.3% premarket BUZZ-Surges as Q2 same store sales look promising ** Walgreens Boots Alliance Inc WBA.O: up 0.6% premarket BUZZ-Underperformance due to COVID-19 is overdone: Cowen ** Tonix Pharmaceuticals Holding Corp TNXP.O: up 5.5% premarket BUZZ-Up after appointing new exec to advance COVID-19 vaccine program ** Oric Pharmaceuticals Inc ORIC.O: up 1.9% premarket BUZZ-Guggenheim sees potential in trial cancer drug, starts with 'buy' ** Southwest Airlines Co LUV.N: up 4% premarket BUZZ-Rises on improving demand for air travel ** Walmart Inc WMT.N: up 3.8% premarket BUZZ-Set to open at 4-week high as stockpiling drives Q1 beat ** Danaos Corp DAC.N: up 11.1% premarket BUZZ-Rises on upbeat Q1, says no impact from COVID-19 yet ** Moderna Inc MRNA.O: down 3.9% premarket ** Bluebird Bio Inc BLUE.O: down 1% premarket ** Turning Point Therapeutics Inc TPTX.O: down 6.5% premarket ** Gossamer Bio Inc GOSS.O: down 15.8% premarket ** Krystal Biotech Inc KRYS.O: down 3.2% premarket ** Clovis Oncology Inc CLVS.O: down 6.6% premarket ** Bellerophon Therapeutics Inc BLPH.O: down 14.2% premarket BUZZ-Biotech blitz: Moderna, Bluebird lead $3 bln capital raise wave ** KemPharm Inc KMPH.O: up 15.6% premarket BUZZ-Rises as FDA agrees to review ADHD drug ** Take-Two Interactive Software Inc TTWO.O: up 1.2% premarket BUZZ-Gains as Benchmark raises PT, sees Q4 results beat (Compiled by Amal S in Bengaluru) ((Amal.S@thomsonreuters.com; within U.S.+1 646 223 8780; outside U.S. +91 80 6749 3677;)) The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. Eikon search string for individual stock moves: STXBZ The Day Ahead newsletter: http://tmsnrt.rs/2ggOmBi The Morning News Call newsletter: http://tmsnrt.rs/2fwPLTh U.S. stock index futures were trading flat on Tuesday, handing back some gains from the S&P 500's best day in six weeks in the previous session, as investors digested a mixed set of quarterly results from retailers including Home Depot and Walmart..N At 9:01 ET, Dow e-minis 1YMc1 were down 0.06% at 24,493. S&P 500 e-minis ESc1 were down 0.20% at 2,942.25, while Nasdaq 100 e-minis NQc1 were up 0.09% at 9,333.5. | The top three NYSE percentage gainers premarket .PRPG.NQ: ** Flotek Industries Inc , up 24.3% ** Armstrong Flooring Inc , up 15.6% ** PAR Technology Corp , up 12.0% The top three NYSE percentage losers premarket .PRPL.NQ: ** Four Seasons Edu Inc , down 22.1% ** Hexo Corp , down 14.2% ** Crescent Point Energy Corp , down 8.4% The top three Nasdaq percentage gainers premarket .PRPG.O: ** Immuron Equity Warrants , up 113.1% ** Nano Dimension Ltd , up 59.8% ** Kirkland's Inc , up 47.2% The top three Nasdaq percentage losers premarket .PRPL.O: ** Gamida Cell Ltd , down 24.4% ** Zions Bancorporation NA , down 19.9% ** Gossamer Bio Inc , down 15.8% ** PBF Energy Inc PBF.N: down 1.8% premarket BUZZ-Barclays cuts to 'underweight' on constrained FCF outlook, leverage ** Dynavax Technologies Inc DVAX.O: up 40.5% premarket BUZZ-Up after co says partners may begin COVID-19 vaccine trial in July ** Home Depot Inc HD.N: down 1.2% premarket BUZZ-Profit misses estimates; scraps FY outlook ** Tilray Inc TLRY.O: up 2.9% premarket BUZZ-Road to profitability a long haul for pot producer - brokerage ** Arbutus Biopharama Corp ABUS.O: up 35.8% premarket BUZZ-Jumps on positive data from hepatitis B treatment study ** Moderna Inc MRNA.O: down 3.9% premarket BUZZ-Slips after pricing upsized stock offering to fund COVID-19 vaccine ** Aptiv Plc APTV.N: up 0.6% premarket BUZZ- "Longer pain but sharper recovery" - UBS ** Flotek Industries Inc FTK.N: up 24.3% premarket BUZZ-Rises on acquisition of data and analytics firm ** Bilibili Inc BILI.O: down 2% premarket BUZZ-Falls on bigger-than-expected Q1 loss as marketing spend soars ** Baidu Inc BIDU.O: up 11% premarket BUZZ-Jefferies sees continued revenue growth in H2, raises PT ** Advance Auto Parts Inc AAP.N: up 7.3% premarket BUZZ-Surges as Q2 same store sales look promising ** Walgreens Boots Alliance Inc WBA.O: up 0.6% premarket BUZZ-Underperformance due to COVID-19 is overdone: Cowen ** Tonix Pharmaceuticals Holding Corp TNXP.O: up 5.5% premarket BUZZ-Up after appointing new exec to advance COVID-19 vaccine program ** Oric Pharmaceuticals Inc ORIC.O: up 1.9% premarket BUZZ-Guggenheim sees potential in trial cancer drug, starts with 'buy' ** Southwest Airlines Co LUV.N: up 4% premarket BUZZ-Rises on improving demand for air travel ** Walmart Inc WMT.N: up 3.8% premarket BUZZ-Set to open at 4-week high as stockpiling drives Q1 beat ** Danaos Corp DAC.N: up 11.1% premarket BUZZ-Rises on upbeat Q1, says no impact from COVID-19 yet ** Moderna Inc MRNA.O: down 3.9% premarket ** Bluebird Bio Inc BLUE.O: down 1% premarket ** Turning Point Therapeutics Inc TPTX.O: down 6.5% premarket ** Gossamer Bio Inc GOSS.O: down 15.8% premarket ** Krystal Biotech Inc KRYS.O: down 3.2% premarket ** Clovis Oncology Inc CLVS.O: down 6.6% premarket ** Bellerophon Therapeutics Inc BLPH.O: down 14.2% premarket BUZZ-Biotech blitz: Moderna, Bluebird lead $3 bln capital raise wave ** KemPharm Inc KMPH.O: up 15.6% premarket BUZZ-Rises as FDA agrees to review ADHD drug ** Take-Two Interactive Software Inc TTWO.O: up 1.2% premarket BUZZ-Gains as Benchmark raises PT, sees Q4 results beat (Compiled by Amal S in Bengaluru) ((Amal.S@thomsonreuters.com; within U.S.+1 646 223 8780; outside U.S. +91 80 6749 3677;)) The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. Eikon search string for individual stock moves: STXBZ The Day Ahead newsletter: http://tmsnrt.rs/2ggOmBi The Morning News Call newsletter: http://tmsnrt.rs/2fwPLTh U.S. stock index futures were trading flat on Tuesday, handing back some gains from the S&P 500's best day in six weeks in the previous session, as investors digested a mixed set of quarterly results from retailers including Home Depot and Walmart..N At 9:01 ET, Dow e-minis 1YMc1 were down 0.06% at 24,493. S&P 500 e-minis ESc1 were down 0.20% at 2,942.25, while Nasdaq 100 e-minis NQc1 were up 0.09% at 9,333.5. | The top three NYSE percentage gainers premarket .PRPG.NQ: ** Flotek Industries Inc , up 24.3% ** Armstrong Flooring Inc , up 15.6% ** PAR Technology Corp , up 12.0% The top three NYSE percentage losers premarket .PRPL.NQ: ** Four Seasons Edu Inc , down 22.1% ** Hexo Corp , down 14.2% ** Crescent Point Energy Corp , down 8.4% The top three Nasdaq percentage gainers premarket .PRPG.O: ** Immuron Equity Warrants , up 113.1% ** Nano Dimension Ltd , up 59.8% ** Kirkland's Inc , up 47.2% The top three Nasdaq percentage losers premarket .PRPL.O: ** Gamida Cell Ltd , down 24.4% ** Zions Bancorporation NA , down 19.9% ** Gossamer Bio Inc , down 15.8% ** PBF Energy Inc PBF.N: down 1.8% premarket BUZZ-Barclays cuts to 'underweight' on constrained FCF outlook, leverage ** Dynavax Technologies Inc DVAX.O: up 40.5% premarket BUZZ-Up after co says partners may begin COVID-19 vaccine trial in July ** Home Depot Inc HD.N: down 1.2% premarket BUZZ-Profit misses estimates; scraps FY outlook ** Tilray Inc TLRY.O: up 2.9% premarket BUZZ-Road to profitability a long haul for pot producer - brokerage ** Arbutus Biopharama Corp ABUS.O: up 35.8% premarket BUZZ-Jumps on positive data from hepatitis B treatment study ** Moderna Inc MRNA.O: down 3.9% premarket BUZZ-Slips after pricing upsized stock offering to fund COVID-19 vaccine ** Aptiv Plc APTV.N: up 0.6% premarket BUZZ- "Longer pain but sharper recovery" - UBS ** Flotek Industries Inc FTK.N: up 24.3% premarket BUZZ-Rises on acquisition of data and analytics firm ** Bilibili Inc BILI.O: down 2% premarket BUZZ-Falls on bigger-than-expected Q1 loss as marketing spend soars ** Baidu Inc BIDU.O: up 11% premarket BUZZ-Jefferies sees continued revenue growth in H2, raises PT ** Advance Auto Parts Inc AAP.N: up 7.3% premarket BUZZ-Surges as Q2 same store sales look promising ** Walgreens Boots Alliance Inc WBA.O: up 0.6% premarket BUZZ-Underperformance due to COVID-19 is overdone: Cowen ** Tonix Pharmaceuticals Holding Corp TNXP.O: up 5.5% premarket BUZZ-Up after appointing new exec to advance COVID-19 vaccine program ** Oric Pharmaceuticals Inc ORIC.O: up 1.9% premarket BUZZ-Guggenheim sees potential in trial cancer drug, starts with 'buy' ** Southwest Airlines Co LUV.N: up 4% premarket BUZZ-Rises on improving demand for air travel ** Walmart Inc WMT.N: up 3.8% premarket BUZZ-Set to open at 4-week high as stockpiling drives Q1 beat ** Danaos Corp DAC.N: up 11.1% premarket BUZZ-Rises on upbeat Q1, says no impact from COVID-19 yet ** Moderna Inc MRNA.O: down 3.9% premarket ** Bluebird Bio Inc BLUE.O: down 1% premarket ** Turning Point Therapeutics Inc TPTX.O: down 6.5% premarket ** Gossamer Bio Inc GOSS.O: down 15.8% premarket ** Krystal Biotech Inc KRYS.O: down 3.2% premarket ** Clovis Oncology Inc CLVS.O: down 6.6% premarket ** Bellerophon Therapeutics Inc BLPH.O: down 14.2% premarket BUZZ-Biotech blitz: Moderna, Bluebird lead $3 bln capital raise wave ** KemPharm Inc KMPH.O: up 15.6% premarket BUZZ-Rises as FDA agrees to review ADHD drug ** Take-Two Interactive Software Inc TTWO.O: up 1.2% premarket BUZZ-Gains as Benchmark raises PT, sees Q4 results beat (Compiled by Amal S in Bengaluru) ((Amal.S@thomsonreuters.com; within U.S.+1 646 223 8780; outside U.S. +91 80 6749 3677;)) The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. Eikon search string for individual stock moves: STXBZ The Day Ahead newsletter: http://tmsnrt.rs/2ggOmBi The Morning News Call newsletter: http://tmsnrt.rs/2fwPLTh U.S. stock index futures were trading flat on Tuesday, handing back some gains from the S&P 500's best day in six weeks in the previous session, as investors digested a mixed set of quarterly results from retailers including Home Depot and Walmart..N At 9:01 ET, Dow e-minis 1YMc1 were down 0.06% at 24,493. S&P 500 e-minis ESc1 were down 0.20% at 2,942.25, while Nasdaq 100 e-minis NQc1 were up 0.09% at 9,333.5. | The top three NYSE percentage gainers premarket .PRPG.NQ: ** Flotek Industries Inc , up 24.3% ** Armstrong Flooring Inc , up 15.6% ** PAR Technology Corp , up 12.0% The top three NYSE percentage losers premarket .PRPL.NQ: ** Four Seasons Edu Inc , down 22.1% ** Hexo Corp , down 14.2% ** Crescent Point Energy Corp , down 8.4% The top three Nasdaq percentage gainers premarket .PRPG.O: ** Immuron Equity Warrants , up 113.1% ** Nano Dimension Ltd , up 59.8% ** Kirkland's Inc , up 47.2% The top three Nasdaq percentage losers premarket .PRPL.O: ** Gamida Cell Ltd , down 24.4% ** Zions Bancorporation NA , down 19.9% ** Gossamer Bio Inc , down 15.8% ** PBF Energy Inc PBF.N: down 1.8% premarket BUZZ-Barclays cuts to 'underweight' on constrained FCF outlook, leverage ** Dynavax Technologies Inc DVAX.O: up 40.5% premarket BUZZ-Up after co says partners may begin COVID-19 vaccine trial in July ** Home Depot Inc HD.N: down 1.2% premarket BUZZ-Profit misses estimates; scraps FY outlook ** Tilray Inc TLRY.O: up 2.9% premarket BUZZ-Road to profitability a long haul for pot producer - brokerage ** Arbutus Biopharama Corp ABUS.O: up 35.8% premarket BUZZ-Jumps on positive data from hepatitis B treatment study ** Moderna Inc MRNA.O: down 3.9% premarket BUZZ-Slips after pricing upsized stock offering to fund COVID-19 vaccine ** Aptiv Plc APTV.N: up 0.6% premarket BUZZ- "Longer pain but sharper recovery" - UBS ** Flotek Industries Inc FTK.N: up 24.3% premarket BUZZ-Rises on acquisition of data and analytics firm ** Bilibili Inc BILI.O: down 2% premarket BUZZ-Falls on bigger-than-expected Q1 loss as marketing spend soars ** Baidu Inc BIDU.O: up 11% premarket BUZZ-Jefferies sees continued revenue growth in H2, raises PT ** Advance Auto Parts Inc AAP.N: up 7.3% premarket BUZZ-Surges as Q2 same store sales look promising ** Walgreens Boots Alliance Inc WBA.O: up 0.6% premarket BUZZ-Underperformance due to COVID-19 is overdone: Cowen ** Tonix Pharmaceuticals Holding Corp TNXP.O: up 5.5% premarket BUZZ-Up after appointing new exec to advance COVID-19 vaccine program ** Oric Pharmaceuticals Inc ORIC.O: up 1.9% premarket BUZZ-Guggenheim sees potential in trial cancer drug, starts with 'buy' ** Southwest Airlines Co LUV.N: up 4% premarket BUZZ-Rises on improving demand for air travel ** Walmart Inc WMT.N: up 3.8% premarket BUZZ-Set to open at 4-week high as stockpiling drives Q1 beat ** Danaos Corp DAC.N: up 11.1% premarket BUZZ-Rises on upbeat Q1, says no impact from COVID-19 yet ** Moderna Inc MRNA.O: down 3.9% premarket ** Bluebird Bio Inc BLUE.O: down 1% premarket ** Turning Point Therapeutics Inc TPTX.O: down 6.5% premarket ** Gossamer Bio Inc GOSS.O: down 15.8% premarket ** Krystal Biotech Inc KRYS.O: down 3.2% premarket ** Clovis Oncology Inc CLVS.O: down 6.6% premarket ** Bellerophon Therapeutics Inc BLPH.O: down 14.2% premarket BUZZ-Biotech blitz: Moderna, Bluebird lead $3 bln capital raise wave ** KemPharm Inc KMPH.O: up 15.6% premarket BUZZ-Rises as FDA agrees to review ADHD drug ** Take-Two Interactive Software Inc TTWO.O: up 1.2% premarket BUZZ-Gains as Benchmark raises PT, sees Q4 results beat (Compiled by Amal S in Bengaluru) ((Amal.S@thomsonreuters.com; within U.S.+1 646 223 8780; outside U.S. +91 80 6749 3677;)) The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. Eikon search string for individual stock moves: STXBZ The Day Ahead newsletter: http://tmsnrt.rs/2ggOmBi The Morning News Call newsletter: http://tmsnrt.rs/2fwPLTh U.S. stock index futures were trading flat on Tuesday, handing back some gains from the S&P 500's best day in six weeks in the previous session, as investors digested a mixed set of quarterly results from retailers including Home Depot and Walmart..N At 9:01 ET, Dow e-minis 1YMc1 were down 0.06% at 24,493. S&P 500 e-minis ESc1 were down 0.20% at 2,942.25, while Nasdaq 100 e-minis NQc1 were up 0.09% at 9,333.5. |
34684.0 | 2020-05-19 00:00:00 UTC | BUZZ-U.S. STOCKS ON THE MOVE-Dynavax Technologies, Home Depot, PBF Energy | ABUS | https://www.nasdaq.com/articles/buzz-u.s.-stocks-on-the-move-dynavax-technologies-home-depot-pbf-energy-2020-05-19 | nan | nan | Eikon search string for individual stock moves: STXBZ
The Day Ahead newsletter: http://tmsnrt.rs/2ggOmBi
The Morning News Call newsletter: http://tmsnrt.rs/2fwPLTh
U.S. stock index futures eased on Tuesday, handing back gains from the S&P 500's best day in six weeks in the previous session, as disappointing results from Home Depot HD.N weighed on sentiment..N
At 6:39 ET, Dow e-minis 1YMc1 were down 0.53% at 24,377. S&P 500 e-minis ESc1 were down 0.52% at 2,932.75, while Nasdaq 100 e-minis NQc1 were down 0.28% at 9,299. The top three NYSE percentage gainers premarket .PRPG.NQ: ** Flotek Industries Inc FTK.N, up 24.4%
** Aurora Cannabis Inc , up 14.0% ** Bright Scholar Education Holdngs Ltd , up 7.9% The top three NYSE percentage losers premarket .PRPL.NQ: ** Hexo Corp , down 10.7% ** Baytex Energy Corp , down 9% ** Targa Resources Corp , down 8.3% The top three Nasdaq percentage gainers premarket .PRPG.O: ** Kirkland Lake Gold Ltd , up 60.2% ** Arbutus Biopharma Corp , up 47.6% ** Nano Dimension Ltd , up 45.5% The top three Nasdaq percentage losers premarket .PRPL.O: ** Chinanet Online Holdings Inc CNET.O, down 15.7%
** Gamida Cell Ltd , down 15.3% ** Acasti Pharma Inc , down 14.3% ** PBF Energy Inc PBF.N: down 7.8% premarket BUZZ-Barclays cuts to 'underweight' on constrained FCF outlook, leverage ** Dynavax Technologies Inc DVAX.O: up 38.3% premarket BUZZ-Up after co says partners may begin COVID-19 vaccine trial in July ** Home Depot Inc HD.N: down 2.2% premarket BUZZ-Profit misses estimates; scraps FY outlook ** Tilray Inc TLRY.O: up 2.5% premarket BUZZ-Road to profitability a long haul for pot producer - brokerage
(Compiled by Amal S in Bengaluru)
((Amal.S@thomsonreuters.com; within U.S.+1 646 223 8780; outside U.S. +91 80 6749 3677;))
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Eikon search string for individual stock moves: STXBZ The Day Ahead newsletter: http://tmsnrt.rs/2ggOmBi The Morning News Call newsletter: http://tmsnrt.rs/2fwPLTh U.S. stock index futures eased on Tuesday, handing back gains from the S&P 500's best day in six weeks in the previous session, as disappointing results from Home Depot HD.N weighed on sentiment..N At 6:39 ET, Dow e-minis 1YMc1 were down 0.53% at 24,377. S&P 500 e-minis ESc1 were down 0.52% at 2,932.75, while Nasdaq 100 e-minis NQc1 were down 0.28% at 9,299. The top three NYSE percentage gainers premarket .PRPG.NQ: ** Flotek Industries Inc FTK.N, up 24.4% ** Aurora Cannabis Inc , up 14.0% ** Bright Scholar Education Holdngs Ltd , up 7.9% The top three NYSE percentage losers premarket .PRPL.NQ: ** Hexo Corp , down 10.7% ** Baytex Energy Corp , down 9% ** Targa Resources Corp , down 8.3% The top three Nasdaq percentage gainers premarket .PRPG.O: ** Kirkland Lake Gold Ltd , up 60.2% ** Arbutus Biopharma Corp , up 47.6% ** Nano Dimension Ltd , up 45.5% The top three Nasdaq percentage losers premarket .PRPL.O: ** Chinanet Online Holdings Inc CNET.O, down 15.7% ** Gamida Cell Ltd , down 15.3% ** Acasti Pharma Inc , down 14.3% ** PBF Energy Inc PBF.N: down 7.8% premarket BUZZ-Barclays cuts to 'underweight' on constrained FCF outlook, leverage ** Dynavax Technologies Inc DVAX.O: up 38.3% premarket BUZZ-Up after co says partners may begin COVID-19 vaccine trial in July ** Home Depot Inc HD.N: down 2.2% premarket BUZZ-Profit misses estimates; scraps FY outlook ** Tilray Inc TLRY.O: up 2.5% premarket BUZZ-Road to profitability a long haul for pot producer - brokerage (Compiled by Amal S in Bengaluru) ((Amal.S@thomsonreuters.com; within U.S.+1 646 223 8780; outside U.S. +91 80 6749 3677;)) The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Eikon search string for individual stock moves: STXBZ The Day Ahead newsletter: http://tmsnrt.rs/2ggOmBi The Morning News Call newsletter: http://tmsnrt.rs/2fwPLTh U.S. stock index futures eased on Tuesday, handing back gains from the S&P 500's best day in six weeks in the previous session, as disappointing results from Home Depot HD.N weighed on sentiment..N At 6:39 ET, Dow e-minis 1YMc1 were down 0.53% at 24,377. S&P 500 e-minis ESc1 were down 0.52% at 2,932.75, while Nasdaq 100 e-minis NQc1 were down 0.28% at 9,299. The top three NYSE percentage gainers premarket .PRPG.NQ: ** Flotek Industries Inc FTK.N, up 24.4% ** Aurora Cannabis Inc , up 14.0% ** Bright Scholar Education Holdngs Ltd , up 7.9% The top three NYSE percentage losers premarket .PRPL.NQ: ** Hexo Corp , down 10.7% ** Baytex Energy Corp , down 9% ** Targa Resources Corp , down 8.3% The top three Nasdaq percentage gainers premarket .PRPG.O: ** Kirkland Lake Gold Ltd , up 60.2% ** Arbutus Biopharma Corp , up 47.6% ** Nano Dimension Ltd , up 45.5% The top three Nasdaq percentage losers premarket .PRPL.O: ** Chinanet Online Holdings Inc CNET.O, down 15.7% ** Gamida Cell Ltd , down 15.3% ** Acasti Pharma Inc , down 14.3% ** PBF Energy Inc PBF.N: down 7.8% premarket BUZZ-Barclays cuts to 'underweight' on constrained FCF outlook, leverage ** Dynavax Technologies Inc DVAX.O: up 38.3% premarket BUZZ-Up after co says partners may begin COVID-19 vaccine trial in July ** Home Depot Inc HD.N: down 2.2% premarket BUZZ-Profit misses estimates; scraps FY outlook ** Tilray Inc TLRY.O: up 2.5% premarket BUZZ-Road to profitability a long haul for pot producer - brokerage (Compiled by Amal S in Bengaluru) ((Amal.S@thomsonreuters.com; within U.S.+1 646 223 8780; outside U.S. +91 80 6749 3677;)) The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Eikon search string for individual stock moves: STXBZ The Day Ahead newsletter: http://tmsnrt.rs/2ggOmBi The Morning News Call newsletter: http://tmsnrt.rs/2fwPLTh U.S. stock index futures eased on Tuesday, handing back gains from the S&P 500's best day in six weeks in the previous session, as disappointing results from Home Depot HD.N weighed on sentiment..N At 6:39 ET, Dow e-minis 1YMc1 were down 0.53% at 24,377. S&P 500 e-minis ESc1 were down 0.52% at 2,932.75, while Nasdaq 100 e-minis NQc1 were down 0.28% at 9,299. The top three NYSE percentage gainers premarket .PRPG.NQ: ** Flotek Industries Inc FTK.N, up 24.4% ** Aurora Cannabis Inc , up 14.0% ** Bright Scholar Education Holdngs Ltd , up 7.9% The top three NYSE percentage losers premarket .PRPL.NQ: ** Hexo Corp , down 10.7% ** Baytex Energy Corp , down 9% ** Targa Resources Corp , down 8.3% The top three Nasdaq percentage gainers premarket .PRPG.O: ** Kirkland Lake Gold Ltd , up 60.2% ** Arbutus Biopharma Corp , up 47.6% ** Nano Dimension Ltd , up 45.5% The top three Nasdaq percentage losers premarket .PRPL.O: ** Chinanet Online Holdings Inc CNET.O, down 15.7% ** Gamida Cell Ltd , down 15.3% ** Acasti Pharma Inc , down 14.3% ** PBF Energy Inc PBF.N: down 7.8% premarket BUZZ-Barclays cuts to 'underweight' on constrained FCF outlook, leverage ** Dynavax Technologies Inc DVAX.O: up 38.3% premarket BUZZ-Up after co says partners may begin COVID-19 vaccine trial in July ** Home Depot Inc HD.N: down 2.2% premarket BUZZ-Profit misses estimates; scraps FY outlook ** Tilray Inc TLRY.O: up 2.5% premarket BUZZ-Road to profitability a long haul for pot producer - brokerage (Compiled by Amal S in Bengaluru) ((Amal.S@thomsonreuters.com; within U.S.+1 646 223 8780; outside U.S. +91 80 6749 3677;)) The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Eikon search string for individual stock moves: STXBZ The Day Ahead newsletter: http://tmsnrt.rs/2ggOmBi The Morning News Call newsletter: http://tmsnrt.rs/2fwPLTh U.S. stock index futures eased on Tuesday, handing back gains from the S&P 500's best day in six weeks in the previous session, as disappointing results from Home Depot HD.N weighed on sentiment..N At 6:39 ET, Dow e-minis 1YMc1 were down 0.53% at 24,377. S&P 500 e-minis ESc1 were down 0.52% at 2,932.75, while Nasdaq 100 e-minis NQc1 were down 0.28% at 9,299. The top three NYSE percentage gainers premarket .PRPG.NQ: ** Flotek Industries Inc FTK.N, up 24.4% ** Aurora Cannabis Inc , up 14.0% ** Bright Scholar Education Holdngs Ltd , up 7.9% The top three NYSE percentage losers premarket .PRPL.NQ: ** Hexo Corp , down 10.7% ** Baytex Energy Corp , down 9% ** Targa Resources Corp , down 8.3% The top three Nasdaq percentage gainers premarket .PRPG.O: ** Kirkland Lake Gold Ltd , up 60.2% ** Arbutus Biopharma Corp , up 47.6% ** Nano Dimension Ltd , up 45.5% The top three Nasdaq percentage losers premarket .PRPL.O: ** Chinanet Online Holdings Inc CNET.O, down 15.7% ** Gamida Cell Ltd , down 15.3% ** Acasti Pharma Inc , down 14.3% ** PBF Energy Inc PBF.N: down 7.8% premarket BUZZ-Barclays cuts to 'underweight' on constrained FCF outlook, leverage ** Dynavax Technologies Inc DVAX.O: up 38.3% premarket BUZZ-Up after co says partners may begin COVID-19 vaccine trial in July ** Home Depot Inc HD.N: down 2.2% premarket BUZZ-Profit misses estimates; scraps FY outlook ** Tilray Inc TLRY.O: up 2.5% premarket BUZZ-Road to profitability a long haul for pot producer - brokerage (Compiled by Amal S in Bengaluru) ((Amal.S@thomsonreuters.com; within U.S.+1 646 223 8780; outside U.S. +91 80 6749 3677;)) The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. |
34685.0 | 2020-05-18 00:00:00 UTC | ABUS Up On HBV Trial Data, VIR's COVID-19 Therapies On Track, All Eyes On DVAX | ABUS | https://www.nasdaq.com/articles/abus-up-on-hbv-trial-data-virs-covid-19-therapies-on-track-all-eyes-on-dvax-2020-05-18 | nan | nan | (RTTNews) - Today's Daily Dose brings you news about positive results from Arbutus' HBV trial; encouraging phase I results of Moderna's COVID-19 vaccine candidate; biotech stocks hitting new highs and Vir Biotechnology's progress in the battle against the novel coronavirus.
Read on…
Shares of Arbutus Biopharma Corp. (ABUS) jumped more than 50% in extended trading on Monday, following positive follow-up data from a Phase 1a/1b clinical trial of a single subcutaneous injection AB-729 in patients having a chronic Hepatitis B Virus infection.
According to the results, at week 12, the 60 mg single-dose of AB-729 achieved equivalent reductions in HBsAg, the surface antigen of the hepatitis B virus, as the 180 mg single-dose.
The Company is also exploring an additional 90 mg single-dose cohort, with results anticipated in the second half of 2020.
ABUS closed Monday's trading at $1.87, down 10.95%. In after-hours, the stock was up 53.48% at $2.87.
Dynavax Technologies Corporation (DVAX) will be providing an update on its early-stage collaborations regarding the potential development of a vaccine for COVID-19 tomorrow, May 19, 2020.
The Company's potential COVID-19 vaccine candidate contains the proprietary toll-like receptor 9 agonist adjuvant CpG-1018 ("CpG-1018"), the adjuvant used in the HEPLISAV-B product.
Dynavax' HEPLISAV-B is a Hepatitis B Vaccine for the prevention of infection caused by all known subtypes of hepatitis B virus in adults age 18 years and older.
DVAX closed Monday's trading at $4.86, up 6.81%. In after-hours, the stock was up 41.56% at $6.88.
Shares of Moderna Inc. (MRNA) hit an all-time high on Monday, following positive interim clinical data from a phase I study of mRNA-1273, its vaccine candidate against novel coronavirus (SARS-CoV-2).
According to the Company, after two doses all participants in the phase I study evaluated to date across the 25 µg and 100 µg dose cohorts developed detectable antibodies in the blood against the novel coronavirus at or above levels seen in convalescent sera.
The mRNA-1273 vaccine candidate elicited neutralizing antibody titer levels in all eight initial participants across the 25 µg and 100 µg dose cohorts, reaching or exceeding neutralizing antibody titers generally seen in convalescent sera, the Company noted. Neutralizing antibodies interferes with a virus/pathogen's ability to infect a cell.
The phase I study was led by the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH).
A phase II study of mRNA-1273 is being conducted by Moderna. Based on the interim Phase 1 data, the Moderna-led Phase 2 study will be amended to study two dose levels, 50 µg, and 100 µg, with the aim of selecting a dose for pivotal studies.
The NIAID-led Phase 1 study is being amended to include a 50 µg dose level cohort. Moderna anticipates the dose for the Phase 3 study, which is expected to be initiated in July, to be between 25 µg and 100 µg.
Later in the day, Moderna announced that it has commenced an underwritten public offering of $1.25 billion in shares of common stock, with underwriters having a 30-day option to purchase up to an additional $187.5 million in shares of common stock.
MRNA touched an all-time high of $87 in intraday trading on Monday, before closing at $80.00, up 19.96%.
Shares of Novavax Inc. (NVAX) closed Monday's trading at a two-year high of $56.96, up 30.55% on no company-specific news. The stock has gained 215% so far this month, thanks to the progress in the Company's COVID-19 vaccine program and the funding it has been receiving for the vaccine development.
NVX-CoV2373, the Company's COVID-19 vaccine candidate, is under phase I portion of the phase I/II trial. The preliminary immunogenicity and safety results from the phase I portion of the NVX-CoV2373 vaccine trial are expected in July.
The top-line data from a phase IIb clinical trial of Serum Institute of India's malaria vaccine candidate, being conducted in Burkina Faso, in West Africa, are expected this quarter. Novavax's Matrix-M vaccine adjuvant is a key component of this malaria vaccine candidate.
Novavax has the rights to sell and distribute the Serum Institute of India-manufactured vaccine in high-income countries, primarily in the travelers and military vaccine markets.
Related reading
The Rise And Rise Of Novavax
NVAX closed Monday's trading at $56.96, up 30.55%.
Sorrento Therapeutics Inc. (SRNE) touched a new 52-week intraday high of $10 in Monday's trading before closing at $6.50.
The Company is also developing potential coronavirus antiviral therapies and vaccines.
In preclinical experiments, STI-1499, one of the antibodies identified by the Company, completely blocked SARS-CoV-2 infection of healthy cells and neutralized the virus infectivity at a very low antibody dose.
Sorrento is planning to generate an antibody cocktail product that would act as a "protective shield" against SARS-CoV-2 coronavirus infection and remain effective even if virus mutations render a single antibody therapy less effective over time.
Given the impressive results, the Company has chosen STI-1499 as the first antibody in the antibody cocktail (COVI-SHIELD) it is developing. STI-1499 is also expected to be developed as a stand-alone therapy, (COVI-GUARD) because of the high potency it has exhibited in experiments to date.
SRNE closed Monday's trading at $6.50, down 3.85%. In after-hours, the stock was up 8.92% at $7.08.
Sophiris Bio Inc. (SPHS.OB), a late-stage clinical biopharmaceutical company, is all set to shut down operations as the Company has not been able to find a partner or raise capital to support its operations.
The Company's shares were delisted from The Nasdaq Stock Market on March 12, 2020, due to non-compliance with the minimum $2.5 million stockholders' equity requirement.
The lead asset of Sophiris is Topsalysin, which has completed two Phase 2 clinical trials for the focal treatment of localized prostate cancer and one Phase 3 study for the treatment of the lower urinary tract symptoms of benign prostatic hyperplasia (BPH).
Commenting on the developments, Randall Woods, president, and CEO said, "We have conducted an extensive year-long process with the assistance of an experienced financial advisor to identify potential strategic buyers and partners to support the continued development of topsalysin. During the process, we had contacts with more than 70 strategic and financial parties including biopharma companies, healthcare investment funds, and strategic financing companies. We held discussions, including management presentations and more extensive due diligence, with many of these parties and the process regrettably did not result in any actionable transaction."
Vir Biotechnology Inc. (VIR) is advancing two clinical development candidates, VIR-7831 and VIR-7832, as potential therapeutics for COVID-19, in collaboration with GlaxoSmithKline plc (GSK).
VIR-7831 and VIR-7832 are based on S309, an antibody isolated from a patient who recovered from severe acute respiratory syndrome (SARS) in 2003, which has been shown to prevent SARS-CoV-2 live virus infection of cells.
Since the S309 antibody likely covers the entire family of related coronaviruses, even as SARS-CoV-2 continues to evolve, it may be quite challenging for it to become resistant to the neutralizing activity of S309, said Herbert "Skip" Virgin, Chief Scientific Officer of the Company.
VIR-7831 and VIR-7832 are expected to enter clinical testing this summer.
VIR closed Monday's trading at $40.10, up 32.13%.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Read on… Shares of Arbutus Biopharma Corp. (ABUS) jumped more than 50% in extended trading on Monday, following positive follow-up data from a Phase 1a/1b clinical trial of a single subcutaneous injection AB-729 in patients having a chronic Hepatitis B Virus infection. ABUS closed Monday's trading at $1.87, down 10.95%. The top-line data from a phase IIb clinical trial of Serum Institute of India's malaria vaccine candidate, being conducted in Burkina Faso, in West Africa, are expected this quarter. | Read on… Shares of Arbutus Biopharma Corp. (ABUS) jumped more than 50% in extended trading on Monday, following positive follow-up data from a Phase 1a/1b clinical trial of a single subcutaneous injection AB-729 in patients having a chronic Hepatitis B Virus infection. ABUS closed Monday's trading at $1.87, down 10.95%. (RTTNews) - Today's Daily Dose brings you news about positive results from Arbutus' HBV trial; encouraging phase I results of Moderna's COVID-19 vaccine candidate; biotech stocks hitting new highs and Vir Biotechnology's progress in the battle against the novel coronavirus. | Read on… Shares of Arbutus Biopharma Corp. (ABUS) jumped more than 50% in extended trading on Monday, following positive follow-up data from a Phase 1a/1b clinical trial of a single subcutaneous injection AB-729 in patients having a chronic Hepatitis B Virus infection. ABUS closed Monday's trading at $1.87, down 10.95%. (RTTNews) - Today's Daily Dose brings you news about positive results from Arbutus' HBV trial; encouraging phase I results of Moderna's COVID-19 vaccine candidate; biotech stocks hitting new highs and Vir Biotechnology's progress in the battle against the novel coronavirus. | Read on… Shares of Arbutus Biopharma Corp. (ABUS) jumped more than 50% in extended trading on Monday, following positive follow-up data from a Phase 1a/1b clinical trial of a single subcutaneous injection AB-729 in patients having a chronic Hepatitis B Virus infection. ABUS closed Monday's trading at $1.87, down 10.95%. NVX-CoV2373, the Company's COVID-19 vaccine candidate, is under phase I portion of the phase I/II trial. |
34686.0 | 2020-05-14 00:00:00 UTC | 3 “Strong Buy” Penny Stocks With Triple-Digit Upside | ABUS | https://www.nasdaq.com/articles/3-strong-buy-penny-stocks-with-triple-digit-upside-2020-05-14 | nan | nan | Given the troubling state of the U.S. economy, what’s driving the bullish sentiment on Wall Street? Stimulus.
Among the bulls is chief investment strategist at CFRA, Sam Stovall, who estimates that the S&P 500 will hit 3,435 within a year. From current levels, this would reflect a double-digit gain, and come in above the 3,393 high-point posted on February 19. Back in March, he even went so far as to call for a new high in the third quarter, but since then he has updated his forecasts.
“We’ve had a lot of people compare it with the Crash of ’29, the Depression of the 1930s, etc. But back then, you had the government actually tightening their reins, balancing their budget — you did not have a reactive Federal Reserve,” Stovall stated. He added, “Who’s to say we don’t go for a retest first? That’s a normal situation. However, I don’t think we’re going to get an even lower low because of the stimulus already injected into the system.”
To this end, risk-tolerant investors are looking to take advantage of lower share prices, which present more attractive entry points. What’s the advantage of stocks with bargain price tags, specifically those trading for less than $5 per share? Should these names, which are deemed “penny stocks," experience even minor share price appreciation, it can translate to massive percentage gains.
Therefore, huge returns are on the table, but penny stocks aren’t everyone’s cup of tea. Some argue that there could be a good reason they are trading at such low levels, and that the risk outweighs the potential rewards.
Understanding the risk involved, we wanted to see if we could track down any compelling penny stocks in the healthcare space. Using TipRanks’ database, we pinpointed three that have received enough support from Wall Street analysts to earn a “Strong Buy” consensus rating. The cherry on top? All three of the tickers could double in the next year. Let’s dive in.
Marinus Pharmaceuticals, Inc. (MRNS)
Focused on the development of neuropsychiatric therapeutics, Marinus is one of the top players in the orphan epileptic disorder space. Following a first quarter update on the company’s progress, Wall Street believes its long-term growth narrative is strong and that its $2.06 share price reflects the ideal entry point.
As part of the update, management announced that the design and dosing for the RSE pivotal Phase 3 trial for its lead development candidate, ganaxolone (GNX), had been confirmed, with it set to begin in the third quarter. The co-primary endpoints for the trial are status cessation within 30 minutes and suppression for at least 24 hours, and it will be powered 90% to hopefully show 30% efficacy for GNX when compared to the placebo.
Commenting for Oppenheimer, analyst Jay Olson said, “We view pivotal Phase 3 design as similar to positive Phase 2 trial while benefiting from longer dosing with 12 hours exposure vs. 8 hours prior. MRNS expects top-line data in the first half of 2022.”
Additionally, the company finished enrolling participants for its CDD pivotal Phase 3 MARIGOLD trial, with the top-line data also slated for release in the third quarter. Olson argues that the discontinuation rate of less than 10% and high enrollment rate imply that tolerability levels are “favorable." The analyst added, “Pre-commercialization and NDA filing preparations remain on track despite COVID-19. We believe MRNS could have a substantial competitive advantage as a first mover.”
If that wasn’t enough, Olson thinks the TSC Phase 2 open-label trial, which should start screening patients in Q2 and could see top-line data published in Q1 2021, could serve as a significant catalyst for shares. While COVID-19's impact on enrollment caused management to downsize the PRE Phase 3 VIOLET trial into a Phase 2 proof-of-concept trial in order to reprioritize resources, MRNS still has plenty going for it.
“We view MRNS as well-positioned despite potential COVID-19 disruptions, with $77.8 million cash balance providing runway into 3Q21. We view MRNS's pipeline as attractive with multiple opportunities and several key near-term catalysts. We believe the current share price provides an attractive entry point,” Olson explained.
To this end, Olson kept his Outperform call and $6 price target as is. Should this target be met, a twelve-month gain of 191% could be in store. (To watch Olson’s track record, click here)
What does the rest of the Street think about Marinus’ long-term growth prospects? It turns out that other analysts also have high hopes. Only Buy ratings have been received in the last three months, so the consensus rating is a Strong Buy. In addition, the $5.50 average price target suggests 168% upside potential. (See Marinus stock analysis on TipRanks)
Arbutus Biopharma Corporation (ABUS)
With a diverse chronic hepatitis B virus (HBV) product pipeline including direct antiviral, host targeting and immune-based approaches, Arbutus Biopharma wants to develop a cure for the condition. Currently going for $1.65 apiece, several members of the Street think now is the time to get on board as multiple catalysts are fast-approaching.
On May 11, the company revealed that it plans to share further results from the week 12 portion of the 60 mg single-dose cohort evaluating its lead candidate, a GalNAc delivered RNAi compound, AB-729, in the second quarter of 2020.
Five-star analyst Mayank Mamtani, of B.Riley FBR, points out that preliminary data from the Phase 1a/1b AB-729 HBV study showed an HBsAg reduction comparable to advanced RNAi peers, even though it enrolled difficult to treat e-antigen negative patients. As HBsAg reduction rose during the study, the analyst argues that this increases the chances of successful follow-up data.
On top of this, ABUS has several ongoing preclinical studies that are progressing right on track, enabling it to advance its next-generation oral capsid inhibitor, AB-836, into the clinic in 2021. This goes hand in hand with the company’s research efforts to develop an oral HBV RNA-destabilizer and an oral anti-PD-L1 inhibitor. Expounding on this, Mamtani commented, “Building on learnings from the previously discontinued AB-506, AB-836 offers increased potency and an enhanced resistance profile with ongoing IND-enabling studies inclusive of a new assay to help better characterize the safety profile.”
It should also be noted that ABUS is going to start working on a therapy for coronaviruses, specifically targeting RNA-dependent polymerase, nsp12, and viral protease, which play key roles in the replication and transcription cycle of COVID-19. Mamtani thinks this approach is promising as Gilead’s experimental COVID-19 treatment, remdesivir, is a nucleotide analog that binds nsp12, which inhibits viral proliferation and produces clinical benefits.
Mamtani added, “Nsp12 has also been implicated in HCV, HIV, and, notably, HBV, areas in which ABUS has extensive antiviral development expertise. In concert with the biotech and pharma COVID-19 consortium, ABUS anticipates pooling resources along with leveraging primary screening and lead optimization capabilities to advance novel candidates against known and unknown targets, which works ideally as a pan coronavirus agent in order to also prepare for future outbreaks.”
Based on all of the above, it’s no wonder Mamtani reiterated his bullish call. Given the $6 price target, shares could soar 253% in the next twelve months. (To watch Mamtani’s track record, click here)
Turning now to the rest of the Street, other analysts are on the same page. With 100% Street support, or 3 Buy ratings to be exact, the consensus is unanimous: ABUS is a Strong Buy. The $5 average price target brings the upside potential to 198.5%. (See Arbutus Biopharma stock analysis on TipRanks)
Geron Corporation (GERN)
Last but not least we have Geron, which is primarily focused on the development of imetelstat, a small molecule telomerase inhibitor active in the treatment of highly transfusion-dependent MDS and r/r myelofibrosis (MF). While it’s very likely that the company will experience some delays as a result of COVID-19, the Street cites its promising technology and bargain $1.36 share price as making it a compelling healthcare play.
Some investors have expressed concern regarding GERN’s announcement that it won’t be able to complete enrollment for the Phase 3 IMerge trial by 2020 due to the impact of COVID-19. BTIG analyst Thomas Shrader acknowledges that the delay will push back imetelstat’s approval and launch, which he now thinks will come in 2024 instead of 2023. However, he argued, “Geron’s patients are as desperate as they come in r/r MDS and AML and we expect data to date leave physicians and patients highly motivated to find something to try.”
Further explaining the MDS opportunity, Shrader believes the program demonstrates robust levels of durability. Not only does the five-star analyst call the 24-week RBC-TI rate “highly compelling”, but he also highlights the strong safety profile.
Shrader said, “Greater than 90% of patients with neutropenias and thrombocytopenias had these AEs resolve prior to the next dose. This reversibility is in contrast to both HMAs and Revlimid where these toxicities result in drug interruptions. A KOL recently commented that the high 68% HI-E response suggests most patients receive some benefit – making any subsequent trials very easy to enroll.”
It should be noted that previously, its IMbark trial had a 32% discontinuation rate thanks to lack of efficacy, but Shrader thinks “these discontinuations may have been premature due to the drug’s slow onset of action and its ‘black box nature’ during the trial.” He added, “Based on increased understanding of how imetelstat works and its promise as a therapeutic, this discontinuation rate is likely to be low in subsequent trials. Imetelstat seems likely to be used after luspatercept in RS+ MDS but could be the only drug after ESAs in other forms of the disease (including RS-).”
With GERN working out the MF trial design and hoping to discuss the regulatory path forward with the FDA in Q2, the deal is sealed for Shrader. Along with a Buy rating, he did trim the price target from $4 to $3, but this still leaves room for 114% upside potential. (To watch Shrader’s track record, click here)
All in all, other analysts echo Shrader’s sentiment. 3 Buys and no Holds or Sells add up to a Strong Buy consensus rating. Based on the $3.50 average price target, the upside potential comes in at 149%. (See Geron stock analysis on TipRanks)
To find good ideas for stocks trading at attractive valuations, visit TipRanks’ Best Stocks to Buy, a newly launched tool that unites all of TipRanks’ equity insights.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Expounding on this, Mamtani commented, “Building on learnings from the previously discontinued AB-506, AB-836 offers increased potency and an enhanced resistance profile with ongoing IND-enabling studies inclusive of a new assay to help better characterize the safety profile.” It should also be noted that ABUS is going to start working on a therapy for coronaviruses, specifically targeting RNA-dependent polymerase, nsp12, and viral protease, which play key roles in the replication and transcription cycle of COVID-19. In concert with the biotech and pharma COVID-19 consortium, ABUS anticipates pooling resources along with leveraging primary screening and lead optimization capabilities to advance novel candidates against known and unknown targets, which works ideally as a pan coronavirus agent in order to also prepare for future outbreaks.” Based on all of the above, it’s no wonder Mamtani reiterated his bullish call. (See Marinus stock analysis on TipRanks) Arbutus Biopharma Corporation (ABUS) With a diverse chronic hepatitis B virus (HBV) product pipeline including direct antiviral, host targeting and immune-based approaches, Arbutus Biopharma wants to develop a cure for the condition. | (See Marinus stock analysis on TipRanks) Arbutus Biopharma Corporation (ABUS) With a diverse chronic hepatitis B virus (HBV) product pipeline including direct antiviral, host targeting and immune-based approaches, Arbutus Biopharma wants to develop a cure for the condition. On top of this, ABUS has several ongoing preclinical studies that are progressing right on track, enabling it to advance its next-generation oral capsid inhibitor, AB-836, into the clinic in 2021. Expounding on this, Mamtani commented, “Building on learnings from the previously discontinued AB-506, AB-836 offers increased potency and an enhanced resistance profile with ongoing IND-enabling studies inclusive of a new assay to help better characterize the safety profile.” It should also be noted that ABUS is going to start working on a therapy for coronaviruses, specifically targeting RNA-dependent polymerase, nsp12, and viral protease, which play key roles in the replication and transcription cycle of COVID-19. | (See Marinus stock analysis on TipRanks) Arbutus Biopharma Corporation (ABUS) With a diverse chronic hepatitis B virus (HBV) product pipeline including direct antiviral, host targeting and immune-based approaches, Arbutus Biopharma wants to develop a cure for the condition. On top of this, ABUS has several ongoing preclinical studies that are progressing right on track, enabling it to advance its next-generation oral capsid inhibitor, AB-836, into the clinic in 2021. Expounding on this, Mamtani commented, “Building on learnings from the previously discontinued AB-506, AB-836 offers increased potency and an enhanced resistance profile with ongoing IND-enabling studies inclusive of a new assay to help better characterize the safety profile.” It should also be noted that ABUS is going to start working on a therapy for coronaviruses, specifically targeting RNA-dependent polymerase, nsp12, and viral protease, which play key roles in the replication and transcription cycle of COVID-19. | (See Marinus stock analysis on TipRanks) Arbutus Biopharma Corporation (ABUS) With a diverse chronic hepatitis B virus (HBV) product pipeline including direct antiviral, host targeting and immune-based approaches, Arbutus Biopharma wants to develop a cure for the condition. On top of this, ABUS has several ongoing preclinical studies that are progressing right on track, enabling it to advance its next-generation oral capsid inhibitor, AB-836, into the clinic in 2021. Expounding on this, Mamtani commented, “Building on learnings from the previously discontinued AB-506, AB-836 offers increased potency and an enhanced resistance profile with ongoing IND-enabling studies inclusive of a new assay to help better characterize the safety profile.” It should also be noted that ABUS is going to start working on a therapy for coronaviruses, specifically targeting RNA-dependent polymerase, nsp12, and viral protease, which play key roles in the replication and transcription cycle of COVID-19. |
34687.0 | 2020-03-24 00:00:00 UTC | 9 Pharma/Biotech Stocks To Watch This Week, Here's Why... | ABUS | https://www.nasdaq.com/articles/9-pharma-biotech-stocks-to-watch-this-week-heres-why...-2020-03-24 | nan | nan | (RTTNews) - The end of the first quarter is just around the corner. Will the biotech/pharma companies like the ones listed below, which are slated to report the trial results this quarter, stick to the deadline?
1. Akero Therapeutics Inc. (AKRO)
Akero Therapeutics is a clinical-stage biotechnology company developing therapies for metabolic diseases like nonalcoholic steatohepatitis (NASH).
The Company's sole product candidate is AKR-001, a potential treatment for patients with NASH, which is under a phase IIa study, dubbed BALANCED.
Catalyst due:
The Company remains on track to report the primary endpoint results of the BALANCED study in the first quarter of 2020. Top-line results related to secondary endpoints, including safety and tolerability as well as paired biopsies for patients who achieve at least 30% relative reduction in liver fat at week 12, are expected n the second quarter of 2020.
Cash position:
Akero's cash, cash equivalents, and short-term marketable securities on December 31, 2019, were $136.4 million.
AKRO has traded in a range of $10.78 to $34.00 in the last 1 year. The stock closed Monday's trading at $16.56, down 1.90%.
2. Allakos Inc. (ALLK)
Allakos is a clinical-stage biotechnology company focused on developing therapeutic antibodies for the treatment of various eosinophil and mast cell-related diseases.
The lone product candidate of Allakos is AK002, which is being developed as treatment for Eosinophilic Gastritis, Eosinophilic Esophagitis, Indolent Systemic Mastocytosis, Chronic Urticaria and Severe allergic conjunctivitis.
Catalyst due:
The clinical safety and efficacy results from a six-month, open-label phase I study of AK002 in patients with Mast Cell Gastrointestinal Disease (MGID), are due in the first quarter of 2020.
Cash position:
Allakos ended the year 2019 with $495.9 million in cash, cash equivalents and marketable securities.
ALLK has traded in a range of $30.32 to $139.99. The stock closed Monday's trading at $56.62, down 3.90%.
3. Arbutus Biopharma Corp. (ABUS)
Arbutus is a biopharmaceutical company developing a cure for patients suffering from chronic Hepatitis B infection.
The Company's lone clinical drug candidate is AB-729 for people with chronic hepatitis B.
Catalyst due:
A phase 1a/1b clinical trial of AB-729 in healthy volunteers and in subjects with chronic hepatitis B (CHB) infection is underway. Preliminary safety and efficacy data from both healthy subjects and several single-dose cohorts of subjects with chronic hepatitis B infection are due this quarter.
Cash position:
Arbutus had cash, cash equivalents and short-term investments totaling $90.8 million as of December 31, 2019.
ABUS has traded in a range of $0.82 to $4.56 in the last 1 year. The stock closed Monday's trading at $1.65, up 14.58%.
4. Axsome Therapeutics Inc. (AXSM)
Axsome is a clinical-stage biopharmaceutical company developing novel medicines for the management of central nervous system disorders.
The Company has two drug candidates in phase III testing - AXS-05 for treatment-resistant depression, Alzheimer's disease and major depressive disorder, and AXS-07 for the treatment of migraine.
Catalyst due:
Topline results from a phase III trial of AXS-05 in treatment-resistant depression, dubbed STRIDE, and topline results from a phase III trial of AXS-07 in treatment of migraine, known as INTERCEPT, are due this quarter.
Cash position:
The Company ended the year 2019 with $220.0 million in cash.
AXSM has traded in a range of $12.76 to $109.94 in the last 1 year. The stock closed Monday's trading at $63.91, up 17.48%.
5.Immunovant Inc. (IMVT)
Immunovant is the result of the merger between publicly-traded Health Sciences Acquisitions Corp. and privately held Immunovant Sciences Ltd. that occurred last December.
The Company's lead product candidate is IMVT-1401, a novel, fully human monoclonal antibody targeting the neonatal Fc receptor (FcRn), with the potential to address a variety of immunoglobulin G (IgG)-mediated autoimmune diseases as a subcutaneous injection.
Catalyst due:
Initial results from ASCEND-GO 1, the phase IIa clinical trial of IMVT-1401 for the treatment of Graves' ophthalmopathy, are due in the first quarter.
Cash position:
The Company ended the year 2019 with cash of $123.5 million.
IMVT has traded in a range of $8.34 to $18.69 in the last 1 year. The stock closed Monday's trading at $11.01, up 18.64%.
6. Iterum Therapeutics plc (ITRM)
Iterum Therapeutics is a clinical-stage pharmaceutical company developing next-generation oral and IV antibiotics to treat infections caused by multi-drug resistant pathogens.
The Company's lead and first compound, Sulopenem, a novel penem anti-infective compound, is in phase III clinical development in oral and IV formulations.
Catalysts due:
The topline results from a phase III trial of oral Sulopenem in uncomplicated urinary tract infections, dubbed SURE 1, and topline results from a phase III trial of oral and IV Sulopenem in complicated urinary tract infections, dubbed SURE 2, are on track to be reported around the end of this quarter.
Cash position:
As of December 31, 2019, Iterum had cash and cash equivalents of $4.8 million. In January 2020, the Company raised net proceeds of $46.7 million from the private placement with accredited investors.
ITRM has traded in a range of $1.40 to $9.30 in the last 1 year. The stock closed Monday's trading at $1.94, up 7.78%.
7. Myovant Sciences (MYOV)
Myovant is a healthcare company focused on developing innovative treatments for women's health and prostate cancer.
The Company's lead drug candidate is Relugolix for the treatment of uterine fibroids, endometriosis, and advanced prostate cancer.
Catalyst due:
Topline data from a phase III study evaluating the safety and efficacy of Relugolix combination therapy in women with pain associated with endometriosis, dubbed SPIRIT 2 is due in the first quarter of 2020.
Cash position:
As of December 31, 2019, the Company had cash, cash equivalents, and marketable securities of $98.9 million and $286.3 million of available borrowing capacity under the loan facility from Sumitomo Dainippon Pharma.
MYOV has traded in a range of $4.14 to $26.02 in the last 1 year. The stock closed Monday's trading at $7.49, unchanged from the previous day's close.
8. Novavax Inc. (NVAX)
Novavax is a late-stage biotechnology company developing next-generation vaccines for serious infectious diseases.
The Company has two late-stage product candidates NanoFlu, a recombinant hemagglutinin (HA) protein nanoparticle influenza vaccine, and ResVax, an aluminum adjuvanted respiratory syncytial virus (RSV) fusion (F) protein recombinant nanoparticle vaccine.
Catalyst due:
Topline data from a phase III clinical trial evaluating the immunogenicity and safety of NanoFlu against the quadrivalent formulation of Fluzone is due this month. The primary objective of this trial is to demonstrate non-inferior immunogenicity of NanoFlu as measured by hemagglutination inhibition (HAI) titers of vaccine homologous influenza strains and safety compared against the approved Fluzone Quadrivalent.
Cash position:
As of December 31, 2019, Novavax had $82.2 million in cash, cash equivalents, marketable securities, and restricted cash.
NVAX has traded in a range of $3.54 to $17.71 in the last 1 year. The stock closed Monday's trading at $10.76, up 3.96%.
9. Ovid Therapeutics Inc. (OVID)
Ovid Therapeutics is a clinical-stage company focused on developing treatments for rare neurological disorders.
The Company's most advanced investigational medicine is OV101, currently in clinical development for the treatment of Angelman syndrome and Fragile X syndrome. Ovid is also developing OV935 (soticlestat) in collaboration with Takeda Pharm for the potential treatment of rare developmental and epileptic encephalopathies (DEE).
Catalyst due:
Initial data from an ongoing open-label phase II study of Soticlestat in CDKL5 deficiency disorder and Dup15q syndrome, dubbed ARCADE, is due by the end of the first quarter of 2020.
Cash position:
As of December 31, 2019, the Company's cash, cash equivalents, and short-term investments totaled $76.7 million.
OVID has traded in a range of $1.53 to $5.24 in the last 1 year. The stock closed Monday's trading at $2.42, up 5.68%.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Arbutus Biopharma Corp. (ABUS) Arbutus is a biopharmaceutical company developing a cure for patients suffering from chronic Hepatitis B infection. ABUS has traded in a range of $0.82 to $4.56 in the last 1 year. The Company's lead product candidate is IMVT-1401, a novel, fully human monoclonal antibody targeting the neonatal Fc receptor (FcRn), with the potential to address a variety of immunoglobulin G (IgG)-mediated autoimmune diseases as a subcutaneous injection. | Arbutus Biopharma Corp. (ABUS) Arbutus is a biopharmaceutical company developing a cure for patients suffering from chronic Hepatitis B infection. ABUS has traded in a range of $0.82 to $4.56 in the last 1 year. Catalyst due: Topline results from a phase III trial of AXS-05 in treatment-resistant depression, dubbed STRIDE, and topline results from a phase III trial of AXS-07 in treatment of migraine, known as INTERCEPT, are due this quarter. | Arbutus Biopharma Corp. (ABUS) Arbutus is a biopharmaceutical company developing a cure for patients suffering from chronic Hepatitis B infection. ABUS has traded in a range of $0.82 to $4.56 in the last 1 year. Catalyst due: Topline results from a phase III trial of AXS-05 in treatment-resistant depression, dubbed STRIDE, and topline results from a phase III trial of AXS-07 in treatment of migraine, known as INTERCEPT, are due this quarter. | Arbutus Biopharma Corp. (ABUS) Arbutus is a biopharmaceutical company developing a cure for patients suffering from chronic Hepatitis B infection. ABUS has traded in a range of $0.82 to $4.56 in the last 1 year. The Company's sole product candidate is AKR-001, a potential treatment for patients with NASH, which is under a phase IIa study, dubbed BALANCED. |
34688.0 | 2019-10-04 00:00:00 UTC | Health Care Sector Update for 10/04/2019: ABUS, HRTX, SPPI, JNJ, PFE, ABT, MRK, AMGN | ABUS | https://www.nasdaq.com/articles/health-care-sector-update-for-10-04-2019%3A-abus-hrtx-sppi-jnj-pfe-abt-mrk-amgn-2019-10-04 | nan | nan | Top Health Care Stocks:
JNJ: +0.21%
PFE: +0.17%
ABT: +0.32%
MRK: -0.69%
AMGN: Flat
Health care giants were mixed pre-bell Friday.
Stocks moving on news include:
(-) Arbutus Biopharma (ABUS), which was slumping by over 25% after saying it has discontinued the clinical development of AB-506, an oral capsid inhibitor, which was in in a phase 1a/1b clinical trial for the treatment of chronic hepatitis B.
(-) Heron Therapeutics (HRTX) was declining by more than 5% after saying it plans to sell 8,571,429 common shares in an underwritten registered public offering at $17.50 per share, for gross proceeds of about $150 million.
(+) Spectrum Pharmaceuticals (SPPI) was gaining more than 3% as it reported positive results from a phase 2 study of poziotinib to treat non-small cell lung cancer (NSCLC) patients.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Stocks moving on news include: (-) Arbutus Biopharma (ABUS), which was slumping by over 25% after saying it has discontinued the clinical development of AB-506, an oral capsid inhibitor, which was in in a phase 1a/1b clinical trial for the treatment of chronic hepatitis B. AMGN: Flat Health care giants were mixed pre-bell Friday. (+) Spectrum Pharmaceuticals (SPPI) was gaining more than 3% as it reported positive results from a phase 2 study of poziotinib to treat non-small cell lung cancer (NSCLC) patients. | Stocks moving on news include: (-) Arbutus Biopharma (ABUS), which was slumping by over 25% after saying it has discontinued the clinical development of AB-506, an oral capsid inhibitor, which was in in a phase 1a/1b clinical trial for the treatment of chronic hepatitis B. Top Health Care Stocks: AMGN: Flat Health care giants were mixed pre-bell Friday. | Stocks moving on news include: (-) Arbutus Biopharma (ABUS), which was slumping by over 25% after saying it has discontinued the clinical development of AB-506, an oral capsid inhibitor, which was in in a phase 1a/1b clinical trial for the treatment of chronic hepatitis B. (-) Heron Therapeutics (HRTX) was declining by more than 5% after saying it plans to sell 8,571,429 common shares in an underwritten registered public offering at $17.50 per share, for gross proceeds of about $150 million. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Stocks moving on news include: (-) Arbutus Biopharma (ABUS), which was slumping by over 25% after saying it has discontinued the clinical development of AB-506, an oral capsid inhibitor, which was in in a phase 1a/1b clinical trial for the treatment of chronic hepatitis B. Top Health Care Stocks: AMGN: Flat Health care giants were mixed pre-bell Friday. |
34689.0 | 2019-06-20 00:00:00 UTC | Health Care Sector Update for 06/20/2019: ABUS,DMAC,EDSA,IDXG | ABUS | https://www.nasdaq.com/articles/health-care-sector-update-for-06-20-2019%3A-abusdmacedsaidxg-2019-06-20 | nan | nan | Top Health Care Stocks
JNJ +0.96%
PFE +0.20%
ABT +0.58%
MRK -0.88%
AMGN +0.58%
Health care stocks were still rising this afternoon, including a nearly 0.3% gain for the NYSE Health Care Index while shares of health care companies in the S&P 500 also were up almost 0.4% as a group. The Nasdaq Biotechnology index was climbing about 0.5%.
Among health care stocks moving on news:
(+) Arbutus Biopharma (ABUS) jumped over 36% higher after the specialty drugmaker said it has cleared by an unnamed "regulatory body" to start phase Ia/Ib testing of its AB-729 prospective treatment for hepatitis B after submitting a revised trial protocol. Arbutus also will first need to complete three- and six-month toxicology studies before beginning the single ascending-dose portion of the early-stage study.
In other sector news:
(+) Edesa Biotech (EDSA) soared 75% on Thursday after the US Food and Drug Administration said the company could proceed with phase IIb testing of its EB01 drug candidate, a sPLA2 inhibitor intended to treat chronic allergic contact dermatitis. Edesa is expecting to begin enrollment during the next quarter after manufacturing enough EB01 to supply the mid-stage trial.
(+) DiaMedica Therapeutics (DMAC) climbed 27% after the biopharmaceuticals company late Wednesday reported encouraging interim results from phase Ib testing of its DM199 drug candidate in patients with moderate to severe chronic kidney disease. DM199 was safe and well tolerated with no drug-related serious adverse events, consistent with earlier DM199 studies in healthy volunteers, the company said, adding pharmacodynamic results from the early-stage trial helped identify the dosing range for future studies.
(+) Interpace Diagnostics Group (IDXG) was 10% higher in late Thursday trade after Independence Blue Cross agreed to cover the costs of the diagnostics company's ThyGeNEXT and ThyraMIR tests for thyroid cancer for its members in Philadelphia and southeastern Pennsylvania.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Among health care stocks moving on news: (+) Arbutus Biopharma (ABUS) jumped over 36% higher after the specialty drugmaker said it has cleared by an unnamed "regulatory body" to start phase Ia/Ib testing of its AB-729 prospective treatment for hepatitis B after submitting a revised trial protocol. (+) DiaMedica Therapeutics (DMAC) climbed 27% after the biopharmaceuticals company late Wednesday reported encouraging interim results from phase Ib testing of its DM199 drug candidate in patients with moderate to severe chronic kidney disease. (+) Interpace Diagnostics Group (IDXG) was 10% higher in late Thursday trade after Independence Blue Cross agreed to cover the costs of the diagnostics company's ThyGeNEXT and ThyraMIR tests for thyroid cancer for its members in Philadelphia and southeastern Pennsylvania. | Among health care stocks moving on news: (+) Arbutus Biopharma (ABUS) jumped over 36% higher after the specialty drugmaker said it has cleared by an unnamed "regulatory body" to start phase Ia/Ib testing of its AB-729 prospective treatment for hepatitis B after submitting a revised trial protocol. Health care stocks were still rising this afternoon, including a nearly 0.3% gain for the NYSE Health Care Index while shares of health care companies in the S&P 500 also were up almost 0.4% as a group. (+) Interpace Diagnostics Group (IDXG) was 10% higher in late Thursday trade after Independence Blue Cross agreed to cover the costs of the diagnostics company's ThyGeNEXT and ThyraMIR tests for thyroid cancer for its members in Philadelphia and southeastern Pennsylvania. | Among health care stocks moving on news: (+) Arbutus Biopharma (ABUS) jumped over 36% higher after the specialty drugmaker said it has cleared by an unnamed "regulatory body" to start phase Ia/Ib testing of its AB-729 prospective treatment for hepatitis B after submitting a revised trial protocol. Health care stocks were still rising this afternoon, including a nearly 0.3% gain for the NYSE Health Care Index while shares of health care companies in the S&P 500 also were up almost 0.4% as a group. In other sector news: (+) Edesa Biotech (EDSA) soared 75% on Thursday after the US Food and Drug Administration said the company could proceed with phase IIb testing of its EB01 drug candidate, a sPLA2 inhibitor intended to treat chronic allergic contact dermatitis. | Among health care stocks moving on news: (+) Arbutus Biopharma (ABUS) jumped over 36% higher after the specialty drugmaker said it has cleared by an unnamed "regulatory body" to start phase Ia/Ib testing of its AB-729 prospective treatment for hepatitis B after submitting a revised trial protocol. Top Health Care Stocks Health care stocks were still rising this afternoon, including a nearly 0.3% gain for the NYSE Health Care Index while shares of health care companies in the S&P 500 also were up almost 0.4% as a group. |
34690.0 | 2019-04-11 00:00:00 UTC | 4 Drug/Biotech Stocks Making a Mark in RNAi Therapeutics | ABUS | https://www.nasdaq.com/articles/4-drugbiotech-stocks-making-mark-rnai-therapeutics-2019-04-11-0 | nan | nan | Biotech bigwig Regeneron Pharmaceuticals, Inc.'s REGN recently extended collaboration agreement with Alnylam Pharmaceuticals, Inc. ALNY brought ribonucleic acid interference (RNAi) therapeutics in focus.
The companies will work together to discover, develop and commercialize RNAi therapeutics for a broad range of diseases by addressing disease targets expressed in the eye and central nervous system (CNS) in addition to a select number of targets expressed in the liver. Regeneron will make a $400-million upfront payment to Alnylam. It will also purchase $400 million of Alnylam equity at $90.00 per share. Additionally, Alnylam is eligible to receive up to an additional $200 million in milestone payments.
The collaboration with Alnylam will give Regeneron an option to have a pipeline based on RNAi technology.
In 2018, the FDA approved Alnylam's Onpattro for the treatment of polyneuropathy of hATTR amyloidosis in adults in the United States and in adults with Stage 1 or Stage 2 polyneuropathy in the EU. This is the first FDA-approved treatment for patients with polyneuropathy caused by hATTR, a rare, and often fatal genetic disease. It is also the first FDA approval of a new class of drugs called small interfering RNA (siRNA) treatment.
What is RNAi?
RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. A revolutionary approach, RNAi therapeutics comprises siRNA and works by silencing messenger RNA, or mRNA, that encode for disease-causing proteins.
Consequently, a lot of companies are investing a sizeable chunk of their R&D budget to develop treatments using RNAi based technology.
4 Companies Developing Candidates Using RNAi Technology
Here we take a look at some other companies that have promising candidates:
Arrowhead Pharmaceuticals Inc . ARWR develops therapies that trigger the RNA interference mechanism. The company has a broad portfolio of RNA chemistries. ARO-AAT, an RNAi therapeutic candidate for the treatment of liver disease associated with alpha-1 antitrypsin deficiency, is one of the key candidates. The company completed a phase I randomized, double-blind, placebo controlled single-ascending dose (SAD) and multiple-ascending dose (MAD) study to evaluate the safety, tolerability, pharmacokinetics, and effect of subcutaneous doses of ARO-AAT on serum alpha-1 antitrypsin levels in healthy adult volunteers in 2018 and plans to initiate a phase II study in 2019.
Other candidates include ARO-APOC3 for hypertriglyceridemia, ARO-ANG3 for dyslipidemia, ARO-ENaC for cystic fibrosis, and ARO-HIF2 for renal cell carcinoma. In 2016, the company out licensed ARO-LPA (AMG 890) for cardiovascular disease to Amgen Inc. The company also has a license and collaboration agreement with Amgen for ARO-AMG1 for an undisclosed genetically validated cardiovascular target. ARO-HBV for chronic hepatitis B virus was out-licensed to Janssen Pharmaceuticals, Inc. in October 2018.
Dicerna Pharmaceuticals, Inc . DRNA is another biopharmaceutical company focused on the discovery and development of innovative, subcutaneously delivered RNAi-based therapeutics using its GalXC RNAi platform intended for the treatment of diseases of the liver, including rare diseases, viral infectious diseases, chronic liver diseases, and cardiovascular diseases. Key candidates include DCR PHXC for the treatment of primary hyperoxaluria ("PH"), currently in a phase I trial; DCR HBVS for the treatment of chronic hepatitis B virus ("HBV"), currently in a phase I trial; and an undisclosed product candidate against a serious rare liver disease, currently in Investigational New Drug application ("IND") enabling studies.
The company has strategic collaborations with Eli Lilly and Company, Alexion Pharmaceuticals, Inc. and Boehringer Ingelheim International GmbH.
Arbutus BiopharmaABUS is another company, which is developing RNAi therapeutics. The company is developing a second-generation RNAi agent, AB-729 that targets a single RNAi trigger sequence that spans all HBV transcripts and reduces all viral antigens, including hepatitis B surface antigen (HBsAg). A phase II clinical trial combining AB-729, Arbutus' oral capsid inhibitor - AB-506 and an approved nucleoside analogue (NA) is expected to be initiated in the first half of 2020.
Arbutus currently carries a Zacks Rank #2 (Buy). You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here.
Moderna, Inc.MRNA is another clinical stage biotechnology company developing messenger RNA (mRNA) therapeutics and vaccines for infectious diseases, immuno-oncology, rare diseases and cardiovascular diseases. Moderna currently has 20 mRNA development candidates in its portfolio, with 11 in clinical studies. The company has collaborations with AstraZeneca, Merck & Co., and Vertex Pharmaceuticals.
Breakout Biotech Stocks with Triple-Digit Profit Potential
The biotech sector is projected to surge beyond $775 billion by 2024 as scientists develop treatments for thousands of diseases. They're also finding ways to edit the human genome to literally erase our vulnerability to these diseases.
Zacks has just released Century of Biology: 7 Biotech Stocks to Buy Right Now to help investors profit from 7 stocks poised for outperformance. Our recent biotech recommendations have produced gains of +98%, +119% and +164% in as little as 1 month. The stocks in this report could perform even better.
See these 7 breakthrough stocks now>>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Alnylam Pharmaceuticals, Inc. (ALNY): Free Stock Analysis Report
Regeneron Pharmaceuticals, Inc. (REGN): Free Stock Analysis Report
Arbutus Biopharma Corporation (ABUS): Free Stock Analysis Report
Dicerna Pharmaceuticals, Inc. (DRNA): Free Stock Analysis Report
Moderna, Inc. (MRNA): Free Stock Analysis Report
Arrowhead Pharmaceuticals, Inc. (ARWR): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Arbutus BiopharmaABUS is another company, which is developing RNAi therapeutics. Click to get this free report Alnylam Pharmaceuticals, Inc. (ALNY): Free Stock Analysis Report Regeneron Pharmaceuticals, Inc. (REGN): Free Stock Analysis Report Arbutus Biopharma Corporation (ABUS): Free Stock Analysis Report Dicerna Pharmaceuticals, Inc. (DRNA): Free Stock Analysis Report Moderna, Inc. (MRNA): Free Stock Analysis Report Arrowhead Pharmaceuticals, Inc. (ARWR): Free Stock Analysis Report To read this article on Zacks.com click here. A revolutionary approach, RNAi therapeutics comprises siRNA and works by silencing messenger RNA, or mRNA, that encode for disease-causing proteins. | Click to get this free report Alnylam Pharmaceuticals, Inc. (ALNY): Free Stock Analysis Report Regeneron Pharmaceuticals, Inc. (REGN): Free Stock Analysis Report Arbutus Biopharma Corporation (ABUS): Free Stock Analysis Report Dicerna Pharmaceuticals, Inc. (DRNA): Free Stock Analysis Report Moderna, Inc. (MRNA): Free Stock Analysis Report Arrowhead Pharmaceuticals, Inc. (ARWR): Free Stock Analysis Report To read this article on Zacks.com click here. Arbutus BiopharmaABUS is another company, which is developing RNAi therapeutics. DRNA is another biopharmaceutical company focused on the discovery and development of innovative, subcutaneously delivered RNAi-based therapeutics using its GalXC RNAi platform intended for the treatment of diseases of the liver, including rare diseases, viral infectious diseases, chronic liver diseases, and cardiovascular diseases. | Click to get this free report Alnylam Pharmaceuticals, Inc. (ALNY): Free Stock Analysis Report Regeneron Pharmaceuticals, Inc. (REGN): Free Stock Analysis Report Arbutus Biopharma Corporation (ABUS): Free Stock Analysis Report Dicerna Pharmaceuticals, Inc. (DRNA): Free Stock Analysis Report Moderna, Inc. (MRNA): Free Stock Analysis Report Arrowhead Pharmaceuticals, Inc. (ARWR): Free Stock Analysis Report To read this article on Zacks.com click here. Arbutus BiopharmaABUS is another company, which is developing RNAi therapeutics. The companies will work together to discover, develop and commercialize RNAi therapeutics for a broad range of diseases by addressing disease targets expressed in the eye and central nervous system (CNS) in addition to a select number of targets expressed in the liver. | Arbutus BiopharmaABUS is another company, which is developing RNAi therapeutics. Click to get this free report Alnylam Pharmaceuticals, Inc. (ALNY): Free Stock Analysis Report Regeneron Pharmaceuticals, Inc. (REGN): Free Stock Analysis Report Arbutus Biopharma Corporation (ABUS): Free Stock Analysis Report Dicerna Pharmaceuticals, Inc. (DRNA): Free Stock Analysis Report Moderna, Inc. (MRNA): Free Stock Analysis Report Arrowhead Pharmaceuticals, Inc. (ARWR): Free Stock Analysis Report To read this article on Zacks.com click here. What is RNAi? |
34691.0 | 2019-03-07 00:00:00 UTC | Arbutus Biopharma Corp (ABUS) Q4 2018 Earnings Conference Call Transcript | ABUS | https://www.nasdaq.com/articles/arbutus-biopharma-corp-abus-q4-2018-earnings-conference-call-transcript-2019-03-07 | nan | nan | Arbutus Biopharma Corp (NASDAQ: ABUS)
Q4 2018 Earnings Conference Call
March 07, 2019 , 4:30 p.m. ET
Contents:
Prepared Remarks
Questions and Answers
Call Participants
Prepared Remarks:
Operator
Good day, ladies and gentlemen, and welcome to the Arbutus Biopharma Fourth Quarter and 2018 Year-End Conference Call. At this time, all participants are in a listen-only mode. Later, we will conduct a question-and-answer session and instructions will be given at that time. (Operator Instructions) As a reminder, today's conference is being recorded.
I'll now like to turn the call over to Ms. Pam Murphy. Ma'am, you may begin.
Pam Murphy -- Investor Relations Consultant
Thank you. Good afternoon and thank you all for joining us. On the call today from the Arbutus management team are Dr. Mark Murray, CEO; Dr. Mike Sofia, Chief Scientific Officer; Dr. Gaston Picchio, Chief Development Officer, and David Hastings, Chief Financial Officer.
Before we begin, we'd like to remind you that some of the statements made during the call today are forward-looking statements including statements regarding expectations for Arbutus as our proprietary HCV pipeline including clinical timelines and results for the lead compounds AB-506, AB-729 and AB-452, our expected cash runway and expected revenues from our current and potential licensing agreement. These forward-looking statements are subject to a number of risks and uncertainties that may cause our actual results to differ materially, including those described in our most recent Annual Report on 10-K and from time to time in our SEC documents. Any forward-looking statements that we make on this call are based on assumptions as of today, and we undertake no obligation to update these statements as a result of new information or future events.
I'd now like to pass the call to Mark Murray.
Mark J. Murray -- President and Chief Executive Officer
Thanks, Pam, and thank you to everyone for joining us on the call today. I'm going to focus my remarks on our key objectives for 2019. Mike Sofia will follow with an update on AB-452 and the HBV RNA Destabilizer Program. David Hastings will then describe our financial results, after which we'll open up the call for Q&A. As you know, we are focused on developing a cure for patients with chronic HBV. We believe that industry achieved by using a combination regimen of complementary therapeutic agents administered for a finite frequent duration. We believe having control over the discovery and development of these compounds is important. To that essence, we have developed a pipeline of diverse proprietary therapeutic agents that target the abscess of chronic HBV infection, we believe, are the most important and are therefore the ones we are focused on, including HBV replication, Hepatitis B surface antigen expression and immune reawakening. Our two lead compounds, AB-506 and AB-729 of the potential to be used in combination with an approved nucleoside analogue and deliver a meaningful events over the current standard of care. AB-506 is our oral capsid inhibitor. It is pan-genotypic, is a favorable PK profile, is quite potent. works against Nuc-resistant variance, is dosed once daily and is complementary with respect to Hepatitis B surface antigen part of the compound. AB-506 is now being evaluated in HBV patients in a 28-day daily dosing monotherapy clinical trial.
This trial includes the evaluation of several doses of AB-506 and may include the cohorts using AB-506 in combination into the nucleoside analogues. We intend to report top-line results of the completed cohorts in this phase 1a/1b study late in the second quarter with full results presented later in the year at an appropriate scientific meeting. We also plan to initiate a Phase II clinical trial combining AB-506 and a nucleoside analogue in the second half of the year to establish long-term safety of AB-506 plus the Nuc to support use of the -- in future combination trials.
Now, regarding surface antigen reduction, as I said in our third quarter call, we confirmed that our first-generation LNP enabled RNAi agent AB-1467 reduced Hepatitis C surface antigen to very low levels in some patients.
We are now focused on our GalNAc conjugated subcutaneously delivered RNAi agent, AB-729. AB-729 employs a single RNAi trigger that spans all of the HBV transcripts, thus reducing all the viral antigens and inhibits HBV replication. This compound employs our proprietary GalNAc, hepatosite targeting technology, which not only allows for subcutaneous dosing, but also provides the important benefit of less frequent dosing, potentially once a month dosing. We are currently completing IND enabling studies and believe AB-729 is on track to begin a Phase 1a/1b clinical trial in the second quarter of this year. We believe that these two agents AB-506, the capsid Inhibitor, which inhibits HBV replication, and AB-729, which reduces Hepatitis B surface antigen will when combined with an approved Nuc has the potential to be an effective, well-tolerated combination regimen.
Provided the monotherapy trials of AB-506 and AB-729 proceed as expected, we anticipate initiating Phase II combination clinical trial with these two agents together with an approved nucleoside in the first half of 2020. I would now like to move to an update on AB-452, our oral RNA destabilizer, which also targets Hepatitis B surface antigen expression, but via a very novel mechanism of action.
We opted to delay the initiation of our Phase 1a/1b clinical trial in order to evaluate a non-clinical safety finding seen in longer term safety studies. Since that announcement, we have initiated a number of studies designed to further characterize these findings, the compound itself and its mechanism of action and to determine the proceeding in the human testing with AB-452 is appropriate. These studies which are still ongoing and we expect to be able to make a go, no-go decision with respect to AB-452 itself in the second half of the year. In a moment, Mike Sofia will describe some of the activities going on to make -- that'll allow us to make this decision.
We are often asked if we remain committed the RNAi-Destabilizer Program. And the answer is a resounding, yes. In addition to AB-452, we have a robust lead optimization efforts under way for other distinct compounds with this novel biological activity. We are confident the RNA destabilizing mechanism we are focused on represents a very relevant and important therapeutic target. And success here could be very meaningful for patients and for Arbutus.
I'd now like to call -- turn the call over to Mike Sofia. Mike?
Michael J. Sofia -- Chief Scientific Officer
Thanks, Mark. All our scientific efforts at Arbutus are focused on developing a cure for chronic hepatitis B using an effective combination of therapeutic agents administered for a finite treatment duration. My target is focused on fully blocking HBV DNA replication and reducing, even eliminating surface antigen and reawakening the host immune response.
Through our work, we have identified a novel, very compelling target, which very selectively destabilizes or degrades all HBV RNAs and thus has effects on many aspects to the viral life cycle, including DNA replication and surface antigen production.
We've also identified a series of molecules exemplified by AB-452, which are potent and highly selective for Hepatitis B virus. These molecules, when in the presence of the Hepatitis B virus PRE sequence, shortened the viral RNA poly A tail, thereby making them susceptible for degradation. This target/mechanism is novel and very exciting and could lead to a more effective oral regimen for HBV patients, a regimen that would include our RNA destabilizer, our capsid Inhibitor and an approved Nuc. We have initiated a series of in vivo and in vitro studies designed to fully understand the nine clinical safety effects we have observed, including determining the effects we had seen are species specific if they're AB-452 specific or if these effects are mechanism-based.
At the time of our announcement in late 2018, AB-452 was ready to enter clinical trials based on a complete CTA (ph) passage, including the 28-day GLP toxicology studies,in the Phase 1a/1b clinical trial CTA had been accepted by the regulatory authority. The nine clinical safety effects that led us to pause the program were observed in a long-term non-clinical study initiated early in order to accelerate the program.
Some of these studies we are conducting will require several months to complete. But we are encouraged by the progress we're making and the data we have seen thus far. We have gained greater insight into how AB-452 works and why is selective for Hepatitis B virus.
We are in the midst of testing various hypotheses that might explain the in vivo safety findings we have observed and whether they have any relevance to the future development of AB-452, the class of molecules or the mechanism of action. We believe, we will be in a position to make a go, no-go decision regarding the clinical development of AB-452 in the second half of this year. In parallel, because we believe that this is an important target. We are advancing several potent (ph) backup compounds of different genotypes (ph) to similar potent RNA-destabilizing activity.
We are also working on other very interesting early stage research programs with different and potentially complementary mechanism of action, including our immuno virology checkpoint inhibitor program.
This program is focused on identifying and developing orally available small molecule candidate. So effects here could complement and strengthen our pipeline, provide additional opportunities to form effective combination treatment regimens for a broad HBV patient population.
I would like now to turn the call over to David.
David C. Hastings -- Chief Financial Officer
Thanks, Mike, and good afternoon, everybody.
I'll start today by discussing the Company's cash position, 2019 cash guidance and our runway. As a reminder, cash and cash use are most important financial metrics. At December 31, 2018, we had a cash and investments balance of $125 million. Our cash used in operating activities during 2018 was $68 million, which was on the lower end of our guidance.
For 2019, we expect to use between $70 million and $75 million in cash, which allows our current cash balance to fund us into 2020. The only other area I would like to touch on today is our Onpattro royalty entitlement. As we have previously disclosed, our royalty rate is in the low-to-mid single-digits tier based on net sales.
Because of that tiering, we do not expect our royalty income to be material this year. However, we are pleased with the trajectory of the launch and the long-term potential of this product. Additionally, while we can't predict when or if a deal may happen, we are still open to monetizing this royalty stream for an upfront cash payment and possible downstream retention of economics, as long as we feel such a transaction aligns with the product's potential.
So, with that, I'll turn the call back to Mark.
Mark J. Murray -- President and Chief Executive Officer
Thanks, Dave.
As you heard, we are in a strong financial position to proceed with advancing our HBV pipeline. We believe we have a very strong team with the skills, experience and commitment to developing a curative combination regimen for HBV patients.
At this point, I'd like to turn the call over for questions. Operator?
Questions and Answers:
Operator
(Operator Instructions) Our first question comes from the line of Liisa Bayko from JMP Securities. You may begin.
Liisa Bayko -- JMP Securities -- Analyst
Hi, this is John on for Liisa. Thanks for taking the questions and congrats on the progress.
Mark J. Murray -- President and Chief Executive Officer
Thank you.
Liisa Bayko -- JMP Securities -- Analyst
I've just a couple, the first on AB-506. You mentioned in the ongoing study, there may be a cohort looking at 506 plus and Nuc and I was wondering if you could talk more about what would trigger that decisions if that is ongoing now.
Mark J. Murray -- President and Chief Executive Officer
Yeah. So, John, it's a question of if we think we can learn something important with that cohort that we are not able to learn, either from the data we see from others or we do see to determine we learned something meaningful during that.
Liisa Bayko -- JMP Securities -- Analyst
Okay. And moving to the destabilizer, you mentioned again the unknown whether it's DCUs, compound or mechanism-specific. But given the backup that you're working on, I think it's safe to say you're more confident in the mechanism of the other two. But can you discuss kind of the backup and how they might differ from 452. Thank you.
Mark J. Murray -- President and Chief Executive Officer
Sure. Maybe I'll ask Mike to comment on that. Mike?
Michael J. Sofia -- Chief Scientific Officer
Sure. So, we have a, as you said, a very aggressive program in this area, because we believe very strongly in this mechanism of action. All the data that we've produced, you know, tells us this is very compelling. So, we've had a continuing large effort in chemistry to look at, not only AB-452 life molecules, but other molecules that are very chemically distinct from AB-452 that have the same mechanism of action and work very similarly. So, I can say is that you have a number of different series that we're working on, all of them work like AB-452. But they're extremely chemically distinct.
Liisa Bayko -- JMP Securities -- Analyst
Great. Thanks again for taking the questions.
Operator
And our next question comes from line of Katherine Xu from William Blair. You may begin.
Katherine Xu -- William Blair -- Analyst
Hi, good afternoon. I'm just wondering, with regards to 729. Can you maybe summarize little bit your donor conjugate RNAi kind of platform, your potential differentiation from others and also to date the animal talk that you have conducted and what you have observed. Thank you.
Mark J. Murray -- President and Chief Executive Officer
Yes. So Katherine, just sort of high level, this is an agent that employs a single RNAi trigger that sequence spans all of the viral transcripts and it has a unique GalNAc ligand and linker, which we had specifically designed to be proprietary to us and it's -- the GalNAc (inaudible) specifically finds to the surface of hepatosites mediates the entry into the hepatosite. We are currently in the process of the IND-enabling studies, including the GLP tox studies and we don't have anything specific to say about that at this time.
Katherine Xu -- William Blair -- Analyst
Thank you.
Operator
Thank you. And our next question comes from the line of Keay Nakae from Chardan. You may begin.
Keay Nakae -- Chardan -- Analyst
I guess question for Dave in terms of the cash burn, how should we think about that in terms of how it's spread out in each of the quarters, should we see that is evenly spread out throughout the year or more front and back-end-loaded?
David C. Hastings -- Chief Financial Officer
Yeah, Keay. Okay, I think it's probably a slight hockey stick in the second half of the year, as our clinical spending ramps, but not dramatic.
Keay Nakae -- Chardan -- Analyst
Okay. Great. And then just follow up question on AB-729 and (inaudible) GalNAc, how much this is allowed you to use a more fully modified scale of?
Mark J. Murray -- President and Chief Executive Officer
Keay. If I understand you properly, what I would say is using this method -- route of administration, which is subcutaneous, you end up chemically modifying the trigger sequence to protect it from degradation.
Keay Nakae -- Chardan -- Analyst
Right. And while -- in doing that modification, what is your expectation of the potency and durability impact?
Mark J. Murray -- President and Chief Executive Officer
Well, the product has obviously been designed (inaudible) potent and durable as we can make it, So, we have looked at a variety of ways to do this and are comfortable that we have found one that is potent and durable.
Michael J. Sofia -- Chief Scientific Officer
So -- this is Mike. So, clearly the triggers as Mark said, we have a number of modifications in the triggers that make it unique in some ways, but as far as the potency, we've certainly disclosed that this molecule demonstrates a very, very potent knockdown in HBV as antigen production in animal models more so than 1467 and also that this molecule has a very nice extended duration of action meeting in the animal models. We've seen a very nice maintenance of S antigen loss or drop after -- one month after the initial dose. So that sort of leads to the belief that we believe this is going to be a once-monthly dosing agent in the clinic.
Keay Nakae -- Chardan -- Analyst
Okay. Yeah, that's helpful, Mike, and will we be seeing any publications on the preclinical work finished?
Mark J. Murray -- President and Chief Executive Officer
We thought actually presented some of this work at ASLD (ph) and EASL at the upcoming EASL work for also 729 combination studies that we've done with other agents. So we have a poster there.
Keay Nakae -- Chardan -- Analyst
Okay, very good. Thanks.
Michael J. Sofia -- Chief Scientific Officer
And Keay, you can find some of the past work on our website.
Keay Nakae -- Chardan -- Analyst
Okay. Thank you.
Operator
Thank you. (Operator Instructions) Our next question comes from line of Mayank Mamtani from B Riley. You may begin.
Mayank Mamtani -- B. Riley -- Analyst
Hey, guys. Congrats on the progress and thanks for taking my question. Just three from me and tagging along the previous question, for 506, just thinking about the class of drug, how do you think about the second goiter readout that we should have and also contextualizing what we may learn at EASL and others in the meanwhile?
And then on 452, I was just curious you said nine clinical studies that you went down the path of just obviously keeping in mind that you may have to move through the clinic. So how much of that is relevant to some other work that you will do for your backup, and once you do learn, what are you anticipating to learn around the two hypotheses, how much of that work would be relevant to back them out molecule there?
And then last minor question, you said immune virology's checkpoint inhibitors, is there a particular target you guys have identified that you may want to prioritize this?
Mark J. Murray -- President and Chief Executive Officer
Yes. So maybe let's start backwards. Mike, do you want to comment on the immune virology and maybe get ask Gaston to comment then on what our expectations are for 506 readout and then you may come back to us, maybe we'll get -- we'll need to get you and repeat the question -- the second question last?
Mayank Mamtani -- B. Riley -- Analyst
Okay, I'll do that needed.
Mark J. Murray -- President and Chief Executive Officer
Let's start with the immunovirology.
Michael J. Sofia -- Chief Scientific Officer
Sure. So, we've identified a while ago that the checkpoint inhibition was going to be a good approach from an immunovirology standpoint and an HBV. We initiated this program in the small molecule area, because we believe the small molecules to be a better modality for HBV as a therapeutic field than an antibody would be. So we've made a lot of progress in our lead optimization on our small molecule program and we believe that we have -- we're in a position to ultimately, you know, in the not too distant future, move one forward into development, but at this point in time we are fully engaged in our lead optimization efforts in that space. Hope I answered your question.
Mayank Mamtani -- B. Riley -- Analyst
Yeah, yeah, no, it does. Can you talk to the target specifically that you may want to pursue there or is that too early?
Michael J. Sofia -- Chief Scientific Officer
Well, yeah, no, no. We've, I think publicly said that we're very interested in PD-L1 as the target. And that's where much of our effort is currently engaged in immunovirology space. We are looking at other targets in immunovirology, but they're still earlier than our PD-L1 checkpoint progress.
Mayank Mamtani -- B. Riley -- Analyst
Great. Thanks.
Mark J. Murray -- President and Chief Executive Officer
Maybe Gaston, do you want to just add a high-level comment on, you know, sort of what we're expecting to see in a couple of cohorts in the 506 study?
Gaston Picchio -- Chief Development Officer
Sure. Yeah. Thank you. So basically we're looking for the classical biomarkers surface antigen, HBV DNA, HVB RNA and others such as correlated antigen and a few more. Also, we're looking at immunological parameters. So at the minimum, we're looking at, say, rapid declines in HBV DNA and RNA mechanism we should go down or a capsid inhibitor and then we'll see what happens with the most precious marker if you wish surface antigen, although you have to remember that this is a short-term course, this is only 28 days. So as others, we do not expect to see dramatic changes there.
Mark J. Murray -- President and Chief Executive Officer
Mayank, did we cover them or did we lose any of your questions?
Operator
(Operator Instructions).
Pam Murphy -- Investor Relations Consultant
I don't think we answered the question Mayank asked about 452. Again, let me go ahead and open his line again. Go ahead, Mayank.
Mayank Mamtani -- B. Riley -- Analyst
Sorry about that. I got cut off. The question on 452 again, happy to repeat. I was just curious about some of the work that you're already doing to characterize the three components. And I was just curious how some of that work, like you said that was basically you were doing earlier than expected like just to be ready to move through that route. I was just curious if that -- some of that work is actually relevant for the backup molecules once you are able to identify what the issue is, you can move with the backup molecules really quickly. Is that the right way to think about it?
Michael J. Sofia -- Chief Scientific Officer
Yes, all right.
Mark J. Murray -- President and Chief Executive Officer
Go ahead, Mike.
Michael J. Sofia -- Chief Scientific Officer
Yeah, I think that's the right way to think about it. We are gaining a lot of knowledge and understanding of how this molecule, the mechanism of action for HBV, we are understanding more and more about the observation that we saw preclinically what's caused -- what maybe causing that and what it does, it informs us as we now move to our next-generation agents and allows us to let's say work around maybe some of the issues that we've seen before, because we know more about how the molecule works and know more about what may be causing the issues that we observed. So I can say that definitely it's having no significant impact on how we progress future agents forward in this program.
Mayank Mamtani -- B. Riley -- Analyst
Great. Thank you for taking my questions.
Operator
Thank you. And I'm showing no further questions. I'd like to turn the call back to Mr. Mark Murray, CEO for closing remarks.
Mark J. Murray -- President and Chief Executive Officer
Thank you, operator. We appreciate your participation in the call today. 2019 promises to be an important and very eventful year and we will fold it sharing our updates on our progress with you in the months ahead. Operator, back to you.
Operator
Thank you. Ladies and gentlemen, thank you for participating in today's conference. This does conclude the program and you may all disconnect. Everyone, have a great day.
Mark J. Murray -- President and Chief Executive Officer
Thank you.
Pam Murphy -- Investor Relations Consultant
Thank you.
Duration: 29 minutes
Call participants:
Pam Murphy -- Investor Relations Consultant
Mark J. Murray -- President and Chief Executive Officer
Michael J. Sofia -- Chief Scientific Officer
David C. Hastings -- Chief Financial Officer
Liisa Bayko -- JMP Securities -- Analyst
Katherine Xu -- William Blair -- Analyst
Keay Nakae -- Chardan -- Analyst
Mayank Mamtani -- B. Riley -- Analyst
Gaston Picchio -- Chief Development Officer
More ABUS analysis
Transcript powered by AlphaStreet
This article is a transcript of this conference call produced for The Motley Fool. While we strive for our Foolish Best, there may be errors, omissions, or inaccuracies in this transcript. As with all our articles, The Motley Fool does not assume any responsibility for your use of this content, and we strongly encourage you to do your own research, including listening to the call yourself and reading the company's SEC filings. Please see ourTerms and Conditionsfor additional details, including our Obligatory Capitalized Disclaimers of Liability.
10 stocks we like better than Arbutus Biopharma
When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor , has quadrupled the market.*
David and Tom just revealed what they believe are the ten best stocks for investors to buy right now... and Arbutus Biopharma wasn't one of them! That's right -- they think these 10 stocks are even better buys.
See the 10 stocks
*Stock Advisor returns as of March 1, 2019
Motley Fool Transcribers has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy .
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Arbutus Biopharma Corp (NASDAQ: ABUS) Q4 2018 Earnings Conference Call March 07, 2019 , 4:30 p.m. Duration: 29 minutes Call participants: Pam Murphy -- Investor Relations Consultant Mark J. Murray -- President and Chief Executive Officer Michael J. Sofia -- Chief Scientific Officer David C. Hastings -- Chief Financial Officer Liisa Bayko -- JMP Securities -- Analyst Katherine Xu -- William Blair -- Analyst Keay Nakae -- Chardan -- Analyst Mayank Mamtani -- B. Riley -- Analyst Gaston Picchio -- Chief Development Officer More ABUS analysis Transcript powered by AlphaStreet This article is a transcript of this conference call produced for The Motley Fool. Through our work, we have identified a novel, very compelling target, which very selectively destabilizes or degrades all HBV RNAs and thus has effects on many aspects to the viral life cycle, including DNA replication and surface antigen production. | Duration: 29 minutes Call participants: Pam Murphy -- Investor Relations Consultant Mark J. Murray -- President and Chief Executive Officer Michael J. Sofia -- Chief Scientific Officer David C. Hastings -- Chief Financial Officer Liisa Bayko -- JMP Securities -- Analyst Katherine Xu -- William Blair -- Analyst Keay Nakae -- Chardan -- Analyst Mayank Mamtani -- B. Riley -- Analyst Gaston Picchio -- Chief Development Officer More ABUS analysis Transcript powered by AlphaStreet This article is a transcript of this conference call produced for The Motley Fool. Arbutus Biopharma Corp (NASDAQ: ABUS) Q4 2018 Earnings Conference Call March 07, 2019 , 4:30 p.m. On the call today from the Arbutus management team are Dr. Mark Murray, CEO; Dr. Mike Sofia, Chief Scientific Officer; Dr. Gaston Picchio, Chief Development Officer, and David Hastings, Chief Financial Officer. | Duration: 29 minutes Call participants: Pam Murphy -- Investor Relations Consultant Mark J. Murray -- President and Chief Executive Officer Michael J. Sofia -- Chief Scientific Officer David C. Hastings -- Chief Financial Officer Liisa Bayko -- JMP Securities -- Analyst Katherine Xu -- William Blair -- Analyst Keay Nakae -- Chardan -- Analyst Mayank Mamtani -- B. Riley -- Analyst Gaston Picchio -- Chief Development Officer More ABUS analysis Transcript powered by AlphaStreet This article is a transcript of this conference call produced for The Motley Fool. Arbutus Biopharma Corp (NASDAQ: ABUS) Q4 2018 Earnings Conference Call March 07, 2019 , 4:30 p.m. On the call today from the Arbutus management team are Dr. Mark Murray, CEO; Dr. Mike Sofia, Chief Scientific Officer; Dr. Gaston Picchio, Chief Development Officer, and David Hastings, Chief Financial Officer. | Duration: 29 minutes Call participants: Pam Murphy -- Investor Relations Consultant Mark J. Murray -- President and Chief Executive Officer Michael J. Sofia -- Chief Scientific Officer David C. Hastings -- Chief Financial Officer Liisa Bayko -- JMP Securities -- Analyst Katherine Xu -- William Blair -- Analyst Keay Nakae -- Chardan -- Analyst Mayank Mamtani -- B. Riley -- Analyst Gaston Picchio -- Chief Development Officer More ABUS analysis Transcript powered by AlphaStreet This article is a transcript of this conference call produced for The Motley Fool. Arbutus Biopharma Corp (NASDAQ: ABUS) Q4 2018 Earnings Conference Call March 07, 2019 , 4:30 p.m. Mark J. Murray -- President and Chief Executive Officer Thanks, Pam, and thank you to everyone for joining us on the call today. |
34692.0 | 2019-02-08 00:00:00 UTC | Notable Friday Option Activity: X, ABUS, CBIO | ABUS | https://www.nasdaq.com/articles/notable-friday-option-activity-x-abus-cbio-2019-02-08 | nan | nan | Among the underlying components of the Russell 3000 index, we saw noteworthy options trading volume today in United States Steel Corp. (Symbol: X), where a total of 49,081 contracts have traded so far, representing approximately 4.9 million underlying shares. That amounts to about 43.1% of X's average daily trading volume over the past month of 11.4 million shares. Especially high volume was seen for the $19 strike put option expiring April 18, 2019 , with 6,181 contracts trading so far today, representing approximately 618,100 underlying shares of X. Below is a chart showing X's trailing twelve month trading history, with the $19 strike highlighted in orange:
Arbutus Biopharma Corp (Symbol: ABUS) options are showing a volume of 771 contracts thus far today. That number of contracts represents approximately 77,100 underlying shares, working out to a sizeable 42.9% of ABUS's average daily trading volume over the past month, of 179,550 shares. Especially high volume was seen for the $5 strike call option expiring June 21, 2019 , with 750 contracts trading so far today, representing approximately 75,000 underlying shares of ABUS. Below is a chart showing ABUS's trailing twelve month trading history, with the $5 strike highlighted in orange:
And Catalyst Biosciences Inc (Symbol: CBIO) options are showing a volume of 1,135 contracts thus far today. That number of contracts represents approximately 113,500 underlying shares, working out to a sizeable 42.8% of CBIO's average daily trading volume over the past month, of 264,900 shares. Particularly high volume was seen for the $10 strike call option expiring March 15, 2019 , with 407 contracts trading so far today, representing approximately 40,700 underlying shares of CBIO. Below is a chart showing CBIO's trailing twelve month trading history, with the $10 strike highlighted in orange:
For the various different available expirations for X options , ABUS options , or CBIO options , visit StockOptionsChannel.com.
Today's Most Active Call & Put Options of the S&P 500 »
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Especially high volume was seen for the $5 strike call option expiring June 21, 2019 , with 750 contracts trading so far today, representing approximately 75,000 underlying shares of ABUS. Below is a chart showing X's trailing twelve month trading history, with the $19 strike highlighted in orange: Arbutus Biopharma Corp (Symbol: ABUS) options are showing a volume of 771 contracts thus far today. That number of contracts represents approximately 77,100 underlying shares, working out to a sizeable 42.9% of ABUS's average daily trading volume over the past month, of 179,550 shares. | Below is a chart showing X's trailing twelve month trading history, with the $19 strike highlighted in orange: Arbutus Biopharma Corp (Symbol: ABUS) options are showing a volume of 771 contracts thus far today. That number of contracts represents approximately 77,100 underlying shares, working out to a sizeable 42.9% of ABUS's average daily trading volume over the past month, of 179,550 shares. Especially high volume was seen for the $5 strike call option expiring June 21, 2019 , with 750 contracts trading so far today, representing approximately 75,000 underlying shares of ABUS. | Especially high volume was seen for the $5 strike call option expiring June 21, 2019 , with 750 contracts trading so far today, representing approximately 75,000 underlying shares of ABUS. Below is a chart showing X's trailing twelve month trading history, with the $19 strike highlighted in orange: Arbutus Biopharma Corp (Symbol: ABUS) options are showing a volume of 771 contracts thus far today. That number of contracts represents approximately 77,100 underlying shares, working out to a sizeable 42.9% of ABUS's average daily trading volume over the past month, of 179,550 shares. | Below is a chart showing CBIO's trailing twelve month trading history, with the $10 strike highlighted in orange: For the various different available expirations for X options , ABUS options , or CBIO options , visit StockOptionsChannel.com. Below is a chart showing X's trailing twelve month trading history, with the $19 strike highlighted in orange: Arbutus Biopharma Corp (Symbol: ABUS) options are showing a volume of 771 contracts thus far today. That number of contracts represents approximately 77,100 underlying shares, working out to a sizeable 42.9% of ABUS's average daily trading volume over the past month, of 179,550 shares. |
34693.0 | 2018-12-31 00:00:00 UTC | 10 RNA Therapeutics Companies To Watch In 2019 | ABUS | https://www.nasdaq.com/articles/10-rna-therapeutics-companies-watch-2019-2018-12-31 | nan | nan | (RTTNews.com) - After decades of research and development in RNA interference (RNAi), considered one of the most exciting discoveries in biology, the year 2018 saw the first-ever RNAi drug pass regulatory muster in the United States.
Alnylam Pharmaceuticals' (ALNY) Onpattro approved, in August of 2018, for the treatment of nerve damage caused by a rare disease called hereditary transthyretin-mediated amyloidosis (hATTR) is the first RNAi drug to hit the U.S. market.
RNA interference, or RNAi, is a natural mechanism present in living cells that selectively "turns off" or "silences" the expression of a specific gene, thereby affecting the production of a specific protein that contributes to disease. This cellular mechanism was discovered in 1998 by American biologists Andrew Fire and Craig Mello, and they were awarded the Nobel Prize in physiology or medicine in 2006 for their discovery. Scientists are leveraging this naturally occurring mechanism to prevent or treat diseases.
Another technology that targets RNA is known as antisense technology. In this technology, synthetic single-stranded strings of nucleic acids, known as antisense oligonucleotides, bind to RNA and thereby alter or reduce expression of the target RNA.
According to a recent report by Grand View Research, the global antisense and RNAi therapeutics market will register an 8.6% CAGR in terms of revenue, reaching $1.81 billion by 2025, from $945.8 million in 2016.
Below is a list of some of the biotechnology companies developing RNA-based therapeutics, and the latest update on their pipeline.
Read the original article on RTTNews (http://www.rttnews.com/2965957/10-rna-therapeutics-companies-to-watch-in-2019.aspx)
For comments and feedback: contact editorial@rttnews.com
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Alnylam Pharmaceuticals' (ALNY) Onpattro approved, in August of 2018, for the treatment of nerve damage caused by a rare disease called hereditary transthyretin-mediated amyloidosis (hATTR) is the first RNAi drug to hit the U.S. market. This cellular mechanism was discovered in 1998 by American biologists Andrew Fire and Craig Mello, and they were awarded the Nobel Prize in physiology or medicine in 2006 for their discovery. According to a recent report by Grand View Research, the global antisense and RNAi therapeutics market will register an 8.6% CAGR in terms of revenue, reaching $1.81 billion by 2025, from $945.8 million in 2016. | (RTTNews.com) - After decades of research and development in RNA interference (RNAi), considered one of the most exciting discoveries in biology, the year 2018 saw the first-ever RNAi drug pass regulatory muster in the United States. RNA interference, or RNAi, is a natural mechanism present in living cells that selectively "turns off" or "silences" the expression of a specific gene, thereby affecting the production of a specific protein that contributes to disease. According to a recent report by Grand View Research, the global antisense and RNAi therapeutics market will register an 8.6% CAGR in terms of revenue, reaching $1.81 billion by 2025, from $945.8 million in 2016. | (RTTNews.com) - After decades of research and development in RNA interference (RNAi), considered one of the most exciting discoveries in biology, the year 2018 saw the first-ever RNAi drug pass regulatory muster in the United States. RNA interference, or RNAi, is a natural mechanism present in living cells that selectively "turns off" or "silences" the expression of a specific gene, thereby affecting the production of a specific protein that contributes to disease. In this technology, synthetic single-stranded strings of nucleic acids, known as antisense oligonucleotides, bind to RNA and thereby alter or reduce expression of the target RNA. | (RTTNews.com) - After decades of research and development in RNA interference (RNAi), considered one of the most exciting discoveries in biology, the year 2018 saw the first-ever RNAi drug pass regulatory muster in the United States. Alnylam Pharmaceuticals' (ALNY) Onpattro approved, in August of 2018, for the treatment of nerve damage caused by a rare disease called hereditary transthyretin-mediated amyloidosis (hATTR) is the first RNAi drug to hit the U.S. market. RNA interference, or RNAi, is a natural mechanism present in living cells that selectively "turns off" or "silences" the expression of a specific gene, thereby affecting the production of a specific protein that contributes to disease. |
34694.0 | 2018-11-09 00:00:00 UTC | Noteworthy Friday Option Activity: AMBA, ABUS, ALKS | ABUS | https://www.nasdaq.com/articles/noteworthy-friday-option-activity-amba-abus-alks-2018-11-09 | nan | nan | Among the underlying components of the Russell 3000 index, we saw noteworthy options trading volume today in Ambarella, Inc. (Symbol: AMBA), where a total of 2,808 contracts have traded so far, representing approximately 280,800 underlying shares. That amounts to about 56.9% of AMBA's average daily trading volume over the past month of 493,360 shares. Particularly high volume was seen for the $38 strike call option expiring November 16, 2018 , with 773 contracts trading so far today, representing approximately 77,300 underlying shares of AMBA. Below is a chart showing AMBA's trailing twelve month trading history, with the $38 strike highlighted in orange:
Arbutus Biopharma Corp (Symbol: ABUS) options are showing a volume of 2,309 contracts thus far today. That number of contracts represents approximately 230,900 underlying shares, working out to a sizeable 55.5% of ABUS's average daily trading volume over the past month, of 415,870 shares. Particularly high volume was seen for the $7.50 strike call option expiring December 21, 2018 , with 1,950 contracts trading so far today, representing approximately 195,000 underlying shares of ABUS. Below is a chart showing ABUS's trailing twelve month trading history, with the $7.50 strike highlighted in orange:
And Alkermes plc (Symbol: ALKS) saw options trading volume of 6,054 contracts, representing approximately 605,400 underlying shares or approximately 54.9% of ALKS's average daily trading volume over the past month, of 1.1 million shares. Particularly high volume was seen for the $35 strike put option expiring December 21, 2018 , with 5,011 contracts trading so far today, representing approximately 501,100 underlying shares of ALKS. Below is a chart showing ALKS's trailing twelve month trading history, with the $35 strike highlighted in orange:
For the various different available expirations for AMBA options , ABUS options , or ALKS options , visit StockOptionsChannel.com.
Today's Most Active Call & Put Options of the S&P 500 »
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Particularly high volume was seen for the $7.50 strike call option expiring December 21, 2018 , with 1,950 contracts trading so far today, representing approximately 195,000 underlying shares of ABUS. Below is a chart showing AMBA's trailing twelve month trading history, with the $38 strike highlighted in orange: Arbutus Biopharma Corp (Symbol: ABUS) options are showing a volume of 2,309 contracts thus far today. That number of contracts represents approximately 230,900 underlying shares, working out to a sizeable 55.5% of ABUS's average daily trading volume over the past month, of 415,870 shares. | Below is a chart showing AMBA's trailing twelve month trading history, with the $38 strike highlighted in orange: Arbutus Biopharma Corp (Symbol: ABUS) options are showing a volume of 2,309 contracts thus far today. Particularly high volume was seen for the $7.50 strike call option expiring December 21, 2018 , with 1,950 contracts trading so far today, representing approximately 195,000 underlying shares of ABUS. Below is a chart showing ABUS's trailing twelve month trading history, with the $7.50 strike highlighted in orange: And Alkermes plc (Symbol: ALKS) saw options trading volume of 6,054 contracts, representing approximately 605,400 underlying shares or approximately 54.9% of ALKS's average daily trading volume over the past month, of 1.1 million shares. | Particularly high volume was seen for the $7.50 strike call option expiring December 21, 2018 , with 1,950 contracts trading so far today, representing approximately 195,000 underlying shares of ABUS. Below is a chart showing ABUS's trailing twelve month trading history, with the $7.50 strike highlighted in orange: And Alkermes plc (Symbol: ALKS) saw options trading volume of 6,054 contracts, representing approximately 605,400 underlying shares or approximately 54.9% of ALKS's average daily trading volume over the past month, of 1.1 million shares. Below is a chart showing AMBA's trailing twelve month trading history, with the $38 strike highlighted in orange: Arbutus Biopharma Corp (Symbol: ABUS) options are showing a volume of 2,309 contracts thus far today. | Particularly high volume was seen for the $7.50 strike call option expiring December 21, 2018 , with 1,950 contracts trading so far today, representing approximately 195,000 underlying shares of ABUS. Below is a chart showing ABUS's trailing twelve month trading history, with the $7.50 strike highlighted in orange: And Alkermes plc (Symbol: ALKS) saw options trading volume of 6,054 contracts, representing approximately 605,400 underlying shares or approximately 54.9% of ALKS's average daily trading volume over the past month, of 1.1 million shares. Below is a chart showing AMBA's trailing twelve month trading history, with the $38 strike highlighted in orange: Arbutus Biopharma Corp (Symbol: ABUS) options are showing a volume of 2,309 contracts thus far today. |
34695.0 | 2018-10-09 00:00:00 UTC | Here's Why Arbutus Biopharma Corp. Is Tanking Today | ABUS | https://www.nasdaq.com/articles/heres-why-arbutus-biopharma-corp-tanking-today-2018-10-09 | nan | nan | What happened
Shares of Arbutus Biopharma Corp. (NASDAQ: ABUS) were down 31.2% as of 3:07 p.m. EDT on Tuesday. The clinical-stage biotech provided an update earlier in the day on a change to its executive team and on its hepatitis B virus (HBV) program.
Arbutus announced that it had hired Dr. Gaston Picchio as its new chief development officer. The bigger story, though, related to the company's HBV pipeline candidates. The good news was that experimental HBV drug AB-506 is advancing in a phase 1 study from being tested in healthy volunteers to being evaluated in HBV patients. In addition, Arbutus stated that a phase 1 study of AB-729 is expected to begin in the second quarter of 2019, and that it will potentially be studied in combination with AB-506 in a clinical study in the second half of next year.
However, the bad news for Arbutus was that it's delaying the start of a phase 1 study for AB-452 while further research is conducted into "emerging nonclinical safety findings." The biotech's update on its phase 2 study evaluating RNA interference (RNAi) agent ARB-1467 in combination with pegylated interferon (PEG-IFN) was also concerning. Three out of six patients dosed with ARB-1467 so far aren't able to proceed to dosing with PEG-IFN because they didn't meet predetermined response criteria after six weeks of treatment.
So what
The hiring of Picchio wasn't enough to move the needle for Arbutus stock. Neither was the progress for early stage candidates AB-506 and AB-729. But the delay for AB-452 hurt since Arbutus had expected the drug to move into phase 1 clinical testing in the fourth quarter of this year.
Arbutus' worst news, though, was the dismal results so far in the phase 2 combination study featuring ARB-1467. It's the biotech's lead candidate, so the fact that half of the patients dosed so far won't move forward in the clinical study is definitely problematic.
It's possible that the worst is yet to come. Two of the six patients in the study haven't yet progressed to the six-week analysis point. If those patients can't continue to the next part of the study -- dosing with PEG-IFN -- that will leave only one patient with a positive response.
Now what
Arbutus plans to provide periodic updates on the phase 2 combination study of ARB-1467. Investors will anxiously await news from the two patients who haven't reached the six-week mark yet. The biotech also stated that the study is still open for enrollment, so there's a possibility that additional patients could participate who experience positive responses from taking ARB-1467.
For now, though, Arbutus stock is likely to be highly volatile. A lot more good news and considerably less bad news is needed for this stock to be a strong pick for long-term investors.
10 stocks we like better than Arbutus Biopharma
When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor , has quadrupled the market.*
David and Tom just revealed what they believe are the 10 best stocks for investors to buy right now... and Arbutus Biopharma wasn't one of them! That's right -- they think these 10 stocks are even better buys.
Click here to learn about these picks!
*Stock Advisor returns as of August 6, 2018
Keith Speights has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy .
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | What happened Shares of Arbutus Biopharma Corp. (NASDAQ: ABUS) were down 31.2% as of 3:07 p.m. EDT on Tuesday. The clinical-stage biotech provided an update earlier in the day on a change to its executive team and on its hepatitis B virus (HBV) program. However, the bad news for Arbutus was that it's delaying the start of a phase 1 study for AB-452 while further research is conducted into "emerging nonclinical safety findings." | What happened Shares of Arbutus Biopharma Corp. (NASDAQ: ABUS) were down 31.2% as of 3:07 p.m. EDT on Tuesday. But the delay for AB-452 hurt since Arbutus had expected the drug to move into phase 1 clinical testing in the fourth quarter of this year. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor , has quadrupled the market. | What happened Shares of Arbutus Biopharma Corp. (NASDAQ: ABUS) were down 31.2% as of 3:07 p.m. EDT on Tuesday. In addition, Arbutus stated that a phase 1 study of AB-729 is expected to begin in the second quarter of 2019, and that it will potentially be studied in combination with AB-506 in a clinical study in the second half of next year. Arbutus' worst news, though, was the dismal results so far in the phase 2 combination study featuring ARB-1467. | What happened Shares of Arbutus Biopharma Corp. (NASDAQ: ABUS) were down 31.2% as of 3:07 p.m. EDT on Tuesday. Arbutus' worst news, though, was the dismal results so far in the phase 2 combination study featuring ARB-1467. A lot more good news and considerably less bad news is needed for this stock to be a strong pick for long-term investors. |
34696.0 | 2018-09-24 00:00:00 UTC | Are Options Traders Betting on a Big Move in Arbutus (ABUS) Stock? | ABUS | https://www.nasdaq.com/articles/are-options-traders-betting-on-a-big-move-in-arbutus-abus-stock-2018-09-24 | nan | nan | Investors in Arbutus Biopharma CorporationABUS need to pay close attention to the stock based on moves in the options market lately. That is because the Dec 21, 2018 $7.50 Call had some of the highest implied volatility of all equity options today.
What is Implied Volatility?
Implied volatility shows how much movement the market is expecting in the future. Options with high levels of implied volatility suggest that investors in the underlying stocks are expecting a big move in one direction or the other. It could also mean there is an event coming up soon that may cause a big rally or a huge sell off. However, implied volatility is only one piece of the puzzle when putting together an options trading strategy.
What do the Analysts Think?
Clearly, options traders are pricing in a big move for Arbutus shares, but what is the fundamental picture for the company? Currently, Arbutus is a Zacks Rank #3 (Hold) in the Medical - Biomedical and Genetics that ranks in the Top 40% of our Zacks Industry Rank. Over the last 60 days, no analysts have increased their earnings estimates for the current quarter, while three have dropped their estimates. The net effect has taken our Zacks Consensus Estimate for the current quarter from a loss of 33 cents per share to a loss of 40 cents in that period.
Given the way analysts feel about Arbutus right now, this huge implied volatility could mean there's a trade developing. Often times, options traders look for options with high levels of implied volatility to sell premium. This is a strategy many seasoned traders use because it captures decay. At expiration, the hope for these traders is that the underlying stock does not move as much as originally expected.
Looking to Trade Options?
Each week, our very own Dave Bartosiak gives his top options trades. Check out his recent live analysis and options trade for NFLX earnings report completely free. See it here: Bartosiak: Trading Netflix's (NFLX) Earnings with Options or check out the embedded video below for more details:
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Arbutus Biopharma Corporation (ABUS): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Investors in Arbutus Biopharma CorporationABUS need to pay close attention to the stock based on moves in the options market lately. Click to get this free report Arbutus Biopharma Corporation (ABUS): Free Stock Analysis Report To read this article on Zacks.com click here. Options with high levels of implied volatility suggest that investors in the underlying stocks are expecting a big move in one direction or the other. | Click to get this free report Arbutus Biopharma Corporation (ABUS): Free Stock Analysis Report To read this article on Zacks.com click here. Investors in Arbutus Biopharma CorporationABUS need to pay close attention to the stock based on moves in the options market lately. Options with high levels of implied volatility suggest that investors in the underlying stocks are expecting a big move in one direction or the other. | Investors in Arbutus Biopharma CorporationABUS need to pay close attention to the stock based on moves in the options market lately. Click to get this free report Arbutus Biopharma Corporation (ABUS): Free Stock Analysis Report To read this article on Zacks.com click here. Options with high levels of implied volatility suggest that investors in the underlying stocks are expecting a big move in one direction or the other. | Investors in Arbutus Biopharma CorporationABUS need to pay close attention to the stock based on moves in the options market lately. Click to get this free report Arbutus Biopharma Corporation (ABUS): Free Stock Analysis Report To read this article on Zacks.com click here. However, implied volatility is only one piece of the puzzle when putting together an options trading strategy. |
34697.0 | 2018-09-21 00:00:00 UTC | Noteworthy Friday Option Activity: CAT, GTN, ABUS | ABUS | https://www.nasdaq.com/articles/noteworthy-friday-option-activity-cat-gtn-abus-2018-09-21 | nan | nan | Looking at options trading activity among components of the Russell 3000 index, there is noteworthy activity today in Caterpillar Inc. (Symbol: CAT), where a total volume of 31,600 contracts has been traded thus far today, a contract volume which is representative of approximately 3.2 million underlying shares (given that every 1 contract represents 100 underlying shares). That number works out to 74.2% of CAT's average daily trading volume over the past month, of 4.3 million shares. Especially high volume was seen for the $150 strike put option expiring October 19, 2018 , with 3,286 contracts trading so far today, representing approximately 328,600 underlying shares of CAT. Below is a chart showing CAT's trailing twelve month trading history, with the $150 strike highlighted in orange:
Gray Television Inc (Symbol: GTN) saw options trading volume of 3,150 contracts, representing approximately 315,000 underlying shares or approximately 71.7% of GTN's average daily trading volume over the past month, of 439,135 shares. Especially high volume was seen for the $17.50 strike call option expiring November 16, 2018 , with 2,484 contracts trading so far today, representing approximately 248,400 underlying shares of | That number works out to 74.2% of CAT's average daily trading volume over the past month, of 4.3 million shares. Especially high volume was seen for the $150 strike put option expiring October 19, 2018 , with 3,286 contracts trading so far today, representing approximately 328,600 underlying shares of CAT. Especially high volume was seen for the $17.50 strike call option expiring November 16, 2018 , with 2,484 contracts trading so far today, representing approximately 248,400 underlying shares of | Looking at options trading activity among components of the Russell 3000 index, there is noteworthy activity today in Caterpillar Inc. (Symbol: CAT), where a total volume of 31,600 contracts has been traded thus far today, a contract volume which is representative of approximately 3.2 million underlying shares (given that every 1 contract represents 100 underlying shares). Especially high volume was seen for the $150 strike put option expiring October 19, 2018 , with 3,286 contracts trading so far today, representing approximately 328,600 underlying shares of CAT. Below is a chart showing CAT's trailing twelve month trading history, with the $150 strike highlighted in orange: Gray Television Inc (Symbol: GTN) saw options trading volume of 3,150 contracts, representing approximately 315,000 underlying shares or approximately 71.7% of GTN's average daily trading volume over the past month, of 439,135 shares. | Looking at options trading activity among components of the Russell 3000 index, there is noteworthy activity today in Caterpillar Inc. (Symbol: CAT), where a total volume of 31,600 contracts has been traded thus far today, a contract volume which is representative of approximately 3.2 million underlying shares (given that every 1 contract represents 100 underlying shares). Especially high volume was seen for the $150 strike put option expiring October 19, 2018 , with 3,286 contracts trading so far today, representing approximately 328,600 underlying shares of CAT. Below is a chart showing CAT's trailing twelve month trading history, with the $150 strike highlighted in orange: Gray Television Inc (Symbol: GTN) saw options trading volume of 3,150 contracts, representing approximately 315,000 underlying shares or approximately 71.7% of GTN's average daily trading volume over the past month, of 439,135 shares. | Looking at options trading activity among components of the Russell 3000 index, there is noteworthy activity today in Caterpillar Inc. (Symbol: CAT), where a total volume of 31,600 contracts has been traded thus far today, a contract volume which is representative of approximately 3.2 million underlying shares (given that every 1 contract represents 100 underlying shares). That number works out to 74.2% of CAT's average daily trading volume over the past month, of 4.3 million shares. Especially high volume was seen for the $150 strike put option expiring October 19, 2018 , with 3,286 contracts trading so far today, representing approximately 328,600 underlying shares of CAT. |
34698.0 | 2018-07-20 00:00:00 UTC | Arbutus Biopharma (ABUS) Shares March Higher, Can It Continue? | ABUS | https://www.nasdaq.com/articles/arbutus-biopharma-abus-shares-march-higher-can-it-continue-2018-07-20 | nan | nan | As of late, it has definitely been a great time to be an investor in Arbutus Biopharma Corporation ABUS . The stock has moved higher by 19.9% in the past month, while it is also above its 20 Day SMA too. This combination of strong price performance and favorable technical, could suggest that the stock may be on the right path.
We certainly think that this might be the case, particularly if you consider ABUS's recent earnings estimate revision activity. From this look, the company's future is quite favorable; as ABUS has earned itself a Zacks Rank #2 (Buy), meaning that its recent run may continue for a bit longer, and that this isn't the top for the in-focus company. You can see the complete list of today's Zacks #1 Rank stocks here.
Will You Make a Fortune on the Shift to Electric Cars?
Here's another stock idea to consider. Much like petroleum 150 years ago, lithium power may soon shake the world, creating millionaires and reshaping geo-politics. Soon electric vehicles (EVs) may be cheaper than gas guzzlers. Some are already reaching 265 miles on a single charge.
With battery prices plummeting and charging stations set to multiply, one company stands out as the #1 stock to buy according to Zacks research.
It's not the one you think.
See This Ticker Free >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Arbutus Biopharma Corporation (ABUS): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | As of late, it has definitely been a great time to be an investor in Arbutus Biopharma Corporation ABUS . We certainly think that this might be the case, particularly if you consider ABUS's recent earnings estimate revision activity. From this look, the company's future is quite favorable; as ABUS has earned itself a Zacks Rank #2 (Buy), meaning that its recent run may continue for a bit longer, and that this isn't the top for the in-focus company. | As of late, it has definitely been a great time to be an investor in Arbutus Biopharma Corporation ABUS . Click to get this free report Arbutus Biopharma Corporation (ABUS): Free Stock Analysis Report To read this article on Zacks.com click here. We certainly think that this might be the case, particularly if you consider ABUS's recent earnings estimate revision activity. | Click to get this free report Arbutus Biopharma Corporation (ABUS): Free Stock Analysis Report To read this article on Zacks.com click here. As of late, it has definitely been a great time to be an investor in Arbutus Biopharma Corporation ABUS . We certainly think that this might be the case, particularly if you consider ABUS's recent earnings estimate revision activity. | From this look, the company's future is quite favorable; as ABUS has earned itself a Zacks Rank #2 (Buy), meaning that its recent run may continue for a bit longer, and that this isn't the top for the in-focus company. As of late, it has definitely been a great time to be an investor in Arbutus Biopharma Corporation ABUS . We certainly think that this might be the case, particularly if you consider ABUS's recent earnings estimate revision activity. |
34699.0 | 2018-07-19 00:00:00 UTC | 5 Biotech Stocks Well Poised to Beat Q2 Earnings Estimates | ABUS | https://www.nasdaq.com/articles/5-biotech-stocks-well-poised-to-beat-q2-earnings-estimates-2018-07-19 | nan | nan | The biotech industry witnessed a turnaround in the last three months after struggling in early 2018. The industry has risen 10.2% in the past three months compared with an increase of 5.6% registered by the broader S&P 500. The industry had declined 5% in the first three months of 2018.
The recovery is aided by investors flocking to the defensive sector as negative macro factors like trade wars and rising oil prices affect other sectors. Moreover, significant cash on the balance sheet of large pharmaceutical companies is fueling mergers and acquisitions in the biotech sector, thus driving returns. Meanwhile, Biogen's positive results from a phase II Alzheimer's study has further boosted the sector.
New drugs, label expansions of prominent drugs and huge demand led to strong first-quarter performance by drug/biotech companies. The FDA has approved 21 novel drugs so far this year, which is expected to accelerate as the year progresses. Potential positive data readouts from clinical studies scheduled ahead should also push the industry higher.
Some strong fundamentals which attract investors to the biotech sector include growing demand for drugs, especially for rare-to-treat diseases, an elderly population and increased health care spending.
Q2 Earnings So Far
For the 48 S&P 500 companies that have reported so far, earnings and sales have risen 23% and 10%, respectively, from the year-ago period.
The biotech industry that falls within the broader Medical sector (includes drug, biotech as well as Medical Device companies) seems to be on a solid footing. Only 5.5% of the total companies in the industry have reported so far. However, these stocks constitute more than one-fifth of the total market cap of the sector. Per the latest Earnings Outlook, earnings are expected to grow 8% on the back of 6.2% growth in revenues for the medical sector in the second quarter.
How to Pick Likely Q2 Winners
Given the enormity of the healthcare space, selecting stocks that have the potential to beat estimates appears to be quite daunting. But our proprietary methodology makes it fairly simple. One way to narrow down the list of choices this earnings season is by looking at stocks that have the combination of a favorable Zacks Rank - Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold) - and a positive Earnings ESP . More often than not, a positive earnings surprise delivered by a company leads to stock price appreciation.
Earnings ESP is our proprietary methodology for identifying stocks that have high chances of delivering a positive surprise in their upcoming earnings announcement. It shows the percentage difference between the Most Accurate estimate and the Zacks Consensus Estimate. Our research shows that for stocks with this combination, the chance of a positive earnings surprise is as high as 70%. You can uncover the best stocks to buy or sell before they're reported with our Earnings ESP Filter .
Here are five biotech stocks that are poised to beat estimates in the second quarter according to our methodology.
Our first pick is Gilead Sciences, Inc. ( GILD ). This Foster City, CA based company has an Earnings ESP of +2.62% and a Zacks Rank #2. You can see the complete list of today's Zacks #1 Rank stocks here .
The Zacks Consensus Estimate for the second quarter is $1.54 per share. The company has a mixed earnings surprise record, having surpassed earnings expectations in three of the last four quarters. The average negative earnings surprise over the four trailing quarters is4.98%.
Acorda is scheduled to report results on Jul 25.
Our next choice is Keryx Biopharmaceuticals, Inc. ( KERX ). Carrying a Zacks Rank #2, the stock has an Earnings ESP of +23.25%. The Zacks Consensus Estimate for the second quarter is pegged at a loss of 14 cents per share. Massachusetts-based Keryx has a mixed earnings surprise track record. The company came up with a positive earnings surprise of 5.26% in the previous quarter.
Keryx is expected to announce results on Jul 26.
Intercept Pharmaceuticals, Inc. ( ICPT )too has a mixed track record with the company beating earnings expectations in three of the last four quarters, with an average positive surprise of 1.12%. It looks poised to beat expectations in the second quarter as well. This New York-based company carries a Zacks Rank #2 and has an Earnings ESP of +9.35%. The Zacks Consensus Estimate is pegged at a loss of $2.90 cents per share.
Intercept is expected to report results on Jul 30.
Arbutus Biopharma Corporation ( ABUS ) is another solid bet. This Zacks Rank #2 stock has an Earnings ESP of +10.58%. This Canada-based company delivered an earnings beat in three of the last four quarters.
Arbutus is expected to release results on Aug 2, with the Zacks Consensus Estimate for the second quarter pegged at a loss of 35 cents per share.
Ardsley, NY-based Acorda Therapeutics, Inc. ( ACOR ) also makes it to our list of likely outperformers in the second quarter by virtue of its Zacks Rank #2 and an Earnings ESP of +66.76%. The Zacks Consensus Estimate is pegged at 61 cents per share.Acorda is expected to report its results on Jul 26.
Bottom Line
Challenges in the form of negative data readouts and regulatory decision remain. Moreover, drug pricing controversy is a headline risk for the industry. President Trump recently attacked Pfizer for hiking prices for several drugs. However, a number of companies in the healthcare space have fared well. Picking some outperformers from the space, backed by a solid Zacks Rank and a positive Earnings ESP, could lead investors to gain this earnings season.
Today's Stocks from Zacks' Hottest Strategies
It's hard to believe, even for us at Zacks. But while the market gained +21.9% in 2017, our top stock-picking screens have returned +115.0%, +109.3%, +104.9%, +98.6%, and +67.1%.
And this outperformance has not just been a recent phenomenon. Over the years it has been remarkably consistent. From 2000 - 2017, the composite yearly average gain for these strategies has beaten the market more than 19X over. Maybe even more remarkable is the fact that we're willing to share their latest stocks with you without cost or obligation.
See Them Free>>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Gilead Sciences, Inc. (GILD): Free Stock Analysis Report
Acorda Therapeutics, Inc. (ACOR): Free Stock Analysis Report
Arbutus Biopharma Corporation (ABUS): Free Stock Analysis Report
Keryx Biopharmaceuticals, Inc. (KERX): Free Stock Analysis Report
Intercept Pharmaceuticals, Inc. (ICPT): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Arbutus Biopharma Corporation ( ABUS ) is another solid bet. Click to get this free report Gilead Sciences, Inc. (GILD): Free Stock Analysis Report Acorda Therapeutics, Inc. (ACOR): Free Stock Analysis Report Arbutus Biopharma Corporation (ABUS): Free Stock Analysis Report Keryx Biopharmaceuticals, Inc. (KERX): Free Stock Analysis Report Intercept Pharmaceuticals, Inc. (ICPT): Free Stock Analysis Report To read this article on Zacks.com click here. Moreover, significant cash on the balance sheet of large pharmaceutical companies is fueling mergers and acquisitions in the biotech sector, thus driving returns. | Click to get this free report Gilead Sciences, Inc. (GILD): Free Stock Analysis Report Acorda Therapeutics, Inc. (ACOR): Free Stock Analysis Report Arbutus Biopharma Corporation (ABUS): Free Stock Analysis Report Keryx Biopharmaceuticals, Inc. (KERX): Free Stock Analysis Report Intercept Pharmaceuticals, Inc. (ICPT): Free Stock Analysis Report To read this article on Zacks.com click here. Arbutus Biopharma Corporation ( ABUS ) is another solid bet. Intercept Pharmaceuticals, Inc. ( ICPT )too has a mixed track record with the company beating earnings expectations in three of the last four quarters, with an average positive surprise of 1.12%. | Click to get this free report Gilead Sciences, Inc. (GILD): Free Stock Analysis Report Acorda Therapeutics, Inc. (ACOR): Free Stock Analysis Report Arbutus Biopharma Corporation (ABUS): Free Stock Analysis Report Keryx Biopharmaceuticals, Inc. (KERX): Free Stock Analysis Report Intercept Pharmaceuticals, Inc. (ICPT): Free Stock Analysis Report To read this article on Zacks.com click here. Arbutus Biopharma Corporation ( ABUS ) is another solid bet. One way to narrow down the list of choices this earnings season is by looking at stocks that have the combination of a favorable Zacks Rank - Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold) - and a positive Earnings ESP . | Arbutus Biopharma Corporation ( ABUS ) is another solid bet. Click to get this free report Gilead Sciences, Inc. (GILD): Free Stock Analysis Report Acorda Therapeutics, Inc. (ACOR): Free Stock Analysis Report Arbutus Biopharma Corporation (ABUS): Free Stock Analysis Report Keryx Biopharmaceuticals, Inc. (KERX): Free Stock Analysis Report Intercept Pharmaceuticals, Inc. (ICPT): Free Stock Analysis Report To read this article on Zacks.com click here. Only 5.5% of the total companies in the industry have reported so far. |
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.